WorldWideScience

Sample records for psa psa density

  1. [Total PSA, PSA density and biopsy Gleason score in predicting the pathologic stage of prostate cancer].

    Science.gov (United States)

    Liu, Shuai; Lü, Jia-ju; Fu, Qiang; Zhang, Hui; Gao, De-xuan; Liu, Zheng

    2010-05-01

    To evaluate the roles of total prostate specific antigen (tPSA), PSA density (PSAD) and biopsy Gleason score in predicting the pathologic stage of prostate cancer. We retrospectively analyzed the clinical data of 124 cases of pathologically confirmed prostate adenocarcinoma, and divided them into Groups A (n=48) and B (n=76) based on the results of bone scanning, CT, MRI, tPSA, PSAD and postoperative biopsy Gleason score, the former with extraprostatic infiltration or distant metastasis, while the latter without. We compared the above parameters between the two groups, screened the main factors that influenced the pathologic staging of prostate cancer by multivariate logistic regression analysis, and appraised the value of each of the parameters in predicting the pathologic stage of prostate cancer with a relative operating characteristic (ROC) curve. The tPSA level and biopsy Gleason score were significantly higher in Group A than in B (P Gleason score had a better predicting value than other parameters (Gleason score + tPSA > tPSA > PSAD + tPSA + Gleason score). Total PSA remains a valuable predictor of the pathologic stage of prostate cancer, and its combination with Gleason score can further improve the predictive accuracy and contribute much to the treatment and prognosis of the disease.

  2. Incidence of histological prostatitis and its correlation with PSA density

    Directory of Open Access Journals (Sweden)

    Affonso Celso Piovesan

    2009-11-01

    Full Text Available OBJECTIVE: The aim of this study was to determine the incidence of asymptomatic, histologically proven prostatitis in men with symptoms of benign prostate hyperplasia and to observe the correlation between asymptomatic prostatitis and prostate specific antigen (PSA density. INTRODUCTION: The incidence of type IV prostatitis is unknown. There is a tendency to correlate the presence of inflammatory prostatitis with an elevation of PSA. MATERIALS AND METHODS: From August 2000 to January 2006, 183 patients who underwent surgical treatment for benign prostate hyperplasia as a result of obstructive or irritative symptoms were prospectively studied. In accordance with the histology findings, these patients were divided into two groups: group I included patients with the presence of histological prostatitis and group II included patients with the absence of histological prostatitis. The mean PSA densities were compared. RESULTS: Histological evidence of prostatitis was observed in 145 patients. In this group, the mean PSA density was 0.136 ± 0.095. In 38 cases, there was no evidence of inflammation upon histological examination of the surgical samples. In these 38 cases, the mean PSA density was 0.126 ± 0.129. No statistically significant differences were detected between the two groups; the p-value is 0.124. CONCLUSION: Abnormal PSA density should not be attributed to the inflammatory prostatitis process.

  3. A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men

    Directory of Open Access Journals (Sweden)

    Nigel P. Murray

    2014-01-01

    Full Text Available Introduction. PSA parameters have been used in an attempt to improve the diagnostic yield of prostate screening tests; the detection of primary malignant circulating prostate cells (CPCs may improve the diagnostic yield of screening and therefore avoid unnecessary biopsies. Patients and Methods. Prospective study of all men undergoing initial prostate biopsy due to an elevated total serum PSA. Free percent PSA, PSA velocity, and PSA density were determined. Primary CPCs were detected using standard immunocytochemistry. A positive test for CPCs was defined as one cell PSA (+ P504S (+ in an 8 ml blood sample. Positive predictive and negative predictive values, specificity, and sensitivity were calculated for each test as well as the number of biopsies avoided and cancers missed. Results. 303 men participated in the study of whom 113/303 (37.3% men had prostate cancer. Of the three PSA based parameters, free percent PSA was superior, sensitivity 70.8%, and specificity 67.4%. Primary CPCs detection had a sensitivity of 88.5% and a specificity of 88.4% avoiding 181 (59.7% biopsies, detecting 93/95 (98% of clinically significant cancers, and missing 13 (11.5% low grade, small volume tumors. Conclusions. The use of primary CPCs as a sequential test could decrease the number of initial prostate biopsies missing those cancers which are treated by active observation.

  4. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA.

    Science.gov (United States)

    Slev, Patricia R; La'ulu, Sonia L; Roberts, William L

    2008-06-01

    Serum prostate-specific antigen (PSA) assays differ in calibration and response to different PSA forms. We examined intermethod differences in total PSA (tPSA) and free PSA (fPSA) measurements. We tested 157 samples with tPSA concentrations of 2 to 10 ng/mL (2-10 microg/L) using 6 PSA/fPSA method pairs and 1 tPSA method: ADVIA Centaur (complexed and total; Siemens Diagnostics, Tarrytown, NY), ARCHITECT i 2000(SR) (Abbott Diagnostics, Abbott Park, IL), AxSYM (Abbott Diagnostics), IMMULITE 2000 (Siemens Diagnostics), Modular E170 (Roche Diagnostics, Indianapolis, IN), UniCel DxI 800 (Beckman Coulter, Brea, CA), and VITROS ECi (tPSA only; Ortho-Clinical Diagnostics, Raritan, NJ). Regression analysis was performed for PSA, fPSA, and percentage of fPSA with the ARCHITECT i 2000(SR) comparison method. Differences between test and comparison methods were estimated at 2.5, 4.0, and 10.0 ng/mL (2.5, 4.0, and 10.0 microg/L) for tPSA and 15%, 20%, and 25% for percentage of fPSA. Relative differences were more than 10% at 4.0 ng/mL (4.0 microg/L) tPSA for the Centaur, IMMULITE, ECi, and DxI methods. At 20% fPSA, the relative difference was more than 10% for all methods except the AxSYM. Additional harmonization is needed for tPSA and fPSA methods.

  5. Comparison of the Formula of PSA, Age, Prostate Volume and Race Versus PSA Density and the Detection of Primary Malignant Circulating Prostate Cells in Predicting a Positive Initial Prostate Biopsy in Chilean Men with Suspicion of Prostate Cancer.

    Science.gov (United States)

    Murray, Nigel P; Reyes, Eduardo; Fuentealba, Cynthia; Orellana, Nelson; Morales, Francisca; Jacob, Omar

    2015-01-01

    Combining risk factors for prostate cancer into a predictive tool may improve the detection of prostate cancer while decreasing the number of benign biopsies. We compare one such tool, age multiplied by prostate volume divided by total serum PSA (PSA-AV) with PSA density and detection of primary malignant circulating prostate cells (CPCs) in a Chilean prostate cancer screening program. The objectives were not only to determine the predictive values of each, but to determine the number of clinically significant cancers that would have been detected or missed. A prospective study was conducted of all men undergoing 12 core ultrasound guided prostate biopsy for suspicion of cancer attending the Hospital DIPRECA and Hospital de Carabineros de Chile. Total serum PSA was registered, prostate volumecalculated at the moment of biopsy, and an 8 ml blood simple taken immediately before the biopsy procedure. Mononuclear cells were obtained from the blood simple using differential gel centrifugation and CPCs identified using immunocytchemistry with anti- PSA and anti-P504S. Biopsy results were classed as positive or negative for cancer and if positive the Gleason score, number of positive cores and percent infiltration recorded. A total of 664 men participated, of whom 234 (35.2%) had cancer detected. They were older, had higher mean PSA, PSA density and lower PSA-AV. Detection of CPCs had high predictive score, sensitivity, sensibility and positive and negative predictive values, PSA-AV was not significantly different from PSA density in this population. The use of CPC detection avoided more biopsies and missed fewer significant cancers. In this screening population the use of CPC detection predicted the presence of clinically significant prostate cancer better than the other parameters. The high negative predictive value would allow men CPC negative to avoid biopsy but remain in follow up. The formula PSA-AV did not add to the predictive performance using PSA density.

  6. Babesiosis PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-04-25

    This 60 second PSA describes babesiosis, a preventable and treatable tickborne disease, including the signs and symptoms of infection and ways to prevent it.  Created: 4/25/2012 by Center for Global Health, Division of Parasitic Diseases and Malaria.   Date Released: 4/26/2012.

  7. Binge Drinking PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2010-10-05

    This PSA is based on the October, 2010 CDC Vital Signs report which indicates that drinking too much, including binge drinking, causes more than 79,000 deaths in the U.S. each year and is the third leading preventable cause of death.  Created: 10/5/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 10/5/2010.

  8. Whooping Cough PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2015-01-22

    This 30 second PSA encourages pregnant women to get the whooping cough vaccine, called Tdap, during the third trimester of each pregnancy in order to pass antibodies to their babies so they are born with protection against this serious disease.  Created: 1/22/2015 by National Center for Immunization and Respiratory Diseases (NCIRD), Division of Bacterial Diseases (DBD), Meningitis and Vaccine Preventable Diseases Branch (MVPDB).   Date Released: 1/22/2015.

  9. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.

    Science.gov (United States)

    Ciezki, Jay P; Reddy, Chandana A; Garcia, Jorge; Angermeier, Kenneth; Ulchaker, James; Mahadevan, Arul; Chehade, Nabil; Altman, Andrew; Klein, Eric A

    2006-02-01

    To analyze prostate-specific antigen (PSA) kinetics in patients treated with prostate brachytherapy (PI) with a minimum of 5 years of PSA follow-up. The records of 162 patients treated with PI for localized prostate cancer with a minimum of 5 years of PSA follow-up were reviewed. A variety of pretreatment and posttreatment variables were examined. Patients were coded as having a PSA bounce if their PSA achieved a nadir, elevated at least 0.2 ng/mL greater than that nadir, and decreased to, or below, the initial nadir. Two definitions of biochemical failure (bF) or biochemical relapse-free survival (bRFS) were used: the classic American Society for Therapeutic Radiology and Oncology consensus definition of three consecutive rises (bF3) and the nadir plus 2 ng/mL definition (bFn+2). Associations between a PSA bounce and the various pre- and posttreatment factors were assessed with logistic regression analysis, and the association between a PSA bounce and bF was examined with the log-rank test. The Mann-Whitney U test was applied to test for differences in the PSA doubling time (PSADT) and the time to a PSA rise between the PSA bounce patients and the bF patients. PSADT was calculated from the nadir to the time of the first PSA rise, because this point is known first in the clinical setting. The 5-year overall bRFS rate was 87% for the bF3 definition and 96% for the bFn+2 definition. A PSA bounce was experienced by 75 patients (46.3%). Patients who experienced a PSA bounce were less likely to have a bF, regardless of the bRFS definition used (bF3: p=0.0015; bFn+2: p=0.0040). Among the pre- and posttreatment factors, only younger age predicted for a PSA bounce on multivariate analysis (p=0.0018). The use of androgen deprivation had no effect on PSA bounce. No difference was found in the PSADT between patients who had a PSA bounce and those with bF. The median PSADT for those with a PSA bounce was 8.3 months vs. 10.3 months using the bF3 definition and 8.8 months using

  10. Serum total PSA and free PSA in breast tumors

    OpenAIRE

    Dash, Prakruti; Pati, Sanghamitra; Mangaraj, Manaswini; Sahu, Pratima Kumari; Mohapatra, Prakash Chandra

    2011-01-01

    Now a days measurement of molecular forms of PSA has gained importance in clinical practice. Several studies have demonstrated the production of PSA in female tissues, such as breast. The present piece of work has been undertaken with an objective to estimate the relative proportion of the molecular forms of PSA in serum along with serum testosterone in benign and malignant breast tumor cases and to analyze their association with the severity of the disease process 34 malignant and 26 benign ...

  11. [Retrospective evaluation of PSA density for selection of biopsy candidates with prostate specific antigen in the gray zone].

    Science.gov (United States)

    Tochigi, T; Kawamura, S; Numahata, K; Tokuyama, S; Kuwahara, M; Horaguchi, T; Satou, S

    2001-09-01

    We examined the usefulness of prostate specific antigen density (PSAD) for selection of biopsy candidate with prostate specific antigen levels between 4.1 and 10.0 ng./ml. in prostate cancer screening retrospectively. The screening was conducted on male candidates in Natori city, aged 55 years or older, for 6 years from 1994 through 1999. We could analyze serum PSA levels and PSA density in 118 men with PSA levels between 4.1 and 10.0 ng./ml. All of 118 men underwent ultrasound guided systematic prostate biopsy regardless of findings of digital rectal examination and transrectal ultrasound. Prostate volume was estimated by transrectal ultrasound measurements using the prolate ellipse formula (pi/6 x length x width x height). PSAD was calculated by dividing serum PSA level by prostate volume. Serum PSA levels were determined by Tandem-R assay. In 118 men, twenty-five men had prostate cancer. There was no significant difference in mean PSA between those with prostate cancer and those without prostate cancer, but the difference was significant in the mean PSA density (mean 0.26 and 0.16, respectively, p PSA and PSAD demonstrated superior benefit for PSAD in 118 men. A sensitivity, a specificity, a positive predictive value and a negative predictive value of PSAD cut-off of 0.15 were 88%, 52.7%, 33.3% and 94.2%. PSAD cut-off of 0.18 showed the highest sum of sensitivity and specificity, which gave a sensitivity of 80%, a specificity of 72%, a positive predictive value of 43.5% and a negative predictive value of 93.1%. PSAD cut-off of 0.15 would seem to be preferable to cut-off of 0.18 because of less cancer missing. Although further studies are needed to determine optimal cut-off value to be used in clinical practice, PASD seems to be useful for the selection of biopsy candidates with PSA levels of 4.1 to 10.0 ng./ml. in the prostate cancer screening.

  12. Serum total PSA and free PSA in breast tumors.

    Science.gov (United States)

    Dash, Prakruti; Pati, Sanghamitra; Mangaraj, Manaswini; Sahu, Pratima Kumari; Mohapatra, Prakash Chandra

    2011-04-01

    Now a days measurement of molecular forms of PSA has gained importance in clinical practice. Several studies have demonstrated the production of PSA in female tissues, such as breast. The present piece of work has been undertaken with an objective to estimate the relative proportion of the molecular forms of PSA in serum along with serum testosterone in benign and malignant breast tumor cases and to analyze their association with the severity of the disease process 34 malignant and 26 benign breast disease cases along with 33 healthy controls of same age group were enrolled in this study for evaluation. Serum testosterone was measured by ELISA, whereas serum total PSA (TPSA) and free PSA (FPSA) were estimated by electrochemiluminescence immunoassay. A significant rise of fasting plasma glucose along with prominent dyslipidemia was observed in breast tumor cases. Marked rise in serum testosterone as well as TPSA and FPSA was documented in both benign and malignant breast tumor cases. Serum testosterone revealed a significant positive association with both TPSA and FPSA pointing towards an etiological association between them. However, surgical removal of tumor mass resulted in a marked decline of presurgical value of both TPSA and FPSA with a non-significant fall in serum testosterone revealing tumor tissue as the source of FPSA and TPSA. Thus, estimation of PSA provides prognostic information that may assist in future treatment.

  13. Effectiveness diagnostic of prostate specific antigen (P.S.A.) radioimmunoassay and the P.S.A. density to assess prostatic state of Ivorian patients; Efficacite diagnostique du dosage radio-isotopique et de la densite de l'antigene specifique de la prostate (P.S.A.) dans le bilan prostatique des sujets ivoiriens

    Energy Technology Data Exchange (ETDEWEB)

    Aboukoua-Kouassi, N.; Kouame-Koutouan, A.; Zunon-Kipre, E.; Achy, O.B.; Ndrin, N.K. [Cocody Univ., UFR sciences Medicales (SMA), Service de Biophysique et Medecine Nucleaire, Abidjan (Cote d' Ivoire); Achy, O.B.; Gnagne, Y.M. [Cocody Univ., Service d' Urologie, UFR/SMA, Abidjan (Cote d' Ivoire)

    2009-10-15

    By this first assay realized during two years, the authors wanted to assess the diagnostic performances of radioimmunoassay P.S.A., still unknown by Ivorian prescribers. It was about 78 patients who presented prostatic affections confirmed by histology. The dosages showed that, in prostate adenoma, a P.S.A. level was 9.5 ng/ml with P.S.A. density (P.S.A.D.) at 0.3. In prostate cancer, a P.S.A. level at 64.9 ng/ml with P.S.A.D. at 1.68. P.S.A. sensibility was good (91%) in spite of the value used, its specificity was about 94% for a level of 20 ng/ml. The predictive positive value was excellent with 20 ng/ml (95%). The risk to have prostate cancer with P.S.A. level of 10 ng/ml was 73.8% when rectal route (R.R.) was abnormal. The risk was low to 14.28% when the R.R. was normal. The radioimmunoassay of P.S.A. and P.S.A.D. rate improved significantly diagnostic indications in prostatic affections. Consequently, it must form part of first-line examination to the health assessment of old patients for a better prostatic lesions management. (authors)

  14. The effect on the sensitivities of PSA and PSA-age volume score of ...

    African Journals Online (AJOL)

    Objective: The PSA-age volume (PSA-AV) score was calculated by multiplying the age and prostate volume and then dividing the total by the prebiopsy PSA level. The aim of this study was to evaluate the effect on the sensitivities of PSA and PSA-AV score of International Prostate Symptom Score (I-PSS) and nocturia in ...

  15. [Fast test serum PSA determination (Sd Bioline PSA)].

    Science.gov (United States)

    Torrijos, Francisco Serrano de la Cruz; Alcina, Emilio López; Escudero, Joaquín Ulises Juan; Deltoro, Milagros Fabuel; García, Ana Montoliu; Romaguera, Arcadio Real; de Campos, Macarena Ramos; Vidal, Emilio Marqués

    2008-01-01

    Over the last years numerous semiquantitative PSA tests have appeared, based on serum or plasma immunochromatography. We present our experience using the SD BIOLINE PSA test, which is performed with plasma or serum for fast qualitative determination of PSA; the cutpoint is 3 ng/ml. We analized 54 patients who were admitted in our hospital ward. Two blood samples were obtained from every patient, one for cuantitative PSA determination at the hospital laboratory and the other one for qualitative determination with the SD BIOLINE PSA test, and the results were compared.. Two urologists independently interpreted the test without knowing the PSA values from the lab. To calculate the effect of test reading time, readings were performed at 15, 20 and 25 minutes. Results were classified in a classic contingency table, which enabled us to calculate sensitivity and specificity of the test, as well as positive and negative predictive values. Mean age was 71. 1 years (range 43-96 yr). From 54 patients in the study 26 (48. 14%) had a PSA > 3 ng/ml (Mean 18.5 ng/ml, range 3.9-66.9 ng/ml) and 28 (51.86%) PSA < 3 ng/ml (mean 0.8 ng/mL, range 0-2.9 ng/mL), in the conventional test. Results for each interval and observer were: 15 min: Observer 1: Sensitivity (S) 76,92%, specificity (E) 100%, positive predictive value (PPV) 100%, negative predictive value (NPV) 82.35%; Observer 2: S 76.92%, E 100%, PPV 100%, NPV 82.35%. 20 minutes: Observer 1: S 100%, E 93.33%, PPV 92.30%, NPV 100%; Observer 2: S 100%, E 93.33%, PPV 92.30%, NPV 100%. 25 minutes: Observer 1: S 100%, E 85.71%, PPV 86.66%, NPV 100%; Observer 2: S 92.30%, E 92.85%, PPV 92.30%, NPV 92.85%. The SD Bioline PSA test complies with the characteristics required to be used as a test for prostate cancer detection, it is simple, fast, cheap, not much invasive, and has a good efficacy.

  16. Prostate-Specific Antigen (PSA) Test

    Science.gov (United States)

    ... Genetics of Prostate Cancer Prostate Cancer Screening Research Prostate-Specific Antigen (PSA) Test On This Page What ... the PSA test for prostate cancer screening? Detecting prostate cancer early may not reduce the chance of ...

  17. Hepatitis Awareness Month PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2011-05-11

    May is National Hepatitis Awareness Month. This 30 second PSA discusses hepatitis and encourages listners to talk to their health care professional about getting tested.  Created: 5/11/2011 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.   Date Released: 5/11/2011.

  18. World AIDS Day PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2011-11-16

    December 1 is World AIDS Day. In this PSA, communities are encouraged to get tested for HIV.  Created: 11/16/2011 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).   Date Released: 11/16/2011.

  19. Raccoon Roundworm Infection PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-08-27

    This 60 second PSA describes the signs and symptoms of and ways to prevent Baylisascaris infection, a parasitic roundworm infection that is spread through raccoon feces.  Created: 8/27/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 8/28/2012.

  20. Development of a PSA information management system

    Energy Technology Data Exchange (ETDEWEB)

    Ho, Seok; Dong Kyu, Kim; Sun Koo, Kang [Korea Power Engineering Company, Inc (Korea, Republic of)

    2007-07-01

    In general, Probabilistic Safety Agreement (PSA) is a very complicated work that uses and generates a lot of resources such as reports, procedures, drawings, assumptions, calculation sheets, PSA model, and so on. In many PSAs, however, the data, materials and knowledge considered and generated during performing PSA are scattered in many documents so that overall structure of PSA and information relationship between documents and models cannot easily be understood. To organize and manage all documents related to PSA, to capture knowledge of analysts, and finally to improve the quality of PSA, a PSA information management system (PIMS) was developed. The PIMS can manage all the documents of a PSA in a database and connect the causal relation between one information to another in the scattered documents via link. The PIMS can manage all the assumptions and technical basis used in PSA, and it can keep the record of the design changes the revision of PSA model. It can also control the review results of PSA models. The link of the PIMS can explicitly describe and reveal the expertise of the PSA analysts, and it enables the users to capture the knowledge and to understand the structure and contents of a PSA with ease. We are planning to apply the PIMS to the PSA of Shin Kori Units 1 and 2 as feasibility study and then to all the PSAs of the nuclear power plants in Korea. The PIMS is expected to contribute to enhancing the quality and confidence of PSA and reducing the efforts and costs of maintenance and update of PSA. (authors)

  1. Time to Nadir PSA: Of Popes and PSA--The Immortality Bias.

    Science.gov (United States)

    Johnson, Skyler B; Jackson, William C; Murgic, Jure; Feng, Felix Y; Hamstra, Daniel A

    2015-10-01

    The objective of the study was to investigate prostate-specific antigen (PSA) nadir (nPSA) and time to nPSA (TnPSA) as prognostic variables for outcomes after definitive high-dose (>75 Gy) external beam radiation therapy (RT) without androgen deprivation therapy while correcting for immortal-time bias. nPSA and TnPSA were available for 410 patients. nPSA and TnPSA's impact on freedom from biochemical failure, freedom from metastasis, and prostate cancer-specific survival was assessed on univariate and multivariate analysis using Kaplan-Meier and Cox proportional hazards regression. Outcomes were also evaluated relative to the time since achieving nPSA and not relative to the time of RT, given the intrinsic time bias in TnPSA. Median nPSA was 0.7 ng/mL (interquartile range: 0.4 to 1.1), with a median TnPSA of 25.0 months (IQR: 15.0 to 40.0). On univariate analysis both nPSA and TnPSA were predictive of all endpoints: freedom from biochemical failure, freedom from metastasis, and prostate cancer-specific survival, as categorical (all Pimmortal-time bias the benefit of long TnPSA was mostly lost. On Cox proportional hazards, a TnPSA12 months from the time of RT the TnPSA was no longer prognostic. For dose-escalated RT a lower nPSA is prognostic, but the benefit of a long TnPSA is largely an immortal-time bias and that a longer TnPSA is not in and of itself a significant favorable factor except as compared with those with the shortest TnPSA of <12 months.

  2. Too Much Sodium PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-02-07

    This 60 second PSA is based on the February 2012 CDC Vital Signs report. Ninety percent of Americans age two and older eat too much sodium which can increase your risk for high blood pressure and often leads to heart disease and stroke, two leading causes of death in the US. Learn several small steps you can take to reduce the amount of sodium in your diet.  Created: 2/7/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 2/7/2012.

  3. Serum Prostate-Specific Antigen (PSA) Concentration, PSA Mass, and Obesity: A Mathematical Analysis.

    Science.gov (United States)

    Vollmer, Robin T

    2018-02-17

    To provide a mathematical background for understanding the phenomenon of analyte hemodilution using a kinetic analysis. The first assumption for this analysis is that change in concentration of any analyte, such as prostate-specific antigen (PSA), is due to the flux of the analyte from an organ into the blood minus its flux from the blood. What results is a relatively simple differential equation that emphasizes the importance of plasma volume, organ mass, and two rate constants. The analyses demonstrate how serum PSA can be affected by plasma volume as well as body mass and how hemodilution due to obesity can be at least partly corrected for by expressing PSA in units of total mass or total mass density. At a time when obesity is prevalent, expressing analytes in units of total mass may make them relate more closely to disease status and prognosis.

  4. Prostate-specific antigen (PSA) blood test

    Science.gov (United States)

    ... look at your PSA result and consider your age, ethnicity, medicines you are taking, and other things to ... things when deciding on the next step: Your age If you had a PSA test ... such as ethnicity and family history Men at high risk may ...

  5. Decision criteria in PSA applications

    Energy Technology Data Exchange (ETDEWEB)

    Holmberg, J.E.; Pulkkinen, U.; Rosqvist, T.; Simola, K. [VTT Automation (Finland)

    2001-11-01

    Along with the adoption of risk informed decision making principles, the need for formal probabilistic decision rule or criteria has been risen. However, there are many practical and theoretical problems in the application of probabilistic criteria. One has to think what is the proper way to apply probabilistic rules together with deterministic ones and how the criteria are weighted with respect to each other. In this report, we approach the above questions from the decision theoretic point of view. We give a short review of the most well known probabilistic criteria, and discuss examples of their use. We present a decision analytic framework for evaluating the criteria, and we analyse how the different criteria behave under incompleteness or uncertainty of the PSA model. As the conclusion of our analysis we give recommendations on the application of the criteria in different decision situations. (au)

  6. Decreased fucosylated PSA as a urinary marker for high Gleason score prostate cancer.

    Science.gov (United States)

    Fujita, Kazutoshi; Hayashi, Takuji; Matsuzaki, Kyosuke; Nakata, Wataru; Masuda, Mika; Kawashima, Atsunari; Ujike, Takeshi; Nagahara, Akira; Tsuchiya, Mutsumi; Kobayashi, Yuka; Nojima, Satoshi; Uemura, Motohide; Morii, Eiichi; Miyoshi, Eiji; Nonomura, Norio

    2016-08-30

    Fucosylation is an important oligosaccharide modification associated with cancer and inflammation. We investigated whether urinary fucosylated PSA (Fuc-PSA) levels could be used for the detection of high Gleason score prostate cancer. Urine samples were collected from men with abnormal digital rectal examination findings or elevated serum PSA levels, before prostate biopsy. Lectin-antibody ELISA was used to quantify the Lewis-type or core-type fucosylated PSA (PSA-AAL) and core-type fucosylated PSA (PSA-PhoSL) in the urine samples. Both types of urinary Fuc-PSA were significantly decreased in the men with prostate cancer compared with the men whose biopsies were negative for cancer (P = 0.026 and P Gleason scores of the biopsy specimens (P = 0.001 and P Gleason score prostate cancer. The area under the receiver-operator characteristic curve (AUC) value for the prediction of cancers of Gleason score ≥ 7 was 0.69 for urinary PSA-AAL and 0.72 for urinary PSA-PhoSL. In contrast, the AUC value was 0.59 for serum PSA, 0.63 for PSA density, and 0.58 for urinary PSA. In conclusion, a decreased urinary Fuc-PSA level is a potential marker for the detection of high Gleason score prostate cancer.

  7. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer

    NARCIS (Netherlands)

    Rybalov, Maxim; Breeuwsma, Anthonius J.; Leliveld, Anna M.; Pruim, Jan; Dierckx, Rudi A.; de Jong, Igle J.

    PURPOSE: To evaluate the effect of total PSA (tPSA) and PSA kinetics on the detection rates of (11)C-Choline PET in patients with biochemical recurrence (BCR) after radical prostatectomy (RP) or external beam radiotherapy (EBRT). METHODS: We included 185 patients with BCR after RP (PSA >0.2 ng/ml)

  8. Multiparametric MRI in the PSA Screening Era

    Directory of Open Access Journals (Sweden)

    Arvin K. George

    2014-01-01

    Full Text Available Prostate cancer remains significant public health concern amid growing controversies regarding prostate specific antigen (PSA based screening. The utility of PSA has been brought into question, and alternative measures are investigated to remedy the overdetection of indolent disease and safeguard patients from the potential harms resulting from an elevated PSA. Multiparametric MRI of the prostate has shown promise in identifying patients at risk for clinically significant disease but its role within the current diagnostic and treatment paradigm remains in question. The current review focuses on recent applications of MRI in this pathway.

  9. The ESA Planetary Science Archive User Group (PSA-UG)

    Science.gov (United States)

    Pio Rossi, Angelo; Cecconi, Baptiste; Fraenz, Markus; Hagermann, Axel; Heather, David; Rosenblatt, Pascal; Svedhem, Hakan; Widemann, Thomas

    2014-05-01

    ESA has established a Planetary Science Archive User Group (PSA-UG), with the task of offering independent advice to ESA's Planetary Science Archive (e.g. Heather et al., 2013). The PSA-UG is an official and independent body that continuously evaluates services and tools provided by the PSA to the community of planetary data scientific users. The group has been tasked with the following top level objectives: a) Advise ESA on future development of the PSA. b) Act as a focus for the interests of the scientific community. c) Act as an advocate for the PSA. d) Monitor the PSA activities. Based on this, the PSA-UG will report through the official ESA channels. Disciplines and subjects represented by PSA-UG members include: Remote Sensing of both Atmosphere and Solid Surfaces, Magnetospheres, Plasmas, Radio Science and Auxilliary data. The composition of the group covers ESA missions populating the PSA both now and in the near future. The first members of the PSA-UG were selected in 2013 and will serve for 3 years, until 2016. The PSA-UG will address the community through workshops, conferences and the internet. Written recommendations will be made to the PSA coordinator, and an annual report on PSA and the PSA-UG activities will be sent to the Solar System Exploration Working Group (SSEWG). Any member of the community and planetary data user can get in touch with individual members of the PSA-UG or with the group as a whole via the contacts provided on the official PSA-UG web-page: http://archives.esac.esa.int/psa/psa-ug. The PSA is accessible via: http://archives.esac.esa.int/psa References: Heather, D., Barthelemy, M., Manaud, N., Martinez, S., Szumlas, M., Vazquez, J. L., Osuna, P. and the PSA Development Team (2013) ESA's Planetary Science Archive: Status, Activities and Plans. EuroPlanet Sci. Congr. #EPSC2013-626

  10. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.

    Science.gov (United States)

    Corcoran, Niall M; Casey, Rowan G; Hong, Matthew K H; Pedersen, John; Connolly, Stephen; Peters, Justin; Harewood, Laurence; Gleave, Martin E; Costello, Anthony J; Hovens, Chris M; Goldenberg, S Larry

    2012-07-01

    Study Type - Diagnostic (exploratory cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Due to sampling error, the Gleason score of clinically localized prostate cancer is frequently underestimated at the time of initial biopsy. Given that this may lead to inappropriate surveillance of patients with high-risk disease, there is considerable interest in identifying predictors of significant undergrading. Recently PSAD has been proposed to be an accurate predictor of subsequent upgrading in patients diagnosed with Gleason 6 disease on biopsy. We examined the predictive characteristics of PSAD in patients with low- and intermediate-risk disease on biopsy subsequently treated with radical prostatectomy. We found that although PSAD was a significant predictor of upgrade of biopsy Gleason 6 and 3 + 4 = 7 tumours, it failed to predict upgrading in patients with Gleason 7 tumours taken as a whole. When we explored reasons for this discrepancy, we found that the amount of PSA produced per unit tumour volume decreased with increasing Gleason score, thereby diminishing the predictive value of PSAD. To analyse the performance of PSA density (PSAD) as a predictor of Gleason score upgrade in a large cohort stratified by Gleason score. We and others have shown that an upgrade in Gleason score between initial prostate biopsy and final radical prostatectomy (RP) pathology is a significant risk factor for recurrence after local therapy. Patients undergoing RP with matching biopsy information were identified from two prospective databases. Patients were analysed according to the concordance between biopsy and final pathology Gleason score in three paired groups: 6/>6, 3 + 4/>3 + 4, 7/>7. Receiver-operating characteristic (ROC) curves were generated stratified by Gleason score, and the area under the curve (AUC) calculated. Logistic regression models were fitted to identify significant predictors of tumour upgrade. From 1516 patients, 435 (29%) had

  11. A Multi-Center Study of [−2]Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range

    Science.gov (United States)

    Catalona, William J.; Partin, Alan W.; Sanda, Martin G.; Wei, John T.; Klee, George G.; Bangma, Chris H.; Slawin, Kevin M.; Marks, Leonard S.; Loeb, Stacy; Broyles, Dennis L.; Shin, Sanghyuk S.; Cruz, Amabelle B.; Chan, Daniel W.; Sokoll, Lori J.; Roberts, William L.; van Schaik, Ron H.N.; Mizrahi, Isaac A.

    2011-01-01

    Purpose PSA and free PSA (fPSA) have limited specificity for detecting clinically significant, curable prostate cancer (PCa), leading to unnecessary biopsies and detection and treatment of some indolent tumors. [−2]proPSA (p2PSA) may improve specificity for detecting clinically significant PCa. Our objective was to evaluate p2PSA, fPSA, and PSA in a mathematical formula (prostate health index [phi] = [−2]proPSA / fPSA) × PSA1/2) to enhance specificity for detecting overall and high-grade PCa. Materials and Methods We enrolled 892 men in a prospective multi-institutional trial with no history of PCa, normal rectal examination, a PSA of 2–10 ng/mL, and ≥6- core prostate biopsy. We examined the relationship of serum PSA, %fPSA and phi with biopsy results. The primary endpoints were the specificity and AUC using phi to detect overall and Gleason ≥7 prostate cancer on biopsy compared with %fPSA. Results For the 2–10 ng/mL PSA range, at 80–95% sensitivity, the specificity and AUC (0.703) of phi exceeded those of PSA and %fPSA. Increasing phi was associated with a 4.7-fold increased risk of PCa and 1.61-fold increased risk of Gleason ≥7 disease on biopsy. The AUC for phi (0.724) exceeded that of %fPSA (0.670) in discriminating between PCa with Gleason ≥ 4+3 vs. lower grade disease or negative biopsies. Phi results were not associated with age and prostate volume. Conclusions Phi may be useful in PCa screening to reduce unnecessary biopsies in men age ≥50 years with PSA 2–10 ng/mL and negative DRE, with minimal loss in sensitivity. PMID:21419439

  12. the discriminative ability of percent free psa in patients with psa > 10 ...

    African Journals Online (AJOL)

    pathology revealed by sextant biopsy under transrectal ultrasound (TRUS) guidance using a 7.5 MHz probe (Panther®, B & K, Denmark). Indications for biopsy were: a PSA > 4 ng/ ml, a suspicious prostatic nodule on digital rectal examination (DRE) and a hypoechoic area on. TRUS. Total and free PSA were assessed us-.

  13. The effect on the sensitivities of PSA and PSA-age volume score of ...

    African Journals Online (AJOL)

    O. Üçer

    2017-04-27

    Apr 27, 2017 ... Conclusions: All our data shows that if we remove most of the factors which effect PSA such as age, prostate volume, prostatitis and BPH, we may increase the sensitivity of PSA for predicting positive prostate biopsy. ... Peer review under responsibility of Pan African Urological Surgeons' Association.

  14. The age-specific reference intervals for tPSA, fPSA, and %fPSA in healthy Han ethnic male.

    Science.gov (United States)

    Yang, Jingjing; Tang, Aiguo; Zhang, Shijie; Sun, Xiaoxu; Ming, Liang

    2017-07-01

    Prostate cancer (PC) is one of the most common malignancies in male, and has become the fastest growing malignancy in recent years. Prostate specific antigen (PSA) is widely used as a tumor marker to screen for PC. Many studies have been performed to define the reference intervals (RIs) for total circulating PSA (tPSA). The results were different among different nations and races, even in the same race. Few researches have been performed on the RIs of free PSA (fPSA) and the ratio of free to total PSA (%fPSA). In this study, we aimed to simultaneously determine the age-specific RIs for tPSA, fPSA, and %fPSA in the healthy Han ethnic male. A total of 1862 apparently healthy male aged from 21 to 94 years were included in our study. Nonparametric 95th percentile intervals were used to define the RIs. The reference limits in different age groups (21-50, 51-60, 61-70, 71-80, and ≥81 years) were 2.07, 3.59, 4.93, 6.83, and 7.73 ng/mL for tPSA, and 0.60, 0.76, 0.83, 1.30, and 2.41 ng/mL for fPSA. The RIs of %fPSA were ≥0.16 for 21-50 years and ≥0.13 for male over 50 years old. We established age-specific RIs for tPSA, fPSA and %fPSA. The newly established RIs should be more suitable for Chinese Han ethnic male. It will be valuable for physicians to make exact medical decision and appropriate medical intervention. © 2016 Wiley Periodicals, Inc.

  15. Insulin promotes cell migration by regulating PSA-NCAM

    Energy Technology Data Exchange (ETDEWEB)

    Monzo, Hector J.; Coppieters, Natacha [Centre for Brain Research, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag, 92019, Auckland (New Zealand); Department of Anatomy and Medical Imaging, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag, 92019, Auckland (New Zealand); Park, Thomas I.H. [Centre for Brain Research, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag, 92019, Auckland (New Zealand); Department of Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag, 92019, Auckland (New Zealand); Dieriks, Birger V.; Faull, Richard L.M. [Centre for Brain Research, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag, 92019, Auckland (New Zealand); Department of Anatomy and Medical Imaging, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag, 92019, Auckland (New Zealand); Dragunow, Mike [Centre for Brain Research, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag, 92019, Auckland (New Zealand); Department of Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag, 92019, Auckland (New Zealand); Curtis, Maurice A., E-mail: m.curtis@auckland.ac.nz [Centre for Brain Research, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag, 92019, Auckland (New Zealand); Department of Anatomy and Medical Imaging, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag, 92019, Auckland (New Zealand)

    2017-06-01

    Cellular interactions with the extracellular environment are modulated by cell surface polysialic acid (PSA) carried by the neural cell adhesion molecule (NCAM). PSA-NCAM is involved in cellular processes such as differentiation, plasticity, and migration, and is elevated in Alzheimer's disease as well as in metastatic tumour cells. Our previous work demonstrated that insulin enhances the abundance of cell surface PSA by inhibiting PSA-NCAM endocytosis. In the present study we have identified a mechanism for insulin-dependent inhibition of PSA-NCAM turnover affecting cell migration. Insulin enhanced the phosphorylation of the focal adhesion kinase leading to dissociation of αv-integrin/PSA-NCAM clusters, and promoted cell migration. Our results show that αv-integrin plays a key role in the PSA-NCAM turnover process. αv-integrin knockdown stopped PSA-NCAM from being endocytosed, and αv-integrin/PSA-NCAM clusters co-labelled intracellularly with Rab5, altogether indicating a role for αv-integrin as a carrier for PSA-NCAM during internalisation. Furthermore, inhibition of p-FAK caused dissociation of αv-integrin/PSA-NCAM clusters and counteracted the insulin-induced accumulation of PSA at the cell surface and cell migration was impaired. Our data reveal a functional association between the insulin/p-FAK-dependent regulation of PSA-NCAM turnover and cell migration through the extracellular matrix. Most importantly, they identify a novel mechanism for insulin-stimulated cell migration. - Highlights: • Insulin modulates PSA-NCAM turnover through upregulation of p-FAK. • P-FAK modulates αv-integrin/PSA-NCAM clustering. • αv-integrin acts as a carrier for PSA-NCAM endocytosis. • Cell migration is promoted by cell surface PSA. • Insulin promotes PSA-dependent migration in vitro.

  16. Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.

    Science.gov (United States)

    Brizmohun Appayya, Mrishta; Sidhu, Harbir S; Dikaios, Nikolaos; Johnston, Edward W; Simmons, Lucy Am; Freeman, Alex; Kirkham, Alexander Ps; Ahmed, Hashim U; Punwani, Shonit

    2018-02-01

    To determine whether indeterminate (Likert-score 3/5) peripheral zone (PZ) multiparametric MRI (mpMRI) studies are classifiable by prostate-specific antigen (PSA), PSA density (PSAD), Prostate Imaging Reporting And Data System version 2 (PI-RADS_v2) rescoring and morphological MRI features. Men with maximum Likert-score 3/5 within their PZ were retrospectively selected from 330 patients who prospectively underwent prostate mpMRI (3 T) without an endorectal coil, followed by 20-zone transperineal template prostate mapping biopsies +/- focal lesion-targeted biopsy. PSAD was calculated using pre-biopsy PSA and MRI-derived volume. Two readers A and B independently assessed included men with both Likert-assessment and PI-RADS_v2. Both readers then classified mpMRI morphological features in consensus. Men were divided into two groups: significant cancer (≥ Gleason 3 + 4) or insignificant cancer (≤ Gleason 3 + 3)/no cancer. Comparisons between groups were made separately for PSA & PSAD using Mann-Whitney test and morphological descriptors with Fisher's exact test. PI-RADS_v2 and Likert-assessment were descriptively compared and percentage inter-reader agreement calculated. 76 males were eligible for PSA & PSAD analyses, 71 for PI-RADS scoring, and 67 for morphological assessment (excluding significant image artefacts). Unlike PSA (p = 0.915), PSAD was statistically different (p = 0.004) between the significant [median: 0.19 ng ml - 2 (interquartile range: 0.13-0.29)] and non-significant/no cancer [median: 0.13 ng ml - 2 (interquartile range: 0.10-0.17)] groups. Presence of mpMRI morphological features was not significantly different between groups. Subjective Likert-assessment discriminated patients with significant cancer better than PI-RADS_v2. Inter-reader percentage agreement was 83% for subjective Likert-assessment and 56% for PI-RADS_v2. PSAD may categorize presence of significant cancer in patients with Likert-scored 3/5 PZ mpMRI findings. Advances in

  17. Seminal plasma PSA in spinal cord injured men

    DEFF Research Database (Denmark)

    Brasso, K; Sønksen, J; Sommer, P

    1998-01-01

    The aim of the study was to evaluate the impact of spinal cord injury on seminal plasma PSA concentration.......The aim of the study was to evaluate the impact of spinal cord injury on seminal plasma PSA concentration....

  18. STD Awareness PSA - College 2 (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-04-22

    This PSA, targeted to college-aged youth and young adults, encourages listeners to get tested for STDs.  Created: 4/22/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/22/2010.

  19. STD Awareness PSA - College 1 (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-04-22

    This PSA, targeted to college-aged youth and young adults, encourages listeners to get tested for STDs.  Created: 4/22/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/22/2010.

  20. STD Awareness PSA - Male Announcer 2 (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-04-22

    This PSA encourages listeners to get tested for STDs. Target - Men who have sex with other men.  Created: 4/22/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/22/2010.

  1. Screen for Life: Meryl Streep PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2013-05-16

    In this 30 second PSA, Academy Award®-winning actress Meryl Streep urges viewers to get screened for colorectal cancer.  Created: 5/16/2013 by Centers for Disease Control and Prevention (CDC).   Date Released: 5/16/2013.

  2. Screen for Life: Meryl Streep PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-05-16

    In this 60 second PSA, Academy Award®-winning actress Meryl Streep urges viewers to get screened for colorectal cancer.  Created: 5/16/2013 by Centers for Disease Control and Prevention (CDC).   Date Released: 5/16/2013.

  3. Secundaire analyses organisatiebeleid psychosociale arbeidsbelasting (PSA)

    NARCIS (Netherlands)

    Kraan, K.O.; Houtman, I.L.D.

    2016-01-01

    Hoe het organisatiebeleid rond psychosociale arbeidsbelasting (PSA) eruit ziet anno 2014 en welke samenhang er is met ander beleid en uitkomstmaten, zijn de centrale vragen in dit onderzoek. De resultaten van deze verdiepende analyses kunnen ten goede komen aan de lopende campagne ‘Check je

  4. Interoperability in the Planetary Science Archive (PSA)

    Science.gov (United States)

    Rios Diaz, C.

    2017-09-01

    The protocols and standards currently being supported by the recently released new version of the Planetary Science Archive at this time are the Planetary Data Access Protocol (PDAP), the EuroPlanet- Table Access Protocol (EPN-TAP) and Open Geospatial Consortium (OGC) standards. We explore these protocols in more detail providing scientifically useful examples of their usage within the PSA.

  5. PSA testing anxiety, psychological morbidity, and PSA utility in the management of prostate cancer.

    OpenAIRE

    Micsunescu, Anamaria Elia

    2017-01-01

    Anecdotal reports from urologists and medical oncologists have suggested that patients with prostate cancer (PCa) often present with anxiety related to ongoing monitoring of their PSA levels as part of their disease management. The purpose of the current study, therefore, was to determine the prevalence and severity of prostate specific antigen (PSA) testing anxiety in a population of patients with either localised or metastatic PCa living in Australia. Other aspects of psychological morbidit...

  6. Take Charge. Take the Test. PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2012-03-07

    As part of the Take Charge. Take the Test. campaign, this 30 second PSA encourages African American women to get tested for HIV. Locations for a free HIV test can be found by visiting hivtest.org/takecharge or calling 1-800-CDC-INFO (1-800-232-4636).  Created: 3/7/2012 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).   Date Released: 3/7/2012.

  7. More Adults Are Walking PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-07-31

    This 60 second PSA is based on the August 2012 CDC Vital Signs report. While more adults are walking, only half get the recommended amount of physical activity. Listen to learn how communities, employers, and individuals may help increase walking.  Created: 7/31/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 8/7/2012.

  8. Safer Food Saves Lives PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-11-03

    This 60 second PSA is based on the November 2015 CDC Vital Signs report. Contaminated food sent to several states can cause multistate outbreaks of foodborne illness and make a lot of people seriously ill. Learn what can be done to prevent and stop outbreaks.  Created: 11/3/2015 by National Center for Emerging and Zoonotic Infectious Diseases (NCEZID).   Date Released: 11/3/2015.

  9. Stop C. difficile Infections PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-03-06

    This 60 second PSA is based on the March 2012 CDC Vital Signs report. C. difficile is a germ that causes diarrhea linked to 14,000 deaths in the US each year. This podcast helps health care professionals learn how to prevent C. difficile infections.  Created: 3/6/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 3/6/2012.

  10. Communication Can Save Lives PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-08-04

    This 60 second public service announcement (PSA) is based on the August 2015 CDC Vital Signs report. Antibiotic-resistant germs cause at least 23,000 deaths each year. Learn how public health authorities and health care facilities can work together to save lives.  Created: 8/4/2015 by National Center for Emerging and Zoonotic Infectious Diseases (NCEZID).   Date Released: 8/4/2015.

  11. Experience from the comparison of two PSA-studies

    Energy Technology Data Exchange (ETDEWEB)

    Holmberg, J.; Pulkkinen, U. [VTTAutomation (Finland)

    2001-03-01

    Two probabilistic safety assessments (PSA) made for nearly identical reactors units (Forsmark 3 and Oskarshamn 3) have been compared. Two different analysis teams made the PSAs, and the analyses became quite different. The goal of the study is to identify, clarify and explain differences between PSA-studies. The purpose is to understand limitations and uncertainties in PSA, to explain reasons for differences between PSA-studies, and to give recommendations for comparison of PSA-studies and for improving the PSA-methodology. The reviews have been made by reading PSA-documentation, using the computer model and interviewing persons involved in the projects. The method and findings have been discussed within the project group. Both the PSA-project and various parts in the PSA-model have been reviewed. A major finding was that the two projects had different purpose and thus had different resources, scope and even methods in their study. The study shows that comparison of PSA results from different plants is normally not meaningful. It takes a very deep knowledge of the PSA studies to make a comparison of the results and usually one has to ensure that the compared studies have the same scope and are based on the same analysis methods. Harmonisation of the PSA-methodology is recommended in the presentation of results, presentation of methods, scope main limitation and assumption, and definitions for end states, initiating events and common cause failures. This would facilitate the comparison of the studies. Methods for validation of PSA for different application areas should be developed. The developed PSA review standards can be applied for a general validation of a study. The most important way to evaluate the real feasibility of PSA can take place only with practical applications. The PSA-documentation and models can be developed to facilitate the communication between PSA-experts and users. In any application consultation with the PSA-expert is however needed. Many

  12. Insulin promotes cell migration by regulating PSA-NCAM.

    Science.gov (United States)

    Monzo, Hector J; Coppieters, Natacha; Park, Thomas I H; Dieriks, Birger V; Faull, Richard L M; Dragunow, Mike; Curtis, Maurice A

    2017-06-01

    Cellular interactions with the extracellular environment are modulated by cell surface polysialic acid (PSA) carried by the neural cell adhesion molecule (NCAM). PSA-NCAM is involved in cellular processes such as differentiation, plasticity, and migration, and is elevated in Alzheimer's disease as well as in metastatic tumour cells. Our previous work demonstrated that insulin enhances the abundance of cell surface PSA by inhibiting PSA-NCAM endocytosis. In the present study we have identified a mechanism for insulin-dependent inhibition of PSA-NCAM turnover affecting cell migration. Insulin enhanced the phosphorylation of the focal adhesion kinase leading to dissociation of αv-integrin/PSA-NCAM clusters, and promoted cell migration. Our results show that αv-integrin plays a key role in the PSA-NCAM turnover process. αv-integrin knockdown stopped PSA-NCAM from being endocytosed, and αv-integrin/PSA-NCAM clusters co-labelled intracellularly with Rab5, altogether indicating a role for αv-integrin as a carrier for PSA-NCAM during internalisation. Furthermore, inhibition of p-FAK caused dissociation of αv-integrin/PSA-NCAM clusters and counteracted the insulin-induced accumulation of PSA at the cell surface and cell migration was impaired. Our data reveal a functional association between the insulin/p-FAK-dependent regulation of PSA-NCAM turnover and cell migration through the extracellular matrix. Most importantly, they identify a novel mechanism for insulin-stimulated cell migration. Copyright © 2017 Elsevier Inc. All rights reserved.

  13. Various Applications of Power Spectrum Analysis (PSA)

    Science.gov (United States)

    2017-03-01

    ications: pro ckaging, and ower Spectru kage; Gamma analysis (P in responses d to dynam in the power s gnatures are fo IC. PSA ha rences betwee...on a d op plot in F re (top black connected to a shown in the m voltage is c rtion in the vo Applicat Paiboo Valid Sandia Na Analysis (P tion...tool. We cess monitor changes due m Analysis ; -ray Exposure SA) measures of an integrat ic stimuli. pectrum associ und to be sen s been an ef n

  14. The role of the percentage free PSA in the diagnosis of prostate ...

    African Journals Online (AJOL)

    K.H. Tijani

    2016-12-24

    Dec 24, 2016 ... Blood samples were collected from these selected patients for repeat tPSA and free PSA (fPSA) thereafter, analyzed within 24 h of sample collection. The analytical procedure used for determination of tPSA and fPSA assay was the Hybritech. Paramagnetic Particle Two-Site Immunoenzymatic (“Sandwich”).

  15. PSA and beyond: alternative prostate cancer biomarkers

    Science.gov (United States)

    2016-01-01

    Background The use of biomarkers for prostate cancer screening, diagnosis and prognosis has the potential to improve the clinical management of the patients. Owing to inherent limitations of the biomarker prostate-specific antigen (PSA), intensive efforts are currently directed towards a search for alternative prostate cancer biomarkers, particularly those that can predict disease aggressiveness and drive better treatment decisions. Methods A literature search of Medline articles focused on recent and emerging advances in prostate cancer biomarkers was performed. The most promising biomarkers that have the potential to meet the unmet clinical needs in prostate cancer patient management and/or that are clinically implemented were selected. Conclusions With the advent of advanced genomic and proteomic technologies, we have in recent years seen an enormous spurt in prostate cancer biomarker research with several promising alternative biomarkers being discovered that show an improved sensitivity and specificity over PSA. The new generation of biomarkers can be tested via serum, urine, or tissue-based assays that have either received regulatory approval by the US Food and Drug Administration or are available as Clinical Laboratory Improvement Amendments-based laboratory developed tests. Additional emerging novel biomarkers for prostate cancer, including circulating tumor cells, microRNAs and exosomes, are still in their infancy. Together, these biomarkers provide actionable guidance for prostate cancer risk assessment, and are expected to lead to an era of personalized medicine. PMID:26790878

  16. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.

    Science.gov (United States)

    Washino, Satoshi; Okochi, Tomohisa; Saito, Kimitoshi; Konishi, Tsuzumi; Hirai, Masaru; Kobayashi, Yutaka; Miyagawa, Tomoaki

    2017-02-01

    To assess the value of the Prostate Imaging Reporting and Data System (PI-RADS) scoring system, for prostate multi-parametric magnetic resonance imaging (mpMRI) to detect prostate cancer, and classical parameters, such as prostate-specific antigen (PSA) level, prostate volume and PSA density, for predicting biopsy outcome in biopsy naïve patients who have suspected prostate cancer. Patients who underwent mpMRI at our hospital, and who had their first prostate biopsy between July 2010 and April 2014, were analysed retrospectively. The prostate biopsies were taken transperineally under transrectal ultrasonography guidance. In all, 14 cores were biopsied as a systematic biopsy in all patients. Two cognitive fusion-targeted biopsy cores were added for each lesion in patients who had suspicious or equivocal lesions on mpMRI. The PI-RADS scoring system version 2.0 (PI-RADS v2) was used to describe the MRI findings. Univariate and multivariate analyses were performed to determine significant predictors of prostate cancer and clinically significant prostate cancer. In all, 288 patients were analysed. The median patient age, PSA level, prostate volume and PSA density were 69 years, 7.5 ng/mL, 28.7 mL, and 0.26 ng/mL/mL, respectively. The biopsy results were benign, clinically insignificant, and clinically significant prostate cancer in 129 (45%), 18 (6%) and 141 (49%) patients, respectively. The multivariate analysis revealed that PI-RADS v2 score and PSA density were independent predictors for prostate cancer and clinically significant prostate cancer. When PI-RADS v2 score and PSA density were combined, a PI-RADS v2 score of ≥4 and PSA density ≥0.15 ng/mL/mL, or PI-RADS v2 score of 3 and PSA density of ≥0.30 ng/mL/mL, was associated with the highest clinically significant prostate cancer detection rates (76-97%) on the first biopsy. Of the patients in this group with negative biopsy results, 22% were subsequently diagnosed as prostate cancer. In contrast, a PI

  17. Comparison of mean prostate-specific antigen (PSA) values ...

    African Journals Online (AJOL)

    All subjects were non-obese, had no prostatic symptoms and were not masturbating. Standard technique of specimen collection, processing and analysis of PSA values using Immunoassay technique were applied. The celibate group had a mean PSA value of 2.6±0.2ng/ml, while the sexually-active group had a mean PSA ...

  18. Policy and System Approach (PSA: A primer

    Directory of Open Access Journals (Sweden)

    Chandrakant Lahariya

    2017-01-01

    Full Text Available A number of public health challenges have emerged at global and national level in the last two decades. The response to these challenges has rarely been swift and often “knee-jerk.” The national and state level program officials responsible for the activities often apportion the blame on weak health systems or fragmented health service delivery mechanisms, amongst other. In India, the viral illnesses (including those due to dengue and chikungunya are becoming the increasing realities. The Public health response of early identification, disease surveillance, reporting and the preventive and curative measures, remains suboptimal. The health challenges which require multidimensional interventions are usuallyattempted to be resolved through piece meal solutions. This article proposes “policy and system approach (PSA,” combining concepts of “Health in all policies” for intersectoral coordination and “health system approach” for intra-sectoral tackling of the emerging and existing health challenges.

  19. Daily Pill Can Prevent HIV PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-11-24

    This 60 second public service announcement (PSA) is based on the November 24, 2015 CDC Vital Signs report. Preexposure prophylaxis, or PrEP, is a daily medicine that can be used to prevent getting HIV. PrEP is for people who don’t have HIV but who are at very high risk for getting it from sex or injection drug use. Unfortunately, many people who can benefit from PrEP aren’t taking it.  Created: 11/24/2015 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).   Date Released: 11/24/2015.

  20. Prognostic implications of immediate PSA response to early salvage radiotherapy.

    Science.gov (United States)

    Turner I I, Robert M; Yabes, Jonathan G; Woldemichael, Elen; Deutsch, Melvin M; Smith, Ryan P; Werner, Robert S; Jacobs, Bruce L; Nelson, Joel B

    2016-12-01

    Up to 25% of men with prostate cancer who undergo radical prostatectomy will recur. In this setting, salvage radiotherapy may cure patients with local recurrence, but is unable to cure those with occult metastatic disease. The objective of this study is to examine how prostate-specific antigen (PSA) response to radiotherapy predicts subsequent disease progression and survival. Using a prospectively populated database of 3089 men who underwent open radical prostatectomy, 212 patients (7%) were identified who received early salvage radiotherapy for biochemical recurrence. The main outcome was time to disease progression after salvage radiotherapy. Patients were stratified by PSA response after radiotherapy: 1) PSA radiotherapy at a median PSA of 0.20 ng/mL (IQR 0.10-0.30 ng/mL). At a median follow up of 47.3 months, a total of 52 (25%) patients experienced disease progression. On multivariable analysis, both persistent PSA (HR 5.12; 95% CI 1.98-13.23) and rising PSA (HR 16.55; 95% CI 6.61-41.48) were associated with increased risk of disease progression compared to those with PSA radiotherapy PSA, Gleason score, margin status, stage, and time to radiotherapy. Only rising PSA was associated with an increased risk of cancer-specific and all-cause mortality. PSA response is associated with the risk of disease progression following salvage radiotherapy. This information can be used to counsel patients on the potential need for additional therapy and identify those at greatest risk for progression and cancer-related mortality.

  1. Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy.

    Science.gov (United States)

    Park, Sung Woon; Kim, Chul Sung; Lee, Gilho

    2010-12-01

    Studies of genetic variation in the prostate-specific antigen (PSA) gene have improved the diagnostic accuracy of PSA for diagnosing prostate diseases in Caucasians. However, the reference ranges and pharmacokinetics of PSA differ significantly according to race. Therefore, we evaluated the association between genetic variations in the PSA promoter area and benign prostatic hyperplasia (BPH) phenotypes in Korean BPH patients. One hundred twenty-one men were enrolled. The initial serum PSA level, prostate size, and PSA changes at 3 months after treatment with dutasteride were determined. We amplified the promoter region of the PSA gene (nucleotide positions -158 to -356 and -5217 to -5429) and sequenced the products. Three relatively well characterized single-nucleotide polymorphisms (SNPs; rs3760722, rs266867, and rs266868), six uncharacterized SNPs (rs17554958, rs266882, rs4802754, rs2739448, rs2569733, and rs17526278), and one novel SNP (nucleotide position -5402) were found. There were no statistically significant correlations between any of the SNPs of the PSA promoter area and age-adjusted prostate sizes, initial PSA levels, or PSA variations after 3 months of dutasteride treatment. SNPs in the PSA promoter area were not associated with BPH phenotypes. We could not predict serum PSA changes after dutasteride treatment on the basis of PSA promoter genotype in Korean patients with BPH.

  2. Prostate Cancer Screening: Should You Get a PSA Test?

    Science.gov (United States)

    ... PSA test result turns out to have prostate cancer. Some prostate cancers, particularly those that grow quickly, may not ... and prevention. Cancer.Net. http://www.cancer.net/cancer-types/prostate-cancer/risk-factors-and-prevention. Accessed Aug. 2, ...

  3. PSA Velocity Does Not Improve Prostate Cancer Detection

    Science.gov (United States)

    A rapid increase in prostate-specific antigen (PSA) levels is not grounds for automatically recommending a prostate biopsy, according to a study published online February 24, 2011, in the Journal of the National Cancer Institute.

  4. PSA LEVEL 3 DAN IMPLEMENTASINYA PADA KAJIAN KESELAMATAN PWR

    Directory of Open Access Journals (Sweden)

    Pande Made Udiyani

    2015-03-01

    Full Text Available Kajian keselamatan PLTN menggunakan metodologi kajian probabilistik sangat penting selain kajian deterministik. Metodologi kajian menggunakan Probabilistic Safety Assessment (PSA Level 3 diperlukan terutama untuk estimasi kecelakaan parah atau kecelakaan luar dasar desain PLTN. Metode ini banyak dilakukan setelah kejadian kecelakaan Fukushima. Dalam penelitian ini dilakukan implementasi PSA Level 3 pada kajian keselamatan PWR, postulasi kecelakan luar dasar desain PWR AP-1000 dan disimulasikan di contoh tapak Bangka Barat. Rangkaian perhitungan yang dilakukan adalah: menghitung suku sumber dari kegagalan teras yang terjadi, pemodelan kondisi meteorologi tapak dan lingkungan, pemodelan jalur paparan, analisis dispersi radionuklida dan transportasi fenomena di lingkungan, analisis deposisi radionuklida, analisis dosis radiasi, analisis perlindungan & mitigasi, dan analisis risiko. Kajian menggunakan rangkaian subsistem pada perangkat lunak PC Cosyma. Hasil penelitian membuktikan bahwa implementasi metode kajian keselamatan PSA Level 3 sangat efektif dan komprehensif terhadap estimasi dampak, konsekuensi, risiko, kesiapsiagaan kedaruratan nuklir (nuclear emergency preparedness, dan manajemen kecelakaan reaktor terutama untuk kecelakaan parah atau kecelakaan luar dasar desain PLTN. Hasil kajian dapat digunakan sebagai umpan balik untuk kajian keselamatan PSA Level 1 dan PSA Level 2. Kata kunci: PSA level 3, kecelakaan, PWR   Reactor safety assessment of nuclear power plants using probabilistic assessment methodology is most important in addition to the deterministic assessment. The methodology of Level 3 Probabilistic Safety Assessment (PSA is especially required to estimate severe accident or beyond design basis accidents of nuclear power plants. This method is carried out after the Fukushima accident. In this research, the postulations beyond design basis accidentsof PWR AP - 1000 would be taken, and simulated at West Bangka sample site. The

  5. Child Injury: What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-04-16

    This 60 second PSA is based on the April 2012 CDC Vital Signs report. Many childhood deaths and injuries are preventable, including those caused by crashes, suffocation, poisoning, drowning, fires, and falls. The PSA discusses ways to help prevent these deaths and injuries.  Created: 4/16/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/16/2012.

  6. THE DISCRIMINATIVE ABILITY OF PERCENT FREE PSA IN ...

    African Journals Online (AJOL)

    Objective To study the discriminative role of % free PSA in patients with a total PSA > 10 ng/ml. Patients and Methods Our patient cohort con-sisted of 90 males aged between 45 and 81 years (mean age: 67 ± 9 years). All patients had a biopsy-proven prostate pathology. Fifty-six patients had BPH (Group I) while 34 had ...

  7. Review of APR+ Level 2 PSA. Revision 2

    Energy Technology Data Exchange (ETDEWEB)

    Lehner, John R. [Brookhaven National Lab. (BNL), Upton, NY (United States); Mubayi, Vinod [Brookhaven National Lab. (BNL), Upton, NY (United States); Pratt, W. Trevor [Brookhaven National Lab. (BNL), Upton, NY (United States); Kim, Do Sam [Korea Institute of Nuclear Safety (KINS), Daejeon (Korea, Republic of); Cho, Yong Jin [Korea Institute of Nuclear Safety (KINS), Daejeon (Korea, Republic of); Cho, Sang Jin [Korea Institute of Nuclear Safety (KINS), Daejeon (Korea, Republic of); Kim, In Goo [Korea Institute of Nuclear Safety (KINS), Daejeon (Korea, Republic of)

    2012-02-17

    Brookhaven National Laboratory (BNL) assisted the Korea Institute of Nuclear Safety (KINS) in reviewing the Level 2 Probabilistic Safety Assessment (PSA) of the APR+ Advanced Pressurized Water Reactor (PWR) prepared by the Korea Hydro & Nuclear Power Co., Ltd (KHNP) and KEPCO Engineering & Construction Co., Inc. (KEPCO-E&C). The work described in this report involves a review of the APR+ Level 2 PSA submittal [Ref. 1]. The PSA and, therefore, the review is limited to consideration of accidents initiated by internal events. As part of the review process, the review team also developed three sets of Requests for Additional Information (RAIs). These RAIs were provided to KHNP and KEPCO-E&C for their evaluation and response. This final detailed report documents the review findings for each technical element of the PSA and includes consideration of all of the RAIs made by the reviewers as well as the associated responses. This final report was preceded by an interim report [Ref. 2] that focused on identifying important issues regarding the PSA. In addition, a final meeting on the project was held at BNL on November 21-22, 2011, where BNL and KINS reviewers discussed their preliminary review findings with KHNP and KEPCO-E&C staffs. Additional information obtained during this final meeting was also used to inform the review findings of this final report. The review focused not only on the robustness of the APR+ design to withstand severe accidents, but also on the capability and acceptability of the Level 2 PSA in terms of level of detail and completeness. The Korean nuclear regulatory authorities will decide whether the PSA is acceptable and the BNL review team is providing its comments for KINS consideration. Section 2.0 provides the basis for the BNL review. Section 3.0 presents the review of each technical element of the PSA. Conclusions and a summary are presented in Section 4.0. Section 5.0 contains the references.

  8. Comparison of SKIFS 2004:1 and Tillsynshandbok PSA against the ASME PRA Standard and European requirements on PSA; Jaemfoerelse av SKIFS 2004:1 och Tillsynshandbok PSA mot ASME PRA Standard och Europeiska krav paa PSA

    Energy Technology Data Exchange (ETDEWEB)

    Hellstroem, Per

    2005-04-15

    Requirements on PSA for risk informed applications are expressed in different international documents. The ASME PRA standard published in spring 2002 is one such document, PSA requirements are also expressed in the European Utility Requirements (EUR) for new reactors. The Swedish PSA requirements are provided in the Swedish regulators (SKI) statutes SKIFS 2004:1. SKI also has a review handbook for PSA activities (SKI report 2003:48). The review handbook is a support during review of the utilities PSA activities and the PSAs themselves. The review handbook expresses SKIs expectations by providing so called important aspects for both the PSA work and the PSAs, A comparison of SKIFS requirements and the important aspects in the Review handbook, on one side, and the requirements on PSA in EUR and ASME on the other side, is presented. The comparison shows a large difference in the level of detail in the different documents, where ASME is most detailed and specific. This is expected since the SKI review handbook not is a 'PSA guide' in the same way as the ASME PRA standard. A direct comparison of the ASME PRA standard requirements with the important aspects in the review handbook cannot answer the question which ASME capacity level that is achieved by a PSA meeting all important aspects. The conclusion is that it is not likely to achieve capacity level 2 and 3, since very few ASME level 3 attributes are explicitly expressed as important aspects, though many are expressed in general terms. The review handbook important aspects that are most similar to the ASME capacity level 1 attributes are initiating events, sequence analysis, and system analysis while less similarity is found for analysis of operator actions data analysis, quantification and containment analysis (level 2). Less similarity is found for capacity level 2 and 3. However, the number of additional ASME attributes on capacity level 2 and 3 are few. There are also important aspects in the review

  9. The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction.

    Science.gov (United States)

    Distler, Florian A; Radtke, Jan P; Bonekamp, David; Kesch, Claudia; Schlemmer, Heinz-Peter; Wieczorek, Kathrin; Kirchner, Marietta; Pahernik, Sascha; Hohenfellner, Markus; Hadaschik, Boris A

    2017-09-01

    Multiparametric magnetic resonance imaging has an emerging role in prostate cancer diagnostics. In addition, clinical information is a reliable predictor of significant prostate cancer. We analyzed whether the negative predictive value of multiparametric magnetic resonance imaging to rule out significant prostate cancer could be improved using clinical factors, especially prostate specific antigen density. A total of 1,040 consecutive men with suspicion of prostate cancer underwent multiparametric magnetic resonance imaging first, followed by transperineal systematic and magnetic resonance imaging-transrectal ultrasound fusion guided biopsy. Logistic regression analyses were performed to test different clinical factors as predictors of significant prostate cancer and build nomograms. To simplify these nomograms for clinical use patients were stratified into 3 prostate specific antigen density groups, including group 1-less than 0.07, group 2-0.07 to 0.15 and group 3-greater than 0.15 ng/ml/ml. After stratification we calculated the negative predictive value of a PI-RADS (Prostate Imaging Reporting and Data System) Likert score of less than 3. Significant prostate cancer was defined as a Gleason score of 3 + 4 or greater. High grade prostate cancer was defined as a Gleason score of 4 + 3 or greater. Overall 451 men were diagnosed with significant prostate cancer, including 187 with a Gleason score of 4 + 3 or greater. On ROC curve analyses the predictive power of the developed nomogram for significant prostate cancer showed a higher AUC than that of PI-RADS alone (0.79 vs 0.75, p PI-RADS scoring. By increasing the probability of ruling out significant prostate cancer approximately 20% of unnecessary biopsies could be avoided safely. Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

  10. A simple computer program for calculating PSA recurrence in prostate cancer patients

    Directory of Open Access Journals (Sweden)

    Liao Zhongyue

    2004-06-01

    Full Text Available Abstract Background Prostate cancer is the most common tumor in men. The most commonly used diagnostic and tumor recurrence marker is Prostate Specific Antigen (PSA. After surgical removal or radiation treatment, PSA levels drop (PSA nadir and subsequent elevated or increased PSA levels are indicative of recurrent disease (PSA recurrence. For clinical follow-up and local care PSA nadir and recurrence is often hand calculated for patients, which can result in the application of heterogeneous criteria. For large datasets of prostate cancer patients used in clinical studies PSA measurements are used as surrogate measures of disease progression. In these datasets a method to measure PSA recurrence is needed for the subsequent analysis of outcomes data and as such need to be applied in a uniform and reproducible manner. This method needs to be simple and reproducible, and based on known aspects of PSA biology. Methods We have created a simple Perl-based algorithm for the calculation of post-treatment PSA outcomes results based on the initial PSA and multiple PSA values obtained after treatment. The algorithm tracks the post-surgical PSA nadir and if present, subsequent PSA recurrence. Times to PSA recurrence or recurrence free intervals are supplied in months. Results Use of the algorithm is demonstrated with a sample dataset from prostate cancer patients. The results are compared with hand-annotated PSA recurrence analysis. The strengths and limitations are discussed. Conclusions The use of this simple PSA algorithm allows for the standardized analysis of PSA recurrence in large datasets of patients who have undergone treatment for prostate cancer. The script is freely available, and easily modifiable for desired user parameters and improvements.

  11. Simulation and optimization of an industrial PSA unit

    Directory of Open Access Journals (Sweden)

    Barg C.

    2000-01-01

    Full Text Available The Pressure Swing Adsorption (PSA units have been used as a low cost alternative to the usual gas separation processes. Its largest commercial application is for hydrogen purification systems. Several studies have been made about the simulation of pressure swing adsorption units, but there are only few reports on the optimization of such processes. The objective of this study is to simulate and optimize an industrial PSA unit for hydrogen purification. This unit consists of six beds, each of them have three layers of different kinds of adsorbents. The main impurities are methane, carbon monoxide and sulfidric gas. The product stream has 99.99% purity in hydrogen, and the recovery is around 90%. A mathematical model for a commercial PSA unit is developed. The cycle time and the pressure swing steps are optimized. All the features concerning with complex commercial processes are considered.

  12. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density

    NARCIS (Netherlands)

    C.H. Bangma (Chris); R. Kranse (Ries); B.G. Blijenberg (Bert); F.H. Schröder (Fritz)

    1995-01-01

    textabstractObjectives: The ratio between free and total prostate-specific antigen (PSA) in serum (F/T ratio) was shown to improve the specificity of total serum PSA for the detection of prostate carcinoma in selected populations. In this study, the value of the F/T ratio for screening of prostate

  13. PSA testing in Austria: induced morbidity and saved mortality.

    Science.gov (United States)

    Vutuc, Christian; Waldhoer, Thomas; Lunglmayr, Gerhard; Hoeltl, Wolfgang; Haidinger, Gerald

    2009-09-01

    Opportunistic screening of healthy men by prostate-specific antigen (PSA) testing led to a steep increase of prostate cancer incidence in Austria. The objective of this study was to quantify how many additional men are diagnosed with prostate cancer by PSA testing, to save one man from prostate cancer death. Regression models for incidence and mortality for the time periods 1983-1991 and 1992-2003 by age groups 50-59 and 60-69 years were estimated. For 1992-2003, expected numbers of incidence and mortality were calculated. The first estimates for the years 1992-2003 were calculated using the regression model including the years 1983-1991. The second estimates were also calculated using the regression model, but including only the years 1992-2003. The difference between estimates was then summed up for 1992-2003. The corresponding sums of incidence and mortality were compared to provide estimates for the effect of the introduction of PSA screening on incidence/mortality ratio. According to our calculation for the time period 1992-2003, in age group 50-69 years, a total of 512 expected prostate cancer deaths were prevented because of opportunistic PSA screening, whereas PSA testing identified a total of 9648 additional men with asymptomatic prostate cancer. In conclusion, to save one man in the age group 50-69 years in the time period 1992-2003 from prostate cancer death by PSA testing, a total of 18.8 men with asymptomatic prostate cancer had to be identified. Although this study probably underestimates the benefit (reduced mortality) and overestimates excess incidence of prostate cancer, it is far from sure that in all of these additionally identified men prostate cancer would ever have surfaced as a clinical disease, if not screened for.

  14. Reducing the Risk of Methadone Overdose PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-07-03

    This 60 second PSA is based on the July 2012 CDC Vital Signs report. Approximately 14 people die every day of overdoses related to methadone. Listen to learn how to reduce your risk of an overdose.  Created: 7/3/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 7/3/2012.

  15. Prognostic Significance of Prostate-Specific Antigen (PSA) Rate of ...

    African Journals Online (AJOL)

    Aim: To investigate the prognostic significance of Prostate-Specific Antigen (PSA) rate of change in patients with advanced prostate cancer . Patients and Methods: A total of forty-nine male patients aged between 42 and 84 years with advanced prostate cancer receiving therapy of maximum androgen bloackade were ...

  16. Association between steroid hormone receptors and PSA gene ...

    African Journals Online (AJOL)

    associated with presence of steroid hormone receptors. The aim of this research was to show differential expression and association between steroid hormone receptors and PSA gene expression in breast cancer cell lines. The cell lines investigated were steroid receptor-negative breast carcinoma cell lines BT-20 and ...

  17. Asian and Pacific Islander HIV/AIDS Awareness PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-05-12

    In this PSA, Asians and Pacific Islanders are encouraged to talk about HIV and get tested for HIV.  Created: 5/12/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 5/12/2010.

  18. Hand Hygiene in Healthcare Settings 1 PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-08-19

    This 30 second PSA encourages people to wash their hands often while in the hospital or visiting someone in the hospital. It also encourages them to remind their healthcare providers to wash their hands, too.  Created: 8/19/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 8/19/2010.

  19. Hand Hygiene in Healthcare Settings 2 PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-08-19

    This 30 second PSA encourages people to wash their hands often while in the hospital or visiting someone in the hospital. It also encourages them to remind their healthcare providers to wash their hands, too.  Created: 8/19/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 8/19/2010.

  20. Lifestyle and Clinical Health Behaviors and PSA Tests

    Science.gov (United States)

    Norris, Cynthia; McFall, Stephanie

    2006-01-01

    This study assessed the association of lifestyle and clinical health behaviors with prostate specific antigen (PSA) tests. The study used cross-sectional data from the 2002 Behavioral Risk Factor Surveillance System (BRFSS). We used Stata 8.0 to take into account the complex sample design in analyses. Both lifestyle and clinical health behaviors…

  1. System analysis procedures for conducting PSA of nuclear power plants

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Yoon Hwan; Jeong, Won Dae; Kim, Tae Un; Kim, Kil You; Han, Sang Hoon; Chang, Seung Chul; Sung, Tae Yong; Yang, Jun Eon; Kang, Dae Il; Park, Jin Hee; Hwang, Mi Jeong; Jin, Young Ho

    1997-03-01

    This document, the Probabilistic Safety Assessment(PSA) procedures guide for system analysis, is intended to provide the guidelines to analyze the target of system consistently and technically in the performance of PSA for nuclear power plants(NPPs). The guide has been prepared in accordance with the procedures and techniques for fault tree analysis(FTA) used in system analysis. Normally the main objective of system analysis is to assess the reliability of system modeled by Event Tree Analysis(ETA). A variety of analytical techniques can be used for the system analysis, however, FTA method is used in this procedures guide. FTA is the method used for representing the failure logic of plant systems deductively using AND, OR or NOT gates. The fault tree should reflect all possible failure modes that may contribute to the system unavailability. This should include contributions due to the mechanical failures of the components, Common Cause Failures (CCFs), human errors and outages for testing and maintenance. After the construction of fault tree is completed, system unavailability is calculated with the CUT module of KIRAP, and the qualitative and quantitative analysis is performed through the process as above stated. As above mentioned, the procedures for system analysis is based on PSA procedures and methods which has been applied to the safety assessments of constructing NPPs in the country. Accordingly, the method of FTA stated in this procedures guide will be applicable to PSA for the NPPs to be constructed in the future. (author). 6 tabs., 11 figs., 7 refs.

  2. Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer

    DEFF Research Database (Denmark)

    Ulmert, David; Vickers, Andrew J; Scher, Howard I

    2012-01-01

    The utility of conventional prostate-specific antigen (PSA) measurements in blood for monitoring rapid responses to treatment for prostate cancer is limited because of its slow elimination rate. Prior studies have shown that free PSA (fPSA), intact PSA (iPSA) and human kallikrein-related peptidase...... of tPSA, fPSA, iPSA and hK2 after rapid induction of castration with degarelix (Firmagon(®)), a novel GnRH antagonist....

  3. Literature Survey on Technical Issues and Insights of Multi-Unit PSA

    Energy Technology Data Exchange (ETDEWEB)

    Baek, Sejin; Park, Soyoung; Heo, Gyunyoung [Kyung Hee Univ., Yongin (Korea, Republic of)

    2016-10-15

    The need consider the risk impact in case of multi-unit in a single site increased after the accident at Fukushima Daiichi in March 2011. This means that we have to consider the single-unit initiators impacting the other units and the simultaneous accidents of the multi-unit on the same site. Particularly, this kind of technical concern is serious in case of the Republic of Korea where multi-units had to be located in high-density population area due to geographical features. The Nuclear Safety and Security Commission (NSSC) in the Republic of Korea has been trying to identify the state of the art of international and domestic regulations and techniques on multi-unit risk assessment and planning the road map for the safety researches. However, we have to say that finding a common accepted methodology along with safety criteria for multi-unit PSA was not an easy task up to now. This paper summarizes and analyzes related international and domestic journals' papers, conferences' papers and reports about the multi-unit PSA classifying categories with themes to understand the technical tendency of multi-unit PSA. In addition, some insights that were obtained from this classification have been arranged too. This paper investigated the technical trend of the multi-unit PSA as collecting of the international and domestic journals' papers, conferences papers and reports, and analyzing them. Upon the literature survey, a few statistics, technical issues, and insights were summarized. Both of the fundamental and practical researches need to find a globally accepted methodology to calculate and determine quantitative objectives for a multi-unit PSA. We want to expect that this paper can be shared to understand the current status of multi-unit PSA.

  4. Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL.

    Science.gov (United States)

    Chang, Chih-Chun; Lee, Yi-Chen; Tsai, Huang-Wen; Yii, Shyi-Chun; Yen, Tzung-Hai; Chu, Fang-Yeh

    2015-01-01

    To examine the effectiveness of serum free-to-total prostate specific antigen ratio (%fPSA) for the detection of prostate cancer (PCa) in men with different serum total PSA (tPSA) categories. From January 2010 to December 2013, a total of 225 patients with lower urinary tract symptoms (LUTS) underwent tPSA and %fPSA measurements. Histological examination with calculation of Gleason score and whole body bone scans were performed in identified cases of PCa. PCa was diagnosed in 44 (19.6%) patients and the remaining 181 patients had benign prostate disease. PCa was detected in 5 (23.8%), 13 (8.7%) and 26 (47.3%) cases with tPSA level ranges≤4 ng/ml, 4 to 10 ng/ml and >10 ng/ml, respectively. The average Gleason score was 7.2±0.2. Some 6 (13.6%) out of 44 PCa patients had bone metastases. The sensitivity was 80% and specificity was 81.3% at the cut-off %fPSA of 15% in PCa patients with a tPSA level below 4 ng/ mL. A lower %fPSA was associated with PCa patients with Gleason score≥7 than those with Gleason score≤6 (11.7±0.98 vs. 16.5±2.25%, P=0.029). No obvious relation of %fPSA to the incidence of bone metastasis was apparent in this study. The clinical application of %fPSA could help to discriminate PCa from benign prostate disease in men with a tPSA concentration below 4 ng/mL.

  5. PSA testing for men at average risk of prostate cancer

    Directory of Open Access Journals (Sweden)

    Bruce K Armstrong

    2017-07-01

    Full Text Available Prostate-specific antigen (PSA testing of men at normal risk of prostate cancer is one of the most contested issues in cancer screening. There is no formal screening program, but testing is common – arguably a practice that ran ahead of the evidence. Public and professional communication about PSA screening has been highly varied and potentially confusing for practitioners and patients alike. There has been much research and policy activity relating to PSA testing in recent years. Landmark randomised controlled trials have been reported; authorities – including the 2013 Prostate Cancer World Congress, the Prostate Cancer Foundation of Australia, Cancer Council Australia, and the National Health and Medical Research Council – have made or endorsed public statements and/or issued clinical practice guidelines; and the US Preventive Services Task Force is revising its recommendations. But disagreement continues. The contention is partly over what the new evidence means. It is also a result of different valuing and prioritisation of outcomes that are hard to compare: prostate cancer deaths prevented (a small and disputed number; prevention of metastatic disease (somewhat more common; and side-effects of treatment such as incontinence, impotence and bowel trouble (more common again. A sizeable proportion of men diagnosed through PSA testing (somewhere between 20% and 50% would never have had prostate cancer symptoms sufficient to prompt investigation; many of these men are older, with competing comorbidities. It is a complex picture. Below are four viewpoints from expert participants in the evolving debate, commissioned for this cancer screening themed issue of Public Health Research & Practice. We asked the authors to respond to the challenge of PSA testing of asymptomatic, normal-risk men. They raise important considerations: uncertainty, harms, the trustworthiness and interpretation of the evidence, cost (e.g. of using multiparametric

  6. A population study of fasting time and serum prostate-specific antigen (PSA) level

    Science.gov (United States)

    Lau, Cheryl K; Guo, Maggie; Viczko, Jeannine A; Naugler, Christopher T

    2014-01-01

    Prostate cancer is one of the most common cancers in men. Traditional screening and diagnostic methods include digital rectal examinations (DREs), biopsies and serum prostate-specific antigen (PSA) tests, with the latter being the more popular. PSA is a biomarker for prostate cancer; however, it is highly sensitive to external factors as well as other prostate diseases. As such, the reliability of of the serum PSA level as a sole screening and diagnostic tool for prostate cancer is controversial. Recently, it has been shown that fasting extremes can affect concentrations of serum chemistry analytes, thus raising the question of whether or not fasting has an effect on the highly sensitive PSA biomarker. Patients testing for serum PSA levels are often concomitantly submitting to other tests that require fasting, subjecting certain patients to a fasting PSA level while others not. The objective of this study was to investigate whether this discrepancy in fasting state translates into an effect on serum PSA levels. Serum PSA levels and fasting time records for 157 276 men who underwent testing at Calgary Laboratory Services (CLS; Calgary, Alberta, Canada) between 01 January 2010 and 31 March 2013 were accessed. Linear regression models of mean PSA levels and fasting times revealed a statistically important relationship at certain fasting times. Applying a dynamic mathematical model to explore the clinical effect of fasting suggests minimal impact on serum PSA result interpretation. Thus, patients can be tested for serum PSA levels regardless of their fasting state. PMID:24994780

  7. A population study of fasting time and serum prostate-specific antigen (PSA) level.

    Science.gov (United States)

    Lau, Cheryl K; Guo, Maggie; Viczko, Jeannine A; Naugler, Christopher T

    2014-01-01

    Prostate cancer is one of the most common cancers in men. Traditional screening and diagnostic methods include digital rectal examinations (DREs), biopsies and serum prostate-specific antigen (PSA) tests, with the latter being the more popular. PSA is a biomarker for prostate cancer; however, it is highly sensitive to external factors as well as other prostate diseases. As such, the reliability of of the serum PSA level as a sole screening and diagnostic tool for prostate cancer is controversial. Recently, it has been shown that fasting extremes can affect concentrations of serum chemistry analytes, thus raising the question of whether or not fasting has an effect on the highly sensitive PSA biomarker. Patients testing for serum PSA levels are often concomitantly submitting to other tests that require fasting, subjecting certain patients to a fasting PSA level while others not. The objective of this study was to investigate whether this discrepancy in fasting state translates into an effect on serum PSA levels. Serum PSA levels and fasting time records for 157 276 men who underwent testing at Calgary Laboratory Services (CLS; Calgary, Alberta, Canada) between 01 January 2010 and 31 March 2013 were accessed. Linear regression models of mean PSA levels and fasting times revealed a statistically important relationship at certain fasting times. Applying a dynamic mathematical model to explore the clinical effect of fasting suggests minimal impact on serum PSA result interpretation. Thus, patients can be tested for serum PSA levels regardless of their fasting state.

  8. Take Charge. Take the Test. "You Know" PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-03-07

    As part of the Take Charge. Take the Test. campaign, this 60 second PSA encourages African American women to get tested for HIV. Locations for a free HIV test can be found by visiting hivtest.org/takecharge or calling 1-800-CDC-INFO (1-800-232-4636).  Created: 3/7/2012 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).   Date Released: 3/7/2012.

  9. Teen Pregnancy - What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-04-05

    This 60 second PSA is based on the April, 2011 CDC Vital Signs report. Having a child during the teen years comes at a high cost to the young mother, her child, and the community. Get tips to help break the cycle of teen pregnancy.  Created: 4/5/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/5/2011.

  10. Asthma - What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-05-03

    This 60 second Public Service Announcement (PSA) is based on the May, 2011 CDC Vital Signs report. Children and adults can have asthma and attacks can be frightening. To help control asthma, know the warning signs of an attack, stay away from asthma triggers, and follow your health care provider's advice.  Created: 5/3/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 5/3/2011.

  11. Image Guided Hypofractionated Radiotherapy by Helical Tomotherapy for Prostate Carcinoma: Toxicity and Impact on Nadir PSA

    Directory of Open Access Journals (Sweden)

    Salvina Barra

    2014-01-01

    Full Text Available Aim. To evaluate the toxicity of a hypofractionated schedule for primary radiotherapy (RT of prostate cancer as well as the value of the nadir PSA (nPSA and time to nadir PSA (tnPSA as surrogate efficacy of treatment. Material and Methods. Eighty patients underwent hypofractionated schedule by Helical Tomotherapy (HT. A dose of 70.2 Gy was administered in 27 daily fractions of 2.6 Gy. Acute and late toxicities were graded on the RTOG/EORTC scales. The nPSA and the tnPSA for patients treated with exclusive RT were compared to an equal cohort of 20 patients treated with conventional fractionation and standard conformal radiotherapy. Results. Most of patients (83% did not develop acute gastrointestinal (GI toxicity and 50% did not present genitourinary (GU toxicity. After a median follow-up of 36 months only grade 1 of GU and GI was reported in 6 and 3 patients as late toxicity. Average tnPSA was 30 months. The median value of nPSA after exclusive RT with HT was 0.28 ng/mL and was significantly lower than the median nPSA (0.67 ng/mL of the conventionally treated cohort (P=0.02. Conclusions. Hypofractionated RT schedule with HT for prostate cancer treatment reports very low toxicity and reaches a low level of nPSA that might correlate with good outcomes.

  12. [Prostate specific antigen--PSA and histopathological findings of endometrium in women with fibrocystic breast disease].

    Science.gov (United States)

    Radowicki, Stanisław; Kunicki, Michał

    2010-02-01

    The aim of the study was to evaluate the relationship between serum free and total PSA and histopathological findings in women with fibrocystic mastopathy. 176 women with fibrocystic breast disease, aged 18 to 45 years.--Group I: comprised 114 patients with cysts 10 mm in diameter. The control group consisted of 46 healthy women aged 18 - 45 years who had no breast pathology Total PSA (PSA-T) and free PSA (PSA-Free) were measured by an ultra-sensitive fluoroimmunometric DELFIA assay (Prostatus PSA Free/Total Wallac, Turku, Finland). The detection limit for PSA was 0.01 ng/ml. Endometrial samples have been obtained with Pipelle probe between 22 and 24 days of the menstrual cycle. In the control group secretory endometrium was more frequently detected than in the mastopathy group (chi2 = 11,15, p = 0.01). Proliferatory (chi2 = 8.27, p = 0.004) and presecretory endometrium (chi2 = 4.61, p = 0.03) were more frequently detected in the mastopathy group than in controls. We did not find statistically significant relationship between the mean PSA concentrations between the groups in relation to histopathological findings. No relationships between free and total PSA measured in the follicular phase of the menstrual cycle and endometrial findings were detected in our study. Further research is required to evaluate the relationship between PSA and endometrial findings.

  13. Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.

    Science.gov (United States)

    Shiota, Masaki; Yokomizo, Akira; Takeuchi, Ario; Kiyoshima, Keijiro; Inokuchi, Junichi; Tatsugami, Katsunori; Shiga, Ken-Ichiro; Koga, Hirofumi; Yamaguchi, Akito; Naito, Seiji; Eto, Masatoshi

    2016-12-01

    To investigate the potential relationship of steroid usage with prostate-specific antigen (PSA) flare as well as the prognostic impact of PSA flare, which is known to occur in 10-20% of patients with metastatic castration-resistant prostate cancer during docetaxel chemotherapy. This study included 71 patients with metastatic castration-resistant prostate cancer treated by docetaxel chemotherapy with co-introduction of a steroid. PSA flare was defined as a transient PSA increase followed by a PSA decrease. PSA flare was recognized in 7.0-23.9% of patients according to the definition used. Intriguingly, men with steroid intake before the initiation of docetaxel chemotherapy experienced significantly fewer PSA flares. The progression-free survival rate in men with PSA flare was equivalent to that of PSA responders, but significantly better than men with PSA failure. Our results suggest that de novo steroid co-introduction with docetaxel chemotherapy induces the PSA flare phenomenon. This novel finding may account for the mechanism of PSA flare as well as being valuable for distinguishing PSA elevation attributable to PSA flare from that attributable to PSA failure. © 2016 The Authors BJU International © 2016 BJU International Published by John Wiley & Sons Ltd.

  14. Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer

    DEFF Research Database (Denmark)

    Thomsen, Frederik Birkebæk; Brasso, Klaus; Berg, Kasper Drimer

    2016-01-01

    BACKGROUND: The prognostic value of prostate-specific antigen (PSA) kinetics in untreated prostate cancer (PCa) patients is debatable. We investigated the association between PSA doubling time (PSAdt), PSA velocity (PSAvel) and PSAvel risk count (PSAvRC) and PCa mortality in a cohort of patients...... were included of which 116, 76 and 71 had a PSA at consent ≤10, 10.1-25, and >25 ng/ml, respectively. Median follow-up was 13.6 years. For patients with PSA at consent between 10.1 and 25 ng/ml, the 13-year risks of PCa mortality were associated with PSA kinetics: PSAdt ≤3 years: 62.0% versus PSAdt >3...... years: 16.3% (Gray's test: P associated with changes of 13-year risks of PCa...

  15. Inhibition of pneumococcal adherence to human nasopharyngeal epithelial cells by anti-PsaA antibodies.

    Science.gov (United States)

    Romero-Steiner, Sandra; Pilishvili, Tamar; Sampson, Jacquelyn S; Johnson, Scott E; Stinson, Annie; Carlone, George M; Ades, Edwin W

    2003-03-01

    The role of pneumococcal (Pnc) surface adhesin A (PsaA) in the adherence of Streptococcus pneumoniae (pneumococcus) to host cells is not well defined. We examined the effect of anti-PsaA antibodies in an inhibition of adherence assay using Detroit 562 nasopharyngeal human epithelial cells. Rabbit polyclonal (Pab) anti-recombinant PsaA (rPsaA) sera, a purified mouse monoclonal antibody (MAb) (MAb 6F62G8E12), and 22 healthy adult sera with known anti-PsaA IgG levels (obtained by enzyme-linked immunosorbent assay) were evaluated for their abilities to inhibit Pnc adherence to confluent monolayers (measured as percent reduction in CFU counts compared to those of uninhibited controls). Pnc adherence was dependent on capsular phenotype (no or low adherence for opaque strains). With an inoculum of 10(4) to 10(5) bacteria/well, the mean +/- standard deviation count in controls was 163 +/- 32 CFU/well for transparent strains. Low adherence was observed for a PsaA-minus mutant even at higher inoculum doses. Mean percent inhibitions of adherence with Pab and MAb were 54 and 50%, respectively. Adult sera showed inhibition in a dose-response fashion with a range of 98 to 8%, depending on the serum anti-PsaA antibody concentration. Absorption of Pab with rPsaA restored Pnc adherence to control levels. Absorption of sera with a PsaA-minus mutant did not result in a significant decrease (P >0.05) of inhibition of adherence activity. Additionally, nearly 100% of Pnc adherence was inhibited by lipidated rPsaA at 2.5 micro g/ml. Our data support the argument that PsaA is an adhesin that mediates Pnc adherence to human nasopharyngeal cells. This functional assay may be useful in evaluating antibodies elicited in response to PsaA vaccination.

  16. A population study of fasting time and serum prostate-specific antigen (PSA) level

    OpenAIRE

    Lau, Cheryl K; Maggie Guo; Viczko, Jeannine A; Naugler, Christopher T

    2014-01-01

    Prostate cancer is one of the most common cancers in men. Traditional screening and diagnostic methods include digital rectal examinations (DREs), biopsies and serum prostate-specific antigen (PSA) tests, with the latter being the more popular. PSA is a biomarker for prostate cancer; however, it is highly sensitive to external factors as well as other prostate diseases. As such, the reliability of of the serum PSA level as a sole screening and diagnostic tool for prostate cancer is controvers...

  17. Colorectal Cancer - What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-07-05

    This 60 second Public Service Announcement (PSA) is based on the July, 2011 CDC Vital Signs report. Colorectal cancer kills about 50,000 men and women every year. Screening can save lives! Screening can find abnormal growths so they can be removed before turning into cancer, and can find the cancer early, when it's easiest to treat. If you're over 50, talk to your doctor about getting screened for colorectal cancer.  Created: 7/5/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 7/5/2011.

  18. The Planetary Science Archive (PSA): Exploration and discovery of scientific datasets from ESA's planetary missions

    Science.gov (United States)

    Vallat, C.; Besse, S.; Barbarisi, I.; Arviset, C.; De Marchi, G.; Barthelemy, M.; Coia, D.; Costa, M.; Docasal, R.; Fraga, D.; Heather, D. J.; Lim, T.; Macfarlane, A.; Martinez, S.; Rios, C.; Vallejo, F.; Said, J.

    2017-09-01

    The Planetary Science Archive (PSA) is the European Space Agency's (ESA) repository of science data from all planetary science and exploration missions. The PSA provides access to scientific datasets through various interfaces at http://psa.esa.int. All datasets are scientifically peer-reviewed by independent scientists, and are compliant with the Planetary Data System (PDS) standards. The PSA has started to implement a number of significant improvements, mostly driven by the evolution of the PDS standards, and the growing need for better interfaces and advanced applications to support science exploitation.

  19. [Clinicopathologic and biological correlations (PSA-PAP) in pathology of the prostate. Apropos of 150 cases].

    Science.gov (United States)

    Amiel, J; Chevallier, D; Peyrottes, A; Benoliel, J; Toubol, J

    1990-01-01

    On the basis of 150 patients (16 controls with no disease of the prostate, 96 cases of benign prostatic hypertrophy (BPH) and 38 cases of carcinoma of the prostate (CP)), the authors intended to answer 3 questions: How can the borderline values of PSA in BPH be interpreted? Is there a correlation between the Gleason and PSA values in carcinomas? Should the simultaneous measurements of PSA and PAP be continued? All patients were examined with a rectal touch, transrectal echography (TRE) and PAS and PAP assays. All CP were examined with bone radionuclide scanning (BR). The correlation coefficient being 0.391 (p 0.001), the PSA value and prostatic weight can be regarded as linearly correlated in BPH (5 g BPH = 1 ng/ml PSA). This lower value of PSA is linked with the increase produced by TRE in the assessment of prostatic weight. On the other hand, the authors did no observe a correlation between the PSA and the Glisson grade in carcinomas with negative BR. Lastly, the sensitivity of PSA is noticeably higher than that of PAP (75% vs. 50%), and no false negative finding with PSA was corrected by PAP measurements.

  20. Analytic expressions for the construction of a fire event PSA model

    Energy Technology Data Exchange (ETDEWEB)

    Kang, Dae Il; Kim, Kil Yoo; Kim, Dong San; Hwang, Mee Jeong; Yang, Joon Eon [KAERI, Daejeon (Korea, Republic of)

    2016-05-15

    In this study, the changing process of an internal event PSA model to a fire event PSA model is analytically presented and discussed. Many fire PSA models have fire induced initiating event fault trees not shown in an internal event PSA model. Fire-induced initiating fault tree models are developed for addressing multiple initiating event issues. A single fire event within a fire compartment or fire scenario can cause multiple initiating events. As an example, a fire in a turbine building area can cause a loss of the main feed-water and loss of off-site power initiating events. Up to now, there has been no analytic study on the construction of a fire event PSA model using an internal event PSA model with fault trees of initiating events. In this paper, the changing process of an internal event PSA model to a fire event PSA model was analytically presented and discussed. This study results show that additional cutsets can be obtained if the fault trees of initiating events for a fire event PSA model are not exactly developed.

  1. Development of a Base Model for the New Fire PSA Training

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Kilyoo; Kang, Daeil [Korea Atomic Energy Research Institute, Daejeon (Korea, Republic of); Kim, Wee Kyong; Do, Kyu Sik [Korea Institute of Nuclear Safety, Daejeon (Korea, Republic of)

    2013-05-15

    US NRC/EPRI issued a new fire PSA method represented by NUREG/CR 6850, and have been training many operators and inspectors to widely spread the new method. However, there is a limitation in time and efficiency for many foreigners, who generally have communication problem, to participate in the EPRI/NRC training to learn the new method. Since it is about time to introduce the new fire PSA method as a regulatory requirement for the fire protection in Korea, a simple and easy-understandable base model for the fire PSA training is required, and KAERI-KINS is jointly preparing the base model for the new fire PSA training. This paper describes how the base model is developed. Using an imaginary simple NPP, a base model of fire PSA following the new fire PSA method was developed in two ways from the internal PSA model. Since we have the base model and know the process of making the fire PSA model, the training for the new fire PSA method can be in detail performed in Korea.

  2. Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016.

    Science.gov (United States)

    Orbai, Ana-Maria; de Wit, Maarten; Mease, Philip J; Callis Duffin, Kristina; Elmamoun, Musaab; Tillett, William; Campbell, Willemina; FitzGerald, Oliver; Gladman, Dafna D; Goel, Niti; Gossec, Laure; Hoejgaard, Pil; Leung, Ying Ying; Lindsay, Chris; Strand, Vibeke; van der Heijde, Désirée M; Shea, Bev; Christensen, Robin; Coates, Laura; Eder, Lihi; McHugh, Neil; Kalyoncu, Umut; Steinkoenig, Ingrid; Ogdie, Alexis

    2017-10-01

    To include the patient perspective in accordance with the Outcome Measures in Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials (RCT) and longitudinal observational studies (LOS). At OMERACT 2016, research conducted to update the PsA Core Domain Set was presented and discussed in breakout groups. The updated PsA Core Domain Set was voted on and endorsed by OMERACT participants. We conducted a systematic literature review of domains measured in PsA RCT and LOS, and identified 24 domains. We conducted 24 focus groups with 130 patients from 7 countries representing 5 continents to identify patient domains. We achieved consensus through 2 rounds of separate surveys with 50 patients and 75 physicians, and a nominal group technique meeting with 12 patients and 12 physicians. We conducted a workshop and breakout groups at OMERACT 2016 in which findings were presented and discussed. The updated PsA Core Domain Set endorsed with 90% agreement by OMERACT 2016 participants included musculoskeletal disease activity, skin disease activity, fatigue, pain, patient's global assessment, physical function, health-related quality of life, and systemic inflammation, which were recommended for all RCT and LOS. These were important, but not required in all RCT and LOS: economic cost, emotional well-being, participation, and structural damage. Independence, sleep, stiffness, and treatment burden were on the research agenda. The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps for the PsA working group include evaluation of PsA outcome measures and development of a PsA Core Outcome Measurement Set.

  3. Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS).

    Science.gov (United States)

    Diamandis, Eleftherios P; Stanczyk, Frank Z; Wheeler, Sarah; Mathew, Anu; Stengelin, Martin; Nikolenko, Galina; Glezer, Eli N; Brown, Marshall D; Zheng, Yingye; Chen, Yen-Hao; Wu, Hsiao-Li; Azziz, Ricardo

    2017-10-26

    Polycystic ovarian syndrome (PCOS) is a common cause of reproductive and metabolic dysfunction. We hypothesized that serum prostate-specific antigen (PSA) may constitute a new biomarker for hyperandrogenism in PCOS. We conducted a cross-sectional study of 45 women with PCOS and 40 controls. Serum from these women was analyzed for androgenic steroids and for complexed PSA (cPSA) and free PSA (fPSA) with a novel fifth- generation assay with a sensitivity of ~10 fg/mL for cPSA and 140 fg/mL for fPSA. cPSA and fPSA levels were about three times higher in PCOS compared to controls. However, in PCOS, cPSA and fPSA did not differ according to waist-to-hip ratio, Ferriman-Gallwey score, or degree of hyperandrogenemia or oligo-ovulation. In PCOS and control women, serum cPSA and fPSA levels were highly correlated with each other, and with free and total testosterone levels, but not with other hormones. Adjusting for age, body mass index (BMI) and race, cPSA was significantly associated with PCOS, with an odds ratio (OR) of 5.67 (95% confidence interval [CI]: 1.86, 22.0). The OR of PCOS for fPSA was 7.04 (95% CI: 1.65, 40.4). A multivariate model that included age, BMI, race and cPSA yielded an area-under-the-receiver-operating-characteristic curve of 0.89. Serum cPSA and fPSA are novel biomarkers for hyperandrogenism in PCOS and may have value for disease diagnosis.

  4. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.

    Science.gov (United States)

    Castellucci, Paolo; Fuccio, Chiara; Nanni, Cristina; Santi, Ivan; Rizzello, Anna; Lodi, Filippo; Franceschelli, Alessandro; Martorana, Giuseppe; Manferrari, Fabio; Fanti, Stefano

    2009-09-01

    The purpose of this study was to investigate the effect of total prostate-specific antigen (PSA) at the time of (11)C-choline PET/CT (trigger PSA), PSA velocity (PSAvel), and PSA doubling time (PSAdt) on (11)C-choline PET/CT detection rate in patients treated with radical prostatectomy for prostate cancer, who showed biochemical failure during follow-up. A total of 190 patients treated with radical prostatectomy for prostate cancer who showed an increase in PSA (mean, 4.2; median, 2.1; range, 0.2-25.4 ng/mL) were retrospectively enrolled. All patients were studied with (11)C-choline PET/CT. Patients were grouped according to trigger PSA (PSA 5 ng/mL). In 106 patients, data were available for calculation of PSAvel and PSAdt. Logistic regression analysis was used to determine whether there was a relationship between PSA levels and PSA kinetics and the rate of detection of relapse using PET. (11)C-choline PET/CT detected disease relapse in 74 of 190 patients (38.9%). The detection rate of (11)C-choline PET/CT was 19%, 25%, 41%, and 67% in the 4 subgroups-PSA 5 ng/mL (49 patients)-respectively. Trigger PSA values were statistically different between PET-positive patients (median PSA, 4.0 ng/mL) and PET-negative patients (median PSA, 1.4 ng/mL) (P = 0.0001). Receiver-operating-characteristic analysis showed an optimal cutoff point for trigger PSA of 2.43 ng/mL (area under the curve, 0.76). In 106 patients, PSAdt and PSAvel values were statistically different between patients with PET-positive and -negative scan findings (P = 0.04 and P = 0.03). The (11)C-choline PET/CT detection rate was 12%, 34%, 42%, and 70%, respectively, in patients with PSAvel 5 ng/mL/y (28 patients). The (11)C-choline PET/CT detection rate was 20%, 40%, 48%, and 60%, respectively, in patients with PSAdt > 6 mo (45 patients), 4 < PSAdt

  5. PSA screening for prostate cancer: why so much controversy?

    Science.gov (United States)

    Labrie, Fernand

    2013-09-01

    Since prostate cancer reaches the advanced and non curable stage in the absence of any specific symptom or sign, it seems reasonable to diagnose this cancer at an early and curable stage. Screening by prostate-specific antigen (PSA) has been the common technology used. The last follow-up of the first two prospective and randomized screening studies for prostate cancer, namely the Quebec and ERSPC (European Randomized Study of Screening for Prostate Cancer) clinical trials started in 1988 and 1991, respectively, have shown reductions of prostate cancer death of 62% (PProstate Lung Colorectal and Ovarian Cancer) screening trial reported no benefit. It has been estimated, however, that 85% of men in the planned 'non-screened' group of the US study have been screened. With such a serious flaw, the PLCO study does not have the statistical power to reach any valid conclusion. In the Quebec study, only 7.3% of men were screened in the control arm. The important benefit observed in the ERSPC study was achieved using a less than optimal 4-year PSA screening interval which misses a significant number of cancers while the Quebec study used the optimal 1-year interval. With proper information obtained from their physicians or otherwise using data collected only from the clinical trials having the required statistical power, men should be in a good position to decide about being or not being screened for prostate cancer.

  6. Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL

    Directory of Open Access Journals (Sweden)

    Katia R. Leite

    2008-06-01

    Full Text Available OBJECTIVE: Cancer detection has been reported in up to 27% of patients when lowering the PSA cutoff to 2.5 ng/mL. Although this practice could increase the number of biopsies performed, it also could lead to more frequent detection of significant prostate cancers at an organ-confined stage and/or a less aggressive state. This study describes the incidence of malignancy and tumor characteristics in extended prostate biopsies with PSA ≤ 4 ng/mL. MATERIALS AND METHODS: Prostate biopsies from 1081 patients where examined, 275 (25.4% patients had PSA level ≤ 4 ng/mL. RESULTS: Cancer was diagnosed in 32.0% and 35.7% of patients with PSA ≤ 4 ng/mL and > 4 ng/mL, respectively (p = 0.906. The median Gleason score was 7 independent of PSA > or ≤ 4 ng/mL (p = 0.078. The median number of cores positive for tumor was 4 and 3, respectively, for PSA > 4 ng/mL and PSA ≤ 4 ng/mL (p = 0.627. There was a difference in the total percent of tumors involving all cores, 11% and 7% for PSA > or ≤ 4 ng/mL (p = 0.042. Fifty-six patients underwent radical prostatectomy, 12 had PSA ≤ 4 ng/mL. In both groups, a diagnosis of cancer was accurate with no differences in Gleason score, tumor volume or staging for both groups. CONCLUSION: When PSA is below 4 ng/mL, cancer is detected in a proportion equal to the proportion diagnosed with a PSA > 4 ng/mL, and tumor characteristics are similar between the two groups. Only clinically significant tumors were diagnosed following radical prostatectomy.

  7. PSA bounce after {sup 125}I-brachytherapy for prostate cancer as a favorable prognosticator

    Energy Technology Data Exchange (ETDEWEB)

    Engeler, Daniel S.; Schwab, Christoph; Schmid, Hans-Peter [Cantonal Hospital St. Gallen, Department of Urology, St. Gallen (Switzerland); Thoeni, Armin F. [Lindenhofspital Berne, Department of Radiation Oncology, Berne (Switzerland); Hochreiter, Werner [Hirslanden Klinik Aarau, Department of Urology, Aarau (Switzerland); Prikler, Ladislav [Klinik Uroviva Buelach, Department of Urology, Buelach (Switzerland); Suter, Stefan [Cantonal Hospital Zug, Department of Urology, Zug (Switzerland); Stucki, Patrick [Cantonal Hospital Lucerne, Department of Urology, Lucerne (Switzerland); Schiefer, Johann; Plasswilm, Ludwig; Putora, Paul Martin [Cantonal Hospital St. Gallen, Department of Radiation Oncology, St. Gallen (Switzerland)

    2015-10-15

    Permanent low-dose-rate brachytherapy (BT) with iodine 125 is an established curative treatment for localized prostate cancer. After treatment, prostate-specific antigen (PSA) kinetics may show a transient rise (PSA bounce). Our aim was to investigate the association of PSA bounce with biochemical control. Patients treated with BT in Switzerland were registered in a prospective database. Only patients with a follow-up of at least 2 years were included in our analysis. Clinical follow-up and PSA measurements were assessed after 1.5, 3, 6, and 12 months, and annually thereafter. If PSA increased, additional follow-up visits were scheduled. Cases of PSA bounce were defined as a rise of at least 0.2 ng/ml above the initial PSA nadir with a subsequent decline to or below the initial nadir without treatment. Biochemical failure was defined as a rise to nadir + 2 ng/ml. Between March 2001 and November 2010, 713 patients with prostate cancer undergoing BT with at least 2 years of follow-up were registered. Median follow-up time was 41 months. Biochemical failure occurred in 28 patients (3.9 %). PSA bounce occurred in 173 (24.3 %) patients; only three (1.7 %) patients with PSA bounce developed biochemical failure, in contrast to 25 (4.6 %) patients without previous bounce (p < 0.05). The median time to bounce was 12 months, the median time to biochemical failure was 30 months. The median bounce increase was 0.78 ng/ml. Twenty-eight patients with bounce (16.5 %) had a transient PSA rise of + 2 ng/ml above the nadir. In most cases, an early increase in PSA after BT indicates PSA bounce and is associated with a lower risk of biochemical failure. (orig.) [German] Die permanente Low-dose-rate-Brachytherapie (BT) mit {sup 125}I ist ein etabliertes kuratives Verfahren bei lokalisiertem Prostatakarzinom. Posttherapeutisch koennen die PSA-Konzentrationen einen voruebergehenden Anstieg zeigen (Bounce-Phaenomen). Untersucht werden sollte ein moeglicher Zusammenhang mit der

  8. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins.

    Science.gov (United States)

    Peracaula, Rosa; Tabarés, Glòria; Royle, Louise; Harvey, David J; Dwek, Raymond A; Rudd, Pauline M; de Llorens, Rafael

    2003-06-01

    Prostate-specific antigen (PSA) is a glycoprotein secreted by prostate epithelial cells. PSA is currently used as a marker of prostate carcinoma because high levels of PSA are indicative of a tumor situation. However, PSA tests still suffer from a lack of specificity to distinguish between benign prostate hyperplasia and prostate cancer. To determine whether PSA glycosylation could provide a means of differentiating between PSA from normal and tumor origins, N-glycan characterization of PSA from seminal fluid and prostate cancer cells (LNCaP cell line) by sequencing analysis and mass spectrometry was carried out. Glycans from normal PSA (that correspond to low and high pI PSA fractions) were sialylated biantennary complex structures, half of them being disialylated in the low pI PSA fraction and mostly monosialylated in the high pI PSA. PSA from LNCaP cells was purified to homogeneity, and its glycan analysis showed a significantly different pattern, especially in the outer ends of the biantennary complex structures. In contrast to normal PSA glycans, which were sialylated, LNCaP PSA oligosaccharides were all neutral and contained a higher fucose content. In 10-15% of the structures fucose was linked alpha1-2 to galactose, forming the H2 epitope absent in normal PSA. GalNAc was increased in LNCaP glycans to 65%, whereas in normal PSA it was only present in 25% of the structures. These carbohydrate differences allow a distinction to be made between PSA from normal and tumor origins and suggest a valuable biochemical tool for diagnosis and follow-up purposes.

  9. Review of UCN 5,6 Fire PSA Model based on ANS Fire PRA Standard

    Energy Technology Data Exchange (ETDEWEB)

    Yang, Joon Eon; Lee, Yoon Hwan

    2006-12-15

    Recently, under the de-regulation environment, nuclear industry has attempted various approaches to improve the economics of Nuclear Power Plants (NPP). This approach uses the fire risk and performance information to manage the resources effectively and efficiently that are used in the operation of NPP. In fire risk informed/performance-based decision/operation, fire PSA quality is one of the most important things. The nuclear industry and regulatory body of U.S.A have developed a measure to evaluate the quality of fire PSA. ANS (American Nuclear Society) has developed a guidance called 'ANS Fire PRA Methodology Standard'. However, in Korea, there have been no attempts to evaluate the quality of fire PSA model itself. Therefore, we cannot be sure about the quality of fire PSA whether or not the present fire PSA model can be used for the risk-informed applications such as mentioned above. We can say that the evaluation of fire PSA model quality is the basis for the fire risk informed/performance-based decision/operation. In this report, we have evaluated the quality of fire PSA model for Ulchin 5 and 6 units based on the ANS Fire PRA Standard. We, also, have derived what items are to be improved to upgrade the quality of fire PSA model and how it can be improved. This report can be used as the base of the fire risk informed/performance-based decision/operation work in Korea.

  10. The role of the percentage free PSA in the diagnosis of prostate ...

    African Journals Online (AJOL)

    Subjects and methods: A total 169 consecutive patients with tPSA of 4–10 ng/ml with non-suspicious findings on digital rectal examination (DRE) had a transrectal ultrasound (TRUS) guided 10-core prostate biopsy. The technique of PSA analysis was the Access hybritech assay technique using the Beckman's Access ...

  11. The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy

    Directory of Open Access Journals (Sweden)

    Nadeem Shaida

    2009-01-01

    Full Text Available Transrectal ultrasound (TRUS–guided prostate biopsy is known to carry a significant false-negative rate, leading some patients to have multiple biopsies. We investigated cancer detection rates in patients with a PSA >20 ng/ml and a negative initial biopsy. We reviewed our database of 2396 TRUS-guided biopsies done between 1997 and 2002 in order to give a follow-up of at least 6 years. PSA, PSA density (PSAD, PSA velocity (PSAV, prostate volume, and DRE findings were analysed in relation to cancer status. Of the patients, 388 (16% had a PSA >20 ng/ml, including 99 (26% with benign biopsies. Of those, 67 were rebiopsied, including 19 (28% with cancer on the first rebiopsy and four (6% on further biopsies. PSAD, DRE, and volume significantly differed between rebiopsied patients with and without cancer (p 20 ng/ml and have an initial negative biopsy have a high chance of malignancy being detected on a second biopsy. However, if a second biopsy is also negative, then the chances of subsequent biopsies showing signs of cancer are very low if the DRE is normal and particularly if the PSAD is >0.35 ng/ml/cm3.

  12. Self-assembled particulate PsaA as vaccine against Streptococcus pneumoniae infection

    Directory of Open Access Journals (Sweden)

    Majela González-Miro

    2017-04-01

    Full Text Available Streptococcus pneumoniae is a human pathogen responsible for the majority of childhood pneumonia and media otitis cases worldwide. The diversity of its capsular polysaccharides (CPS results in more than 91 serotypes of which at least 23 are virulent. Various CPS conjugated to immunogenic carrier proteins are currently licensed and provide protection against the infection caused by the respective serotypes but not against new and emerging virulent serotypes. In this study, we considered the conserved protein antigen PsaA, the pneumococcal surface adhesin A, in order to overcome the limitations of CPS antigens. The PsaA was translationally fused to a polyhydroxybutyrate (PHB synthase which mediated production of PsaA displayed on PHB inclusions in recombinant Escherichia coli. This suggested that the PsaA fusion to the PHB synthase did not interfere with PHB synthase activity and its ability to mediate formation of nano-sized inclusions composed of a PHB core surrounded by the PHB synthase fused to PsaA. Isolated PHB beads showed a negative surface charge. Transmission electron microscopy analysis suggested that the PsaA fusion to the PHB synthase reduced the size of PHB beads from about 500 nm to 100 nm. The integrity and antigenicity of the fusion protein attached to isolated PHB beads was confirmed by SDS-PAGE, tryptic peptide fingerprinting analysis using MALDI-TOF-MS/MS and immunoblotting using a monoclonal anti-PsaA antibody. Mice immunized with PsaA displaying PHB beads produced high and specific IgG levels dominated by IgG1 isotype. While IgG1 titer were similar between soluble and insoluble PsaA, the IgG2 titers were strongly increased upon vaccination with insoluble PsaA i.e. PsaA displayed on PHB beads. Particulate PsaA-PHB beads elicited IgG antibodies recognizing PsaA in whole cell lysates of seven different serotypes of S. pneumoniae. This study suggested that PHB beads are suitable carriers for PsaA in order to induce a significant

  13. Multi-span transmission using phase and amplitude regeneration in PPLN-based PSA.

    Science.gov (United States)

    Umeki, T; Asobe, M; Takara, H; Miyamoto, Y; Takenouchi, H

    2013-07-29

    We demonstrated multi-span transmission using a periodically poled LiNbO(3) (PPLN) based phase sensitive amplifier (PSA). An in-line PSA with a carrier recovery and phase locking system is implemented as a repeater amplifier in a recirculating loop. We achieved a PSA gain as high as + 18 dB and a high external gain of + 12 dB for the in-line PSA as a black box. The impairments caused by phase noise resulting from fiber nonlinearity and intensity noise caused by the amplified spontaneous emission (ASE) of an optical amplifier are largely suppressed using the phase and amplitude regeneration capabilities of the PSA. The ultra long-haul transmission of a 28-Gb/s binary phase shift keying (BPSK) signal over 5400 km was achieved with phase and amplitude regeneration.

  14. EOP Improvement Proposal for SGTR based on The OPR PSA Update

    Energy Technology Data Exchange (ETDEWEB)

    Park, Jin Hee; Cho, Jae Hyun; Kim, Dong San; Yang, Joon Eon [KAERI, Daejeon (Korea, Republic of)

    2016-05-15

    This updating process was also focused to enhance the PSA quality and to respect the as built and as operated conditions of target plants. For this purpose, the EOP(Emergency Operating Procedure) and AOP(Abnormal Operating Procedure) of target plant were reviewed in detail and various thermal hydraulic(T/H) analysis were also performed to analyze the realistic PSA accident sequence model. In this paper, the unreasonable point of SGTR (Steam Generator Tube Rupture) EOP based on PSA perspective was identified and the initial proposal for EOP change items from PSA insight was proposed. In this paper, the unreasonable point of SGTR EOP based on PSA perspective was identified and the EOP improvement items are proposed to enhance safety and operator's convenience for the target plant.

  15. Lessons learnt from PSA for new and advanced reactors in Russia

    Energy Technology Data Exchange (ETDEWEB)

    Tokmachev, G.; Morozov, V. [JSC ' ' Atomenergoproekt' ' , Moscow (Russian Federation)

    2011-11-15

    Customer requirements to probabilistic safety targets are usually stronger than existing Regulatory or IAEA ones. It appears that industry takes the lead over regulation in this case and forces the designer to find and implement appropriate means to enhance safety, which sometimes have no reference to practical experience. On the other hand, regulatory documents and the existing PSA methodology are mainly oriented to operating plants. This creates problems when developing a PSA as well as performing regulatory reviews. The scope of the PSA may be different depending on a design stage such as the development conceptual, basic or detailed design. In addition, the base case PSA is usually performed for NPP in design. However, a customer may require additional PSA applications to consider, for instance, risk monitoring. In this case the scope of the PSA should be extended to implement special attributes of the application needed that often requires specific information not available at the design stage. Lack of design information affecting PSA development may be associated with incompleteness of the design that is typical for interim design stages and communication problems caused by the involvement of many different companies in the deign activity. To deal with this issue bounding technologies and the iterative PSA development are used. However this sometimes contradicts to the ''best estimate'' approach recommended by regulatory guides. PSA development for advanced NPPs has raised some issues originated from unknown new components, processes and technologies incorporated into the design of an advanced plant. The paper addresses some issues resolved while carrying out PSAs for advanced NPPs. Some PSA results for new advanced VVER plants under construction and the first lessons learnt from the Fukushima accident are also discussed. (orig.)

  16. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.

    Science.gov (United States)

    DiPaola, Robert S; Chen, Yu-Hui; Bubley, Glenn J; Stein, Mark N; Hahn, Noah M; Carducci, Michael A; Lattime, Edmund C; Gulley, James L; Arlen, Philip M; Butterfield, Lisa H; Wilding, George

    2015-09-01

    E9802 was a phase 2 multi-institution study conducted to evaluate the safety and effectiveness of vaccinia and fowlpox prostate-specific antigen (PSA) vaccine (step 1) followed by combination with androgen ablation therapy (step 2) in patients with PSA progression without visible metastasis. To test the hypothesis that vaccine therapy in this early disease setting will be safe and have a biochemical effect that would support future studies of immunotherapy in patients with minimal disease burden. Patients who had PSA progression following local therapy were treated with PROSTVAC-V (vaccinia)/TRICOM on cycle 1 followed by PROSTVAC-F (fowlpox)/TRICOM for subsequent cycles in combination with granulocyte-macrophage colony-stimulating factor (step 1). Androgen ablation was added on progression (step 2). Step 1 primary end points included progression at 6 mo and characterization of change in PSA velocity pretreatment to post-treatment. Step 2 end points included PSA response with combined vaccine and androgen ablation. In step 1, 25 of 40 eligible patients (63%) were progression free at 6 mo after registration (90% confidence interval [CI], 48-75). The median pretreatment PSA velocity was 0.13 log(PSA)/mo, in contrast to median postregistration velocity of 0.09 log(PSA)/mo (p=0.02), which is an increase in median PSA doubling time from 5.3 mo to 7.7 mo. No grade ≥4 treatment-related toxicity was observed. In the 27 patients eligible and treated for step 2, 20 patients achieved a complete response (CR) at 7 mo (CR rate: 74%; 90% CI, 57-87). Although supportive of larger studies in the cooperative group setting, this study is limited by the small number of patients and the absence of a control group as in a phase 3 study. A viral PSA vaccine can be administered safely in the multi-institutional cooperative group setting to patients with minimal disease volume alone and combined with androgen ablation, supporting the feasibility of future phase 3 studies in this

  17. Postoperative monitoring of prostate-specific antigen (PSA after treatment with high-intensive focused ultrasound (HIFU

    Directory of Open Access Journals (Sweden)

    Blyumberg B.I.

    2012-12-01

    Full Text Available Research objective: to estimate efficiency of treatment of prostate cancer using high-intensive focused ultrasound on the basis of laboratory analysis of postoperative level prostate-specific antigen (PSA. Objects of research. Objects of research consisted of 110 patients treated in urological clinic of Hospital n.a. S. R. Mirotvortsev (Saratov State Medical University during the period February, 2009 — March, 2012. Patients took 110 sessions of primary operative treatment of prostate cancer by HIFU therapy method. Technique and research methods. Concentration of PSA in blood changed in all patients every 1,5 month within 6 months after operation, irrespective of its kind (including after repeated HIFU, further — after every 3 month till one year, and later on after 6 months. We were guided by references of the International Consensus, which considers PSA level more than 0,5 ng/ml in blood after 3 months of treatment to be unsatisfactory result. We also headed for PSA level before treatment and oncological risk degree. Results. Median nadir formed 0,5 ng/ml PSA by 3 months after treatment. Patients demonstrated different indicators of PSA dynamics depending on oncological risk, stage and hormonal therapy management. Patients with low oncological risk had initially lower PSA concentration, further PSA concentration reached nadir level faster. At patients with widespread forms of prostate cancer accurate dependence of PSA concentration according to prevalence of process was traced. Time of PSA nadir amount did not differ and was marked as 12-14 weeks on average. At patients received hormonal therapy, lower value of PSA nadir was marked. The conclusion. Monitoring of PSA concentration (PSA nadir by 3 months, dynamics of PSA concentration change is of great importance in early revealing of relapse after prostate HIFU therapy. High level of PSA nadir and PSA growth according to time period are important prognostic factors.

  18. Key Characteristics of Combined Accident including TLOFW accident for PSA Modeling

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Bo Gyung; Kang, Hyun Gook [KAIST, Daejeon (Korea, Republic of); Yoon, Ho Joon [Khalifa University of Science, Technology and Research, Abu Dhabi (United Arab Emirates)

    2015-05-15

    The conventional PSA techniques cannot adequately evaluate all events. The conventional PSA models usually focus on single internal events such as DBAs, the external hazards such as fire, seismic. However, the Fukushima accident of Japan in 2011 reveals that very rare event is necessary to be considered in the PSA model to prevent the radioactive release to environment caused by poor treatment based on lack of the information, and to improve the emergency operation procedure. Especially, the results from PSA can be used to decision making for regulators. Moreover, designers can consider the weakness of plant safety based on the quantified results and understand accident sequence based on human actions and system availability. This study is for PSA modeling of combined accidents including total loss of feedwater (TLOFW) accident. The TLOFW accident is a representative accident involving the failure of cooling through secondary side. If the amount of heat transfer is not enough due to the failure of secondary side, the heat will be accumulated to the primary side by continuous core decay heat. Transients with loss of feedwater include total loss of feedwater accident, loss of condenser vacuum accident, and closure of all MSIVs. When residual heat removal by the secondary side is terminated, the safety injection into the RCS with direct primary depressurization would provide alternative heat removal. This operation is called feed and bleed (F and B) operation. Combined accidents including TLOFW accident are very rare event and partially considered in conventional PSA model. Since the necessity of F and B operation is related to plant conditions, the PSA modeling for combined accidents including TLOFW accident is necessary to identify the design and operational vulnerabilities.The PSA is significant to assess the risk of NPPs, and to identify the design and operational vulnerabilities. Even though the combined accident is very rare event, the consequence of combined

  19. BIOCARBURANTS PSA Peugeot Citroën et les biocarburants

    Directory of Open Access Journals (Sweden)

    Maurer Béatrice

    2002-09-01

    Full Text Available Les biocarburants représentent une filière essentielle pour PSA Peugeot Citroën dans le cadre de la protection de l’environnement, un axe stratégique majeur pour le groupe - de la production de ses véhicules au recyclage, de la qualité de l’air à l’effet de serre et au développement d’énergies renouvelables. Depuis plusieurs années, PSA a intégré la filière huiles végétales/biocarburants dans ses activités pour atteindre ses objectifs globaux d’innovation et de croissance. De nombreuses flottes de véhicules circulent en France avec du gazole contenant 30 % de biocarburant issu des oléagineux : une expérience réussie, qui dure depuis plus de dix ans. Le constructeur est favorable à l’utilisation de biocarburants en mélange dans les carburants pétroliers conventionnels, essence et gazole - une voie qui présente plusieurs avantages : * Un bilan CO2 global favorable (par absorption de CO2 lors de la photosynthèse de la plante-source, qui contribue à limiter « l’effet de serre ». * Une source complémentaire de carburant pour réduire les importations de pétrole (et de gazole. * Un soutien au secteur agricole (débouché supplémentaire, dans le cadre de la valorisation des terres en jachère. Issus de la transformation des céréales ou de la betterave à sucre, ou des plantes oléagineuses comme le colza, le tournesol ou le soja, les biocarburants sont par essence des énergies renouvelables. Outre leur bilan exceptionnellement favorable pour lutter contre l’effet de serre, ces carburants offrent de réelles performances environnementales, en particulier par la réduction des émissions de particules (cas des EMHV.

  20. Accuracy of PSA Self-Reports among Low-Income Men with Prostate Cancer after a Public Health Nursing Intervention.

    Science.gov (United States)

    Zavala, Mary Wassel; Yule, Arthur; Kwan, Lorna; Lambrechts, Sylvia; Maliski, Sally L; Litwin, Mark S

    2016-11-01

    To examine accuracy of patient-reported prostate-specific antigen (PSA) levels among indigent, uninsured men in a state-funded prostate cancer treatment program that provides case management, care coordination, and health education. Program evaluation. About 114 men with matched self- and lab-reported PSA levels at program enrollment and another time point within 18 months. Abstraction of self- and lab-reported PSA levels to determine self-report as "accurate" or "inaccurate," and evaluate accuracy change over time, before and after nursing interventions. Chi-square tests compared patients with accurate versus inaccurate PSA values. Nonlinear multivariate analyses explored trends in self-reported accuracy over time. Program enrollees receive prostate cancer education from a Nurse Case Manager (NCM), including significance of PSA levels. Men self-report PSA results to their NCM following lab draws and appointments. The NCM provides ongoing education about PSA levels. Of the sample, 46% (n = 53) accurately reported PSA levels. Accuracy of PSA self-reports improved with increasing time since program enrollment. Compared with men at public facilities, those treated at private facilities showed increasing accuracy in self-reported PSA (p = .038). A targeted nursing intervention may increase specific knowledge of PSA levels. Additionally, the provider/treatment setting significantly impacts a patient's disease education and knowledge. © 2016 Wiley Periodicals, Inc.

  1. Potentiometric stripping analysis (PSA) for monitoring of antimony in samples of vegetation from a mining area

    Energy Technology Data Exchange (ETDEWEB)

    Toro Gordillo, M.C.; Pinilla Gil, E. [Dept. de Quimica Analitica y Electroquimica, Universidad de Extremadura, Badajoz (Spain); Rodriguez Gonzalez, M.A.; Murciego Murciego, A. [Area de Cristalografia y Mineralogia, Universidad de Extremadura, Badajoz (Spain); Ostapczuk, P. [Forschungszentrum Juelich GmbH (Germany)

    2001-06-01

    A potentiometric stripping analysis (PSA) method has been developed and checked for the fast and reliable determination of antimony in vegetation samples of Cistus ladanifer from a mining area in Badajoz, Southwest Spain. The method, modified from previous PSA methods for Sb in environmental samples, is based on dry ashing of the homogenized leaves, dissolution in hydrochloric acid, and PSA analysis on a mercury film plated on to a glassy carbon disk electrode. The influence of experimental variables such as the deposition potential, the deposition time, the signal stability and the calibration parameters, has been investigated. The method has been compared with an independent technique (instrumental neutron activation analysis) by analysis of standards and reference materials and comparison of the results. As a result of automation of the PSA equipment, the proposed method enables unattended analysis of 20 digested samples in a total time of 2 h, thus providing a useful tool for Sb monitoring of a large number of samples. (orig.)

  2. Potentiometric stripping analysis (PSA) for monitoring of antimony in samples of vegetation from a mining area.

    Science.gov (United States)

    Toro Gordillo, M C; Pinilla Gil, E; Rodríguez González, M A; Murciego Murciego, A; Ostapczuk, P

    2001-06-01

    A potentiometric stripping analysis (PSA) method has been developed and checked for the fast and reliable determination of antimony in vegetation samples of Cistus ladanifer from a mining area in Badajoz, Southwest Spain. The method, modified from previous PSA methods for Sb in environmental samples, is based on dry ashing of the homogenized leaves, dissolution in hydrochloric acid, and PSA analysis on a mercury film plated on to a glassy carbon disk electrode. The influence of experimental variables such as the deposition potential, the deposition time, the signal stability and the calibration parameters, has been investigated. The method has been compared with an independent technique (instrumental neutron activation analysis) by analysis of standards and reference materials and comparison of the results. As a result of automation of the PSA equipment, the proposed method enables unattended analysis of 20 digested samples in a total time of 2 h, thus providing a useful tool for Sb monitoring of a large number of samples.

  3. A Diet, Physical Activity, and Meditation Intervention in Men With Rising Prostate-Specific Antigen (PSA)

    National Research Council Canada - National Science Library

    Hebert, James R

    2006-01-01

    ... physical activity and mindfulness-based stress reduction. This randomized trial will enroll 60 men with rising PSA levels along with a partner of their choice, half of whom will be randomized to the intervention and half to usual care...

  4. A Diet, Physical Activity, and Mediation Intervention in Men With Rising Prostate-Specific Antigen (PSA)

    National Research Council Canada - National Science Library

    Hebert, James

    2004-01-01

    ... physical activity and mindfulness-based stress reduction. This randomized trial will enroll 60 men with rising PSA levels along with a partner of their choice, half of whom will be randomized to the intervention and half to usual care...

  5. A Diet, Physical Activity, and Meditation Intervention in Men With Rising Prostate-Specific Antigen (PSA)

    National Research Council Canada - National Science Library

    Hebert, James R

    2007-01-01

    ... physical activity and mindfulness-based stress reduction. This randomized trial will enroll 60 men with rising PSA levels along with a partner of their choice, half of whom will be randomized to the intervention and half to usual care...

  6. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer

    DEFF Research Database (Denmark)

    Bryce, A H; Alumkal, J J; Armstrong, A

    2017-01-01

    BACKGROUND: Advanced prostate cancer is a phenotypically diverse disease that evolves through multiple clinical courses. PSA level is the most widely used parameter for disease monitoring, but it has well-recognized limitations. Unlike in clinical trials, in practice, clinicians may rely on PSA...... monitoring alone to determine disease status on therapy. This approach has not been adequately tested. METHODS: Chemotherapy-naive asymptomatic or mildly symptomatic men (n=872) with metastatic castration-resistant prostate cancer (mCRPC) who were treated with the androgen receptor inhibitor enzalutamide...... treated with enzalutamide. As restaging in advanced prostate cancer patients is often guided by increases in PSA levels, our results demonstrate that disease progression on enzalutamide can occur without rising PSA levels. Therefore, a disease monitoring strategy that includes imaging not entirely reliant...

  7. A population study of fasting time and serum prostate-specific antigen (PSA) level

    National Research Council Canada - National Science Library

    Lau, Cheryl K; Guo, Maggie; Viczko, Jeannine A; Naugler, Christopher T

    2014-01-01

    .... Recently, it has been shown that fasting extremes can affect concentrations of serum chemistry analytes, thus raising the question of whether or not fasting has an effect on the highly sensitive PSA biomarker...

  8. Safety analyses: the importance of PSA and ZEDB. ZEDB: tool determining plant-specific reliability data; Sicherheitsanalysen, Bedeutung von PSA und ZEDB. ZEDB: Instrument zur Ermittlung anlagenspezifischer Zuverlaessigkeitsdaten

    Energy Technology Data Exchange (ETDEWEB)

    Brahmstaedt, Kai-Uwe [E.ON Kernkraft GmbH, Kernkraftwerk Brokdorf (Germany); Schubert, Bernd [Vattenfall Europe Nuclear Energy GmBH, Stoerfall- und Zuverlaessigkeitsanalysen, Anlagentechnik, Hamburg (Germany); Seidel, Andre [VGB Power Tech e.V., Essen (Germany)

    2009-06-15

    Safety inspections of nuclear power plants under the Atomic Energy Act are regulated, inter alia, in the Probabilistic Safety Analysis (PSA) guideline. These analyses are performed in addition to the safety assessments based, on deterministic principles. In this way, the influence of components, systems, and structures, as well as actions by personnel, on plant behavior in terms of technical safety can be described in a holistic approach and the safety level thus can be assessed quantitatively. Conducting a PSA requires plant-specific reliability data which are determined in the plant in question, but are also collected and stored centrally in the central reliability and event database (ZEDB). (orig.)

  9. The association of general practitioners’ risk attitudes, level of empathy and burnout status with PSA testing

    DEFF Research Database (Denmark)

    Pedersen, Anette Fischer; Carlsen, Anders Helles; Vedsted, Peter

    2015-01-01

    Når alment praktiserende læger sammenlignes, finder man ofte stor variation i raten af PSA-tests foretaget på mandlige patienter. Dette studie viser, at lægens risikovillighed influerer på raten af PSA-tests. Således har patienter, som er registreret hos en læge, som har mange bekymringer for fej...

  10. utility of prostate specific antigen (psa) in the indigenous african man

    African Journals Online (AJOL)

    categories of ≤4ng/ml and >4ng/ml in ratios of 3.3:1 and 1.5:1 respectively. It, however, had PSA levels between 2 and 15 ng/ml. The odd ratio for BPH to be in the normal range was 2.0 while cancer of the prostate had a 1.7 odd ratio for elevated PSA. Seven patients clinically diagnosed as BPH had histological findings of ...

  11. The Hidden Burden of Outpatient Repeat PSA Testing in a Prospective Cohort

    LENUS (Irish Health Repository)

    Browne, E

    2017-05-01

    PSA testing is widespread throughout Europe for diagnostic purposes and follow up. We performed a prospective outpatient cohort study of 250 men (2013-2015) in two hospital sites. Included were those men being followed up by urology with PSA blood testing. First appointments and those men in whom non-PSA tests were ordered by urology were excluded. The median age was 67.2yrs (46-88). Eighty-one point two percent of samples had a combination of 21 different serology tests at an added cost of >€18,000. Abnormal serology resulted in 53 referrals. Twenty-six-six percentof correspondence referenced abnormal serology other than PSA. Follow up of non-PSA test results poses a challenge in an outpatient setting with failure to appropriately follow-up on abnormal results, increased costs, and medico-legal implications. There is currently no Irish legislature in place to safeguard hospital physicians. This study quantifies the levels of expenditure, resources and risk associated with ambulant PSA testing.

  12. Can the Free/Total PSA Ratio Predict the Gleason Score Before Prostate Biopsy?

    Science.gov (United States)

    Ceylan, Cavit; Gazel, Eymen; Keleş, İbrahim; Doluoğlu, Ömer; Yığman, Metin

    2016-02-01

    To determine whether there is a correlation between high Gleason score and free/total (f/t) prostate specific antigen (PSA) in patients newly diagnosed with prostate carcinoma. The study included 272 prostate biopsy patients whose total PSA value ranged from 4-10 ng/ml. The patients were divided into 2 groups according to the f/t PSA ratio: Group 1 ≤ 15% and Group 2 > 15%. Furthermore, the groups were also compared to each other in terms of mild (≤ 6), moderate (= 7), and high (≥ 8) Gleason score. Group 1 consisted of 135 (49.6%) patients and Group 2 consisted of 137 (50.4%) patients. While 27 (20%) patients had a high Gleason score in Group 1, only 10 (7.3%) patients had a high Gleason score in Group 2 (p = 0.008). Using Spearman's correlation test, we found that the f/t PSA ratios were observed to decrease significantly in all patients with increased Gleason scores (p = 0.002, r = -0.185). According to our study, there is a relationship between higher Gleason score and decreased f/t PSA ratio. Therefore, f/t PSA can be an indicator for predicting the Gleason score.

  13. Development of computing code system for level 3 PSA

    Energy Technology Data Exchange (ETDEWEB)

    Jeong, Jong Tae; Yu, Dong Han; Kim, Seung Hwan

    1997-07-01

    Among the various research areas of the level 3 PSA, the effect of terrain on the transport of radioactive material was investigated through wind tunnel experiment. These results will give a physical insight in the development of a new dispersion model. Because there are some discrepancies between the results from Gaussian plume model and those from field test, the effect of terrain on the atmospheric dispersion was investigated by using CTDMPLUS code. Through this study we find that the model which can treat terrain effect is essential in the atmospheric dispersion of radioactive materials and the CTDMPLUS model can be used as a useful tool. And it is suggested that modification of a model and experimental study should be made through the continuous effort. The health effect assessment near the Yonggwang site by using IPE (Individual plant examination) results and its site data was performed. The health effect assessment is an important part of consequence analysis of a nuclear power plant site. The MACCS was used in the assessment. Based on the calculation of CCDF for each risk measure, it is shown that CCDF has a slow slope and thus wide probability distribution in cases of early fatality, early injury, total early fatality risk, and total weighted early fatality risk. And in cases of cancer fatality and population dose within 48km and 80km, the CCDF curve have a steep slope and thus narrow probability distribution. The establishment of methodologies for necessary models for consequence analysis resulting form a server accident in the nuclear power plant was made and a program for consequence analysis was developed. The models include atmospheric transport and diffusion, calculation of exposure doses for various pathways, and assessment of health effects and associated risks. Finally, the economic impact resulting form an accident in a nuclear power plant was investigated. In this study, estimation models for each cost terms that considered in economic

  14. Evaluating the Impact of PSA as a Selection Criteria for Nerve Sparing Radical Prostatectomy in a Screened Cohort

    Directory of Open Access Journals (Sweden)

    Shyam K. Tanguturi

    2014-01-01

    Full Text Available Purpose. We investigated whether NS-RP increased risk of PSA failure and whether PSA should be included as a selection criterion for NS. Methods. We evaluated 357 consecutive men with screen-detected PC who underwent open RP without adjuvant radiotherapy between 9/11/2001 and 12/30/2008. Criteria for NS included Gleason score ≤3 + 4, percentage of positive biopsies (PPB ≤50%, percentage of core involvement ≤50%, nonapical location, no perineural invasion, and no palpable disease on pre- or intraoperative exam but did not include a PSA threshold. Cox multivariable regression assessed whether increasing PSA or unilateral- or bilateral-NS versus non-NS-RP was associated with PSA failure adjusting for prognostic factors. Results. After a median follow-up of 3.96 years, 34 men sustained PSA failure (9.5%. Increasing PSA was significantly associated with increased risk of PSA failure in the interaction model (adjusted hazard ratio (AHR: 1.09 [95% CI: 1.03–1.16]; P=0.005, whereas unilateral (AHR: 1.24 [95% CI: 0.36–4.34]; P=0.73 or bilateral NS (AHR: 0.41 [95% CI: 0.06–2.59]; P=0.34 versus non-NS RP was not. Conclusion. NS-RP in a screened cohort did not increase risk of PSA failure using NS criteria not including PSA.

  15. Guidance to risk-informed evaluation of technical specifications using PSA

    Energy Technology Data Exchange (ETDEWEB)

    Baeckstroem, O.; Haeggstroem, A. (Scandpower AB, Stockholm (Sweden)); Maennistoe, I. (VTT, Helsingfors (Finland))

    2010-04-15

    This report presents guidance for evaluation of Technical Specification conditions with PSA. It covers quality in PSA, how to verify that the PSA model is sufficiently robust and sufficiently complete and general requirements on methods. Acceptance criteria for evaluation of changes in the TS conditions are presented. As the probabilistic safety assessment (PSA) has developed over the years, it has demonstrated to constitute a useful tool for evaluating many aspects of the TS from a risk point of view. and in that way making the PSAs as well as the decision tools better. This also means that it will be possible to take credit for safety system overcapacity as well as inherent safety features and strength of non-safety classed systems. However, PSA is only one of the tools that shall be used in an evaluation process of TS changes (strengthening/relaxation). PSA is an excellent tool to be used to verify the importance, and thereby possibly relaxation, of TS requirements. But, since PSA is only one tool in the evaluation, it is not sufficient in itself for defining which equipment that shall or shall not have TS requirements. The purpose of this guidance document is to provide general requirements, requirements on methods and acceptance criteria on risk-informed evaluation of TS changes based on PSA. The purpose is not to provide a single solution. As part of the review of the TS conditions this guidance specify requirements on: - Quality verification of the PSA model; - Verification that the PSA model is sufficiently robust with regard to SSCs for which requirements both are and are not defined by the TS; - Verification that the SSCs, for which TS demands are to be evaluated, are modelled in a sufficient manner; - Methods for performing the evaluation; - Which evaluation criteria that shall be used (and how that is verified to be correct); - Acceptance criteria: This guidance also briefly discusses the documentation of the analysis of the TS changes. This guidance

  16. Automated installation for gas separation and purification using the Pressure Swing Adsorption (PSA) process; Instalacao automatizada para separacao e purificacao de gases por PSA

    Energy Technology Data Exchange (ETDEWEB)

    Neves, Celia F. Cordeiro; Schvartzman, Monica M.A.M. [Centro de Desenvolvimento da Tecnologia Nuclear (CDTN), Belo Horizonte, MG (Brazil); Jordao, Elizabete [Universidade Estadual de Campinas, SP (Brazil). Dept. de Engenharia de Sistemas Quimicos e Informatica

    1999-11-01

    This paper describes the first laboratorial PSA (Pressure Swing Adsorption) unit designed and built in Brazil for gas separation by adsorption process. It consists of a stainless steel column, which was filled with zeolite 5A molecular sieve. Six solenoid valves located at the feed., product, countercurrent and high-pressure air lines were used to regulate the flow directions of different streams. Pressure and flowrate transducers and thermocouples were used to record respectively the pressure, flowrate of both feed and product stream and temperature history of the process. These instruments and the solenoid valves were joined to a programmable logic controller. By the use of a computer the unit can be automatically operated to simulate all steps in the PSA cycle and data can be easily acquired and recorded. The unit will be used to study basic parameters of PSA processes and to separate several gas mixtures. As a first goal the unit will be operated to produce oxygen-enriched air using synthetic zeolites. This PSA laboratory unit is an important step in CDTN`s objective of consolidating a research group in gas separation by adsorption processes. (author) 7 refs., 8 figs., 2 tabs.

  17. Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau).

    Science.gov (United States)

    Randazzo, Marco; Beatrice, Josef; Huber, Andreas; Grobholz, Rainer; Manka, Lukas; Wyler, Stephen F; Chun, Felix F; Recker, Franz; Kwiatkowski, Maciej

    2015-08-01

    To analyze the effect of the oral antidiabetic drug metformin on PSA level, free-to-total PSA ratio (f/t-ratio), PCa incidence and grade as well as mortality in men participating in a population-based screening trial. Data from 4,314 men aged 55-70 years from a population-based PSA-screening trial (ERSPC Aarau) were analyzed. Information on metformin exposure was obtained by a self-administered questionnaire. Serum PSA threshold at ≥3 ng/ml triggered prostate biopsy. Data on PCa incidence and mortality were obtained through registry linkages. Median follow-up time was 7.6 years. Mean age at baseline was 65.5 years (±SD 4.4). In all, n = 150 (3.5 %) men used metformin [metf+]. Mean baseline PSA levels were comparable between both groups ([metf+] 1.6 ng/ml ± 2.4 vs. [metf-] 1.8ug/l ± 2.2, p = 0.4) while f/t-ratio was slightly higher in metformin users ([metf+] 30.7 % ± 10.9 vs. [metf-] 27.3 % ± 10.9, p = 0.01). Overall, n = 372 (8.6 %) PCa cases were detected. Neither cumulative PCa incidence (n = 11; 7.3 % [metf+] vs. n = 361 8.7 % [metf-]; p = 0.5) nor d`Amico risk groups were significantly different between both groups. One man in each group (metf+ 0.7 % and metf- 0.02 %) died from PCa (p incidence and grade were observed. The slightly higher f/t-ratio did not result in lower PCa detection rate. Metformin users were at significantly higher risk of all-cause mortality. The relatively small number of men on metformin is a main limitation of the study.

  18. Serum PSA and cure perspective for prostate cancer in males with nonpalpable tumor

    Directory of Open Access Journals (Sweden)

    Marcos F. Dall'Oglio

    2005-10-01

    Full Text Available INTRODUCTION: Many studies have shown the association between PSA levels and the subsequent detection of prostate cancer. In the present trial, we have studied the relationship between preoperative PSA levels and clinical outcome following radical prostatectomy in men with clinical stage T1c. MATERIALS AND METHODS: 257 individuals with clinical stage T1c undergoing retropubic radical prostatectomy were selected in the period from 1991 to 2000. Following surgery, biochemical recurrence-free survival curves were constructed according to PSA levels between 0-4; 4.1-10; 10.1-20 and > 20 ng/mL. RESULTS: Of the total of 257 selected patients, 206 (80% had Gleason scores from 2 to 6 and 51 (20%, presented Gleason scores 7 and 8, as defined by the pathological report from prostate biopsy. There was no biochemical recurrence of disease when the PSA was lower than 4, regardless of Gleason score. Biochemical recurrence-free survival according to PSA between 0-4; 4.1-10; 10.1-20 and > 20 was 100%, 87.6%, 79% and 68.8% for Gleason scores 2-6 and 100%; 79.4%; 40% and 100% for Gleason scores 7-8 respectively. When all individuals were grouped, regardless of their Gleason scores, the probability of biochemical recurrence-free survival was 100%, 65.1%, 53.4% and 72.2% according to PSA between 0-4; 4.1-10; 10.1-20 and > 20 ng/mL respectively. CONCLUSION: Non-palpable prostate cancer presents higher chances of cure when the PSA is inferior to 4 ng/mL.

  19. Correlation Between MRS and Serum PSA in the Diagnosis of Local Recurrence After Radical Prostatectomy

    Directory of Open Access Journals (Sweden)

    M Ghafuri

    2012-08-01

    Full Text Available Background: Multifocality, multicentricity and extension beyond the prostate capsule are all characteristics of prostatic adenocarcinoma that may escape diagnosis by conventional CT scanning or MRI. This study was designed to assess the diagnostic value of magnetic resonance spectroscopy (MRS in prostatic carcinoma and its compatibility with prostatic specific antigen (PSA as the conventional method.Methods: In this cross-sectional study, we recruited 139 patients with previous radical prostatectomy referring to Radiology department of Hazrate-e-Rasul Hospital during the first half of 2011 for the evaluation of local recurrence. Traditionally, local recurrence is defined as serum PSA concentration >0.2 ng/dl. We used 1.5-tesla Siemens Avanto MRI unit with endorectal coil and measured creatine, choline and citrate levels before calculating choline-creatine/citrate ratio. Correlation between MRS findings with PSA concentration was evaluated in regards to the multiple levels of the previously mentioned ratio.Results: Local recurrence was found in 107 (77% patients based on PSA levels. The mean values for serum PSA levels and creatine-choline/citrate ratio were significantly different in patients with and without local recurrence. Creatine-choline/citrate ratios greater than 50, 100 and 150 (as different cut-off points of recurrence were respectively seen in 104, 102 and 97 patients and agreement ratio between MRS and PSA in these levels were 94.1%, 94.4% and 85.1%, respectively. Correlation coefficient between these two methods was 0.481.Conclusion: MRS is a valuable tool for evaluating recurrence inpatients with prostate cancer treated by radical prostatectomy and it is in good agreement with serum PSA levels.

  20. Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values.

    Science.gov (United States)

    Yilmaz, Hasan; Ciftci, Seyfettin; Yavuz, Ufuk; Ustuner, Murat; Saribacak, Ali; Dillioglugil, Ozdal

    2015-06-01

    The aim of this study was to evaluate the predictive role of percentage of free prostate-specific antigen (%fPSA) cut-points in prostate cancer (PCa) detection in patients with total PSA (tPSA) levels between 2.5 ng/mL and 10.0 ng/mL. In total, 1321 consecutive initial transrectal ultrasound (TRUS)-guided 12-core biopsies performed between 2005 and 2011 were evaluated retrospectively. Benign pathologies, high-grade prostatic intraepithelial neoplasia, and atypical small acinary proliferations were categorized as noncancerous (benign), and prostate adenocarcinomas were categorized as cancerous (malignant). The patients were categorized according to: Catalona's published %fPSA categories ( 25%); digital rectal examination (DRE) results [benign (negative) or suspicious of malignancy (positive)]. There was a significant relationship between the %fPSA cut-points and detection of PCa in DRE-negative patients. The presence of a 10% cut-point increased the probability of PCa threefold. The %fPSA was significantly more related to PCa than the tPSA value in receiver operating characteristic (ROC) curve analyses (p = 0.001). Based on our findings, a lower %fPSA, especially <10%, is an important parameter when deciding whether to perform a biopsy on patients with a tPSA between 2.5 ng/mL and 10 ng/mL. Copyright © 2015. Published by Elsevier Taiwan.

  1. The New Planetary Science Archive (PSA): Exploration and Discovery of Scientific Datasets from ESA's Planetary Missions

    Science.gov (United States)

    Heather, David; Besse, Sebastien; Vallat, Claire; Barbarisi, Isa; Arviset, Christophe; De Marchi, Guido; Barthelemy, Maud; Coia, Daniela; Costa, Marc; Docasal, Ruben; Fraga, Diego; Grotheer, Emmanuel; Lim, Tanya; MacFarlane, Alan; Martinez, Santa; Rios, Carlos; Vallejo, Fran; Saiz, Jaime

    2017-04-01

    The Planetary Science Archive (PSA) is the European Space Agency's (ESA) repository of science data from all planetary science and exploration missions. The PSA provides access to scientific datasets through various interfaces at http://psa.esa.int. All datasets are scientifically peer-reviewed by independent scientists, and are compliant with the Planetary Data System (PDS) standards. The PSA is currently implementing a number of significant improvements, mostly driven by the evolution of the PDS standard, and the growing need for better interfaces and advanced applications to support science exploitation. As of the end of 2016, the PSA is hosting data from all of ESA's planetary missions. This includes ESA's first planetary mission Giotto that encountered comet 1P/Halley in 1986 with a flyby at 800km. Science data from Venus Express, Mars Express, Huygens and the SMART-1 mission are also all available at the PSA. The PSA also contains all science data from Rosetta, which explored comet 67P/Churyumov-Gerasimenko and asteroids Steins and Lutetia. The year 2016 has seen the arrival of the ExoMars 2016 data in the archive. In the upcoming years, at least three new projects are foreseen to be fully archived at the PSA. The BepiColombo mission is scheduled for launch in 2018. Following that, the ExoMars Rover Surface Platform (RSP) in 2020, and then the JUpiter ICy moon Explorer (JUICE). All of these will archive their data in the PSA. In addition, a few ground-based support programmes are also available, especially for the Venus Express and Rosetta missions. The newly designed PSA will enhance the user experience and will significantly reduce the complexity for users to find their data promoting one-click access to the scientific datasets with more customized views when needed. This includes a better integration with Planetary GIS analysis tools and Planetary interoperability services (search and retrieve data, supporting e.g. PDAP, EPN-TAP). It will also be up

  2. Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA screening

    Directory of Open Access Journals (Sweden)

    Black Amanda

    2011-04-01

    Full Text Available Abstract Background Despite the recent publication of results from two randomized clinical trials, prostate specific antigen (PSA screening for prostate cancer remains a controversial issue. There is lack of agreement across studies that PSA screening significantly reduces prostate cancer mortality. In spite of these facts, the widespread use of PSA testing in the United States leads to overdetection and overtreatment of clinically indolent prostate cancer, and its associated harms of incontinence and impotence. Discussion Given the inconclusive results from clinical trials and incongruent PSA screening guidelines, the decision to screen for prostate cancer with PSA testing is an uncertain one for patients and health care providers. Screening guidelines from some health organizations recommend an informed decision making (IDM or shared decision making (SDM approach for deciding on PSA screening. These approaches aim to empower patients to choose among the available options by making them active participants in the decision making process. By increasing involvement of patients in the clinical decision-making process, IDM/SDM places more of the responsibility for a complex decision on the patient. Research suggests, however, that patients are not well-informed of the harms and benefits associated with prostate cancer screening and are also subject to an assortment of biases, emotion, fears, and irrational thought that interferes with making an informed decision. In response, the IDM/SDM approaches can be augmented with strategies from the philosophy of libertarian paternalism (LP to improve decision making. LP uses the insights of behavioural economics to help people better make better choices. Some of the main strategies of LP applicable to PSA decision making are a default decision rule, framing of decision aids, and timing of the decision. In this paper, we propose that applying strategies from libertarian paternalism can help with PSA

  3. Proteins Annexin A2 and PSA in Prostate Cancer Biopsies Do Not Predict Biochemical Failure.

    Science.gov (United States)

    Lamb, David S; Sondhauss, Sven; Dunne, Jonathan C; Woods, Lisa; Delahunt, Brett; Ferguson, Peter; Murray, Judith; Nacey, John N; Denham, James W; Jordan, T William

    2017-12-01

    We previously reported the use of mass spectrometry and western blotting to identify proteins from tumour regions of formalin-fixed paraffin-embedded biopsies from 16 men who presented with apparently localized prostate cancer, and found that annexin A2 (ANXA2) appeared to be a better predictor of subsequent biochemical failure than prostate-specific antigen (PSA). In this follow-up study, ANXA2 and PSA were measured using western blotting of proteins extracted from biopsies from 37 men from a subsequent prostate cancer trial. No significant differences in ANXA2 and PSA levels were observed between men with and without biochemical failure. The statistical effect sizes were small, d=0.116 for ANXA2, and 0.266 for PSA. ANXA2 and PSA proteins measured from biopsy tumour regions are unlikely to be good biomarkers for prediction of the clinical outcome of prostate cancer presenting with apparently localized disease. Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

  4. Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners.

    LENUS (Irish Health Repository)

    Drummond, Frances J

    2009-01-01

    BACKGROUND: Increased use of prostate specific antigen (PSA) has been associated with increased prostate cancer incidence. Ireland is estimated to have one of the highest prostate cancer incidences in Europe and has no national guidelines for prostate cancer screening. GPs have a pivotal role in influencing PSA testing, therefore, our aim was to describe GP testing practices and to identify factors influencing these. METHODS: A postal survey, including questions on clinical practice and experience, knowledge and demographics was distributed to all GPs (n = 3,683). The main outcomes were (i) PSA testing asymptomatic men and (ii) "inappropriate" PSA testing, defined as testing asymptomatic men aged < 50 or > 75 years. Factors associated with these outcomes were identified using logistic regression. RESULTS: 1,625 GPs responded (response rate corrected for eligibility = 53%). Most respondents (79%) would PSA test asymptomatic men. Of these, 34% and 51% would test asymptomatic men < 50 and > 75 years, respectively. In multivariate analyses, GPs were more likely to test asymptomatic men if they were >or= 50 years, in practice >or= 10 years, female or less knowledgeable about PSA efficacy. Male GPs who would have a PSA test themselves were > 8-times more likely to PSA test asymptomatic men than GPs who would not have a test. GPs who had an asymptomatic patient diagnosed with prostate cancer following PSA testing, were > 3-times more likely to test asymptomatic men. Practice-related factors positively associated with testing included: running \\'well man\\' clinics, performing occupational health checks and performing other tests routinely with PSA. Factors positively associated with \\'inappropriate\\' testing included; being male and willing to have a PSA test, having worked\\/trained in the UK and supporting annual PSA testing. 91% of respondents supported the development of national PSA testing guidelines. CONCLUSION: Our findings suggest that widespread PSA testing

  5. Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.

    Science.gov (United States)

    Conteduca, Vincenza; Caffo, Orazio; Lolli, Cristian; Aieta, Michele; Scarpi, Emanuela; Bianchi, Emanuela; Maines, Francesca; Schepisi, Giuseppe; Salvi, Samanta; Massari, Francesco; Carrozza, Francesco; Veccia, Antonello; Chiuri, Vincenzo E; Campadelli, Enrico; Facchini, Gaetano; De Giorgi, Ugo

    2017-06-01

    Early changes in PSA have been evaluated in association to treatment outcome. The aim of this study was to assess PSA surge phenomenon in castration-resistant prostate cancer (CRPC) patients treated with abiraterone and to correlate those variations with long-term treatment outcome. We retrospectively evaluated 330 CRPC patients in 11 Italian hospitals, monitoring PSA levels at baseline and every 4 weeks. Other clinical, biochemical and molecular parameters were determined at baseline. We considered PSA surge as PSA increase within the first 8 weeks from starting abiraterone more than 1% from baseline followed by a PSA decline. The log-rank test was applied to compare survival between groups of patients according to PSA surge. The impact of PSA surge on survival was evaluated by Cox regression analyses. A total of 330 patients with CRPC, median age 74 years (range, 45-90), received abiraterone (281 chemotherapy-treated and 49 chemotherapy-naïve). PSA surge was observed in 20 (7%) post-chemotherapy and 2 (4%) chemotherapy-naïve patients. For overall patients presenting PSA surge, timing of PSA peak from baseline was 5 ± 1.8 weeks and PSA rise from baseline was 21 ± 18.4%. The overall median follow-up was 23 months (range 1-62). No significant differences in progression-free survival and overall survival were observed between patients with and without PSA surge (P = 0.16 and =0.86, respectively). In addition, uni- and multivariate analyses showed no baseline factors related to PSA surge. PSA surge occurs in both chemotherapy-treated and chemotherapy-naïve patients treated with abiraterone resulting, however, in no long-term impact on outcome. Physicians and patients should be aware of PSA surge challenge to prevent a premature discontinuation of potentially effective therapy with abiraterone. Further larger and prospective studies are warranted to investigate this not infrequent phenomenon. © 2017 Wiley Periodicals, Inc.

  6. The preoperative serum ratio of total prostate specific antigen (PSA to free testosterone (FT, PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy

    Directory of Open Access Journals (Sweden)

    Antonio B. Porcaro

    2016-03-01

    Full Text Available Objectives: To evaluate associations of preoperative total prostate specific antigen (PSA to free testosterone (FT, the PSA/FT index ratio, with features of pathology prostate cancer (PCA and to investigate its prognostic potential in clustering the PCA population. Patients and methods: After excluding criteria, the records of 220 patients who underwent radical prostatectomy (RP were retrospectively reviewed. Serum samples of PSA, total testosterone (TT and FT were collected at 8.00 A.M., one month after biopsies and before RP. The PSA/FT ratio was computed in the population of patients who were clustered in groups according to ranking intervals of the PSA/FT ratio which identified at least 4 clusters which were coded as A, B, C, and D. The independent associations of the PSA/FT index ratio were assessed by statistical methods and a two-sided P < 0.05 was considered to indicate statistical significance. Results: TT correlated to FT which was a significant predictor of PSA in the population of patients who were subsequently clustered, according to increasing interval values of the PSA/FT index ratio, in groups that showed a stronger linear association of FT with PSA. The PSA/FT index ratio significantly associated with pathology features of prostate cancer such as pathology Gleason score (pGS, invasion of the seminal vesicles (pT3b, proportion of positive cores (P+ and proportion of cancer involving the volume of the prostate. In the population of patients, TT, PSA/FT index ratio and P+ independently associated with pGS ≥ 7 and pT3b; moreover, the odds ratio (OR of the PSA/FT index ratio resulted 9.11 which was stronger than TT (OR = 1.11 and P+ (OR = 8.84. In the PCA population, TT, PSA/FT index ratio and P+ also independently associated with pT3b PCA; interestingly, the OR of PSA/FT index resulted 54.91 which was stronger than TT (OR = 1.31 and P+ (26.43. Conclusions: Preoperative PSA/FT index ratio is an independent strong factor which

  7. The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy.

    Science.gov (United States)

    Porcaro, Antonio B; Caruso, Beatrice; Terrin, Alessandro; De Luyk, Nicolò; Cacciamani, Giovanni; Corsi, Paolo; Inverardi, Davide; De Marchi, Davide; Baldassarre, Roberto; Cerruto, Mariangela; Ghimenton, Claudio; Brunelli, Matteo; Zecchini Antoniolli, Stefano; Petrozziello, Aldo; Artibani, Walter

    2016-03-31

    To evaluate associations of preoperative total prostate specific antigen (PSA) to free testosterone (FT), the PSA/FT index ratio, with features of pathology prostate cancer (PCA) and to investigate its prognostic potential in clustering the PCA population. After excluding criteria, the records of 220 patients who underwent radical prostatectomy (RP) were retrospectively reviewed. Serum samples of PSA, total testosterone (TT) and FT were collected at 8.00 A.M., one month after biopsies and before RP. The PSA/FT ratio was computed in the population of patients who were clustered in groups according to ranking intervals of the PSA/FT ratio which identified at least 4 clusters which were coded as A, B, C, and D. The independent associations of the PSA/FT index ratio were assessed by statistical methods and a two-sided P < 0.05 was considered to indicate statistical significance. TT correlated to FT which was a significant predictor of PSA in the population of patients who were subsequently clustered, according to increasing interval values of the PSA/FT index ratio, in groups that showed a stronger linear association of FT with PSA. The PSA/FT index ratio significantly associated with pathology features of prostate cancer such as pathology Gleason score (pGS), invasion of the seminal vesicles (pT3b), proportion of positive cores (P+) and proportion of cancer involving the volume of the prostate. In the population of patients, TT, PSA/FT index ratio and P+ independently associated with pGS ≥ 7 and pT3b; moreover, the odds ratio (OR) of the PSA/FT index ratio resulted 9.11 which was stronger than TT (OR = 1.11) and P+ (OR = 8.84). In the PCA population, TT, PSA/FT index ratio and P+ also independently associated with pT3b PCA; interestingly, the OR of PSA/FT index resulted 54.91 which was stronger than TT (OR = 1.31) and P+ (26.43). Preoperative PSA/FT index ratio is an independent strong factor which directly associates with aggressive features of pathology PCA

  8. Study of possibility using LANL PSA-methodology for accident probability RBMK researches

    Energy Technology Data Exchange (ETDEWEB)

    Petrin, S.V.; Yuferev, V.Y.; Zlobin, A.M.

    1995-12-31

    The reactor facility probabilistic safety analysis methodologies are considered which are used at U.S. LANL and RF NIKIET. The methodologies are compared in order to reveal their similarity and differences, determine possibilities of using the LANL technique for RBMK type reactor safety analysis. It is found that at the PSA-1 level the methodologies practically do not differ. At LANL the PHA, HAZOP hazards analysis methods are used for more complete specification of the accounted initial event list which can be also useful at performance of PSA for RBMK. Exchange of information regarding the methodology of detection of dependent faults and consideration of human factor impact on reactor safety is reasonable. It is accepted as useful to make a comparative study result analysis for test problems or PSA fragments using various computer programs employed at NIKIET and LANL.

  9. Polymorphisms in the AR and PSA genes as markers of susceptibility and aggressiveness in prostate cancer

    DEFF Research Database (Denmark)

    Kuasne, Hellen; Rodrigues, Iara Sant'Ana; Fuganti, Paulo Emílio

    2010-01-01

    The study of genes involved in androgen pathway can contribute to a better knowledge of prostate cancer. Our aim was to examine if polymorphisms in prostate-specific antigen (PSA) and androgen receptor (AR) genes were involved in prostate cancer risk and aggressiveness. Genotypes were determined...... by PCR-RFLP (PSA) or using a 377 ABI DNA Sequencer (AR). PSA(G/G) genotype (OR = 1.78, 95% CI = 1.06–2.99) and AR short CAG repeats (OR = 1.89, 95% CI = 1.21–2.96) increased risk for prostate cancer and were related with tumor aggressiveness. About 38.3% of tumors showed microsatellite instability...

  10. Positive surgical margins at radical prostatectomy: Population-based averages within PSA and Gleason strata.

    Science.gov (United States)

    Izard, Jason P; Salazar, Marco A; Chatterjee, Suman; Lin, Daniel W; Wright, Jonathan L

    2013-01-01

    Positive surgical margins (PSM) are an important determinant of biochemical recurrence after radical prostatectomy (RP). We use a population-based cancer registry to evaluate PSM by stage, Gleason and prostate-specific antigen (PSA). We identified men undergoing RP from the Surveillance, Epidemiology and End Results (SEER) database between 2004 and 2007. Differences between those with and without PSM were compared with chi-squared tests. The proportion of cases with PSM were stratified by PSA and Gleason sum for both pT2 and pT3a tumours. Factors associated with PSM were analyzed using chi square and multivariate logistic regression analysis. A composite variable was used in a second multivariate analysis to display the odds ratio (OR) for a PSM for each discrete combination of PSA, Gleason score and pT stage. In total, 28 461 RP patients were identified and a PSM was present in 19.5%. PSM were 42% in pT3a and 16% in pT2 cases. Higher PSAs (10) were associated with higher proportions of PSM (12%, 20% and 28%, p strata compared to those with pT2 tumours, reaching 63% for those with pT3a, Gleason 8-10, PSA >10 disease. On multivariate analysis, stage was the largest predictor for PSM (OR 3.05, 95% confidence interval 2.81-3.30), although Gleason score and PSA remained statistically significant. In this population-based study of PSM after RP, the proportion of PSM vary significantly within different PSA and Gleason strata for organ-confined and extracapsular disease. These data can be used as a reference for urologist self-assessment.

  11. Metastatic Prostate Cancer Diagnosed by Bone Marrow Aspiration in an Elderly Man Not Undergoing PSA Screening

    Directory of Open Access Journals (Sweden)

    Ridwan Alam

    2017-02-01

    Full Text Available Prostate cancer screening by PSA testing remains controversial, particularly in the elderly. Practice guidelines from most clinical societies suggest discontinuing PSA screening at age 70 while the USPSTF recommends against screening at any age. Recent reports have demonstrated an increased incidence of metastatic prostate cancer, with men aged 75 or older accounting for roughly half of those newly diagnosed at an incurable stage. We herein describe the case of an elderly gentleman with no history of prostate cancer screening who presented with anorexia and back pain of unclear etiology. Evaluation with bone marrow aspiration revealed a diagnosis of metastatic prostate cancer.

  12. PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK.

    NARCIS (Netherlands)

    Brett, J.; Watson, E.; Hewitson, P.; Bukach, C.; Edwards, A.; Elwyn, G.; Austoker, J.

    2005-01-01

    BACKGROUND: The role of Prostate Specific Antigen (PSA) testing in the early detection of prostate cancer is controversial. Current UK policy stipulates that any man who wishes to have a PSA test should have access to the test, provided he has been given full information about the benefits and

  13. Association of GPs' risk attitudes, level of empathy, and burnout status with PSA testing in primary care

    DEFF Research Database (Denmark)

    Pedersen, Anette F; Carlsen, Anders H; Vedsted, Peter

    2015-01-01

    Denne artikel undersøger, om variationen i raten af PSA-tests mellem alment praktiserende læger kan forklares af psykologiske faktorer som f.eks. lægens risikovillighed. Resultaterne viser, at lægens risikovillighed influerer på raten af PSA-tests. Forfatterne finder blandt andet, at patienter, s...

  14. The low molecular weight protein PsaI stabilizes the light-harvesting complex II docking site of photosystem I

    DEFF Research Database (Denmark)

    Plöchinger, Magdalena; Torabi, Salar; Rantala, Marjaana

    2016-01-01

    PsaI represents one of three low molecular weight peptides of PSI. Targeted inactivation of the plastid PsaI gene in Nicotiana tabacum has no measurable effect on photosynthetic electron transport around PSI or on accumulation of proteins involved in photosynthesis. Instead, the lack of PsaI dest...... of mutant plants into state 2 in darkness represents a compensatory and/or protective metabolic mechanism. This involves an increased reduction and/or reduced oxidation of the PQ pool, presumably to sustain a balanced excitation of both photosystems upon the onset of light.......PsaI represents one of three low molecular weight peptides of PSI. Targeted inactivation of the plastid PsaI gene in Nicotiana tabacum has no measurable effect on photosynthetic electron transport around PSI or on accumulation of proteins involved in photosynthesis. Instead, the lack of Psa......I destabilizes the association of PsaL and PsaH to PSI, both forming the light-harvesting complex (LHC)II docking site of PSI. These alterations at the LHCII binding site surprisingly did not prevent state transition but led to an increased incidence of PSI-LHCII complexes, coinciding with an elevated...

  15. Reduction in uptake of PSA tests following decision aids: systematic review of current aids and their evaluations.

    NARCIS (Netherlands)

    Evans, R.; Edwards, A.; Brett, J.; Bradburn, M.; Watson, E.; Austoker, J.; Elwyn, G.

    2005-01-01

    A man's decision to have a prostate-specific antigen (PSA) test should be an informed one. We undertook a systematic review to identify and appraise PSA decision aids and evaluations. We searched 15 electronic databases and hand-searched key journals. We also contacted key authors and organisations.

  16. Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer

    DEFF Research Database (Denmark)

    See, W; Iversen, P; Wirth, M

    2003-01-01

    To evaluate the effect of bicalutamide ('Casodex') 150mg (in addition to standard care), on the risk of prostate-specific antigen (PSA) progression, in patients with early prostate cancer.......To evaluate the effect of bicalutamide ('Casodex') 150mg (in addition to standard care), on the risk of prostate-specific antigen (PSA) progression, in patients with early prostate cancer....

  17. PSA-based prostate cancer screening: The role of active surveillance and informed and shared decision making

    NARCIS (Netherlands)

    L.D.F. Venderbos (Lionne); M.J. Roobol-Bouts (Monique)

    2011-01-01

    textabstractSince the first publication describing the identification of prostate-specific antigen (PSA) in the 1960s, much progress has been made. The PSA test changed from being initially a monitoring tool to being also used as a diagnostic tool. Over time, the test has been heavily debated due to

  18. Treatment for A2-B2 prostatic carcinoma: results of hormone-radiotherapy combination in PSA era; Traitement des cancers prostatiques A2-B2: resultats d`une association hormonoradiotherapique dans l`ere du PSA

    Energy Technology Data Exchange (ETDEWEB)

    Salem, N.; Richaud, P.; Gaston, R.; Chacon, B.; Mauriac, L.; Bussieres, E. [Institut Bergonie, Centre Regional de Lutte Contre le Cancer, 33 - Bordeaux (France)

    1998-05-01

    Prospective analysis of results of combined neo-adjuvant hormonotherapy and external beam radiation therapy in A2-B2 prostate adenocarcinoma. Between 1986 and 1994, 36 patients with clinical stage A2 (five patients), B1 (12 patients) and B2 (19 patients) N0 adenocarcinoma of the prostate declined for radical surgery, underwent a brief neo-adjuvant hormonal therapy before external beam radiotherapy at our radiation therapy department. They all had a PSA determination before the combined treatment and no evidence of local extension or metastatic spread. They were followed clinically and with serial PSA levels for a median time of 58 months. Relapse was defined by a PSA level {>=}2.5 ng/mL. Median pre-treatment PSA level was 16.5 ng/mL; 16 patients had less than 15 ng/mL. Combined treatment was very well tolerated. After 3 months of neo-adjuvant hormonotherapy, digital rectal examination was normalized in 27 cases with a PSA value {<=} 1 ng/mL in 23. Only four tumors have relapsed (one local failure, two metastases and one PSA failure). The single factor that predicted biochemical relapse was pre-treatment PSA level: the 5-year actuarial rate of PSA failure when PSA level < 15 ng/ml was 0% and 27.5% if it was {>=} 15 ng/mL (p = 0.05). During follow- up only two patients suffered grade 2 rectitis and seven complained a total impotency. This limited study advocates hormonal neo-adjuvant therapy and radiotherapy association in intra-capsular prostatic carcinoma in patients declined for surgery or when pre-treatment PSA is above 15 ng/mL, with mild acute and late toxicity. (authors)

  19. Study on communicating risk information obtained from PSA within nuclear power plants

    Energy Technology Data Exchange (ETDEWEB)

    Nunogane, Nobuaki; Onoue, Akira [Institute of Nuclear Technology, Institute of Nuclear Safety System, Inc., Mihama, Fukui (Japan); Kojima, Shigeo [Computer Software Development Corp., Tokyo(Japan)

    2000-09-01

    In this study, the communication of PSA information in nuclear power plants (NPPs), namely, how the risk information obtained from the probabilistic safety assessment (PSA) should be presented and communicated to plant personnel, was examined assuming that the safety management system based on the risk information was introduced to NPPs. This is called PSA communication. First, when risk-informed safety management is to be introduced into NPPs, plant personnel should have sufficient related knowledge. In order to provide such knowledge to the personnel through training, risk information is classified into three types: basic information, detailed information and task information. A hierarchical risk information summary for reporting, coordinating and communicating tasks is proposed. In this summary, the concerns of those who have received the information are placed at the top and the related risk information positioned below. At the same time, and by way of a trial, the risk information relating to on-line maintenance (OLM) is prepared. In order to enhance the safety-consciousness and the safety of the entire plant, specific plans such as 'risk tags' which indicate the safety significance of equipment is proposed. Finally, a guideline providing examination procedures for developing detailed PSA communication plans is introduced. (author)

  20. Cancer - What You Don't Know Can Kill You PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2010-07-22

    This 60 second PSA is based on the July 2010 CDC Vital Signs report which provides information on colorectal and breast cancer and the importance of getting screened.  Created: 7/22/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 7/22/2010.

  1. Tools Related to the Federal Tobacco Products Regulations: What Retailers Need to Know PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-09-16

    PSA to announce a new mobile text message program that will help raise retailers' awareness of the new federal tobacco regulations.  Created: 9/16/2010 by The CDC Division of News and Electronic Media and the FDA Center for Tobacco Products.   Date Released: 9/16/2010.

  2. IMPROVEMENT OF THE LOCA PSA MODEL USING A BEST-ESTIMATE THERMAL-HYDRAULIC ANALYSIS

    Directory of Open Access Journals (Sweden)

    DONG HYUN LEE

    2014-08-01

    Full Text Available Probabilistic Safety Assessment (PSA has been widely used to estimate the overall safety of nuclear power plants (NPP and it provides base information for risk informed application (RIA and risk informed regulation (RIR. For the effective and correct use of PSA in RIA/RIR related decision making, the risk estimated by a PSA model should be as realistic as possible. In this work, a best-estimate thermal-hydraulic analysis of loss-of-coolant accidents (LOCAs for the Hanul Nuclear Units 3&4 is first carried out in a systematic way. That is, the behaviors of peak cladding temperature (PCT were analyzed with various combinations of break sizes, the operating conditions of safety systems, and the operator's action time for aggressive secondary cooling. Thereafter, the results of the thermal-hydraulic analysis have been reflected in the improvement of the PSA model by changing both accident sequences and success criteria of the event trees for the LOCA scenarios.

  3. Student-Designed Public Service Announcement (PSA) Videos to Enhance Motivation and Engagement

    Science.gov (United States)

    Abrams, Kenneth

    2012-01-01

    Educators often focus on enhancing student motivation and engagement. This article describes an activity with these aims, in which undergraduates (a) learn about theories and research on means of persuasion and (b) in small groups design and record a public service announcement (PSA) video, write a brief paper that outlines the theories used to…

  4. Should baseline PSA testing be performed in men aged 40 to detect ...

    African Journals Online (AJOL)

    Objective. We aimed to evaluate the presenting features and treatment outcome of prostate cancer in men aged <50 years, in a region where prostate specific antigen (PSA) screening is not readily available and most men present with symptoms. Methods. We analysed the data of 1 571 men with prostatic adenocarcinoma ...

  5. National STD Awareness Month and GYT: Get Yourself Tested PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-03-03

    April is National STD Awareness Month. In this PSA, native communities, especially adolescents and young adults, are encouraged to get educated, tested, and treated by visiting gytnow.org.  Created: 3/3/2011 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.   Date Released: 3/3/2011.

  6. PSA Velocity Does Not Improve Prostate Cancer Detection | Division of Cancer Prevention

    Science.gov (United States)

    A rapid increase in prostate-specific antigen (PSA) levels is not grounds for automatically recommending a prostate biopsy, according to a study published online February 24 in the Journal of the National Cancer Institute. |

  7. Unpackaged Cigarettes and Smokeless Tobacco: What Retailers Need to Know PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-10-28

    This PSA helps retailers understand new federal regulations surrounding the sale of unpackaged cigarettes and smokeless tobacco.  Created: 10/28/2010 by The CDC Division of News and Electronic Media and the FDA Center for Tobacco Products.   Date Released: 10/28/2010.

  8. Don't Sell Tobacco to Minors: What Retailers Need to Know PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-07-08

    PSA helps raise retailers awareness of the new federal tobacco regulations related to sale of cigarettes and smokeless tobacco products to people under 18.  Created: 7/8/2010 by The CDC Division of News and Electronic Media and the FDA Center for Tobacco Products.   Date Released: 7/8/2010.

  9. Put Out the Myth: There Is No Such Thing as a Safe Cigarette PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-07-21

    PSA helps raise retailers' and manufacturers' awareness of the new federal tobacco regulations related to the production and sale of cigarettes labeled as "light," "low," or "mild.".  Created: 7/21/2010 by The CDC Division of News and Electronic Media and the FDA Center for Tobacco Products.   Date Released: 7/21/2010.

  10. CDC: Tips from Former Smokers – Cessation PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2012-04-04

    You can quit smoking! This inspiring 30 second PSA features three people who successfully quit smoking after many years. They share their practical tips on how to quit for good.  Created: 4/4/2012 by Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion.   Date Released: 4/4/2012.

  11. The Obesity Epidemic – What Can Be Done? PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2010-08-03

    This 60 second PSA is based on the August 2010 CDC Vital Signs report which provides information on obesity and what you can do to help fight the epidemic.  Created: 8/3/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 8/3/2010.

  12. Time from first detectable PSA following radical prostatectomy to biochemical recurrence: A competing risk analysis

    NARCIS (Netherlands)

    L. De Boo (Leonora); M. Pintilie (Melania); P. Yip (Paul); J. Baniel (Jack); N.E. Fleshner (Neil); D. Margel (David)

    2015-01-01

    textabstractIntroduction: In this study, we estimated the time from first detectable prostate-specific antigen (PSA) following radical prostatectomy (RP) to commonly used definitions of biochemical recurrence (BCR). We also identified the predictors of time to BCR. Methods: We identified subjects

  13. Patients with Central Lines - What You Need to Know to Avoid a Bloodstream Infection PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-03-01

    This 60 second PSA is based on the March, 2011 CDC Vital Signs report which indicates bloodstream infections in patients with central lines are largely preventable when healthcare providers use CDC-recommended infection control steps.  Created: 3/1/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 3/1/2011.

  14. Graphic Health Warnings for Cigarettes: What You Need to Know PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-11-18

    PSA about new graphic health warnings for cigarette packages and advertisements.  Created: 11/18/2010 by The CDC Division of News and Electronic Media and the FDA Center for Tobacco Products.   Date Released: 11/18/2010.

  15. New Hope for Stopping HIV - Testing and Medical Care Save Lives PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-11-29

    This 60 second PSA is based on the December 2011 CDC Vital Signs report, "HIV Prevention through Care and Treatment" that shares new hope for preventing HIV and improving the health of people with HIV.  Created: 11/29/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 11/29/2011.

  16. Utility of Prostate Specific Antigen (PSA) in the Indigenous African Man

    African Journals Online (AJOL)

    Objectives: To examine the great possibility that the indigenous black African man with prostate diseases requires a different diagnostic approach and strategies beyond the standard PSA reference levels generated in non-African study subjects. Design: A hospital based cross-sectional descriptive study. Setting: The ...

  17. Evaluating engrailed-2 and cytokines in urine with serum PSA as ...

    African Journals Online (AJOL)

    Evaluating engrailed-2 and cytokines in urine with serum PSA as potential biomarkers in patients with prostatism at Moi Teaching and Referral Hospital, Eldoret, Kenya. ... Conclusion: EN-2 expression in urine was not a predictive marker, however, IL-6 and TNF-α levels were elevated in urine of CaP patients. The potential ...

  18. Total Order Reliability in PSA: Importance of Basic Events and Systems

    Energy Technology Data Exchange (ETDEWEB)

    E. Borgonovo; C. Smith

    2010-06-01

    The purpose of this work is twofold. First, to formalize the properties of the total order reliability importance measure for PSA models. Second, to extend the definition of the total order importance measure to groups of basic events. This allows one to obtain the importance of systems and to address the relevance of interactions among systems.

  19. Deciding on PSA-screening - Quality of current consumer information on the Internet.

    Science.gov (United States)

    Korfage, Ida J; van den Bergh, Roderick C N; Essink-Bot, Marie-Louise

    2010-11-01

    Given that screening for prostate cancer has the potential to reduce prostate cancer mortality at the expense of considerable overdiagnosis and overtreatment, the availability of core consumer information - correct, balanced and supportive of autonomous decision-making - is a must. We assessed the quality of consumer information available through the Internet per November 2009 and its possible contribution to informed decision-making by potential screenees. Consumer information on PSA-screening was sought through the Internet in November 2009. Materials had to be targeted at potential consumers, offered by not-for-profit organisations, released in 2005 or after, in English or Dutch. Per material 2 of the authors assessed independently from each other whether standardised pre-defined topics were addressed, whether the content was correct and which approach was taken towards the decision-making process about uptake. Twenty-three materials were included, of which 11 were released (shortly) after the results of 2 large randomized-controlled trials (RCTs) that evaluated the effectiveness of screening for prostate cancer had been published in March 2009. That a PSA-test result can be abnormal because of non-cancerous conditions (false positive) and that it may miss prostate cancer (false negative) was not addressed in 2/23 and 8/23 materials, respectively. The risk of overdiagnosis and overtreatment was not mentioned in 6 out of 23. PSA-screening was presented as a usual thing to do in some materials, whereas other materials emphasised the voluntary nature of PSA-screening ('it is your decision'). The content of 19/23 materials was considered sufficiently informative according to the pre-defined criteria, 12/23 materials were considered supportive of informed decision-making by men. Most materials of not-for-profit organizations supplied adequate information about PSA-screening, whilst the degree of persuasion towards uptake reflected variations in opinions on men

  20. Testing the variability of PSA expression by different human prostate cancer cell lines by means of a new potentiometric device employing molecularly antibody assembled on graphene surface

    Energy Technology Data Exchange (ETDEWEB)

    Rebelo, Tânia S.C.R. [BioMark-CINTESIS/ISEP, Instituto Superior de Engenharia do Instituto Politécnico do Porto (Portugal); LAQV, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica (Portugal); Laboratory for Bone Metabolism and Regeneration, Faculdade de Medicina Dentária, Universidade do Porto, Porto (Portugal); Noronha, João P.; Galésio, Marco; Santos, Hugo; Diniz, Mário [LAQV, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica (Portugal); Sales, M. Goreti F. [BioMark-CINTESIS/ISEP, Instituto Superior de Engenharia do Instituto Politécnico do Porto (Portugal); Fernandes, Maria H. [Laboratory for Bone Metabolism and Regeneration, Faculdade de Medicina Dentária, Universidade do Porto, Porto (Portugal); Costa-Rodrigues, João, E-mail: jrodrigues@fmd.up.pt [Laboratory for Bone Metabolism and Regeneration, Faculdade de Medicina Dentária, Universidade do Porto, Porto (Portugal); ESTSP — Escola Superior de Tecnologia da Saúde do Porto, Instituto Politécnico do Porto (Portugal)

    2016-02-01

    Prostate Specific Antigen (PSA) is widely used as a biomarker for prostate cancer. Recently, an electrochemical biosensor for PSA detection by means of molecularly imprinted polymers (MIPs) was developed. This work evaluated the performance and the effectiveness of that PSA biosensor in screening the biomarker PSA in biological media with complex composition, collected from different human prostate cell line cultures. For that, the prostate cancer LNCaP and PC3 cells, and the non-cancerous prostate cell line PNT2 were cultured for 2, 7 and 14 days in either α-MEM or RPMI in the presence of 10% or 30% fetal bovine serum. Human gingival fibroblasts were used as a non-cancerous non-prostatic control. The different culture conditions modulated cellular proliferation and the expression of several prostate markers, including PSA. The electrochemical biosensor was able to specifically detect PSA in the culture media and values obtained were similar to those achieved by a commercial Enzyme-Linked Immunosorbent Assay (ELISA) kit, the most commonly used method for PSA quantification in prostate cancer diagnosis. Thus, the tested biosensor may represent a useful alternative as a diagnostic tool for PSA determination in biological samples. - Highlights: • PSA quantification was performed in prostate cancer cell culture media. • Culture media composition and culture period significantly affect PSA production. • The PSA biosensor detected a wide range of PSA levels in complex media. • A high data correlation was observed between the biosensor and the ELISA analysis.

  1. Extent of disease in recurrent prostate cancer determined by [{sup 68}Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score

    Energy Technology Data Exchange (ETDEWEB)

    Verburg, Frederik A.; Mottaghy, Felix M. [RWTH University Hospital Aachen, Department of Nuclear Medicine, Aachen (Germany); Maastricht University Medical Center, Department of Nuclear Medicine, Maastricht (Netherlands); Pfister, David; Heidenreich, Axel [RWTH University Hospital Aachen, Department of Urology, Aachen (Germany); Vogg, Andreas; Drude, Natascha I.; Behrendt, Florian F. [RWTH University Hospital Aachen, Department of Nuclear Medicine, Aachen (Germany); Voeoe, Stefan [Maastricht University Medical Center, Department of Nuclear Medicine, Maastricht (Netherlands)

    2016-03-15

    To examine the relationship between the extent of disease determined by [{sup 68}Ga]PSMA-HBED-CC-PET/CT and the important clinical measures prostate-specific antigen (PSA), PSA doubling time (PSAdt) and Gleason score. We retrospectively studied the first 155 patients with recurrent prostate cancer (PCA) referred to our university hospital for [{sup 68}Ga]PSMA-HBED-CC PET/CT. PET/CT was positive in 44 %, 79 % and 89 % of patients with PSA levels of ≤1, 1 - 2 and ≥2 ng/ml, respectively. Patients with high PSA levels showed higher rates of local prostate tumours (p < 0.001), and extrapelvic lymph node (p = 0.037) and bone metastases (p = 0.013). A shorter PSAdt was significantly associated with pelvic lymph node (p = 0.026), extrapelvic lymph node (p = 0.001), bone (p < 0.001) and visceral (p = 0.041) metastases. A high Gleason score was associated with more frequent pelvic lymph node metastases (p = 0.039). In multivariate analysis, both PSA and PSAdt were independent determinants of scan positivity and of extrapelvic lymph node metastases. PSAdt was the only independent marker of bone metastases (p = 0.001). Of 20 patients with a PSAdt <6 months and a PSA ≥2 ng/ml, 19 (95 %) had a positive scan and 12 (60 %) had M1a disease. Of 14 patients with PSA <1 ng/ml and PSAdt >6 months, only 5 (36 %) had a positive scan and 1 (7 %) had M1a disease. [{sup 68}Ga]PSMA-HBED-CC PET/CT will identify PCA lesions even in patients with very low PSA levels. Higher PSA levels and shorter PSAdt are independently associated with scan positivity and extrapelvic metastases, and can be used for patient selection for [{sup 68}Ga]PSMA-HBED-CC PET/CT. (orig.)

  2. Porous silicon antibody microarrays for quantitative analysis: measurement of free and total PSA in clinical plasma samples.

    Science.gov (United States)

    Järås, Kerstin; Adler, Belinda; Tojo, Axel; Malm, Johan; Marko-Varga, György; Lilja, Hans; Laurell, Thomas

    2012-12-24

    The antibody microarrays have become widespread, but their use for quantitative analyses in clinical samples has not yet been established. We investigated an immunoassay based on nanoporous silicon antibody microarrays for quantification of total prostate-specific-antigen (PSA) in 80 clinical plasma samples, and provide quantitative data from a duplex microarray assay that simultaneously quantifies free and total PSA in plasma. To further develop the assay the porous silicon chips was placed into a standard 96-well microtiter plate for higher throughput analysis. The samples analyzed by this quantitative microarray were 80 plasma samples obtained from men undergoing clinical PSA testing (dynamic range: 0.14-44 ng/ml, LOD: 0.14 ng/ml). The second dataset, measuring free PSA (dynamic range: 0.40-74.9 ng/ml, LOD: 0.47 ng/ml) and total PSA (dynamic range: 0.87-295 ng/ml, LOD: 0.76 ng/ml), was also obtained from the clinical routine. The reference for the quantification was a commercially available assay, the ProStatus PSA Free/Total DELFIA. In an analysis of 80 plasma samples the microarray platform performs well across the range of total PSA levels. This assay might have the potential to substitute for the large-scale microtiter plate format in diagnostic applications. The duplex assay paves the way for a future quantitative multiplex assay, which analyzes several prostate cancer biomarkers simultaneously. Copyright © 2012 Elsevier B.V. All rights reserved.

  3. Effects of cyclic adenosine-monophosphate on growth and PSA secretion of human prostate cancer cell line.

    Science.gov (United States)

    Macchia, V; Di Carlo, A; De Luca, C; Mariano, A

    2001-05-01

    Prolonged increase of cyclic adenosine-monophosphate (cAMP) level in the culture medium of a well differentiated human prostatic cancer cell (LNCaP) inhibits cellular growth and stimulates PSA secretion. The differentiation of the cells tested was documented by their responsiveness to androgens and the ability to synthesize cellular markers of differentiation (PSA). The raise in cAMP level was produced by dibutyryl cyclic AMP (DBcAMP) or by agents acting at distinct levels in the pathway of cAMP generation (forskolin) or degradation (IBMX). Each of these three agents in a range of concentrations between 10-4-10-6 M had an inhibitory effect on the growth which is dose and time-dependent. The inhibition was reversible as demonstrated by complete restoration of cell growth soon after the withdrawal of the substances from the culture medium. When cAMP levels in culture medium was raised, an increase in PSA content was observed. However, the effects of cAMP on PSA content was not due to increase in PSA synthesis, since simultaneous measurement of secreted and cellular PSA indicated that the principal effect of the cyclic nucleotide was to enhance the secretion of stored PSA. Furthermore the inhibition of cellular growth by cAMP suggests new approaches in prostatic carcinoma therapy.

  4. Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients.

    Science.gov (United States)

    Logozzi, Mariantonia; Angelini, Daniela F; Iessi, Elisabetta; Mizzoni, Davide; Di Raimo, Rossella; Federici, Cristina; Lugini, Luana; Borsellino, Giovanna; Gentilucci, Alessandro; Pierella, Federico; Marzio, Vittorio; Sciarra, Alessandro; Battistini, Luca; Fais, Stefano

    2017-09-10

    Prostate specific antigen (PSA) test is the most common, clinically validated test for the diagnosis of prostate cancer (PCa). While neoplastic lesions of the prostate may cause aberrant levels of PSA in the blood, the quantitation of free or complexed PSA poorly discriminates cancer patients from those developing benign lesions, often leading to invasive and unnecessary surgical procedures. Microenvironmental acidity increases exosome release by cancer cells. In this study we evaluated whether acidity, a critical phenotype of malignancy, could influence exosome release and increase the PSA expression in nanovesicles released by PCa cells. To this aim, we exploited Nanoparticle Tracking Analysis (NTA), an immunocapture-based ELISA, and nanoscale flow-cytometry. The results show that microenvironmental acidity induces an increased release of nanovesicles expressing both PSA and the exosome marker CD81. In order to verify whether the changes induced by the local selective pressure of extracellular acidity may correspond to a clinical pathway we used the same approach to evaluate the levels of PSA-expressing exosomes in the plasma of PCa patients and controls, including subjects with benign prostatic hypertrophy (BPH). The results show that only PCa patients have high levels of nanovesicles expressing both CD81 and PSA. This study shows that tumor acidity exerts a selective pressure leading to the release of extracellular vesicles that express both PSA and exosome markers. A comparable scenario was shown in the plasma of prostate cancer patients as compared to both BPH and healthy controls. These results suggest that microenvironmental acidity may represent a key factor which determines qualitatively and quantitatively the release of extracellular vesicles by malignant tumors, including prostate cancer. This condition leads to the spill-over of nanovesicles into the peripheral blood of prostate cancer patients, where the levels of tumor biomarkers expressed by

  5. Acute activation of CB1 cannabinoid receptors transiently decreases PSA-NCAM expression in the dentate gyrus of the rat hippocampus.

    Science.gov (United States)

    Maćkowiak, Marzena; Chocyk, Agnieszka; Markowicz-Kula, Katarzyna; Wedzony, Krzysztof

    2007-05-07

    Recent evidence indicates that the polysialylated neural cell adhesion molecule (PSA-NCAM) is involved in hippocampal plasticity. On the other hand, CB1 receptor activation is known to disturb some hippocampal processes involving plastic changes, such as learning and memory. Therefore, the present study investigated the effect of HU-210, a CB1 receptor agonist, on the expression of PSA-NCAM protein in the dentate gyrus (DG) and CA3 region of the rat hippocampus. It was found that at a dose of 0.1 mg/kg i.p. of HU-210, the number of PSA-NCAM immunoreactive (IR) cells in the DG declined in a time-dependent manner. The decrease in PSA-NCAM expression was observed at 1 and 2 days (ca. 21% and 30%, respectively), but not after 4 h and 4 days following HU-210 administration. However, HU-210 treatment did not change the length density of PSA-NCAM immunopositive processes in CA3 mossy fibers at all the time points measured. The effect observed in the DG on day 2 was blocked by AM-251 (1 mg/kg, i.p.), a CB1 receptor antagonist, given 30 min before HU-210. Neither the number of Ki-67 (IR) cells (a marker of proliferation) nor the number of doublecortin-IR cells (a marker of immature neurons) was affected by HU-210 (0.1 mg/kg, i.p.) treatment at any of the time points. An analysis of co-localization of CB1 receptor protein with PSA-NCAM protein revealed that both proteins were not present in the same population of neurons in the subgranular layer of the DG. The observed changes in PSA-NCAM expression were not related to the reduction of proliferation or differentiation of newly born cells, but were possible due to alternations in the synaptic activity in the DG. However, such alteration in the PSA-NCAM expression may change the timing of the functional maturation of newly born neurons. Moreover, the above finding suggests that acute activation of CB1 receptors may result in the stiffening of the hippocampal structure and susceptibility to plastic changes and may lead to

  6. Predictive simulations and optimization of nanowire field-effect PSA sensors including screening

    KAUST Repository

    Baumgartner, Stefan

    2013-05-03

    We apply our self-consistent PDE model for the electrical response of field-effect sensors to the 3D simulation of nanowire PSA (prostate-specific antigen) sensors. The charge concentration in the biofunctionalized boundary layer at the semiconductor-electrolyte interface is calculated using the propka algorithm, and the screening of the biomolecules by the free ions in the liquid is modeled by a sensitivity factor. This comprehensive approach yields excellent agreement with experimental current-voltage characteristics without any fitting parameters. Having verified the numerical model in this manner, we study the sensitivity of nanowire PSA sensors by changing device parameters, making it possible to optimize the devices and revealing the attributes of the optimal field-effect sensor. © 2013 IOP Publishing Ltd.

  7. Take Charge. Take the Test. "Look Out For Yourself" PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-03-07

    As part of the Take Charge. Take the Test. campaign, this 60 second PSA encourages African American women to get tested for HIV. Locations for a free HIV test can be found by visiting hivtest.org/takecharge or calling 1-800-CDC-INFO (1-800-232-4636).  Created: 3/7/2012 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).   Date Released: 3/7/2012.

  8. We Can Stop HIV One Conversation at a Time Radio PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2014-08-27

    As part of the We Can Stop HIV One Conversation at a Time campaign, this 30 second PSA encourages Hispanics/Latinos to talk openly about HIV and AIDS with their families, friends, partners, and communities.  Created: 8/27/2014 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).   Date Released: 8/27/2014.

  9. Binge Drinking – Nationwide Problem, Local Solutions PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-01-03

    This 60 second PSA is based on the January 2012 CDC Vital Signs report. One in six adults binge drinks about four times a month. It's a problem nationwide but community-based strategies, such as reducing access to alcohol and increasing the price, can prevent binge drinking.  Created: 1/3/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 1/3/2012.

  10. Face-to-face Tobacco Sales: What Retailers Need to Know PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-09-30

    PSA to help raise retailers' awareness of the new federal tobacco regulations related to the sale of cigarettes and smokeless tobacco products to people under 18 and the requirement to sell products face-to-face.  Created: 9/30/2010 by The CDC Division of News and Electronic Media and the FDA Center for Tobacco Products.   Date Released: 9/30/2010.

  11. Exploring Functional ?-Cell Heterogeneity In Vivo Using PSA-NCAM as a Specific Marker

    OpenAIRE

    Karaca, Melis; Castel, Julien; Tourrel-Cuzin, C?cile; Brun, Manuel; G?ant, Anne; Dubois, Mathilde; Catesson, Sandra; Rodriguez, Marianne; Luquet, Serge; Cattan, Pierre; Lockhart, Brian; Lang, Jochen; Ktorza, Alain; Magnan, Christophe; Kargar, Catherine

    2009-01-01

    BACKGROUND: The mass of pancreatic beta-cells varies according to increases in insulin demand. It is hypothesized that functionally heterogeneous beta-cell subpopulations take part in this process. Here we characterized two functionally distinct groups of beta-cells and investigated their physiological relevance in increased insulin demand conditions in rats. METHODS: Two rat beta-cell populations were sorted by FACS according to their PSA-NCAM surface expression, i.e. beta(high) and beta(low...

  12. Making Food Safer to Eat - What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-06-07

    This 60 second Public Service Announcement (PSA) is based on the June, 2011 CDC Vital Signs report. One in six Americans gets sick from eating contaminated food each year. To reduce your risk, remember to clean, separate, cook, and chill.  Created: 6/7/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 6/7/2011.

  13. The Tobacco Use Epidemic - What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2010-09-07

    This PSA is based on the September, 2010 CDC Vital Signs report which indicates that, despite the dangers of tobacco use, about 46.6 million adults in the U.S. smoke, and 88 million nonsmokers are exposed to secondhand smoke. .  Created: 9/7/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 9/7/2010.

  14. Use of PSA and severe accident assessment results for the accident management

    Energy Technology Data Exchange (ETDEWEB)

    Jang, S. H.; Kim, H. G.; Jang, H. S.; Moon, S. K.; Park, J. U. [Korea Advanced Institute of Science and Technology, Daejeon (Korea, Republic of)

    1993-12-15

    The objectives for this study are to investigate the basic principle or methodology which is applicable to accident management, by using the results of PSA and severe accident research, and also facilitate the preparation of accidents management program in the future. This study was performed as follows: derivation of measures for core damage prevention, derivation of measures for accident mitigation, application of computerized tool to assess severe accident management.

  15. Guidelines for reliability analysis of digital systems in PSA context - Phase 2 Status report

    Energy Technology Data Exchange (ETDEWEB)

    Authen, S. (Risk Pilot AB, Stockholm (Sweden)); Gustafsson, J. (Royal Institute of Technology (Sweden)); Holmberg, J.-E. (VTT Technical Research Centre of Finland (Finland))

    2012-02-15

    The OECD/NEA CSNI Working Group on Risk Assessment (WGRisk) has set up a task group called DIGREL to develop a taxonomy of failure modes of digital components for the purposes of probabilistic safety assessment (PSA). A parallel Nordic activity carried out a pre-study where a comparison of Nordic experiences and a literature review were performed. The study showed a wide range of approaches and solutions to the challenges given by digital I and C. In 2011, a proposal for the failure modes taxonomy was defined. This is based on a set of requirements agreed on the purpose of the taxonomy. The following levels of details can be distinguished from the hardware point of view: (1) the entire system, (2) a division, (3) processing units (and cabinets), (4) modules, i.e. subcomponents of processing units and (5) generic components, i.e. subcomponents of modules. Module level seems to be the most appropriate from the PSA modelling point of view. The software failure modes taxonomy is still an open issue. An existing simplified PSA model has been complemented with fault tree models for a four-redundant distributed protection system in order to study and demonstrate the effect of design features and modelling approaches. The example shows that even rather simple I and C design leads to rather complex model despite of the fact that many things have been simplified and only a few protection signals are considered. One lesson from the example is that the Alpha factor model should be used to model common cause failures instead of the Beta factor model. Two options were developed to the comparison of different fail-safe principles. The role of detectable and undetectable failure modes with respect to the failed versus spurious actuations can be clearly seen in the results, showing the importance to model these features in PSA. (Author)

  16. CDC: Tips from Former Smokers – Jessica PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2012-04-04

    Exposure to secondhand smoke can trigger a life-threatening asthma attack. This 30 second PSA features Jessica, a mother with a young son who suffers from asthma attacks triggered by secondhand smoke exposure.  Created: 4/4/2012 by Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion.   Date Released: 4/4/2012.

  17. Galectin-3 Is a Substrate for Prostate Specific Antigen (PSA) in Human Seminal Plasma

    Science.gov (United States)

    Saraswati, Sarika; Block, Ashley S.; Davidson, Mari. K.; Rank, Roger. G.; Mahadevan, Maha; Diekman, Alan B.

    2012-01-01

    Background Galectin-3 is a multivalent carbohydrate-binding protein involved in cell adhesion, cell cycle control, immunomodulation, and cancer progression, including prostate cancer. Galectin-3 function is regulated by proteolytic cleavage that destroys galectin-3 multivalency while preserving carbohydrate-binding activity. In human semen, galectin-3 is present in seminal plasma and is also associated with prostasomes, exosome-like vesicles secreted by the prostate. In the current study, we characterized the proteolytic activity that cleaves galectin-3 in human seminal plasma. Methods An in vitro assay was developed to investigate galectin-3 cleavage in seminal plasma. The effect of protease inhibitors, divalent ion chelators, and Zn2+ on the cleavage activity was determined. Proteases enriched from seminal plasma were tested for their ability to cleave galectin-3. Affinity purification and microsequence analysis were used to identify the cleavage site in galectin-3. Results Galectin-3 was identified in human seminal plasma in an intact and truncated form. Gelatinases enriched from seminal plasma did not cleave galectin-3. Inhibitor studies indicated that the galectin-3 cleavage activity in seminal plasma is a Zn2+ sensitive, serine protease. Prostate specific antigen (PSA) was demonstrated to cleave galectin-3 between tyrosine107-glycine108 and produce a functionally-active, monovalent lectin. Conclusions PSA is a chymotrypsin-like serine protease secreted by the prostatic epithelium and normally functions in liquefaction of semen following ejaculation. Furthermore, PSA is implicated in the promotion of localized prostate tumors and bone metastases by its roles in immunomodulation, invasion, and apoptosis. Our results indicate that PSA regulates galectin-3 in human semen and may regulate galectin-3 function during prostate cancer progression. PMID:20672323

  18. Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands.

    Science.gov (United States)

    Jyoti, Shravana Kumar; Blacke, Camille; Patil, Pallavi; Amblihalli, Vibha P; Nicholson, Amanda

    2018-01-01

    The common tool for diagnosing prostate cancer is prostate-specific antigen (PSA), but the high sensitivity and low specificity of PSA testing are the problems in clinical practice. There are no proper guidelines to investigate the suspected prostate cancer in the Cayman Islands. We correlated PSA levels with the incidence of prostate cancers by tissue diagnosis and proposed logical protocol for prostate screening by using PSA test in this small population. A total of 165 Afro Caribbean individuals who had prostate biopsy done after the investigations for PSA levels from year 2005 to 2015 were studied retrospectively. The patients were divided into subgroups by baseline PSA levels as follows: 100 ng/mL and were correlated to the age and presence of cancer. Benign lesions had lower PSA levels compared to cancer which generally had higher values. Only three cases that had less than 4 ng/mg were turned out to be malignant. When PSA value was more than 100 ng/mL, all the cases were malignant. Between PSA values of 4-100 ng/mL, the probability of cancer diagnosis was 56.71% (76 cancers out of 134 in this range). Limitation of PSA testing has the risk of over diagnosis and the resultant negative biopsies owing to poor specificity. Whereas the cutoff limit for cancer diagnosis still remains 4 ng/mL from our study, most of the patients can be assured of benign lesion below this level and thus morbidity associated with the biopsy can be prevented. When the PSA value is greater than 100 ng, biopsy procedure was mandatory as there were 100% cancers above this level. On the background of vast literature linking PSA to prostate cancer and its difficulty in implementing in clinical practice, we studied literature of this conflicting and complex topic and tried to bring relevant protocols to the small population of Cayman Islands for the screening of prostate cancer. In this study, a total of 165 Afro Caribbean individuals who had prostate biopsy done after the

  19. Lycopene Supplementation in the Complementary Management of PSA Failure: A Randomized Placebo-Controlled Trial for Prostate Cancer Survivors

    National Research Council Canada - National Science Library

    Ukoli, Flora A; Kucuk, Omer; Fowke, Jay H

    2007-01-01

    ...) or whole-food supplement (Lyc-O-Mato(Registered)) in control of biochemical (PSA) failure in 78 African-American prostate cancer survivors treated initially by radical prostatectomy or radiation...

  20. Einschätzung des PSA-Rezidivs nach kurativer Therapie des Prostatakarzinoms

    Directory of Open Access Journals (Sweden)

    Weißbach L

    2004-01-01

    Full Text Available Das in die Nachsorge kurativ behandelter Patienten mit Prostatakarzinom aufgenommene PSA-Monitoring schafft einen neuen klinischen Status. Wir haben es jetzt mit einem "bio-chemisch Kranken" zu tun, bei dem nicht selten kein lokales Rezidivgeschehen und schon gar nicht eine Fernmetastasierung nachgewiesen werden kann. Um zwischen der lokalen und systemischen Erkrankung unterscheiden zu können, hat man sich früher der "pathohistologischen Prädiktion" bedient. Hierauf beruht auch ein großer Teil der häufig eingesetzten Nomogramme. Mit der Bestimmung der PSA-DT ist eine Methode in das diagnostische Repertoire aufgenommen worden, die nach weiterer Evaluierung dazu dienen könnte, lokale Maßnahmen (RT nach RP oder Salvage-Prostatektomie, HIFU bzw. Kryotherapie oder eine Androgendeprivation vorzunehmen. Vieles deutet darauf hin, daß wir in Zukunft nicht nur mit einer Berechnung der PSA-DT die lokale von der systemischen Progression unterscheiden können, sondern auch das Übergangsstadium zur klinischen Metastasenerkrankung voraussagen und das Risiko, am Prostatakrebs zu sterben, einschätzen können.

  1. Multiple external hazards compound level 3 PSA methods research of nuclear power plant

    Science.gov (United States)

    Wang, Handing; Liang, Xiaoyu; Zhang, Xiaoming; Yang, Jianfeng; Liu, Weidong; Lei, Dina

    2017-01-01

    2011 Fukushima nuclear power plant severe accident was caused by both earthquake and tsunami, which results in large amount of radioactive nuclides release. That accident has caused the radioactive contamination on the surrounding environment. Although this accident probability is extremely small, once such an accident happens that is likely to release a lot of radioactive materials into the environment, and cause radiation contamination. Therefore, studying accidents consequences is important and essential to improve nuclear power plant design and management. Level 3 PSA methods of nuclear power plant can be used to analyze radiological consequences, and quantify risk to the public health effects around nuclear power plants. Based on multiple external hazards compound level 3 PSA methods studies of nuclear power plant, and the description of the multiple external hazards compound level 3 PSA technology roadmap and important technical elements, as well as taking a coastal nuclear power plant as the reference site, we analyzed the impact of off-site consequences of nuclear power plant severe accidents caused by multiple external hazards. At last we discussed the impact of off-site consequences probabilistic risk studies and its applications under multiple external hazards compound conditions, and explained feasibility and reasonableness of emergency plans implementation.

  2. Hybrid approach for the assessment of PSA models by means of binary decision diagrams

    Energy Technology Data Exchange (ETDEWEB)

    Ibanez-Llano, Cristina, E-mail: cristina.ibanez@iit.upcomillas.e [Instituto de Investigacion Tecnologica (IIT), Escuela Tecnica Superior de Ingenieria ICAI, Universidad Pontificia Comillas, C/Santa Cruz de Marcenado 26, 28015 Madrid (Spain); Rauzy, Antoine, E-mail: Antoine.RAUZY@3ds.co [Dassault Systemes, 10 rue Marcel Dassault CS 40501, 78946 Velizy Villacoublay Cedex (France); Melendez, Enrique, E-mail: ema@csn.e [Consejo de Seguridad Nuclear (CSN), C/Justo Dorado 11, 28040 Madrid (Spain); Nieto, Francisco, E-mail: nieto@iit.upcomillas.e [Instituto de Investigacion Tecnologica (IIT), Escuela Tecnica Superior de Ingenieria ICAI, Universidad Pontificia Comillas, C/Santa Cruz de Marcenado 26, 28015 Madrid (Spain)

    2010-10-15

    Binary decision diagrams are a well-known alternative to the minimal cutsets approach to assess the reliability Boolean models. They have been applied successfully to improve the fault trees models assessment. However, its application to solve large models, and in particular the event trees coming from the PSA studies of the nuclear industry, remains to date out of reach of an exact evaluation. For many real PSA models it may be not possible to compute the BDD within reasonable amount of time and memory without considering the truncation or simplification of the model. This paper presents a new approach to estimate the exact probabilistic quantification results (probability/frequency) based on combining the calculation of the MCS and the truncation limits, with the BDD approach, in order to have a better control on the reduction of the model and to properly account for the success branches. The added value of this methodology is that it is possible to ensure a real confidence interval of the exact value and therefore an explicit knowledge of the error bound. Moreover, it can be used to measure the acceptability of the results obtained with traditional techniques. The new method was applied to a real life PSA study and the results obtained confirm the applicability of the methodology and open a new viewpoint for further developments.

  3. Penile Metastases of Recurrent Prostatic Adenocarcinoma without PSA Level Increase: A Case Report

    Directory of Open Access Journals (Sweden)

    Antonio Pierro

    2012-01-01

    Full Text Available We report a case of penile metastases from recurrent prostatic adenocarcinoma that was the first sign of a widespread metastatic disease in the absence of any increase in prostate-specific antigen (PSA level. In April 2011, an 80-year-old man presented to our Radiotherapy Unit with multiple palpable hard nodules in the penis, dysuria, and moderate perineal pain, 7 years after he had received radiotherapy for prostate cancer. Nodules in the penis had appeared in February 2011. The ultrasound and magnetic resonance (MR imaging suggested the diagnosis of multiple penile metastases. A total body computed tomography scan revealed a systemic spread of the disease, with multiple metastases in the liver, bones, and lungs. PSA level was 0.126 ng/ml. A fine needle aspiration biopsy of the liver lesion was undertaken, and the histopathologic examination revealed the prostatic origin of the metastases, so androgen deprivation therapy was started. The diagnosis of metastases should be considered in a patient with prior history of prostate malignancies presenting with solid nodules in the penis, even if the PSA level is low.

  4. A randomised controlled trial of the effects of a web-based PSA decision aid, Prosdex. Protocol

    Directory of Open Access Journals (Sweden)

    Griffiths Jeff

    2007-10-01

    Full Text Available Abstract Background Informed decision making is the theoretical basis in the UK for men's decisions about Prostate Specific Antigen (PSA testing for prostate cancer testing. The aim of this study is to evaluate the effect of a web-based PSA decision-aid, Prosdex, on informed decision making in men. The objective is to assess the effect of Prosdex on six specific outcomes: (i knowledge of PSA and prostate cancer-related issues – the principal outcome of the study; (ii attitudes to testing; (iii decision conflict; (iv anxiety; (v intention to undergo PSA testing; (vi uptake of PSA testing. In addition, a mathematical simulation model of the effects of Prosdex will be developed. Methods A randomised controlled trial with four groups: two intervention groups, one viewing Prosdex and the other receiving a paper version of the site; two control groups, the second controlling for the potential Hawthorn effect of the questionnaire used with the first control group. Men between the ages of 50 and 75, who have not previously had a PSA test, will be recruited from General Practitioners (GPs in Wales, UK. The principal outcome, knowledge, and four other outcome measures – attitudes to testing, decision conflict, anxiety and intention to undergo testing – will be measured with an online questionnaire, used by men in three of the study groups. Six months later, PSA test uptake will be ascertained from GP records; the online questionnaire will then be repeated. These outcomes, and particularly PSA test uptake, will be used to develop a mathematical simulation model, specifically to consider the impact on health service resources. Trial registration Current Controlled Trial: ISRCTN48473735.

  5. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA Induce Protective Immune Responses in Dogs.

    Directory of Open Access Journals (Sweden)

    Elodie Petitdidier

    2016-05-01

    Full Text Available Preventive vaccination is a highly promising strategy for interrupting leishmaniasis transmission that can, additionally, contribute to elimination. A vaccine formulation based on naturally excreted secreted (ES antigens was prepared from L. infantum promastigote culture supernatant. This vaccine achieved successful results in Phase III trials and was licensed and marketed as CaniLeish. We recently showed that newly identified ES promastigote surface antigen (PSA, from both viable promastigotes and axenically-grown amastigotes, represented the major constituent and the highly immunogenic antigen of L. infantum and L. amazonensis ES products. We report here that three immunizations with either the recombinant ES LaPSA-38S (rPSA or its carboxy terminal part LaPSA-12S (Cter-rPSA, combined with QA-21 as adjuvant, confer high levels of protection in naive L. infantum-infected Beagle dogs, as checked by bone marrow parasite absence in respectively 78.8% and 80% of vaccinated dogs at 6 months post-challenge. The parasite burden in infected vaccinated dogs was significantly reduced compared to placebo group, as measured by q-PCR. Moreover, our results reveal humoral and cellular immune response clear-cut differences between vaccinated and control dogs. An early increase in specific IgG2 antibodies was observed in rPSA/QA-21- and Cter-rPSA/QA-21-immunized dogs only. They were found functionally active in vitro and were highly correlated with vaccine protection. In vaccinated protected dogs, IFN-γ and NO productions, as well as anti-leishmanial macrophage activity, were increased. These data strongly suggest that ES PSA or its carboxy-terminal part, in recombinant forms, induce protection in a canine model of zoonotic visceral leishmaniasis by inducing a Th1-dominant immune response and an appropriate specific antibody response. These data suggest that they could be considered as important active components in vaccine candidates.

  6. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.

    Science.gov (United States)

    Petitdidier, Elodie; Pagniez, Julie; Papierok, Gérard; Vincendeau, Philippe; Lemesre, Jean-Loup; Bras-Gonçalves, Rachel

    2016-05-01

    Preventive vaccination is a highly promising strategy for interrupting leishmaniasis transmission that can, additionally, contribute to elimination. A vaccine formulation based on naturally excreted secreted (ES) antigens was prepared from L. infantum promastigote culture supernatant. This vaccine achieved successful results in Phase III trials and was licensed and marketed as CaniLeish. We recently showed that newly identified ES promastigote surface antigen (PSA), from both viable promastigotes and axenically-grown amastigotes, represented the major constituent and the highly immunogenic antigen of L. infantum and L. amazonensis ES products. We report here that three immunizations with either the recombinant ES LaPSA-38S (rPSA) or its carboxy terminal part LaPSA-12S (Cter-rPSA), combined with QA-21 as adjuvant, confer high levels of protection in naive L. infantum-infected Beagle dogs, as checked by bone marrow parasite absence in respectively 78.8% and 80% of vaccinated dogs at 6 months post-challenge. The parasite burden in infected vaccinated dogs was significantly reduced compared to placebo group, as measured by q-PCR. Moreover, our results reveal humoral and cellular immune response clear-cut differences between vaccinated and control dogs. An early increase in specific IgG2 antibodies was observed in rPSA/QA-21- and Cter-rPSA/QA-21-immunized dogs only. They were found functionally active in vitro and were highly correlated with vaccine protection. In vaccinated protected dogs, IFN-γ and NO productions, as well as anti-leishmanial macrophage activity, were increased. These data strongly suggest that ES PSA or its carboxy-terminal part, in recombinant forms, induce protection in a canine model of zoonotic visceral leishmaniasis by inducing a Th1-dominant immune response and an appropriate specific antibody response. These data suggest that they could be considered as important active components in vaccine candidates.

  7. Selective Activation of a Perforin-Granzyme B Fusion Protein Toxin by PSA as Therapy for Metastatic Prostate Cancer

    Science.gov (United States)

    2016-10-01

    SUPPLEMENTARY NOTES 14. ABSTRACT Protein toxins represent a class of agents that can kill cells in a proliferation independent manner. Many such...PSA and PSMA 15. SUBJECT TERMS Granzyme B, PSA, PSMA, protoxin, protease, zymogen 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18...NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON a. REPORT b. ABSTRACT c. THIS PAGE 19b. TELEPHONE NUMBER (include area code) Standard Form 298 (Rev. 8

  8. Methodological approaches to perform a site specific PSA on the effects of comprehensive events; Methodische Ansaetze zur Durchfuehrung einer standortspezifischen PSA zu den Auswirkungen uebergreifender Einwirkungen

    Energy Technology Data Exchange (ETDEWEB)

    Tuerschmann, Michael; Sperbeck, Silvio; Frey, Walter

    2016-12-15

    Main objective of the project 3612R01550 performed on behalf of the Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety (BMUB) is the development of an approach for systematic consideration of dependencies in case of internal and external hazards and their combinations in the probabilistic plant model for nuclear power plants. One of the major aspects of a site specific Level 1 PSA carried out for a nuclear power plant outlined in this report is taking comprehensively into account the entire risks resulting from internal and external hazards. In a first step, all the hazards which may occur at the site under investigation have to be identified. This requires a compilation of the potential hazards and their possible combinations: Based on this compilation of generic hazards a site specific list of hazards to be considered in the analysis can be derived based on a screening process taking into account regulatory requirements and insights from site and plant walk-downs. In a second step, the hazards to be considered for the specific site have to be classified with respect to the depth of the probabilistic analyses to be carried out. This classification covers three categories: hazards with a negligible contribution to the overall risk, hazards with such a low risk contribution that a rough quantitative assessment is sufficient, and hazards which need in-depth probabilistic analysis. Based on the available Level 1 PSA model for internal events, a systematic approach for in-depth probabilistic analyses of hazards and their combinations is proposed. In this context, lists of those structures, systems and components, which can be impaired in their required function resulting in a risk increase, are provided. One of these lists contains the equipment, the other one the dependencies to be considered for the corresponding hazard. In addition to the general approach for performing site specific PSA, a procedure for modelling dependencies in

  9. Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven.

    Science.gov (United States)

    Woynarowska BAHigdon, A L; Muñoz, R M; Bushong, P; Waters, S J

    2001-01-01

    Irofulven (hydroxymethylacylfulvene, HMAF, MGI 114) is a novel agent with alkylating activity and a potent inducer of apoptosis. It is currently undergoing Phase II clinical trials for several tumor types, including hormone-refractory prostate cancer. Reduction of serum prostate-specific antigen (PSA) levels has been proposed as a generally useful endpoint for evaluating the antitumor efficacy of treatments for prostate cancer. However, the utility of PSA as a marker of tumor cell burden could be compromised, if drugs directly affected PSA secretion and/or expression. In these studies, we evaluated the effects of irofulven on PSA protein and mRNA levels during the course of treatment of prostate tumor cells in vitro. The rate of PSA secretion (normalized per equal cell number) by control and drug treated cells was similar, as determined by a solid phase, two-site immunoradiometric assay. Consistent with the lack of effect of irofulven on PSA protein level, the drug does not appear to affect the expression of PSA mRNA (on a per cell basis) as assessed by RT-PCR. Thus, changes in PSA secretion and expression appear to reflect irofulven-induced cell growth inhibition rather than reflecting a direct effect of the drug on PSA. These results suggest that PSA should be a reasonable marker of tumor burden in irofulven-treated prostate cancer patients.

  10. PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK

    Directory of Open Access Journals (Sweden)

    Elwyn Glyn

    2005-06-01

    Full Text Available Abstract Background The role of Prostate Specific Antigen (PSA testing in the early detection of prostate cancer is controversial. Current UK policy stipulates that any man who wishes to have a PSA test should have access to the test, provided he has been given full information about the benefits and limitations of testing. This study aimed to determine UK GPs' current reported practice regarding PSA testing, and their views towards informed decision-making and PSA testing. Method Online questionnaire survey, with a sample of 421 GPs randomly selected from a database of GPs across the UK. Results 95% (400/421 of GPs responded. 76% of GPs reported having performed a PSA test for an asymptomatic man at least once in the previous three months, with 13% reported having tested more than five men in this period. A majority of GPs reported they would do a PSA test for men presenting with a family history and requesting a test, for asymptomatic men requesting a test and also for men presenting with lower urinary tract symptoms. Reported testing rates were highest for men with a family history. Amongst men with lower urinary tract symptoms and men with no symptoms, reported testing rates were significantly higher for older than younger men. The majority of GPs expressed support for the current policy (67%, and favoured both the general practitioner and the man being involved in the decision making process (83%. 90% of GPs indicated that they would discuss the benefits and limitation of testing with the man, with most (61% preferring to ask the man to make a further appointment if he decides to be tested. Conclusion This study indicates that PSA testing in asymptomatic men is a regular occurrence in the UK, and that there is general support from GPs for the current policy of making PSA tests available to 'informed' men who are concerned about prostate cancer. While most GPs indicated they would discuss the benefits and limitations prior to PSA testing

  11. Increasing Fractional Doses Increases the Probability of Benign PSA Bounce in Patients Undergoing Definitive HDR Brachytherapy for Prostate Cancer

    Energy Technology Data Exchange (ETDEWEB)

    Hauck, Carlin R.; Ye, Hong; Chen, Peter Y.; Gustafson, Gary S.; Limbacher, Amy; Krauss, Daniel J., E-mail: Daniel.krauss@beaumont.edu

    2017-05-01

    Purpose: Prostate-specific antigen (PSA) bounce is a temporary elevation of the PSA level above a prior nadir. The purpose of this study was to determine whether the frequency of a PSA bounce following high-dose-rate (HDR) interstitial brachytherapy for the treatment of prostate cancer is associated with individual treatment fraction size. Methods and Materials: Between 1999 and 2014, 554 patients underwent treatment of low- or intermediate-risk prostate cancer with definitive HDR brachytherapy as monotherapy and had ≥3 subsequent PSA measurements. Four different fraction sizes were used: 950 cGy × 4 fractions, 1200 cGy × 2 fractions, 1350 cGy × 2 fractions, 1900 cGy × 1 fraction. Four definitions of PSA bounce were applied: ≥0.2, ≥0.5, ≥1.0, and ≥2.0 ng/mL above the prior nadir with a subsequent return to the nadir. Results: The median follow-up period was 3.7 years. The actuarial 3-year rate of PSA bounce for the entire cohort was 41.3%, 28.4%, 17.4%, and 6.8% for nadir +0.2, +0.5, +1.0, and +2.0 ng/mL, respectively. The 3-year rate of PSA bounce >0.2 ng/mL was 42.2%, 32.1%, 41.0%, and 59.1% for the 950-, 1200-, 1350-, and 1900-cGy/fraction levels, respectively (P=.002). The hazard ratio for bounce >0.2 ng/mL for patients receiving a single fraction of 1900 cGy compared with those receiving treatment in multiple fractions was 1.786 (P=.024). For patients treated with a single 1900-cGy fraction, the 1-, 2-, and 3-year rates of PSA bounce exceeding the Phoenix biochemical failure definition (nadir +2 ng/mL) were 4.5%, 18.7%, and 18.7%, respectively, higher than the rates for all other administered dose levels (P=.025). Conclusions: The incidence of PSA bounce increases with single-fraction HDR treatment. Knowledge of posttreatment PSA kinetics may aid in decision making regarding management of potential biochemical failures.

  12. Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China.

    Science.gov (United States)

    Na, Rong; Ye, Dingwei; Qi, Jun; Liu, Fang; Helfand, Brian T; Brendler, Charles B; Conran, Carly A; Packiam, Vignesh; Gong, Jian; Wu, Yishuo; Zheng, Siqun L; Mo, Zengnan; Ding, Qiang; Sun, Yinghao; Xu, Jianfeng

    2017-08-01

    The performance of prostate health index (phi) in predicting prostate biopsy outcomes has been well established for patients with prostate-specific antigen (PSA) values between 2 and 10 ng/mL. However, the performance of phi remains unknown in patients with PSA >10 ng/mL, the vast majority in Chinese biopsy patients. We aimed to assess the ability of phi to predict prostate cancer (PCa) and high-grade disease (Gleason Score ≥7) on biopsy in a Chinese population. This is a prospective, observational, multi-center study of consecutive patients who underwent a transrectal ultrasound guided prostate biopsy at four hospitals in Shanghai, China from August 2013 to December 2014. In the cohort of 1538 patients, the detection rate of PCa was 40.2%. phi had a significantly better predictive performance for PCa than total PSA (tPSA). The areas under the receiver operating characteristic curve (AUC) were 0.90 and 0.79 for phi and tPSA, respectively, P 10 ng/mL (N = 838, 54.5%). The detection rates of PCa were 35.9% and 57.7% in patients with tPSA 10.1-20 and 20.1-50 ng/mL, respectively. The AUCs of phi (0.79 and 0.89, for these two groups, respectively) were also significantly higher than tPSA (0.57 and 0.63, respectively), both P 10 ng/mL). © 2017 Wiley Periodicals, Inc.

  13. Contribuição da densidade do PSA para predizer o câncer da próstata em pacientes com valores de PSA entre 2,6 e 10,0 ng/ml

    Directory of Open Access Journals (Sweden)

    Hugo Alexandre Sócrates de Castro

    2011-08-01

    Full Text Available OBJETIVO: Estudar o perfil dos pacientes submetidos a biópsia prostática, determinando possíveis padrões que, associados aos níveis de PSA entre 2,6 e 10,0 ng/ml, possam levar a uma diminuição de biópsias desnecessárias. MATERIAIS E MÉTODOS: De 2007 a 2009, foi realizado um estudo transversal com 1.282 indivíduos submetidos a biópsia prostática e que apresentavam níveis de PSA entre 2,6 e 10,0 ng/ml. RESULTADOS: A prevalência de câncer foi de 28,6%. Pacientes com câncer eram, em média, mais idosos, com valores de PSA e densidade de PSA mais altos e menor volume da próstata. Na análise da densidade de PSA, os pacientes com câncer tiveram média de 0,31 ng/ml/cc, enquanto nos pacientes com resultado negativo a média foi de 0,10 ng/ml/cc. Utilizando como critério de positividade para câncer o ponto de corte de densidade de PSA de 0,15 ng/ml/cc, obtivemos especificidade de 74% e sensibilidade de 70%. Para aumentar a sensibilidade é preciso reduzir o ponto de corte. Com o valor 0,09 ng/ml/cc, obtivemos sensibilidade de 84% (IC 95%: 80-87% e especificidade de 75% (IC 95%: 72-78%. CONCLUSÃO: O uso sistemático da densidade de PSA na indicação de prosseguimento da investigação do paciente com biópsia poderia reduzir a quantidade de procedimentos desnecessários.

  14. Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?

    Science.gov (United States)

    Lee, Seung Hwan; Chung, Mun Su; Park, Kyung Kgi; Yom, Chan Dong; Lee, Dae Hoon; Chung, Byung Ha

    2012-04-01

    We evaluated the relationship between bone metastasis (BM) and clinical or pathological variables, including the serum prostate-specific antigen (PSA) concentration. This retrospective study included 579 consecutive patients with newly diagnosed prostate cancer (Pca) who underwent a bone scan study at our institution between 2002 and 2010. We used receiver operating characteristics curves to evaluate accuracy of bone metastasis between serum PSA 10 and 20 ng/mL. A positive bone scan result was found in 83 men (14.3%) with PCa. However, 27 men (4.6%) with serum PSA between 10 and 20 ng/mL, 29/579 men (5.0%) with GS ≤ 7, and 21/83 (25.3%) with serum PSA ≤ 20 ng/mL and Gleason score (GS) ≤ 7 had positive bone scans. In the logistic regression analyses, clinical T stage (odds ratio [OR] = 3.26; 95% CI, 2.29-4.33; P = 0.021), GS (OR = 3.41; 95% CI, 2.91-4.63; P = 0.019), and serum PSA (OR = 8.37; 95% CI, 3.91-19.21; P bone scans for the detection of BM was 0.640 (P = 0.020; 95% CI, 0.563-0.717). With serum PSA at 10 ng/mL and GS ≤ 7, the AUC values of bone scans were 0.828 (P Bone scans might be necessary in men with serum PSA between 10 and 20 ng/mL. New guidelines for eliminating bone scans in patients with newly diagnosed Pca are needed, especially in Asians.

  15. The Effect of Increasing Doses of Saw Palmetto Fruit Extract on Serum PSA Levels: Analysis of the CAMUS Randomized Trial

    Science.gov (United States)

    Andriole, Gerald L.; McCullum-Hill, Christie; Sandhu, Gurdarshan S.; Crawford, E. David; Barry, Michael J.; Cantor, Alan

    2014-01-01

    Purpose Saw palmetto extracts are used for treating lower urinary tract symptoms in men despite level I evidence concluding that saw palmetto was ineffective in reducing lower urinary symptoms. We sought to determine whether higher doses of saw palmetto as studied in CAMUS affect serum PSA levels. Materials and Methods The CAMUS trial was a randomized, placebo-controlled double blind multi-centered North American trial conducted between June 5, 2008 and October 10, 2012 in which 369 men >45 years of age with AUA symptom score ≥ 8 and ≤ 24 were randomly assigned to placebo or dose escalation saw palmetto, which consisted of 320mg for first 24 weeks to 640mg for next 24 weeks to 960mg for last 24 weeks of this 72 week trial. Serum PSA levels (Beckman-Coulter) were obtained at baseline and at weeks 24, 48 and 72 and were compared between treatment groups using the pooled t and Fisher's exact tests. Results Serum PSA levels were similar at baseline for the placebo (1.93 ± 1.59 ng/ml) and saw palmetto groups (2.20 ± 1.95, p = 0.16). Changes in PSA levels over the course of the study were similar: placebo group mean change 0.16 ± 1.08 ng/ml and saw palmetto group mean change 0.23 ± 0.83 ng/ml (p value 0.50). Additionally, no differential effect on serum PSA levels was observed between treatment arms when groups were stratified by baseline PSA values. Conclusions Saw palmetto extract does not affect serum PSA levels more than placebo even at relatively high doses. PMID:23253958

  16. Exploring functional beta-cell heterogeneity in vivo using PSA-NCAM as a specific marker.

    Directory of Open Access Journals (Sweden)

    Melis Karaca

    Full Text Available BACKGROUND: The mass of pancreatic beta-cells varies according to increases in insulin demand. It is hypothesized that functionally heterogeneous beta-cell subpopulations take part in this process. Here we characterized two functionally distinct groups of beta-cells and investigated their physiological relevance in increased insulin demand conditions in rats. METHODS: Two rat beta-cell populations were sorted by FACS according to their PSA-NCAM surface expression, i.e. beta(high and beta(low-cells. Insulin release, Ca(2+ movements, ATP and cAMP contents in response to various secretagogues were analyzed. Gene expression profiles and exocytosis machinery were also investigated. In a second part, beta(high and beta(low-cell distribution and functionality were investigated in animal models with decreased or increased beta-cell function: the Zucker Diabetic Fatty rat and the 48 h glucose-infused rat. RESULTS: We show that beta-cells are heterogeneous for PSA-NCAM in rat pancreas. Unlike beta(low-cells, beta(high-cells express functional beta-cell markers and are highly responsive to various insulin secretagogues. Whereas beta(low-cells represent the main population in diabetic pancreas, an increase in beta(high-cells is associated with gain of function that follows sustained glucose overload. CONCLUSION: Our data show that a functional heterogeneity of beta-cells, assessed by PSA-NCAM surface expression, exists in vivo. These findings pinpoint new target populations involved in endocrine pancreas plasticity and in beta-cell defects in type 2 diabetes.

  17. Study on LOOP and SBO Frequency for Multi-Unit PSA

    Energy Technology Data Exchange (ETDEWEB)

    Jin, Kyung Ho; Heo, Gyun Young [Kyunghee University, Yongin (Korea, Republic of)

    2016-05-15

    In conventional single unit PSA, it was assumed that all accidents or events are independent and the risk of only one unit has been evaluated. In other words, the possibility that simultaneous events occur on multiple units was excluded because it was assumed that the probability of concurrent events were extremely low. After Fukushima accidents, however, it was found that external hazards such as tsunami may impact on multiple units; that means, for the sake of proper mitigation the risk of accidents in shared SSCs should be reevaluated. New risk metrics to improve conventional CDF (Core Damage frequency) based on reactor-year is needed to perform MUPSA (Multi-Unit Probabilistic Safety Assessment). IAEA suggested SCDF (Site CDF) as a risk metrics for MUPSA. The frequency based on reactor-year was converted to the frequency based on site-year. In addition, shared SSCs were modeled in single unit PSA as if those units have independent shared SSCs. Therefore, the risk of shared SSCs should be reevaluated. In this paper, the frequency of LOOP (Loss of Offsite Power), which is typically a multi-unit event, was evaluated and the frequency of SBO (Station Blackout) depending on LOOP frequency and emergency power systems such as EDG (Emergency Diesel Generator) and AAC (Alternate AC), that can mitigate SBO events, was modeled. This paper describes how to calculate LOOP and SBO frequency from the simple example for two-unit site with shared AAC. The events impacting on multiple units, which were excluded in conventional PSA, should be considered for MUPSA.

  18. Exploring Functional β-Cell Heterogeneity In Vivo Using PSA-NCAM as a Specific Marker

    Science.gov (United States)

    Karaca, Melis; Castel, Julien; Tourrel-Cuzin, Cécile; Brun, Manuel; Géant, Anne; Dubois, Mathilde; Catesson, Sandra; Rodriguez, Marianne; Luquet, Serge; Cattan, Pierre; Lockhart, Brian; Lang, Jochen; Ktorza, Alain

    2009-01-01

    Background The mass of pancreatic β-cells varies according to increases in insulin demand. It is hypothesized that functionally heterogeneous β-cell subpopulations take part in this process. Here we characterized two functionally distinct groups of β-cells and investigated their physiological relevance in increased insulin demand conditions in rats. Methods Two rat β-cell populations were sorted by FACS according to their PSA-NCAM surface expression, i.e. βhigh and βlow-cells. Insulin release, Ca2+ movements, ATP and cAMP contents in response to various secretagogues were analyzed. Gene expression profiles and exocytosis machinery were also investigated. In a second part, βhigh and βlow-cell distribution and functionality were investigated in animal models with decreased or increased β-cell function: the Zucker Diabetic Fatty rat and the 48 h glucose-infused rat. Results We show that β-cells are heterogeneous for PSA-NCAM in rat pancreas. Unlike βlow-cells, βhigh-cells express functional β-cell markers and are highly responsive to various insulin secretagogues. Whereas βlow-cells represent the main population in diabetic pancreas, an increase in βhigh-cells is associated with gain of function that follows sustained glucose overload. Conclusion Our data show that a functional heterogeneity of β-cells, assessed by PSA-NCAM surface expression, exists in vivo. These findings pinpoint new target populations involved in endocrine pancreas plasticity and in β-cell defects in type 2 diabetes. PMID:19440374

  19. Guidelines for reliability analysis of digital systems in PSA context. Phase 3. Status report

    Energy Technology Data Exchange (ETDEWEB)

    Authen, S. [Risk Pilot AB, Stockholm (Sweden); Holmberg, J.-E. [VTT Technical Research Centre of Finland, Espoo (Finland)

    2013-03-15

    Digital protection and control systems appear as upgrades in older plants, and are commonplace in new nuclear power plants. To assess the risk of nuclear power plant operation and to determine the risk impact of digital systems, there is a need to quantitatively assess the reliability of the digital systems in a justifiable manner. In 2007, the OECD/NEA CSNI directed the Working Group on Risk Assessment (WGRisk) to set up a task group to coordinate an activity in this field. One of the recommendations was to develop a taxonomy of failure modes of digital components for the purposes of probabilistic safety assessment (PSA), resulting in a follow-up task group called DIGREL. The taxonomy will be the basis of future modelling and quantification efforts. It will also help define a structure for data collection and to review PSA studies. This an interim report of the project. A draft guidelines document on the failure modes taxonomy has been developed. The taxonomy is rather complete covering all levels from the system level down to module and basic component level failure modes, including hardware and software aspects. There are still open issues to be resolved by the task group, especially related to I and C unit and module level taxonomy. In a parallel Nordic activity, a comparison of Nordic experiences and a literature review on main international references has been performed. The study showed a wide range of approaches and solutions to the challenges given by digital I and C, and also indicated that no state-of-the-art currently exists. An existing simplified PSA model has been complemented with fault tree models for a four-redundant distributed protection system in order to study and demonstrate the effect of design features and modelling approaches. The model has been used to test the effect of CCF modelling, fail-safe principle and voting logic. A comparison has been made between unit-level and module-level modelling. (Author)

  20. The OMERACT psoriatic arthritis magnetic resonance imaging scoring system (PsAMRIS): definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PsA Hands

    DEFF Research Database (Denmark)

    Østergaard, Mikkel; McQueen, Fiona; Wiell, Charlotte

    2009-01-01

    This article describes a preliminary OMERACT psoriatic arthritis magnetic resonance image scoring system (PsAMRIS) for evaluation of inflammatory and destructive changes in PsA hands, which was developed by the international OMERACT MRI in inflammatory arthritis group. MRI definitions of important...... pathologies in peripheral PsA and suggestions concerning appropriate MRI sequences for use in PsA hands are also provided....

  1. Childhood Obesity – Prevention Begins with Breastfeeding PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-08-02

    This 60 second Public Service Announcement (PSA) is based on the August, 2011 CDC Vital Signs report. Childhood obesity is an epidemic in the US. Breastfeeding can help prevent obesity, but one in three moms stop without hospital support. About 95% of hospitals lack policies that fully support breastfeeding moms. Hospitals need to do more to help moms start and continue breastfeeding.  Created: 8/2/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 8/2/2011.

  2. Drinking and Driving – What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-10-04

    This 60 second PSA is based on the October, 2011 CDC Vital Signs report. Drinking and driving is still a serious problem. Crashes involving alcohol-impaired drivers kill nearly 11,000 people each year. If you’re drinking, designate a non-drinking driver before you start, call a cab, or get a ride home. Also, always wear your seat belt. Seat belts reduce the risk of serious injuries and death in a crash by 50 percent.  Created: 10/4/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 10/4/2011.

  3. The Tobacco Use Epidemic – What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-09-06

    This 60 second PSA is based on the September, 2011 CDC Vital Signs report. Fewer Americans are smoking cigarettes, and daily smokers are smoking less; however, even occasional smoking causes harm. The best option for any smoker is to quit completely. Quitting at any age has benefits, and the sooner you quit, the sooner your body can begin to heal.  Created: 9/6/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 9/6/2011.

  4. An Hipotesis for PSA's solar furnace mirror improvement

    Energy Technology Data Exchange (ETDEWEB)

    La Padula, C.D.; Bartolini, C.; Beskin, G.; Cosentino, G.; Guarnieri, A.; Nanni, D.; Piccioni, A.

    2002-07-01

    The PSA's Solar Furnace capabilities can be greatly improved by replacing the present array mirrors with new ones. We will explain a rather cheap method (now under test) for the fabrication of the new mirrors, with a simple spherical figuring, and everyone identical to each other. Furthermore, we will describe the geometry the new array should have in order to avoid excessive aberrations due to the high obliquity of the rays with which most of the mirrors in the array have to deal with. (Author) 8 refs.

  5. HIV Testing – What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2010-11-30

    This 60 second PSA is based on the December, 2010 CDC Vital Signs report which indicates that last year, 82.9 million adults between 18 and 64 reported having been tested for HIV, yet 55 percent of adults – and 28.3 percent of adults with a risk factor for HIV – haven't been tested.  Created: 11/30/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 11/30/2010.

  6. CDC: Tips from Former Smokers – Tiffany PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-03-28

    When Tiffany was 16, her mother—a cigarette smoker—died of lung cancer. Tiffany quit smoking at 34 because she wanted to be around for her own daughter, who had just turned 16. In this 60 second PSA from CDC's Tips From Former Smokers campaign, Tiffany offers tips on how to quit.  Created: 3/28/2013 by Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion.   Date Released: 8/8/2013.

  7. Baseline PSA in a Spanish male population aged 40-49 years anticipates detection of prostate cancer.

    Science.gov (United States)

    Angulo, J C; Viñas, M A; Gimbernat, H; Fata, F Ramón de; Granados, R; Luján, M

    2015-12-01

    We researched the usefulness of optimizing prostate cancer (PC) screening in our community using baseline PSA readings in men between 40-49 years of age. A retrospective study was performed that analyzed baseline PSA in the fifth decade of life and its ability to predict the development of PC in a population of Madrid (Spain). An ROC curve was created and a cutoff was proposed. We compared the evolution of PSA from baseline in patients with consecutive readings using the Friedman test. We established baseline PSA ranges with different risks of developing cancer and assessed the diagnostic utility of the annual PSA velocity (PSAV) in this population. Some 4,304 men aged 40-49 years underwent opportunistic screening over the course of 17 years, with at least one serum PSA reading (6,001 readings) and a mean follow-up of 57.1±36.8 months. Of these, 768 underwent biopsy of some organ, and 104 underwent prostate biopsy. Fourteen patients (.33%) were diagnosed with prostate cancer. The median baseline PSA was .74 (.01-58.5) ng/mL for patients without PC and 4.21 (.76-47.4) ng/mL for those with PC. The median time from the reading to diagnosis was 26.8 (1.5-143.8) months. The optimal cutoff for detecting PC was 1.9ng/mL (sensitivity, 92.86%; specificity, 92.54%; PPV, 3.9%; NPV, 99.97%), and the area under the curve was 92.8%. In terms of the repeated reading, the evolution of the PSA showed no statistically significant differences between the patients without cancer (p=.56) and those with cancer (P=.64). However, a PSAV value >.3ng/mL/year revealed high specificity for detecting cancer in this population. A baseline PSA level ≥1.9ng/mL in Spanish men aged 40-49 years predicted the development of PC. This value could therefore be of use for opportunistic screening at an early age. An appropriate follow-up adapted to the risk of this population needs to be defined, but an annual PSAV ≥.3ng/mL/year appears of use for reaching an early diagnosis. Copyright © 2015 AEU

  8. Artificial neural network (ANN velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity

    Directory of Open Access Journals (Sweden)

    Lein Michael

    2008-09-01

    Full Text Available Abstract Background To validate an artificial neural network (ANN based on the combination of PSA velocity (PSAV with a %free PSA-based ANN to enhance the discrimination between prostate cancer (PCa and benign prostate hyperplasia (BPH. Methods The study comprised 199 patients with PCa (n = 49 or BPH (n = 150 with at least three PSA estimations and a minimum of three months intervals between the measurements. Patients were classified into three categories according to PSAV and ANN velocity (ANNV calculated with the %free based ANN "ProstataClass". Group 1 includes the increasing PSA and ANN values, Group 2 the stable values, and Group 3 the decreasing values. Results 71% of PCa patients typically have an increasing PSAV. In comparison, the ANNV only shows this in 45% of all PCa patients. However, BPH patients benefit from ANNV since the stable values are significantly more (83% vs. 65% and increasing values are less frequently (11% vs. 21% if the ANNV is used instead of the PSAV. Conclusion PSAV has only limited usefulness for the detection of PCa with only 71% increasing PSA values, while 29% of all PCa do not have the typical PSAV. The ANNV cannot improve the PCa detection rate but may save 11–17% of unnecessary prostate biopsies in known BPH patients.

  9. Development of a fully-coupled, all atates, all hazards level 2 PSA at leibstadt nuclear power plant

    Energy Technology Data Exchange (ETDEWEB)

    Zvoncek, Pavol; Nusbaumer, Olivier [Safety Compliance and Technical Support Department, Leibstadt Nuclear Power Plant, Leibstadt (Sweden); Torri, Alfred [Risk Management Associates, Inc., Encinitas (United States)

    2017-03-15

    This paper describes the development process, the innovative techniques used and insights gained from the latest integrated, full scope, multistate Level 2 PSA analysis conducted at the Leibstadt Nuclear Power Plant (KKL), Switzerland. KKL is a modern single-unit General Electric Boiling Water Reactor (BWR/6) with Mark III Containment, and a power output of 3600MWth/1200MWe, the highest among the five operating reactors in Switzerland. A Level 2 Probabilistic Safety Assessment (PSA) analyses accident phenomena in nuclear power plants, identifies ways in which radioactive releases from plants can occur and estimates release pathways, magnitude and frequency. This paper attempts to give an overview of the advanced modeling techniques that have been developed and implemented for the recent KKL Level 2 PSA update, with the aim of systematizing the analysis and modeling processes, as well as complying with the relatively prescriptive Swiss requirements for PSA. The analysis provides significant insights into the absolute and relative importance of risk contributors and accident prevention and mitigation measures. Thanks to several newly developed techniques and an integrated approach, the KKL Level 2 PSA report exhibits a high degree of reviewability and maintainability, and transparently highlights the most important risk contributors to Large Early Release Frequency (LERF) with respect to initiating events, components, operator actions or seismic component failure probabilities (fragilities)

  10. [Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: comparisons among ASTRO and Phoenix biochemical failure definitions].

    Science.gov (United States)

    Quero, L; Mongiat-Artus, P; Ravery, V; Hennequin, V; Maylin, C; Desgrandchamps, F; Hennequin, C

    2009-07-01

    Study about the efficacy of salvage radiotherapy (RT), in terms of biochemical disease free survival (bDFS), according to ASTRO and Phoenix (nadir+2) definitions, for persistent or rising PSA after radical prostatectomy. Retrospective analysis of 59 patients who underwent RT between 1990 and 2003 for PSA recurrence after radical prostatectomy. Patients received a median of 66Gy to the prostate bed with 3D or 2D RT. The main end point was bDFS according to ASTRO and Phoenix (nadir+2) definitions. Different criterion sets were analysed to calculate bDFS and pretreatment factors that might predict biochemical relapse were sought for each. After a 38-month median follow-up, the 3-year bDFS rates were: 60 and 72% for ASTRO and Phoenix (nadir+2 ng/ml) definitions respectively. According to univariate analysis, pre-RT PSA> or =1 ng/ml and seminal vesicle involvement were associated with biochemical relapse. Multivariate analysis retained only pre-RT PSA> or =1 ng/ml as an independent predictor of biochemical relapse for the two definitions. Salvage RT is an effective treatment after radical prostatectomy according to ASTRO or Phoenix definitions. Only pre-RT PSA> or =1 ng/ml predicted relapse.

  11. Lassen Veränderungen des Prostata-spezifischen Antigen- (PSA- Spiegels nach Prostatastanzbiopsie Rückschlüsse auf das pathologische Ergebnis zu?

    Directory of Open Access Journals (Sweden)

    Volkmer BG

    2004-01-01

    Full Text Available Einleitung: Die diagnostische Biopsie der Prostata führt bekanntermaßen zum Anstieg des Serum-PSA-Spiegels. Diese prospektive Untersuchung sollte die Frage klären, ob die Änderungen des Serum-PSA-Spiegels nach Stanzbiopsie Rückschlüsse auf das histologische Ergebnis zulassen und so als Entscheidungshilfe bei der Frage der Rebiopsie dienen können. Patienten und Methoden: Insgesamt 79 konsekutive Patienten mit klinischem Verdacht auf das Vorliegen eines Prostatakarzinoms (PCA und einem Gesamt-PSA 50 ng/ml wurden in die Studie eingeschlossen. Ausschlußkriterien waren klinische Hinweise für eine Prostatitis und Prostatabiopsie innerhalb der letzten 3 Monate. Die Serum-PSA-Werte wurden mit einem ultrasensitiven Enzymimmunoassay bestimmt. Die Bestimmung des Gesamt-PSA und des freien PSA im Serum erfolgte unmittelbar vor und 60 Minuten nach der Biopsie. Die Spiegel des Gesamt-PSA und freien PSA, sowie die f/t-PSA-Ratio vor und nach Biopsie wurden in Korrelation zum histologischen Ergebnis gesetzt. Ergebnisse: 86 Biopsieserien wurden bei 79 Patienten durchgeführt. 38 Biopsieserien diagnostizierten ein PCA, 48 eine benigne Prostatahyperplasie (BPH. Die abschließende Histologie nach wiederholter Biopsie war PCA und BPH in je 43 Fällen. Insgesamt fand sich ein Anstieg des durchschnittlichen Gesamt-PSA von 18,39 ng/ml auf 107,8 ng/ml, des durchschnittlichen freien PSA von 3,43 ng/ml auf 33,7 ng/ml und der durchschnittlichen f/t PSA-Ratio von 18,1 % auf 52,0 %. Es fand sich keine Korrelation zwischen dem Anstieg dieser Parameter und der Anzahl der Biopsiezylinder (4–51. Bezüglich des histologischen Befundes ergaben sich statistisch signifikante Unterschiede für das Gesamt-PSA vor und die f/t PSA-Ratio vor und nach Stanzbiopsie. Schlußfolgerung: Die Analyse der PSA-Parameter nach Stanzbiopsie bietet keine zusätzliche Information über die konventionellen PSA-Parameter vor der Biopsie hinaus. Sie korrelieren vor allem nicht mit falsch

  12. Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era.

    Science.gov (United States)

    Shahabi, Ahva; Satkunasivam, Raj; Gill, Inderbir S; Lieskovsky, Gary; Daneshmand, Sia; Pinski, Jacek K; Stern, Mariana C

    2016-01-01

    We sought to determine predictors for early and late biochemical recurrence following radical prostatectomy among localized prostate cancer patients. The study included localized prostate cancer patients treated with radical prostatectomy (RP) at the University of Southern California from 1988 to 2008. Competing risks regression models were used to determine risk factors associated with earlier or late biochemical recurrence, defined using the median time to biochemical recurrence in this population (2.9 years after radical prostatectomy). The cohort for this study included 2262 localized prostate cancer (pT2-3N0M0) patients who did not receive neoadjuvant or adjuvant therapies. Of these patients, 188 experienced biochemical recurrence and a subset continued to clinical recurrence, either within (n=19, 10%) or following (n=13, 7%) 2.9 years after RP. Multivariable stepwise competing risks analysis showed Gleason score ≥7, positive surgical margin status, and ≥pT3a stage to be associated with biochemical recurrence within 2.9 years following surgery. Predictors of biochemical recurrence after 2.9 years were Gleason score 7 (4+3), preoperative prostate-specific antigen (PSA) level, and ≥pT3a stage. Higher stage was associated with biochemical recurrence at any time following radical prostatectomy. Particular attention may need to be made to patients with stage ≥pT3a, higher preoperative PSA, and Gleason 7 prostate cancer with primary high-grade patterns when considering longer followup after RP.

  13. Radical prostatectomy outcome when performed with PSA above 20 ng/ml.

    LENUS (Irish Health Repository)

    Connolly, S S

    2012-02-01

    Many centres currently do not offer radical prostatectomy (RP) to men with high-risk localised prostate cancer due to concerns regarding poor outcome, despite evidence to the contrary. We identified 18 men undergoing RP with serum PSA >20 ng\\/ml (high-risk by National Comprehensive Cancer Network definition) and minimum follow-up of 12 years (mean 13.5). Mean preoperative PSA was 37.0 ng\\/ml (Range 21.1-94.0). Prostatectomy pathology reported extracapsular disease in 16 (88.9%), positive surgical margins in 15 (83%) and positive pelvic lymph nodes in 5 (27.8%). Overall and cancer-specific survival at 5 and 10-years was 83.3%, 88.2%, 72% and 76.5% respectively. With complete follow-up 11 (61.1%) are alive, and 5 (27.8%) avoided any adjuvant therapy. Complete continence (defined as no involuntary urine leakage and no use of pads) was achieved in 60%, with partial continence in the remainder. We conclude that surgery for this aggressive variant of localised prostate cancer can result in satisfactory outcome.

  14. MODIFICATION OF THE SPAR-H METHOD TO SUPPORT HRA FOR LEVEL 2 PSA

    Energy Technology Data Exchange (ETDEWEB)

    St. Germain, S.; Boring, R.; Banaseanu, G.; Akl, Y.; Xu, M.

    2016-10-01

    Currently, available Human Reliability Analysis (HRA) methods were generally developed to support Level 1 Probabilistic Safety Analysis (PSA) models. There has been an increased emphasis placed on Level 2 PSA in recent years; however, the currently used HRA methods are not ideal for this application, including the SPAR-H method. Challenges that will likely be present during a severe accident such as degraded or hazardous operating conditions, shift in control from the main control room to the technical support center, unavailability of instrumentation, and others are not routinely considered for Level 1 HRA analysis. These factors combine to create a much more uncertain condition to be accounted for in the HRA analysis. While the SPAR-H shaping factors were established to support Level 1 HRA, previous studies have shown it may be used for Level 2 HRA analysis as well. The Canadian Nuclear Safety Commission (CNSC) and Idaho National Laboratory (INL) in a joint project are investigating modifications to the SPAR-H method to create more consistency in applying the performance shaping factors used in the method for Level 2 analysis.

  15. Zušlechťování bioplynu metodou PSA

    OpenAIRE

    Krhut, Štěpán

    2017-01-01

    Tato práce řeší zušlechťování bioplynu metodou PSA a zmodernizování laboratorní jednotky. Surový bioplyn obsahuje mnoho nežádoucích složek, které snižují jeho energetický potenciál, a to v nejvyšší míře oxid uhličitý. Pro rozšíření možností využití bioplynu je třeba tuto složku odstranit. Jednou z rozšířených metod pro odstranění CO2 z bioplynu je metoda Pressure Swing Adsorption (PSA – česky adsorpce za měnícího se tlaku). Tato práce popisuje tuto metodu a porovnává ji s jinými metodami čišt...

  16. Research on the improvement of nuclear safety -Development of computing code system for level 3 PSA

    Energy Technology Data Exchange (ETDEWEB)

    Jeong, Jong Tae; Kim, Dong Ha; Park, Won Seok; Hwang, Mi Jeong [Korea Atomic Energy Research Institute, Taejon (Korea, Republic of)

    1995-07-01

    Among the various research areas of the level 3 PSA, the effect of terrain on the transport of radioactive material was investigated. These results will give a physical insight in the development of a new dispersion model. A wind tunnel experiment with bell shaped hill model was made in order to develop a new dispersion model. And an improved dispersion model was developed based on the concentration distribution data obtained from the wind tunnel experiment. This model will be added as an option to the atmospheric dispersion code. A stand-alone atmospheric code using MS Visual Basic programming language which runs at the Windows environment of a PC was developed. A user can easily select a necessary data file and type input data by clicking menus, and can select calculation options such building wake, plume rise etc., if necessary. And a user can easily understand the meaning of concentration distribution on the map around the plant site as well as output files. Also the methodologies for the estimation of radiation exposure and for the calculation of risks was established. These methodologies will be used for the development of modules for the radiation exposure and risks respectively. These modules will be developed independently and finally will be combined to the atmospheric dispersion code in order to develop a level 3 PSA code. 30 tabs., 56 figs., refs. (Author).

  17. A new method to consider human actions in the framework of a dynamic PSA

    Energy Technology Data Exchange (ETDEWEB)

    Kloos, M.; Peschke, J. [Gesellschaft fuer Anlagen- und Reaktorsicherheit mbH (GRS), Braunschweig (Germany)

    2006-07-01

    The variety of accident sequences to be considered in the framework of a PSA derives from mutual dependencies between the physical process, the behaviour of the technical system, human actions and stochastic influences along the time axis. Because the conventional PSA approach is not able to adequately account for these interactions, so-called probabilistic dynamics methods have been developed. They generally achieve a more realistic modelling of accident scenarios and a more realistic safety assessment. At GRS, the method MCDET - a combination of Monte Carlo Simulation und the Discrete Dynamic Event Tree method - was developed. The implementation of MCDET was supplemented by a so called Crew-Module which allows - together with a deterministic dynamics code - to simulate human actions as a dynamic process evolving over time in interaction with the system and process dynamics. The Crew-Module accounts for communications between crew members and for performance shaping factors like stress, knowledge or ergonomics. This paper presents the Crew- Module and gives an overview of the results which may be obtained from its combination with MCDET and a deterministic dynamics code. The emergency operating procedure 'Secondary Side Bleed and Feed' in a German PWR is selected as an illustrative application. (authors)

  18. Advancement of the methodology for automated integration of external hazards into level 1 PSA modeling. Technical report; Weiterentwicklung der Methodik zur automatisierten Integration uebergreifender Einwirkungen in PSA-Modelle der Stufe 1. Technischer Fachbericht

    Energy Technology Data Exchange (ETDEWEB)

    Berner, Nadine; Herb, Joachim

    2017-03-15

    In the course of the research and development project RS1539 funded by the German Federal Ministry for Economics and Energy (BMWi) the methodology for the automated integration of hazards in Level 1 PSA models has been enhanced. Thereby, the analysis tool pyRiskRobot provides the methodological framework for mapping a generic spectrum of internal and external hazards onto complex PSA plant models. The reimplementation of the software tool via the programming language python extends the applicability and facilitates the handling of pyRiskRobot in comparison to the previous Ruby-based version RiskRobot. Moreover, the development of functions to perform the topological modelling of fault trees and the probabilistic specification of modified fault tree elements have been continued. Due to the reimplementation and further developments, the tool enables to systematically generate fault trees of varying complexity, to flexibly integrate fault trees in existing PSA models and to automatically duplicate interconnected topologies. Thus, pyRiskRobot allows the efficient and traceable realization of hazard specific, usually laborious modifications of PSA models. In addition, pyRiskRobot has been extended to serve as a functional interface between the data compilations comprising the potential influences of hazards on PSA relevant components and the data base of a PSA plant model. Based on this conceptual design, additional analyses of the data can be carried out prior to the integration within the PSA model topology. The reimplemented functionalities of pyRiskRobot have been validated with respect to reference applications, such as the modelling of an internal fire scenario, against the previous version RiskRobot. The existing method collection for the automated modification of fault tree topologies has been extended based on the requirements for further applications, among others the modelling of an external flooding scenario. The deduced hazard specific modelling approaches

  19. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA: results from the alpha omega trial.

    Directory of Open Access Journals (Sweden)

    Ingeborg A Brouwer

    Full Text Available Alpha linolenic acid (ALA is the major omega-3 fatty acid in the diet. Evidence on health effects of ALA is not conclusive, but some observational studies found an increased risk of prostate cancer with higher intake of ALA. We examined the effect of ALA supplementation on serum concentrations of prostate-specific antigen (PSA, a biomarker for prostate cancer.The Alpha Omega Trial (ClinicalTrials.gov Identifier: NCT00127452 was a double-blind, placebo-controlled trial of ALA and the fish fatty acids eicosapentanoic acid (EPA and docosahexanoic acid (DHA on the recurrence of cardiovascular disease, using a 2×2 factorial design. Blood was collected at the start and the end of the intervention period. The present analysis included 1622 patients with a history of a myocardial infarction, aged 60-80 years with an initial PSA concentration 4 ng/mL.Mean serum PSA increased by 0.42 ng/mL on placebo (n = 815 and by 0.52 ng/mL on ALA (n = 807, a difference of 0.10 (95% confidence interval: -0.02 to 0.22 ng/mL (P = 0·12. The odds ratio for PSA rising above 4 ng/mL on ALA versus placebo was 1.15 (95% CI: 0.84-1.58.An additional amount of 2 g of ALA per day increased PSA by 0.10 ng/mL, but the confidence interval ranged from -0.02 to 0.22 ng/mL and included no effect. Therefore, more studies are needed to establish whether or not ALA intake has a clinically significant effect on PSA or prostate cancer.ClinicalTrials.gov; Identifier: NCT00127452. URL: http://www.clinicaltrials.gov/ct2/show/NCT00127452.

  20. The contribution of the Patient Support Assistant to direct patient care: an exploration of nursing and PSA role perceptions.

    Science.gov (United States)

    Conway, Jane; Kearin, Mark

    2007-04-01

    Health care systems have seen the introduction of the unregulated worker into patient care areas to assist Registered Nurses (RNs) in the provision of health care. A study was undertaken to identify the perceptions of both nurses and unregulated workers of the unregulated worker role in direct patient care in a regional hospital in New South Wales, Australia. The nomenclature used for a non regulated worker in the workplace in which this study occurred is Patient Support Assistant (PSA). Separate surveys were designed for PSA and nursing staff. Twenty seven per cent of PSAs (n=21) and 36% of nursing staff surveyed (n=120) responded. Results identified that both groups identified the main role of PSAs were attending to general cleaning and providing physical assistance to nurses, medical and physiotherapy staff, primarily for manual handling of heavy or difficult patients. Some activities of the role identified in the job description, such as pre-operative shaves on male patients and assisting with the application of traction, appeared no longer to be relevant for current practices. Both groups identified a positive team working relationship between nurses and PSAs. However, there was evidence to suggest that not all RNs had a clear understanding of the role of the PSA and the PSAs believed that they did not receive adequate feedback about their work. There was a mixed view as to whom the PSA should report. A high percentage of RNs felt they should be responsible for the supervision of the PSA. This was in contrast to a high percentage also believing that RNs should not be accountable either for PSA work or for delegating tasks to PSAs. Challenges voiced by PSAs included being expected to achieve both allocated cleaning tasks and provide patient support, being requested to assist with aggressive patients and working with other PSAs. A major recommendation of the study is that employment of Assistants in Nursing may provide enhanced scope and role clarity for

  1. Phytohormone and Putative Defense Gene Expression Differentiates the Response of ‘Hayward’ Kiwifruit to Psa and Pfm Infections

    Directory of Open Access Journals (Sweden)

    Kirstin V. Wurms

    2017-08-01

    Full Text Available Pseudomonas syringae pv. actinidiae (Psa and Pseudomonas syringae pv. actinidifoliorum (Pfm are closely related pathovars infecting kiwifruit, but Psa is considered one of the most important global pathogens, whereas Pfm is not. In this study of Actinidia deliciosa ‘Hayward’ responses to the two pathovars, the objective was to test whether differences in plant defense responses mounted against the two pathovars correlated with the contrasting severity of the symptoms caused by them. Results showed that Psa infections were always more severe than Pfm infections, and were associated with highly localized, differential expression of phytohormones and putative defense gene transcripts in stem tissue closest to the inoculation site. Phytohormone concentrations of jasmonic acid (JA, jasmonate isoleucine (JA-Ile, salicylic acid (SA and abscisic acid were always greater in stem tissue than in leaves, and leaf phytohormones were not affected by pathogen inoculation. Pfm inoculation induced a threefold increase in SA in stems relative to Psa inoculation, and a smaller 1.6-fold induction of JA. Transcript expression showed no effect of inoculation in leaves, but Pfm inoculation resulted in the greatest elevation of the SA marker genes, PR1 and glucan endo-1,3-beta-glucosidase (β-1,3-glucosidase (32- and 25-fold increases, respectively in stem tissue surrounding the inoculation site. Pfm inoculation also produced a stronger response than Psa inoculation in localized stem tissue for the SA marker gene PR6, jasmonoyl-isoleucine-12-hydrolase (JIH1, which acts as a negative marker of the JA pathway, and APETALA2/Ethylene response factor 2 transcription factor (AP2 ERF2, which is involved in JA/SA crosstalk. WRKY40 transcription factor (a SA marker was induced equally in stems by wounding (mock inoculation and pathovar inoculation. Taken together, these results suggest that the host appears to mount a stronger, localized, SA-based defense response to Pfm

  2. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the alpha omega trial.

    Science.gov (United States)

    Brouwer, Ingeborg A; Geleijnse, Johanna M; Klaasen, Veronique M; Smit, Liesbeth A; Giltay, Erik J; de Goede, Janette; Heijboer, Annemieke C; Kromhout, Daan; Katan, Martijn B

    2013-01-01

    Alpha linolenic acid (ALA) is the major omega-3 fatty acid in the diet. Evidence on health effects of ALA is not conclusive, but some observational studies found an increased risk of prostate cancer with higher intake of ALA. We examined the effect of ALA supplementation on serum concentrations of prostate-specific antigen (PSA), a biomarker for prostate cancer. The Alpha Omega Trial (ClinicalTrials.gov Identifier: NCT00127452) was a double-blind, placebo-controlled trial of ALA and the fish fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) on the recurrence of cardiovascular disease, using a 2×2 factorial design. Blood was collected at the start and the end of the intervention period. The present analysis included 1622 patients with a history of a myocardial infarction, aged 60-80 years with an initial PSA concentration 4 ng/mL). Mean serum PSA increased by 0.42 ng/mL on placebo (n = 815) and by 0.52 ng/mL on ALA (n = 807), a difference of 0.10 (95% confidence interval: -0.02 to 0.22) ng/mL (P = 0·12). The odds ratio for PSA rising above 4 ng/mL on ALA versus placebo was 1.15 (95% CI: 0.84-1.58). An additional amount of 2 g of ALA per day increased PSA by 0.10 ng/mL, but the confidence interval ranged from -0.02 to 0.22 ng/mL and included no effect. Therefore, more studies are needed to establish whether or not ALA intake has a clinically significant effect on PSA or prostate cancer. ClinicalTrials.gov; Identifier: NCT00127452. URL: http://www.clinicaltrials.gov/ct2/show/NCT00127452.

  3. Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence

    Directory of Open Access Journals (Sweden)

    Mazeron Renaud

    2012-03-01

    Full Text Available Abstract Purpose To evaluate predictive factors for PSA bounce after 125I permanent seed prostate brachytherapy and identify criteria that distinguish between benign bounces and biochemical relapses. Materials and methods Men treated with exclusive permanent 125I seed brachytherapy from November 1999, with at least a 36 months follow-up were included. Bounce was defined as an increase ≥ 0.2 ng/ml above the nadir, followed by a spontaneous return to the nadir. Biochemical failure (BF was defined using the criteria of the Phoenix conference: nadir +2 ng/ml. Results 198 men were included. After a median follow-up of 63.9 months, 21 patients experienced a BF, and 35.9% had at least one bounce which occurred after a median period of 17 months after implantation (4-50. Bounce amplitude was 0.6 ng/ml (0.2-5.1, and duration was 13.6 months (4.0-44.9. In 12.5%, bounce magnitude exceeded the threshold defining BF. Age at the time of treatment and high PSA level assessed at 6 weeks were significantly correlated with bounce but not with BF. Bounce patients had a higher BF free survival than the others (100% versus 92%, p = 0,007. In case of PSA increase, PSA doubling time and velocity were not significantly different between bounce and BF patients. Bounces occurred significantly earlier than relapses and than nadir + 0.2 ng/ml in BF patients (17 vs 27.8 months, p Conclusion High PSA value assessed 6 weeks after brachytherapy and young age were significantly associated to a higher risk of bounces but not to BF. Long delays between brachytherapy and PSA increase are more indicative of BF.

  4. 11C–Choline PET / CT in the detection of prostate cancer relapse in patients with rising PSA

    Directory of Open Access Journals (Sweden)

    I. P. Aslanidis

    2015-01-01

    Full Text Available Objective. To evaluate the diagnostic impact of 11C–Choline PET / CT in the detection of recurrent prostate cancer (PCa in patients with biochemical relapse after radical prostatectomy and to assess the correlation between PSA levels and PET / CT detection rate of PCa relapse.Subjects and methods. 85 patients with biochemical relapse (mean PSA 3.51 ± 3.87 ng / ml after radical prostatectomy (n = 64 and radiotherapy (n = 21 underwent 11C–Choline PET / CT. According to PSA level, patients were divided into three groups:  2 ng / ml, 2 to 9 ng / ml and > 9 ng / ml.Results. Overall, 11C–Choline PET / CT detected PCa relapse in 33 of 85 patients (39 %. The mean PSA value in PET-positive patients was 5.78 ± 4.95 (0.22–17.80 ng / ml, while in PET-negative patients – 1.43 ± 1.08 (0.28–4.57 ng / ml. Positive PET / CT results were obtained in 9 of 40 patients (22 % with PSA of < 2 ng / ml, in 17 of 38 patients (45 % with PSA of 2 to 9 ng / ml, and in 7 of 7 patients (100 % with PSA of > 9 ng / ml. Local relapse was detected in 42 % (14 / 33 patients. Both local and distant metastases were diagnosed in 39 % (13 / 33 cases. Distant relapsewas identified in 19 % (6 / 33 cases. PET / CT allowed to assess the efficacy of treatment in 26 % (12 / 47 PET-negative patients under hormone therapy at the scan time. However, PET / CT wasn’t able to localize the site of PCa recurrence in these hormone-ensitive patients what might have affected the overall detection rate.Conclusion. 1 11C–Choline PET / CT was able to detect and correctly identify the site of PCa relapse in 39 % cases and therefore was useful in determining the further therapeutic approach. 2 Our data confirmed the strong correlation between PSA levels and 11C–Choline PET / CT detection rate of PCa relapse (r = 0.9; p < 0.001. 3 11C–Choline PET / CT has limited utility in localizing the site of PCa recurrence in some patients under hormone therapy.

  5. The role of the percentage free PSA in the diagnosis of prostate cancer in Blacks: Findings in indigenous West African men using TRUS guided biopsy

    Directory of Open Access Journals (Sweden)

    K.H. Tijani

    2017-03-01

    Conclusion: The %fPSA is an effective discriminating tool in determining the need for prostate biopsy in indigenous West African men with PSA 4–10 ng/ml. A cut off of 15% was associated with the highest performance.

  6. Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?

    Science.gov (United States)

    Harrison, Sean; Tilling, Kate; Turner, Emma L; Lane, J Athene; Simpkin, Andrew; Davis, Michael; Donovan, Jenny; Hamdy, Freddie C; Neal, David E; Martin, Richard M

    2016-12-01

    Previous studies indicate a possible inverse relationship between prostate-specific antigen (PSA) and body mass index (BMI), and a positive relationship between PSA and age. We investigated the associations between age, BMI, PSA, and screen-detected prostate cancer to determine whether an age-BMI-adjusted PSA model would be clinically useful for detecting prostate cancer. Cross-sectional analysis nested within the UK ProtecT trial of treatments for localized cancer. Of 18,238 men aged 50-69 years, 9,457 men without screen-detected prostate cancer (controls) and 1,836 men with prostate cancer (cases) met inclusion criteria: no history of prostate cancer or diabetes; PSA BMI between 15 and 50 kg/m(2). Multivariable linear regression models were used to investigate the relationship between log-PSA, age, and BMI in all men, controlling for prostate cancer status. In the 11,293 included men, the median PSA was 1.2 ng/ml (IQR: 0.7-2.6); mean age 61.7 years (SD 4.9); and mean BMI 26.8 kg/m(2) (SD 3.7). There were a 5.1% decrease in PSA per 5 kg/m(2) increase in BMI (95% CI 3.4-6.8) and a 13.6% increase in PSA per 5-year increase in age (95% CI 12.0-15.1). Interaction tests showed no evidence for different associations between age, BMI, and PSA in men above and below 3.0 ng/ml (all p for interaction >0.2). The age-BMI-adjusted PSA model performed as well as an age-adjusted model based on National Institute for Health and Care Excellence (NICE) guidelines at detecting prostate cancer. Age and BMI were associated with small changes in PSA. An age-BMI-adjusted PSA model is no more clinically useful for detecting prostate cancer than current NICE guidelines. Future studies looking at the effect of different variables on PSA, independent of their effect on prostate cancer, may improve the discrimination of PSA for prostate cancer.

  7. Advanced Reactor PSA Methodologies for System Reliability Analysis and Source Term Assessment

    Energy Technology Data Exchange (ETDEWEB)

    Grabaskas, D.; Brunett, A.; Passerini, S.; Grelle, A.; Bucknor, M.

    2017-06-26

    Beginning in 2015, a project was initiated to update and modernize the probabilistic safety assessment (PSA) of the GE-Hitachi PRISM sodium fast reactor. This project is a collaboration between GE-Hitachi and Argonne National Laboratory (Argonne), and funded in part by the U.S. Department of Energy. Specifically, the role of Argonne is to assess the reliability of passive safety systems, complete a mechanistic source term calculation, and provide component reliability estimates. The assessment of passive system reliability focused on the performance of the Reactor Vessel Auxiliary Cooling System (RVACS) and the inherent reactivity feedback mechanisms of the metal fuel core. The mechanistic source term assessment attempted to provide a sequence specific source term evaluation to quantify offsite consequences. Lastly, the reliability assessment focused on components specific to the sodium fast reactor, including electromagnetic pumps, intermediate heat exchangers, the steam generator, and sodium valves and piping.

  8. Correlação entre prostatite assintomatica com PSA elevado e cancer de prostata

    OpenAIRE

    Rafael Mamprin Stopiglia

    2009-01-01

    Resumo: A prostatite assintomática é definida através da detecção laboratorial do aumento de células inflamatórias em secreções uretrais ou urina após massagem da glândula prostática e também detectada em biópsias. Esta alteração inflamatória é reconhecidamente uma causa de elevação dos níveis do PSA. Devido esta elevação também estar associada ao câncer prostático, desenvolvemos um estudo para avaliar a correlação entre prostatite assintomática com a referida doença maligna. No período de ja...

  9. Guidelines for reliability analysis of digital systems in PSA context. Phase 1 status report

    Energy Technology Data Exchange (ETDEWEB)

    Authen, S.; Larsson, J. (Risk Pilot AB, Stockholm (Sweden)); Bjoerkman, K.; Holmberg, J.-E. (VTT, Helsingfors (Finland))

    2010-12-15

    Digital protection and control systems are appearing as upgrades in older nuclear power plants (NPPs) and are commonplace in new NPPs. To assess the risk of NPP operation and to determine the risk impact of digital system upgrades on NPPs, quantitative reliability models are needed for digital systems. Due to the many unique attributes of these systems, challenges exist in systems analysis, modeling and in data collection. Currently there is no consensus on reliability analysis approaches. Traditional methods have clearly limitations, but more dynamic approaches are still in trial stage and can be difficult to apply in full scale probabilistic safety assessments (PSA). The number of PSAs worldwide including reliability models of digital I and C systems are few. A comparison of Nordic experiences and a literature review on main international references have been performed in this pre-study project. The study shows a wide range of approaches, and also indicates that no state-of-the-art currently exists. The study shows areas where the different PSAs agree and gives the basis for development of a common taxonomy for reliability analysis of digital systems. It is still an open matter whether software reliability needs to be explicitly modelled in the PSA. The most important issue concerning software reliability is proper descriptions of the impact that software-based systems has on the dependence between the safety functions and the structure of accident sequences. In general the conventional fault tree approach seems to be sufficient for modelling reactor protection system kind of functions. The following focus areas have been identified for further activities: 1. Common taxonomy of hardware and software failure modes of digital components for common use 2. Guidelines regarding level of detail in system analysis and screening of components, failure modes and dependencies 3. Approach for modelling of CCF between components (including software). (Author)

  10. PSA velocity in conservatively managed BPH: can it predict the need for BPH-related invasive therapy?

    NARCIS (Netherlands)

    Mochtar, C.A.; Kiemeney, L.A.L.M.; Laguna, M.P.; Debruyne, F.M.J.; Rosette, J.J.M.H.C. de la

    2006-01-01

    OBJECTIVE: To study the value of PSA velocity (PSAV) to predict benign prostatic hyperplasia (BPH) progression in patients managed with alpha(1)-blockers or watchful waiting (WW). METHODS: Nine hundred and forty two BPH patients treated with alpha(1)-blocker or WW were reviewed. PSAV was defined as:

  11. What If I Don't Treat My PSA-Detected Prostate Cancer? Answers from Three Natural History Models

    NARCIS (Netherlands)

    Gulati, Roman; Wever, Elisabeth M.; Tsodikov, Alex; Penson, David F.; Inoue, Lurdes Y. T.; Katcher, Jeffrey; Lee, Shih-Yuan; Heijnsdijk, Eveline A. M.; Draisma, Gerrit; de Koning, Harry J.; Etzioni, Ruth

    Background: Making an informed decision about treating a prostate cancer detected after a routine prostate-specific antigen (PSA) test requires knowledge about disease natural history, such as the chances that it would have been clinically diagnosed in the absence of screening and that it would

  12. A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy.

    Science.gov (United States)

    Iwamura, Hiromichi; Hatakeyama, Shingo; Tanaka, Yoshimi; Tanaka, Toshikazu; Tokui, Noriko; Yamamoto, Hayato; Imai, Atsushi; Yoneyama, Takahiro; Hashimoto, Yasuhiro; Koie, Takuya; Yoshikawa, Kazuaki; Ohyama, Chikara

    2014-01-29

    Prostate-specific antigen (PSA) is a widely used specific tumor marker for prostate cancer. We experienced a case of metastatic prostate cancer that was difficult to detect by repeat prostate biopsy despite a markedly elevated serum PSA level. A 64-year-old man was referred to our hospital with lumbar back pain and an elevated serum PSA level of 2036 ng/mL. Computed tomography, bone scintigraphy, and magnetic resonance imaging showed systemic lymph node and osteoblastic bone metastases. Digital rectal examination revealed a small, soft prostate without nodules. Ten-core transrectal prostate biopsy yielded negative results. Androgen deprivation therapy (ADT) was started because of the patient's severe symptoms. Twelve-core repeat transrectal prostate biopsy performed 2 months later, and transurethral resection biopsy performed 5 months later, both yielded negative results. The patient refused further cancer screening because ADT effectively relieved his symptoms. His PSA level initially decreased to 4.8 ng/mL, but he developed castration-resistant prostate cancer 7 months after starting ADT. He died 21 months after the initial prostate biopsy from disseminated intravascular coagulation. CUP remains a considerable challenge in clinical oncology. Biopsies of metastatic lesions and multimodal approaches were helpful in this case.

  13. A Human Reliability Analysis of Post- Accident Human Errors in the Low Power and Shutdown PSA of KSNP

    Energy Technology Data Exchange (ETDEWEB)

    Kang, Daeil; Kim, J. H.; Jang, S. C

    2007-03-15

    Korea Atomic Energy Research Institute, using the ANS low power and shutdown (LPSD) probabilistic risk assessment (PRA) Standard, evaluated the LPSD PSA model of the KSNP, Yonggwang Units 5 and 6, and identified the items to be improved. The evaluation results of human reliability analysis (HRA) of the post-accident human errors in the LPSD PSA model for the KSNP showed that 10 items among 19 items of supporting requirements for those in the ANS PRA Standard were identified as them to be improved. Thus, we newly carried out a HRA for post-accident human errors in the LPSD PSA model for the KSNP. Following tasks are the improvements in the HRA of post-accident human errors of the LPSD PSA model for the KSNP compared with the previous one: Interviews with operators in the interpretation of the procedure, modeling of operator actions, and the quantification results of human errors, site visit. Applications of limiting value to the combined post-accident human errors. Documentation of information of all the input and bases for the detailed quantifications and the dependency analysis using the quantification sheets The assessment results for the new HRA results of post-accident human errors using the ANS LPSD PRA Standard show that above 80% items of its supporting requirements for post-accident human errors were graded as its Category II. The number of the re-estimated human errors using the LPSD Korea Standard HRA method is 385. Among them, the number of individual post-accident human errors is 253. The number of dependent post-accident human errors is 135. The quantification results of the LPSD PSA model for the KSNP with new HEPs show that core damage frequency (CDF) is increased by 5.1% compared with the previous baseline CDF It is expected that this study results will be greatly helpful to improve the PSA quality for the domestic nuclear power plants because they have sufficient PSA quality to meet the Category II of Supporting Requirements for the post

  14. A Human Reliability Analysis of Pre-Accident Human Errors in the Low Power and Shutdown PSA of the KSNP

    Energy Technology Data Exchange (ETDEWEB)

    Kang, Daeil; Jang, Seungchul

    2007-03-15

    Korea Atomic Energy Research Institute, using the ANS Low Power /Shutdown (LPSD)PRA Standard, evaluated the LPSD PSA model of the KSNP, Younggwang (YGN) Units 5 and 6, and identified the items to be improved. The evaluation results of human reliability analysis (HRA) of the pre-accident human errors in the LPSD PSA model of the KSNP showed that 13 items among 15 items of supporting requirements for those in the ANS PRA Standard were identified as them to be improved. Thus, we newly carried out a HRA for pre-accident human errors in the LPSD PSA model for the KSNP to improve its quality. We considered potential pre-accident human errors for all manual valves and control/instrumentation equipment of the systems modeled in the KSNP LPSD PSA model except reactor protection system/ engineering safety features actuation system. We reviewed 160 manual valves and 56 control/instrumentation equipment. The number of newly identified pre-accident human errors is 101. Among them, the number of those related to testing/maintenance tasks is 56. The number of those related to calibration tasks is 45. The number of those related to only shutdown operation is 10. It was shown that the pre-accident human errors related to only shutdown operation contributions to the core damage frequency of LPSD PSA model for the KSNP was negligible.The self-assessment results for the new HRA results of pre-accident human errors using the ANS LPSD PRA Standard show that above 80% items of its supporting requirements for post-accident human errors were graded as its Category II or III. It is expected that the HRA results for the pre-accident human errors presented in this study will be greatly helpful to improve the PSA quality for the domestic nuclear power plants because they have sufficient PSA quality to meet the Category II of supporting requirements for the postaccident human errors in the ANS LPSD PRA Standard.

  15. Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence

    Science.gov (United States)

    2012-01-01

    Purpose To evaluate predictive factors for PSA bounce after 125I permanent seed prostate brachytherapy and identify criteria that distinguish between benign bounces and biochemical relapses. Materials and methods Men treated with exclusive permanent 125I seed brachytherapy from November 1999, with at least a 36 months follow-up were included. Bounce was defined as an increase ≥ 0.2 ng/ml above the nadir, followed by a spontaneous return to the nadir. Biochemical failure (BF) was defined using the criteria of the Phoenix conference: nadir +2 ng/ml. Results 198 men were included. After a median follow-up of 63.9 months, 21 patients experienced a BF, and 35.9% had at least one bounce which occurred after a median period of 17 months after implantation (4-50). Bounce amplitude was 0.6 ng/ml (0.2-5.1), and duration was 13.6 months (4.0-44.9). In 12.5%, bounce magnitude exceeded the threshold defining BF. Age at the time of treatment and high PSA level assessed at 6 weeks were significantly correlated with bounce but not with BF. Bounce patients had a higher BF free survival than the others (100% versus 92%, p = 0,007). In case of PSA increase, PSA doubling time and velocity were not significantly different between bounce and BF patients. Bounces occurred significantly earlier than relapses and than nadir + 0.2 ng/ml in BF patients (17 vs 27.8 months, p brachytherapy and young age were significantly associated to a higher risk of bounces but not to BF. Long delays between brachytherapy and PSA increase are more indicative of BF. PMID:22449081

  16. Prostate cancer-specific death in brachytherapy treated high-risk patients stratified by pre-treatment PSA

    Science.gov (United States)

    Galbreath, Robert W.; Butler, Wayne M.; Fiano, Ryan; Adamovich, Edward

    2017-01-01

    Purpose To evaluate prostate-cancer specific mortality (PCSM) in a cohort of high-risk patients treated with a permanent prostate brachytherapy approach, stratified by pre-treatment PSA. Material and methods 448 high-risk patients (NCCN criteria) underwent permanent prostate brachytherapy. High risk patients were stratified by pre-treatment PSA (≤ 10.0, 10.1-20, and > 20 ng/ml). Biochemical failure (BF), prostate cancer-specific mortality (PCSM), distant failure (DM), and overall mortality (OM) were assessed as a function of prognostic group. Multiple clinical, treatment, and dosimetric parameters were evaluated for impact on outcome. Results The 10-year OM, BF, and PCSM for the entire cohort were 28.5%, 13.3%, and 4.9%, respectively. At 10 years, PCSM was 2.5%, 10.7%, and 4.5% in the PSA ≤ 10, 10.1-20, and > 20 ng/ml groups, respectively. No statistically significant differences in BF or overall survival (OS) were noted when stratified by pre-treatment PSA. DF was the most common in the 10.1-20 ng/ml cohort (8.6% at 10 years). In multivariate analysis, PCSM was most closely related to percent positive biopsies (p = 0.001) and tobacco (p = 0.042). Conclusions High-risk prostate cancer treated with permanent prostate brachytherapy and supplemental external beam radiotherapy resulted in excellent long-term biochemical control and PCSM. Overall, PCSM was low in all cohorts but highest in the intermediate PSA group (10.1-20 ng/ml). PMID:28951747

  17. Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?

    Directory of Open Access Journals (Sweden)

    Pedro Galego

    2015-04-01

    Full Text Available Purpose To evaluate the clinical outcome of a cohort of localized prostate cancer patients treate with 125-I permanent brachytherapy at the São José Hospital – CHLC, Lisbon. Materials and Methods A retrospective analysis was carried out on 429 patients with low and intermediate-risk of prostate adenocarcinoma, according to the recommendations of the EORTC, who underwent 125I brachytherapies in intraoperative dosimetry “real-time” system between September 2003 and September 2013. Results The mean follow-up was 71.98 months. Biochemical relapse of disease by rising PSA (Phoenix criterion was observed in 18 patients (4.2%. Through the application of Kaplan-Meier survival curves in this sample, the rate of survival at 6 years without biochemical relapse was higher than 95%. By Iog rank test comparing biochemical relapse with initial PSA (15-10 and <10 and Gleason values (7 and <7, there was no statistical difference (P=0.830 of the initial PSA in the probability of developing biochemical relapse. In relation to Gleason score, it was noted a statistical difference (P<0.05, demonstrating that patients with Gleason 7 are more likely to develop biochemical relapse. Conclusions Brachytherapy as monotherapy is at present an effective choice in the treatment of localized prostate adenocarcinoma. Biochemical relapses are minimal. The initial PSA showed no statistically difference in the rate of relapses, unlike the value Gleason, where it was demonstrated that patients with Gleason 7 have a higher probability of biochemical relapse. Cases with PSA bounce should be controlled before starting a salvage treatment.

  18. Prostate Specific Antigen (PSA as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT in Combination with Additional External Beam Radiation Therapy (EBRT for High Risk Prostate Cancer

    Directory of Open Access Journals (Sweden)

    Thorsten H. Ecke

    2016-11-01

    Full Text Available High-dose-rate brachytherapy (HDR-BT with external beam radiation therapy (EBRT is a common treatment option for locally advanced prostate cancer (PCa. Seventy-nine male patients (median age 71 years, range 50 to 79 with high-risk PCa underwent HDR-BT following EBRT between December 2009 and January 2016 with a median follow-up of 21 months. HDR-BT was administered in two treatment sessions (one week interval with 9 Gy per fraction using a planning system and the Ir192 treatment unit GammaMed Plus iX. EBRT was performed with CT-based 3D-conformal treatment planning with a total dose administration of 50.4 Gy with 1.8 Gy per fraction and five fractions per week. Follow-up for all patients was organized one, three, and five years after radiation therapy to evaluate early and late toxicity side effects, metastases, local recurrence, and prostate-specific antigen (PSA value measured in ng/mL. The evaluated data included age, PSA at time of diagnosis, PSA density, BMI (body mass index, Gleason score, D’Amico risk classification for PCa, digital rectal examination (DRE, PSA value after one/three/five year(s follow-up (FU, time of follow-up, TNM classification, prostate volume, and early toxicity rates. Early toxicity rates were 8.86% for gastrointestinal, and 6.33% for genitourinary side effects. Of all treated patients, 84.81% had no side effects. All reported complications in early toxicity were grade 1. PSA density at time of diagnosis (p = 0.009, PSA on date of first HDR-BT (p = 0.033, and PSA on date of first follow-up after one year (p = 0.025 have statistical significance on a higher risk to get a local recurrence during follow-up. HDR-BT in combination with additional EBRT in the presented design for high-risk PCa results in high biochemical control rates with minimal side-effects. PSA is a negative predictive biomarker for local recurrence during follow-up. A longer follow-up is needed to assess long-term outcome and toxicities.

  19. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.

    Science.gov (United States)

    Ecke, Thorsten H; Huang-Tiel, Hui-Juan; Golka, Klaus; Selinski, Silvia; Geis, Berit Christine; Koswig, Stephan; Bathe, Katrin; Hallmann, Steffen; Gerullis, Holger

    2016-11-10

    High-dose-rate brachytherapy (HDR-BT) with external beam radiation therapy (EBRT) is a common treatment option for locally advanced prostate cancer (PCa). Seventy-nine male patients (median age 71 years, range 50 to 79) with high-risk PCa underwent HDR-BT following EBRT between December 2009 and January 2016 with a median follow-up of 21 months. HDR-BT was administered in two treatment sessions (one week interval) with 9 Gy per fraction using a planning system and the Ir192 treatment unit GammaMed Plus iX. EBRT was performed with CT-based 3D-conformal treatment planning with a total dose administration of 50.4 Gy with 1.8 Gy per fraction and five fractions per week. Follow-up for all patients was organized one, three, and five years after radiation therapy to evaluate early and late toxicity side effects, metastases, local recurrence, and prostate-specific antigen (PSA) value measured in ng/mL. The evaluated data included age, PSA at time of diagnosis, PSA density, BMI (body mass index), Gleason score, D'Amico risk classification for PCa, digital rectal examination (DRE), PSA value after one/three/five year(s) follow-up (FU), time of follow-up, TNM classification, prostate volume, and early toxicity rates. Early toxicity rates were 8.86% for gastrointestinal, and 6.33% for genitourinary side effects. Of all treated patients, 84.81% had no side effects. All reported complications in early toxicity were grade 1. PSA density at time of diagnosis (p = 0.009), PSA on date of first HDR-BT (p = 0.033), and PSA on date of first follow-up after one year (p = 0.025) have statistical significance on a higher risk to get a local recurrence during follow-up. HDR-BT in combination with additional EBRT in the presented design for high-risk PCa results in high biochemical control rates with minimal side-effects. PSA is a negative predictive biomarker for local recurrence during follow-up. A longer follow-up is needed to assess long-term outcome and toxicities.

  20. Polysialic Acid Neural Cell Adhesion Molecule (PSA-NCAM is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines

    Directory of Open Access Journals (Sweden)

    Metellus Philippe

    2010-03-01

    Full Text Available Abstract Background Glioblastoma multiforme (GBM is the most aggressive and frequent brain tumor, albeit without cure. Although patient survival is limited to one year on average, significant variability in outcome is observed. The assessment of biomarkers is needed to gain better knowledge of this type of tumor, help prognosis, design and evaluate therapies. The neurodevelopmental polysialic acid neural cell adhesion molecule (PSA-NCAM protein is overexpressed in various cancers. Here, we studied its expression in GBM and evaluated its prognosis value for overall survival (OS and disease free survival (DFS. Methods We set up a specific and sensitive enzyme linked immunosorbent assay (ELISA test for PSA-NCAM quantification, which correlated well with PSA-NCAM semi quantitative analysis by immunohistochemistry, and thus provides an accurate quantitative measurement of PSA-NCAM content for the 56 GBM biopsies analyzed. For statistics, the Spearman correlation coefficient was used to evaluate the consistency between the immunohistochemistry and ELISA data. Patients' survival was estimated by using the Kaplan-Meier method, and curves were compared using the log-rank test. On multivariate analysis, the effect of potential risk factors on the DFS and OS were evaluated using the cox regression proportional hazard models. The threshold for statistical significance was p = 0.05. Results We showed that PSA-NCAM was expressed by approximately two thirds of the GBM at variable levels. On univariate analysis, PSA-NCAM content was an adverse prognosis factor for both OS (p = 0.04 and DFS (p = 0.0017. On multivariate analysis, PSA-NCAM expression was an independent negative predictor of OS (p = 0.046 and DFS (p = 0.007. Furthermore, in glioma cell lines, PSA-NCAM level expression was correlated to the one of olig2, a transcription factor required for gliomagenesis. Conclusion PSA-NCAM represents a valuable biomarker for the prognosis of GBM patients.

  1. Comparison between Use of PSA Kinetics and Bone Marrow Micrometastasis to Define Local or Systemic Relapse in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer.

    Science.gov (United States)

    Murray, Nigel P; Reyes, Eduardo; Fuentealba, Cynthia; Orellana, Nelson; Jacob, Omar

    2015-01-01

    Treatment of biochemical failure after radical prostatectomy for prostate cancer is largely empirically based. The use of PSA kinetics has been used as a guide to determine local or systemic treatment of biochemical failure. We here compared PSA kinetics with detection of bone marrow micrometastasis as methods to determine local or systemic relapse. A transversal study was conducted of men with biochemical failure, defined as a serum PSA >0.2ng/ml after radical prostatectomy. Consecutive patients having undergone radical prostatectomy and with biochemical failure were enrolled and clinical and pathological details were recorded. Bone marrow biopsies were obtained from the iliac crest and touch prints made, micrometastasis (mM) being detected using anti-PSA. The clinical parameters of total serum PSA, PSA velocity, PSA doubling time and time to biochemical failure, age, Gleason score and pathological stage were registered. A total of 147 men, mean age 71.6 ± 8.2 years, with a median time to biochemical failure of 5.5 years (IQR 1.0-6.3 years) participated in the study. Bone marrow samples were positive for micrometastasis in 98/147 (67%) of patients at the time of biochemical failure. The results of bone marrow micrometastasis detected by immunocytochemistry were not concordant with local relapse as defined by PSA velocity, time to biochemical failure or Gleason score. In men with a PSA doubling time of 2,5ng/ml at the time of biochemical failure the detection of bone marrow micrometastasis was significantly higher. The detection of bone marrow micrometastasis could be useful in defining systemic relapse, this minimally invasive procedure warranting further studies with a larger group of patients.

  2. 68Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml

    DEFF Research Database (Denmark)

    Petersen, Lars J; Nielsen, Julie B; Dettmann, Katja

    2017-01-01

    /computed tomography ((68)Ga-PSMA PET/CT) is a novel and promising method for imaging in prostate cancer. The present study reports two cases of patients with prostate cancer with biochemical recurrence, with evidence of bone metastases on (68)Ga-PSMA PET/CT images and low prostate specific antigen PSA levels (...Localization of prostate cancer recurrence, particularly in the bones, is a major challenge with standard of care imaging in patients with biochemical recurrence following curatively intended treatment. Gallium-68-labeled prostate specific membrane antigen positron emission tomography...... with prostate cancer with biochemical recurrence, including patients with low PSA levels and low PSA kinetics....

  3. Identification of the vital digital assets based on PSA results analysis

    Energy Technology Data Exchange (ETDEWEB)

    Choi, Moon Kyoung; Seong, Poong Hyun [KAIST, Daejeon (Korea, Republic of); Son, Han Seong [Joongbu Univiersity, Geumsan (Korea, Republic of); Kim, Hyundoo [Korea Institute of Nuclear Nonproliferation and Control, Daejeon (Korea, Republic of)

    2016-10-15

    As the main systems for managing totally about the operation, control, monitoring, measurement, and safety function in an emergency, instrumentation and control systems (I and C) in nuclear power plants have been digitalized gradually for the precise operation and its convenience. The digitalization of infrastructure makes systems vulnerable to cyber threats and hybrid attacks. According to ICS-CERT report, as time goes by, the number of vulnerabilities in ICS industries increases rapidly. Recently, due to the digitalization of I and C, it has begun to rise the need of cyber security in the digitalized I and C in NPPs. However, there are too many critical digital assets (CDAs) in NPPs. More than 60% of the total critical systems are digital system. Addressing more than 100 security controls for each CDA needs too much effort for both licensee and inspector. It is necessary to focus on more significant CDAs for effective regulation. Probabilistic Safety Analysis (PSA) results are analyzed in order to identify more significant CDAs which could evoke an accident of NPPs by digital malfunction or cyber-attacks. By eliciting minimal cut sets using fault tree analyses, accident-related CDAs are drawn. Also the CDAs that must be secured from outsiders are elicited in case of some accident scenario. It is expected that effective cyber security regulation based on the graded approach can be implemented. Furthermore, defense-in-depth of digital assets for NPPs safety can be built up. Digital technologies such as computers, control systems, and data networks currently play essential roles in modern NPPs. Further, the introduction of new digitalized technologies is also being considered. These digital technologies make the operation of NPPs more convenient and economical; however, they are inherently susceptible to problems such as digital malfunction of components or cyber-attacks. Recently, needs for cyber security on digitalized nuclear Instrumentation and Control (I and C

  4. Generación de anticuerpos monoclonales contra el antígeno específico de próstata (psa)para la detección del psa y su purificación

    OpenAIRE

    Acevedo Castro, Boris Ernesto

    2012-01-01

    El cáncer de próstata en Cuba es un problema de salud (2 672 casos diagnosticados y 2 769 defunciones en el 2007). Varios métodos diagnósticos se han implementado para la detección y manejo de esta enfermedad, destacando entre ellos la determinación serológica del antígeno específico de próstata (PSA). En el presente trabajo se generó y caracterizó un panel de 11 anticuerpos monoclonales (AcMs) IgG1 que detectan con alta afinidad los epítopos principales descritos del PSA, tanto en solución c...

  5. Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance

    Science.gov (United States)

    Kim, Jeri; Ebertowski, James; Janiga, Matthew; Arzola, Jorge; Gillespie, Gayle; Fountain, Michael; Soderdahl, Douglas; Canby-Hagino, Edith; Elsamanoudi, Sally; Gurski, Jennifer; Davis, John W.; Parker, Patricia A.; Boyd, Douglas D.

    2012-01-01

    SUMMARY Objective To identify a population of young men (aged 30-fold. Data for a subset of men (174) with PSA screen-detected cancer were evaluable for disease risk assessment. Of the 174 men with screen-detected disease, 81 (47%) had very-low-risk disease. Of that group, 96% (78/81) selected treatment and, of 57 men undergoing radical prostatectomy (RP), the tumours of 49 (86%) carried favourable pathology (organ confined, < 10% gland involvement, Gleason ≤ 6). Conclusions Nearly half of young men with PSA screen-detected prostate cancer are AS candidates but the overwhelming majority seek treatment. Considering that many tumours show favourable pathology at RP, there is a possibility that these patients may benefit from AS management. PMID:23350937

  6. Validation of detection method prostatic specific antigen (PSA) by inmunocromatrografyc (Orgenics) applied to seminal liquid in stain dry and swabs

    OpenAIRE

    Cifuentes, Sandra Liliana

    2016-01-01

    El antígeno prostático específico (PSA) es generalmente usado para detectar y monitorear cuantitativamente el desarrollo de cáncer de próstata por niveles en suero de esta proteína, esta también es encontrada en altas concentraciones en semen. Diversos métodos reproducibles, sensibles y simples han sido desarrollados para el análisis de la presencia de PSA incluyendo técnicas inmunocromatográficas. Los procedimientos más comunes para la detección forense de semen se han enfocado en la identif...

  7. Risk-based configuration control: Application of PSA in improving technical specifications and operational safety

    Energy Technology Data Exchange (ETDEWEB)

    Samanta, P.K.; Kim, I.S. [Brookhaven National Lab., Upton, NY (United States); Vesely, W.E. [Science Applications International Corp., Dublin, OH (United States)

    1992-11-01

    Risk-based configuration control is the management of component configurations using a risk perspective to control risk and assure safety. A configuration, as used here, is a set of component operability statuses that define the state of a nuclear power plant. If the component configurations that have high risk implications do not occur, then the risk from the operation of nuclear power plants would be minimal. The control of component configurations, i.e., the management of component statuses, to minimize the risk from components being unavailable, becomes difficult, because the status of a standby safety system component is often not apparent unless it is tested. Controlling plant configuration from a risk-perspective can provide more direct risk control and also more operational flexibility by allowing looser controls in areas unimportant to risk. Risk-based configuration control approaches can be used to replace parts of nuclear power plant Technical Specifications. With the advances in probabilistic safety assessment (PSA) technology, such approaches to improve Technical Specifications and operational safety are feasible. In this paper, we present an analysis of configuration risks, and a framework for risk-based configuration control to achieve the desired control of risk-significant configurations during plant operation.

  8. Risk-based configuration control: Application of PSA in improving technical specifications and operational safety

    Energy Technology Data Exchange (ETDEWEB)

    Samanta, P.K.; Kim, I.S. (Brookhaven National Lab., Upton, NY (United States)); Vesely, W.E. (Science Applications International Corp., Dublin, OH (United States))

    1992-01-01

    Risk-based configuration control is the management of component configurations using a risk perspective to control risk and assure safety. A configuration, as used here, is a set of component operability statuses that define the state of a nuclear power plant. If the component configurations that have high risk implications do not occur, then the risk from the operation of nuclear power plants would be minimal. The control of component configurations, i.e., the management of component statuses, to minimize the risk from components being unavailable, becomes difficult, because the status of a standby safety system component is often not apparent unless it is tested. Controlling plant configuration from a risk-perspective can provide more direct risk control and also more operational flexibility by allowing looser controls in areas unimportant to risk. Risk-based configuration control approaches can be used to replace parts of nuclear power plant Technical Specifications. With the advances in probabilistic safety assessment (PSA) technology, such approaches to improve Technical Specifications and operational safety are feasible. In this paper, we present an analysis of configuration risks, and a framework for risk-based configuration control to achieve the desired control of risk-significant configurations during plant operation.

  9. Study of Scenarios Related to Design Extension Conditions of PHWR Using PSA Methodology

    Energy Technology Data Exchange (ETDEWEB)

    Kim, H. Y.; Yi, S. D.; Kim, S. R. [NESS, Daejeon (Korea, Republic of)

    2016-05-15

    Studies to establish the event classification framework and acceptance criteria for an event that exceeds the existing DBAs in order to enhance the safety operation of nuclear power plants in accordance with the domestic nuclear safety laws amended recently have been doing briskly in the country. In this perspective, a study of DECs for domestic PWRs has already begun, and accordingly, studies to cope with BDBAs including DECs for domestic CANDU plants also are required. In this paper, a postulated event which might be included into DECs for domestic CANDU is analyzed by CATHENA code, and Probabilistic Safety Assessment(PSA) data needed for selecting events for DECs are drawn. In this paper, based on the assumption that all the heat sinks and power are not available, countermeasure capability against loss of safety functions such as power supply system in domestic CANDU are assessed. The results and available power and heat sink source which are the required coping facilities for mitigating the accident are presented and the available limited time also are assessed. Provided that ways of long-term core cooling are secured later, it is expected that the safety functions of a plant can be secured even in the extremely severe natural disasters.

  10. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA to Exosomal Biomarkers

    Directory of Open Access Journals (Sweden)

    Xavier Filella

    2016-10-01

    Full Text Available Prostate specific antigen (PSA remains the most used biomarker in the management of early prostate cancer (PCa, in spite of the problems related to false positive results and overdiagnosis. New biomarkers have been proposed in recent years with the aim of increasing specificity and distinguishing aggressive from non-aggressive PCa. The emerging role of the prostate health index and the 4Kscore is reviewed in this article. Both are blood-based tests related to the aggressiveness of the tumor, which provide the risk of suffering PCa and avoiding negative biopsies. Furthermore, the use of urine has emerged as a non-invasive way to identify new biomarkers in recent years, including the PCA3 and TMPRSS2:ERG fusion gene. Available results about the PCA3 score showed its usefulness to decide the repetition of biopsy in patients with a previous negative result, although its relationship with the aggressiveness of the tumor is controversial. More recently, aberrant microRNA expression in PCa has been reported by different authors. Preliminary results suggest the utility of circulating and urinary microRNAs in the detection and prognosis of PCa. Although several of these new biomarkers have been recommended by different guidelines, large prospective and comparative studies are necessary to establish their value in PCa detection and prognosis.

  11. Development of a Fully-Coupled, All States, All Hazards Level 2 PSA at Leibstadt Nuclear Power Plant

    Directory of Open Access Journals (Sweden)

    Pavol Zvoncek

    2017-03-01

    The analysis provides significant insights into the absolute and relative importances of risk contributors and accident prevention and mitigation measures. Thanks to several newly developed techniques and an integrated approach, the KKL Level 2 PSA report exhibits a high degree of reviewability and maintainability, and transparently highlights the most important risk contributors to Large Early Release Frequency (LERF with respect to initiating events, components, operator actions or seismic component failure probabilities (fragilities.

  12. Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.

    Science.gov (United States)

    Suzman, D L; Zhou, X C; Zahurak, M L; Lin, J; Antonarakis, E S

    2015-03-01

    Multiple phase-2 trials in men with biochemically-recurrent prostate cancer (BRPC) have assessed the impact of nonhormonal agents on PSA kinetics. We have previously demonstrated that changes in PSA kinetics correlate with metastasis-free survival; however, it is unknown whether these changes also correlate with overall survival (OS). We performed a combined retrospective analysis of 146 men with BRPC treated on phase-2 trials using one of four investigational drugs: lenalidomide (n=60), marimastat (n=39), ATN-224 (n=22) and imatinib (n=25). We examined factors influencing OS, including within-subject changes in PSA kinetics (PSA slope, PSA doubling time and PSA velocity), before and 6 months after treatment initiation. After a median follow-up of 83.1 months, 49 of 146 men had died. In univariate Cox regression analysis, two factors were associated with OS: baseline PSA velocity and change in PSA velocity on therapy. In a landmark multivariable model, stratified by study (which controlled for age, Gleason score, type of local therapy and use of androgen-deprivation therapy prior to metastases), baseline PSA velocity and increase in PSA velocity on therapy remained independent predictors of OS. Median OS for men with an increase in PSA velocity on treatment was 115.4 months and was not reached for men with a decrease in PSA velocity (hazard ratio=0.47, 95% confidence interval 0.25-0.88; P=0.02). This hypothesis-generating study suggests that within-subject changes in PSA velocity after initiation of nonhormonal therapy may correlate with OS in men with BRPC. If validated in prospective trials, change in PSA velocity may represent a reasonable intermediate end point for screening new agents in these patients.

  13. The cutoff level of free/total prostate specific antigen (f/t PSA ratios in the diagnosis of prostate cancer: A validation study on a Turkish patient population in different age categories

    Directory of Open Access Journals (Sweden)

    Bulent Erol

    2014-11-01

    Full Text Available We investigated an optimal cutoff level of free/total PSA ratios (f/t PSA in predicting prostate cancer in different age groups, focusing on the avoidance of unnecessary prostate biopsies. A total of 4955 men were enrolled into the study. Serum tPSA, fPSA, and f/t PSA ratios were determined for the study population. All males who had suspicious digital rectal examination and tPSA > 4 ng/mL underwent transrectal ultrasonography-guided prostate biopsy. Receiver operating characteristic (ROC curves for each group were generated by plotting the sensitivity versus 1-specificity for the f/t PSA ratio. The sensitivity, specificity, positive likelihood ratio (PLR, and negative likelihood ratio (NLR were obtained using various f/t PSA ratio cutoffs for different age groups. There were 657 patients with a PSA level of 4–10 ng/mL. According to sensitivity and specificity f/t% PSA cutoff points were determined to be 10%, 15%, 15%, and 10% in 50–59 years, 60–69 years, >70 years, and all ages categories, respectively, in patients with initial PSA level of 4–10 ng/mL. f/t PSA ratio had an area under the curve (AUC value of 0.81 (95% confidence level: 0.80–0.82 for all age groups in detecting prostate cancer. f/t PSA ratio has an AUC value of 0.669 (0.632–0.705 in detecting prostate cancer among patients with a PSA level of 4–10 ng/mL. Ten percent of f/t PSA ratio had the highest specificity with PLR and 30% f/t PSA ratio had the highest sensitivity with lower NLR in the all-age categories. The current study shows that the use of f/t PSA ratio in patients with PSA levels of 4–10 ng/mL should enhance the specificity of PSA screening and decrease the number of unnecessary biopsies. The age-related changes warrant further investigation in a large, multicentric, and multinational population to improve the clinical use of f/t PSA cutoffs.

  14. Prostate cancer in patients from rural and suburban areas – PSA value, Gleason score and presence of metastases in bone scan

    Directory of Open Access Journals (Sweden)

    Wojciech Szot

    2014-11-01

    Full Text Available [b]Introduction[/b]. Prostate cancer is the second most common neoplasm among men both worldwide and in Poland. In prostate cancer, bone metastasis is related to a poorer prognosis. A diagnosis of metastatic bone disease is important in prostate cancer patients prior to therapy. Prostate specific antigen (PSA serum value is used both as a screening tool and for staging of prostate cancer. aim. To evaluate whether there is a link between symptoms presented by patients, pain in particular, and the presence, number and location of bone metastases as assessed by bone scan scintigraphy in concordance with PSA values and Gleason scores. [b]material[/b]. A group of 186 patients (aged: 68.38±6.16 diagnosed with prostate cancer, from rural and suburban areas of Małopolska province, that was directed for bone scan scintigraphy to the Nuclear Medicine Dept, John Paul II Hospital in Kraków. [b]methods[/b]. Analysis of all laboratory findings (including PSA value and a biopsy were performed. Then, bone scan scintigraphy was done with the use of methylene disphosphonate (MDP labeled with Tc-99m. [b]results[/b]. In patients with a Gleason value ≤7 and a PSA value ≤20 ng/ml, the cutoff value for a negative bone scan with a confidence interval of 0.95 was established at a PSA value below 10 ng/ml (p<0.01. Correlations were established between PSA value and presence of metastases in bone scan (r=0.45, p=0.05, the number of metastases (r=0.66, p<0.01, and their presence in particular body regions. [b]conclusions[/b]. The correlation between PSA value and both presence and number of metastases confirms the usefulness of bone scan scintigraphy in prostate cancer staging. The cutoff value for negative bone scan with a 95% confidence interval was established at PSA = 10 ng/ml.

  15. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.

    Science.gov (United States)

    Caster, Joseph M; Falchook, Aaron D; Hendrix, Laura H; Chen, Ronald C

    2015-06-01

    Radiation oncologists rely on available clinical information (biopsy Gleason score and prostate-specific antigen [PSA]) to determine the optimal treatment regimen for each prostate cancer patient. Existing published nomograms correlating clinical to pathologic extent of disease were based on patients treated in the 1980s and 1990s at select academic institutions. We used the Surveillance, Epidemiology, and End Results (SEER) database to examine pathologic outcomes (Gleason score and cancer stage) in early prostate cancer patients based on biopsy Gleason score and PSA concentration. This analysis included 25,858 patients whose cancer was diagnosed between 2010 and 2011, with biopsy Gleason scores of 6 to 7 and clinical stage T1 to T2 disease, who underwent radical prostatectomy. In subgroups based on biopsy Gleason score and PSA level, we report the proportion of patients with pathologically advanced disease (positive surgical margin or pT3-T4 disease) or whose Gleason score was upgraded. Logistic regression was used to examine factors associated with pathologic outcomes. For patients with biopsy Gleason score 6 cancers, 84% of those with PSA Gleason score upgrading was seen in 43% (PSA: Gleason 6 patients. Patients with biopsy Gleason 7 cancers had a one-third (Gleason 3 + 4; PSA: Gleason 4 + 3; PSA: 20-29.9 ng/mL) probability of having pathologically advanced disease. Gleason score upgrading was seen in 11% to 19% of patients with biopsy Gleason 4 + 3 cancers. Multivariable analysis showed that higher PSA and older age were associated with Gleason score upgrading and pathologically advanced disease. This is the first population-based study to examine pathologic extent of disease and pathologic Gleason score upgrading based on clinically available information in modern patients. These data inform the selection of radiation therapy strategies and an understanding of whether prostatectomy alone is likely to be curative for patients with early prostate cancers

  16. Genome-wide Association Study Identifies Loci at ATF7IP and KLK2 Associated with Percentage of Circulating Free PSA

    Directory of Open Access Journals (Sweden)

    Guangfu Jin

    2013-01-01

    RESULTS: We identified two loci that were associated with %fPSA at a genome-wide significance level (P <5 ×10−8. The first associated SNP was rs3213764 (P = 6.45 × 10−10, a nonsynonymous variant (K530R in the ATF7IP gene at 12p13. This variant was also nominally associated with tPSA (P = .015. The second locus was

  17. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.

    Science.gov (United States)

    Wu, Kai-Jie; Pei, Xin-Qi; Tian, Ge; Wu, Da-Peng; Fan, Jin-Hai; Jiang, Yu-Mei; He, Da-Lin

    2017-09-12

    Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) in China; however, the prognostic factors associated with effects in these patients are still controversial. In this study, we retrospectively reviewed the data from 71 eligible Chinese patients who received docetaxel chemotherapy from 2009 to 2016 in our hospital and experienced a reduction of prostate-specific antigen (PSA) level ≥50% during the treatment and investigated the potential role of time to nadir (TTN) of PSA. TTN was defined as the time from start of chemotherapy to the nadir of PSA level during the treatment. Multivariable Cox regression models and Kaplan-Meier analysis were used to predict overall survival (OS). In these patients, the median of TTN was 17 weeks. Patients with TTN ≥17 weeks had a longer response time to chemotherapy compared to TTN time to PSA progression in patients with TTN ≥17 weeks was 11.44 weeks compared to 5.63 weeks when TTN was Class 1 [Class 2 [0-50% response], HR: 3.978, 95% CI: 1.278-12.387, P = 0.017). In conclusion, TTN of PSA remains an important prognostic marker in predicting therapeutic outcome in Chinese population who receive chemotherapy for mCRPC and have >50% PSA remission.

  18. Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.

    Science.gov (United States)

    Habib, Fouad K; Ross, Margaret; Ho, Clement K H; Lyons, Valerie; Chapman, Karen

    2005-03-20

    The phytotherapeutic agent Serenoa repens is an effective dual inhibitor of 5alpha-reductase isoenzyme activity in the prostate. Unlike other 5alpha-reductase inhibitors, Serenoa repens induces its effects without interfering with the cellular capacity to secrete PSA. Here, we focussed on the possible pathways that might differentiate the action of Permixon from that of synthetic 5alpha-reductase inhibitors. We demonstrate that Serenoa repens, unlike other 5alpha-reductase inhibitors, does not inhibit binding between activated AR and the steroid receptor-binding consensus in the promoter region of the PSA gene. This was shown by a combination of techniques: assessment of the effect of Permixon on androgen action in the LNCaP prostate cancer cell line revealed no suppression of AR and maintenance of PSA protein expression at control levels. This was consistent with reporter gene experiments showing that Permixon failed to interfere with AR-mediated transcriptional activation of PSA and that both testosterone and DHT were equally effective at maintaining this activity. Our results demonstrate that despite Serenoa repens effective inhibition of 5alpha-reductase activity in the prostate, it did not suppress PSA secretion. Therefore, we confirm the therapeutic advantage of Serenoa repens over other 5alpha-reductase inhibitors as treatment with the phytotherapeutic agent will permit the continuous use of PSA measurements as a useful biomarker for prostate cancer screening and for evaluating tumour progression. (c) 2004 Wiley-Liss, Inc.

  19. Research on the improvement of nuclear safety -Development of level 2 PSA technology-

    Energy Technology Data Exchange (ETDEWEB)

    Jin, Yung Hoh; Park, Soo Yong; Kim, Si Dal; Song, Yong Man; An, Kwang Il [Korea Atomic Energy Research Institute, Taejon (Korea, Republic of)

    1995-07-01

    The objective of this project is the development of the computer code system for level 2 probabilistic safety assessment (PSA) of nuclear power plants. The scope of the project can be divided into three areas. The first area is to develop the computer code (CONPAS) which can quantify the accident progression event trees. CONPAS beta version has been developed this year and it is comprised of two modules: (1) EDITOR for generating the event tree logic diagrams and (2) QUANTIFICATION for event tree quantification and for additional use of the calculated results. Comparing with the existing computer code, the present code provides a flexible code reusability and user interface, convenient edition of logic diagram, data operation, and systematic quantification of the results. The methodology development of containment structural analysis is the second area. Over twenty large dry PWR containments, the database for containment failure mode and pressure has been constructed and the simplified fragility model has been proposed to calculate the containment failure probability. They will be used as an important input not only in the containment analysis but also in the source term analysis. The last one is to develop the source term analysis methodology which will be used to characterize the source term release for various accidents. One generic parametric equation for PWR and BWR has been composed and parametric database of 6 nuclear plants (4 PWR plants and 2 BWR plants) has been established whose characteristics is then analyzed through the comparison of parameter and data difference among plants. In addition, the characteristics of parameters themselves have been also investigated and the complemental idea of the parametric data base has been briefly suggested. 50 figs, 43 tabs, 50 refs. (Author).

  20. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients

    Energy Technology Data Exchange (ETDEWEB)

    Caster, Joseph M.; Falchook, Aaron D. [Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (United States); Hendrix, Laura H. [Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (United States); Chen, Ronald C., E-mail: Ronald_chen@med.unc.edu [Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (United States); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (United States); Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (United States)

    2015-06-01

    Purpose: Radiation oncologists rely on available clinical information (biopsy Gleason score and prostate-specific antigen [PSA]) to determine the optimal treatment regimen for each prostate cancer patient. Existing published nomograms correlating clinical to pathologic extent of disease were based on patients treated in the 1980s and 1990s at select academic institutions. We used the Surveillance, Epidemiology, and End Results (SEER) database to examine pathologic outcomes (Gleason score and cancer stage) in early prostate cancer patients based on biopsy Gleason score and PSA concentration. Methods and Materials: This analysis included 25,858 patients whose cancer was diagnosed between 2010 and 2011, with biopsy Gleason scores of 6 to 7 and clinical stage T1 to T2 disease, who underwent radical prostatectomy. In subgroups based on biopsy Gleason score and PSA level, we report the proportion of patients with pathologically advanced disease (positive surgical margin or pT3-T4 disease) or whose Gleason score was upgraded. Logistic regression was used to examine factors associated with pathologic outcomes. Results: For patients with biopsy Gleason score 6 cancers, 84% of those with PSA <10 ng/mL had surgical T2 disease with negative margins; this decreased to 61% in patients with PSA of 20 to 29.9 ng/mL. Gleason score upgrading was seen in 43% (PSA: <10 ng/mL) to 61% (PSA: 20-29.9 ng/mL) of biopsy Gleason 6 patients. Patients with biopsy Gleason 7 cancers had a one-third (Gleason 3 + 4; PSA: <10 ng/mL) to two-thirds (Gleason 4 + 3; PSA: 20-29.9 ng/mL) probability of having pathologically advanced disease. Gleason score upgrading was seen in 11% to 19% of patients with biopsy Gleason 4 + 3 cancers. Multivariable analysis showed that higher PSA and older age were associated with Gleason score upgrading and pathologically advanced disease. Conclusions: This is the first population-based study to examine pathologic extent of disease and pathologic Gleason score

  1. A Diet, Physical Activity, and Stress Reduction Intervention in Men with Rising Prostate-Specific Antigen (PSA) after Treatment for Prostate Cancer

    Science.gov (United States)

    Hébert, James R.; Hurley, Thomas G.; Harmon, Brook E.; Heiney, Sue; Hebert, Christine J.; Steck, Susan E.

    2011-01-01

    Background Nearly 35% of men treated for prostate cancer (PrCA) will experience biochemically defined recurrence, noted by a rise in PSA, within ten years of definitive therapy. Diet, physical activity, and stress reduction may affect tumor promotion and disease progression. Methods A randomized trial of an intensive diet, physical activity, and meditation intervention was conducted in men with rising post-treatment PSA after definitive treatment for PrCA. Intention-to-treat methods were used to compare usual care to the intervention in 47 men with complete data. Signal detection methods were used to identify dietary factors associated with PSA change. Results The intervention and control groups did not differ statistically on any demographic or disease-related factor. Although the intervention group experienced decreases of 39% in intakes of saturated fatty acid (SFA as percent of total calories) (p<0.0001) and 12% in total energy intake (218 kcal/day p<0.05)], no difference in PSA change was observed by intervention status. Signal detection methods indicated that in men increasing their consumption of fruit, 56% experienced no rise in PSA (vs. 29% in men who did not increase their fruit intake). Among men who increased fruit and fiber intakes, PSA increased in 83% of participants who also increased saturated fatty acid intake (vs. 44% in participants who decreased or maintained saturated fatty acid intake). Conclusion Results are discussed in the context of conventional treatment strategies that were more aggressive when this study was being conducted in the mid-2000s. Positive health changes in a number of lifestyle parameters were observed with the intervention, and both increased fruit and reduced saturated fat intakes were associated with maintaining PSA levels in men with biochemically recurrent disease. PMID:22018935

  2. High-Risk Prostate Cancer With Gleason Score 8-10 and PSA Level {<=}15 ng/ mL Treated With Permanent Interstitial Brachytherapy

    Energy Technology Data Exchange (ETDEWEB)

    Fang, L. Christine [Department of Radiation Oncology, University of Washington, Seattle, WA (United States); Merrick, Gregory S., E-mail: gmerrick@urologicresearchinstitute.org [Schiffler Cancer Center, Wheeling Jesuit University, Wheeling, WV (United States); Butler, Wayne M.; Galbreath, Robert W.; Murray, Brian C.; Reed, Joshua L. [Schiffler Cancer Center, Wheeling Jesuit University, Wheeling, WV (United States); Adamovich, Edward [Department of Pathology, Wheeling Hospital, Wheeling, WV (United States); Wallner, Kent E. [Puget Sound Veterans Affairs Hospital, Seattle, WA (United States)

    2011-11-15

    Purpose: With widespread prostate-specific antigen (PSA) screening, there has been an increase in men diagnosed with high-risk prostate cancer defined by a Gleason score (GS) {>=}8 coupled with a relatively low PSA level. The optimal management of these patients has not been defined. Cause-specific survival (CSS), biochemical progression-free survival (bPFS), and overall survival (OS) were evaluated in brachytherapy patients with a GS {>=}8 and a PSA level {<=}15 ng/mL with or without androgen-deprivation therapy (ADT). Methods and Materials: From April 1995 to October 2005, 174 patients with GS {>=}8 and a PSA level {<=}15 ng/mL underwent permanent interstitial brachytherapy. Of the patients, 159 (91%) received supplemental external beam radiation, and 113 (64.9%) received ADT. The median follow-up was 6.6 years. The median postimplant Day 0 minimum percentage of the dose covering 90% of the target volume was 121.1% of prescription dose. Biochemical control was defined as a PSA level {<=}0.40 ng/mL after nadir. Multiple parameters were evaluated for impact on survival. Results: Ten-year outcomes for patients without and with ADT were 95.2% and 92.5%, respectively, for CSS (p = 0.562); 86.5% and 92.6%, respectively, for bPFS (p = 0.204); and 75.2% and 66.0%, respectively, for OS (p = 0.179). The median post-treatment PSA level for biochemically controlled patients was <0.02 ng/mL. Multivariate analysis failed to identify any predictors for CSS, whereas bPFS and OS were most closely related to patient age. Conclusions: Patients with GS {>=}8 and PSA level {<=}15 ng/mL have excellent bPFS and CSS after brachytherapy with supplemental external beam radiotherapy. The use of ADT did not significantly impact bPFS, CSS, or OS.

  3. Macrophage inhibitory cytokine 1 biomarker serum immunoassay in combination with PSA is a more specific diagnostic tool for detection of prostate cancer.

    Directory of Open Access Journals (Sweden)

    Ji Li

    Full Text Available Prostate cancer (PCa is the most common malignancy among men in the United States. Though highly sensitive, the often-used prostate-specific antigen (PSA test has low specificity which leads to overdiagnosis and overtreatment of PCa. This paper presents results of a retrospective study that indicates that testing for macrophage inhibitory cytokine 1 (MIC-1 concentration along with the PSA assay could provide much improved specificity to the assay.The MIC-1 serum level was determined by a novel p-Chip-based immunoassay run on 70 retrospective samples. The assay was configured on p-Chips, small integrated circuits (IC capable of storing in their electronic memories a serial number to identify the molecular probe immobilized on its surface. The distribution of MIC-1 and pre-determined PSA concentrations were displayed in a 2D plot and the predictive power of the dual MIC-1/PSA assay was analyzed.MIC-1 concentration in serum was elevated in PCa patients (1.44 ng/ml compared to normal and biopsy-negative individuals (0.93 ng/ml and 0.88 ng/ml, respectively. In addition, the MIC-1 level was correlated with the progression of PCa. The area under the receiver operator curve (AUC-ROC was 0.81 providing an assay sensitivity of 83.3% and specificity of 60.7% by using a cutoff of 0.494 for the logistic regression value of MIC-1 and PSA. Another approach, by defining high-frequency PCa zones in a two-dimensional plot, resulted in assay sensitivity of 78.6% and specificity of 89.3%.The analysis based on correlation of MIC-1 and PSA concentrations in serum with the patient PCa status improved the specificity of PCa diagnosis without compromising the high sensitivity of the PSA test alone and has potential for PCa prognosis for patient therapy strategies.

  4. PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy.

    Science.gov (United States)

    Kao, Kenneth R; Popadiuk, Paul; Thoms, John; Aoki, Satoko; Anwar, Shahgul; Fitzgerald, Emily; Andrews, Phillip; Voisey, Kim; Gai, Luis; Challa, Satya; He, Zhijian; Gonzales-Aguirre, Paola; Simmonds, Andrea; Popadiuk, Catherine

    2017-09-18

    Prostate cancer (PrCa) is the most frequently diagnosed non-cutaneous cancer in men. Without clear pathological indicators of disease trajectory at diagnosis, management of PrCa is challenging, given its wide-ranging manifestation from indolent to highly aggressive disease. This study examines the role in PrCa of the Pygopus (PYGO)2 chromatin effector protein as a risk stratification marker in PrCa. RNA expression was performed in PrCa cell lines using Northern and RT-PCR analyses. Protein levels were assessed using immunoblot and immunofluorescence. Immunohistochemistry was performed on tissue microarrays constructed from radical prostatectomies with 5-year patient follow-up data including Gleason score tumour staging, margin and lymph node involvement and prostate serum antigen (PSA) levels. Biochemical recurrence (BR) was defined as a postoperative PSA level of >0.2 nL. Univariate and multivariate analyses were performed using SAS and Kaplan-Meier curves using graphPad (Prism). In vitro depletion of PYGO2 by RNAi in both androgen receptor positive and negative PrCa cell lines attenuated growth and reduced Ki67 and 47S rRNA expression, while PYGO2 protein was localised to the nuclei of tumours as determined by immunohistochemistry. High expression levels of PYGO2 in tumours (n=156) were correlated with BR identified as PSA progression, after 7-year follow-up independent of other traditional risk factors. Most importantly, high PYGO2 levels in intermediate grade tumours suggested increased risk of recurrence over those with negative or weak expression. Our data suggest that elevated PYGO2 expression in primary prostate adenocarcinoma is a potential risk factor for BR. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

  5. Prescription Painkiller Overdoses in the U.S. – What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-11-01

    This 60 second PSA is based on the November, 2011 CDC Vital Signs report. Overdose deaths from prescription painkillers have skyrocketed in the past decade. Every year, nearly 15,000 people die from these overdoses—more than those who die from heroin and cocaine combined. Learn the steps you can take to prevent an overdose.  Created: 11/1/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 11/1/2011.

  6. Importance of prostate-specific antigen (PSA as a predictive factor for concordance between the Gleason scores of prostate biopsies and RADICAL prostatectomy specimens

    Directory of Open Access Journals (Sweden)

    Nelson Gianni de Lima

    2013-06-01

    Full Text Available OBJECTIVE: To evaluate the concordance between the Gleason scores of prostate biopsies and radical prostatectomy specimens, thereby highlighting the importance of the prostate-specific antigen (PSA level as a predictive factor of concordance. METHODS: We retrospectively analyzed 253 radical prostatectomy cases performed between 2006 and 2011. The patients were divided into 4 groups for the data analysis and dichotomized according to the preoperative PSA, <10 ng/mL and ≥10 ng/mL. A p-score <0.05 was considered significant. RESULTS: The average patient age was 63.3±7.8 years. The median PSA level was 9.3±4.9 ng/mL. The overall concordance between the Gleason scores was 52%. Patients presented preoperative PSA levels <10 ng/mL in 153 of 235 cases (65% and ≥10 ng/mL in 82 of 235 cases (35%. The Gleason scores were identical in 86 of 153 cases (56% in the <10 ng/mL group and 36 of 82 (44% cases in the ≥10 ng/mL group (p = 0.017. The biopsy underestimated the Gleason score in 45 (30% patients in the <10 ng/mL group and 38 (46% patients in the ≥10 ng/mL (p = 0.243. Specifically, the patients with Gleason 3 + 3 scores according to the biopsies demonstrated global concordance in 56 of 110 cases (51%. In this group, the patients with preoperative PSA levels <10 ng/dL had higher concordance than those with preoperative PSA levels ≥10 ng/dL (61% x 23%, p = 0.023, which resulted in 77% upgrading after surgery in those patients with PSA levels ≥10 ng/dl. CONCLUSION: The Gleason scores of needle prostate biopsies and those of the surgical specimens were concordant in approximately half of the global sample. The preoperative PSA level was a strong predictor of discrepancy and might improve the identification of those patients who tended to be upgraded after surgery, particularly in patients with Gleason scores of 3 + 3 in the prostate biopsy and preoperative PSA levels ≥10 ng/mL.

  7. Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy

    Directory of Open Access Journals (Sweden)

    Novaes Paulo ERS

    2007-02-01

    Full Text Available Abstract Objectives To evaluate the results of salvage conformal radiation therapy (3DC-EBRT for patients submitted to radical prostatectomy (RP who have achieved complete PSA response and who have never been treated with hormonal therapy (HT. To present the results of biochemical control, a period free from hormonal therapy and factors related to its prognosis. Materials and methods from August 2002 to December 2004, 43 prostate cancer patients submitted to RP presented biochemical failure after achieving a PSA Results 3-year biochemical non-evidence of disease (BNED was 71%. PSA doubling time lower than 4 months (p = 0.01 and time from recurrence to salvage EBRT (p = 0.04 were associated with worse chance of biochemical control. Biochemical control of 76% was achieved when RT had been introduced with a PSA lower than 1 ng/ml vs. 48% with a PSA higher than 1 (p = 0.19. Late toxicity was acceptable. Conclusion 70% of biochemical control in 3 years can be achieved with salvage radiotherapy in selected patients. The importance of PSADT was confirmed in this study and radiotherapy should be started as early as possible. Longer follow up is necessary, but it is possible to conclude that a long interval free from hormonal therapy was achieved with low rate of toxicity avoiding or at least delaying several important adverse effects related to hormonal treatment.

  8. [Identification of low-molecular weight prostate-specific antigen(PSA) and lactoferrin in the prostatic secretion of benign prostatic hyperplasia].

    Science.gov (United States)

    Xu, Ke-xin; Wang, Xiao-feng

    2006-12-18

    To investigate the expression of low-molecular-weight PSA(lw-PSA) and lactoferrin in the expressed prostatic secretion (EPS) from both benign prostatic hyperplasia (BPH) and normal prostate. Forty human EPS samples obtained from 20 BPH patients and 20 normal males were subjected to two-dimensional gel electrophoresis (2-DE). Mass spectrometry was performed to confirm the nature of the secreted proteins in EPS. One uniquely expressed protein in BPH was detected and mass spectrometry determined its nature as lw-PSA (molecular weight 10x10(3), pI 8.5-9.3). More importantly, Western blotting analysis also revealed that lw-PSA detected in BPH-EPS, but was undetectable in BPH-free EPS. In addition, up-regulation of Lactoferrin (molecular weight 35x10(3), pI 7-7.5) in BPH-EPS, as compared with BPH-free EPS, was also observed. More interestingly, lactoferrin was absent in prostate cancer tissues. Our results indicate lw-PSA may be produced specifically by BPH epithelium and it has a potential to be used as a specific biological marker for the diagnosis of BPH. In addition, benign prostatic epithelium can produce more lactoferrin while prostate cancer tissues go without its lactoferrin secretion.

  9. Distribution characteristics of leukocytes in EPS and correlation with serum PSA levels: results from a Chinese male population survey.

    Science.gov (United States)

    Wu, Yongming; Gao, Yong; Tan, Aihua; Liao, Ming; Yang, Xiaobo; Zhang, Haiying; Qin, Xue; Mo, Linjian; Li, Li; Mo, Zengnan

    2013-02-01

    To explore the distribution characteristics of leukocytes in expressed prostatic secretions (EPS) in a large Chinese male population and the correlation with leukocytes and prostate-specific antigen (PSA) levels. From September to December 2009, EPS specimens were collected from 2504 men (age 20-69 years) who had undergone prostatic massage and were recruited from a large-scale community-based population survey in Southern China. The EPS specimens were divided into 5 categories according to the leukocyte count. The lifestyle and demographic characteristics were obtained by questionnaire. Asymptomatic and symptomatic men were defined according to the findings from the National Institutes of Health-Chronic Prostatitis Symptom Index questionnaire. EPS specimens were successfully collected from 1779 of the 2504 participants (71%). The degree of inflammation in the EPS specimens progressively increased with age, education, and body mass index (P EPS progressively increases with increasing age, body mass index, and education. Moreover, an increase of leukocytes in the EPS specimen correlated with increasing PSA levels. Prospective studies are needed to determine whether the minor elevations have clinical significance for prostatitis assessment. Copyright © 2013 Elsevier Inc. All rights reserved.

  10. Importance of the multi-modules study in PSA; Importancia del estudio de multi-modulos en APS

    Energy Technology Data Exchange (ETDEWEB)

    Gonzalez R, V. J.; Nelson E, P. F., E-mail: judith_gonzalez_rodriguez@outlook.es [UNAM, Facultad de Ingenieria, Departamento de Sistemas Energeticos, Paseo Cuauhnahuac 8532, 62550 Jiutepec, Morelos (Mexico)

    2015-09-15

    The current approach that has taken the Probabilistic Safety Analysis (PSA) consists of doing all the APS analysis including the existence of multi-units in the nuclear power plants (NPP), this new approach seeks to analyze the risk of site, evaluating all reactors together. The main reasons for this trend are: the accident occurred on March 2011 in Fukushima Daiichi in Japan, with serious consequences in more than one reactor of the NPP and the current planning and construction of new Small Modular Reactors, which host more than one module on the same NPP and are connected to a single control room. This study analyzes how to model the risk of a multi-module NPP. In 2013, the ASME/ANS standard for advanced reactors that are not light-water reactors was published, in which the requirements to realize a PSA including multi-units or modules are shown; however, does not describe the methodology to do that. This article presents a methodology to calculate the risk of the site in a PBMR plant with two modules. This methodology consists of two models of trees of different events, one that evaluates to a single PBMR module and another that evaluates the two modules together. Both models are responsible to show their differences and compare results to finally demonstrate the need for new methodologies for risk analysis site in multi-modules and units. (Author)

  11. Long-Term PSA Control with Repeated Stereotactic Body Radiotherapy in a Patient with Oligometastatic Castration-Resistant Prostate Cancer.

    Science.gov (United States)

    Pasqualetti, Francesco; Cocuzza, Paola; Coraggio, Gabriele; Ferrazza, Patrizia; Derosa, Lisa; Galli, Luca; Pasqualetti, Giuseppe; Locantore, Luisa; Boni, Roberto; Fabrini, Maria G; Erba, Paola A

    2016-01-01

    Prostate cancer (PCa) is one of the most common malignancies and main causes of cancer death in Western countries. In the presence of metastatic disease, systemic treatment remains the main clinical option. However, since the introduction of highly sensitive imaging techniques, a new clinical 'entity' of metastatic patients with a limited number of lesions has been defined: oligometastatic patients. In this patient group, the use of stereotactic body radiotherapy (SBRT) or other local therapies against all active sites of disease revealed by 18F-choline positron emission tomography/computed tomography (PET/CT) could achieve sufficient prostate-specific antigen (PSA) control. However, a clear benefit of this procedure in terms of significant endpoints is yet to be demonstrated. This case report describes our experience with treating a castration-resistant PCa patient with 18F-choline PET/CT-guided SBRT. Because of the occurrence of 5 metachronous lesions over 4 years, the pattern of recurrence was defined by the local multidisciplinary team as oligometastatic disease, and the patient was treated with 5 courses of SBRT which yielded good PSA control. He started systemic therapy with abiraterone acetate almost 5 years after the diagnosis of recurrent PCa. © 2016 S. Karger GmbH, Freiburg.

  12. Methods and results of a PSA level 2 for a German BWR of the 900 MWe class

    Energy Technology Data Exchange (ETDEWEB)

    Loffler, H.; Sonnenkalb, M. [Gesellschaft fuer Anlagen- und Reaktorsicherheit (GRS) mbH, Koln (Germany)

    2006-07-01

    On behalf of the federal Ministry for Environment, Nature Conservation and Reactor Safety (BMU) GRS has performed a PSA level 2 for a BWR type 69 NPP of the 900 MWe class, equipped with a N{sub 2} inerted steel containment and a pressure suppression system. Integral deterministic accident analyses have been performed with the computer code MELCOR 1.8.5. Additional analyses have been done for those events and phenomena which are not or not sufficiently covered by MELCOR. The probabilistic event tree analysis begins with the core damage states received from PSA level 1, and it ends with the definition of release categories and the determination of their frequencies. Uncertainties about the frequency of core damage states and about events during the accident progression are taken into account by means of Monte Carlo simulations. If there is a core damage state there is a high probability (>50 %) for a very high and rapid release of radionuclides into the environment. This high conditional probability is due to the very low probability to retain a partly destroyed core inside the reactor pressure vessel (RPV) and because the containment almost certainly fails at the bottom of the control rod drives room after melt release from the failed RPV. (authors)

  13. A case report of monitoring PSA level changes in two prostate cancer patients treated with Mountain Ginseng Pharmacopuncture and Sweet Bee Venom along with western anticancer therapy

    Directory of Open Access Journals (Sweden)

    Yeonhee Lee

    2011-12-01

    Full Text Available Objectives: The purpose of this report is to find out how Mountain Ginseng Pharmacopuncture(MGP and Sweet Bee Venom(SBV treatments are effective on prostate cancer patients by monitoring Prostate specific antigen(PSA values. Methods: We treated two prostate cancer patients with MGP and SBV from October 2008 to April 2011. One patient had localized prostate cancer, the other was in the terminal stage of prostate cancer with lung and bone metastasis and both had been receiving western anticancer therapy. We had monitored the changes of PSA value. Results: In case 1, MGP and SBV treatments seemed to be helpful in preventing the recurrence of localized prostate cancer. In case 2, PSA value was decreased by MGP treatment. Conclusions: It is conceivable that MGP and SBV are effective treatments for patients with prostate cancer.

  14. Effect of a 2-year home-based endurance training intervention on physiological function and PSA doubling time in prostate cancer patients

    DEFF Research Database (Denmark)

    Hvid, Thine; Lindegaard, Birgitte; Winding, Kamilla

    2016-01-01

    AIM: Physical activity after prostate cancer diagnosis has been shown to reduce the risk of disease progression. Here, we aimed to evaluate the effect of a 2-year home-based endurance training intervention on body composition, biomarkers levels, and prostate-specific antigen (PSA) doubling time...... as a surrogate end-point for progressing disease. METHODS: Out-clinic patients with either biochemical recurrence following radical prostatectomy or patients managed on active surveillance were randomized to either 24 months (3 times/week) of home-based endurance training or usual care. Aerobic fitness, body...... composition, insulin sensitivity, and biomarkers were measured at 0, 6, and 24 months of intervention. PSA doubling time (PSADT) was calculated based on monthly PSA measurements. RESULTS: Twenty-five patients were enrolled, and 19 patients completed the study. PSADT increased in the training group from 28...

  15. Limitações da abordagem coaseana à definição do instrumento de Pagamento por Serviços Ambientais (PSA

    Directory of Open Access Journals (Sweden)

    Daniel Caixeta Andrade

    2013-07-01

    Full Text Available A despeito da popularidade dos instrumentos de PSA, existem questionamentos sobre a adequação de sua base teórico-conceitual. Este artigo apresenta uma pesquisa teórica e de caráter revisional cujo objetivo é contribuir para o debate sobre o desenvolvimento de novas abordagens conceituais capazes de conciliar teoria e prática do PSA. A discussão desenvolvida aponta para as contribuições da Economia Ecológica e Institucional para a ampliação do conceito de PSA, uma vez que as mesmas permitem incorporar os diferentes contextos ambientais, sociais e econômicos, e buscam lidar com os efeitos de eficiência e equidade.

  16. Prostate cancer in patients from rural and suburban areas--PSA value, Gleason score and presence of metastases in bone scan.

    Science.gov (United States)

    Szot, Wojciech; Kostkiewicz, Magdalena; Zając, Joanna; Owoc, Alfred; Bojar, Iwona

    2014-01-01

    Prostate cancer is the second most common neoplasm among men both worldwide and in Poland. In prostate cancer, bone metastasis is related to a poorer prognosis. A diagnosis of metastatic bone disease is important in prostate cancer patients prior to therapy. Prostate specific antigen (PSA) serum value is used both as a screening tool and for staging of prostate cancer. To evaluate whether there is a link between symptoms presented by patients, pain in particular, and the presence, number and location of bone metastases as assessed by bone scan scintigraphy in concordance with PSA values and Gleason scores. A group of 186 patients (aged: 68.38±6.16) diagnosed with prostate cancer, from rural and suburban areas of Małopolska province, that was directed for bone scan scintigraphy to the Nuclear Medicine Dept, John Paul II Hospital in Kraków. Analysis of all laboratory findings (including PSA value) and a biopsy were performed. Then, bone scan scintigraphy was done with the use of methylene disphosphonate (MDP) labeled with Tc-99m. In patients with a Gleason value≤7 and a PSA value≤20 ng/ml, the cutoff value for a negative bone scan with a confidence interval of 0.95 was established at a PSA value below 10 ng/ml (pbone scan (r=0.45, p=0.05), the number of metastases (r=0.66, pbone scan scintigraphy in prostate cancer staging. The cutoff value for negative bone scan with a 95% confidence interval was established at PSA=10 ng/ml.

  17. Impact of PSA testing and prostatic biopsy on cancer incidence and mortality: comparative study between the Republic of Ireland and Northern Ireland.

    Science.gov (United States)

    Carsin, A-E; Drummond, F J; Black, A; van Leeuwen, P J; Sharp, L; Murray, L J; Connolly, D; Egevad, L; Boniol, M; Autier, P; Comber, H; Gavin, A

    2010-09-01

    To investigate the impact of different PSA testing policies and health-care systems on prostate cancer incidence and mortality in two countries with similar populations, the Republic of Ireland (RoI) and Northern Ireland (NI). Population-level data on PSA tests, prostate biopsies and prostate cancer cases 1993-2005 and prostate cancer deaths 1979-2006 were compiled. Annual percentage change (APC) was estimated by joinpoint regression. Prostate cancer rates were similar in both areas in 1994 but increased rapidly in RoI compared to NI. The PSA testing rate increased sharply in RoI (APC = +23.3%), and to a lesser degree in NI (APC = +9.7%) to reach 412 and 177 tests per 1,000 men in 2004, respectively. Prostatic biopsy rates rose in both countries, but were twofold higher in RoI. Cancer incidence rates rose significantly, mirroring biopsy trends, in both countries reaching 440 per 100,000 men in RoI in 2004 compared to 294 in NI. Median age at diagnosis was lower in RoI (71 years) compared to NI (73 years) (p Mortality rates declined from 1995 in both countries (APC = -1.5% in RoI, -1.3% in NI) at a time when PSA testing was not widespread. Prostatic biopsy rates, rather than PSA testing per se, were the main driver of prostate cancer incidence. Because mortality decreases started before screening became widespread in RoI, and mortality remained low in NI, PSA testing is unlikely to be the explanation for declining mortality.

  18. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.

    Science.gov (United States)

    Ramos, Christian G; Valdevenito, Raul; Vergara, Ivonne; Anabalon, Patricio; Sanchez, Catherine; Fulla, Juan

    2013-11-01

    Prostate Cancer Gene 3 (PCA3) is a recently described and highly specific urinary marker for prostate cancer (CaP). Its introduction in clinical practice to supplement low specificity of prostate specific antigen (PSA) can improve CaP diagnosis and follow-up. However, before its introduction, it is necessary to validate the method of PCA3 detection in distinct geographic populations. Our aim was to describe for the first time in Latin America, the application of the PROGENSA PCA3 assay for PCA3 detection in urine in Chilean men and its utility for CaP diagnosis in men with an indication of prostate biopsy. Sixty-four Chilean patients (mean age, 64 years) with indication of prostate biopsy because of elevated PSA and/or suspicious digital rectal examination (DRE) were prospectively recruited. PCA3 scores were assessed from urine samples obtained after DRE, before biopsy, and compared with PSA levels and biopsy outcome. The median PSA value and mean PCA3 score were 5.8 ng/ml and 31.7, respectively. Using a cutoff PCA3 score of 35, the sensitivity and specificity for detecting CaP were 52% and 87%, respectively. The receiver operating characteristic (ROC) curve analysis showed an area under the curve of 0.77 for PCA3 and 0.57 for PSA, for the same group of patients. In patients with previous negative biopsy, PCA3 specificity increased by 2.2%. This is the first report in Latin America on the use of PCA3 in diagnosing CaP. Our results are comparable to those reported in other populations in the literature, demonstrating the reproducibility of the test. PCA3 score was highly specific and we specially recommend its use in patients with persistent elevated PSA and prior negative biopsies. Copyright © 2013 Elsevier Inc. All rights reserved.

  19. The effect of PTZ-induced epileptic seizures on hippocampal expression of PSA-NCAM in offspring born to kindled rats

    Directory of Open Access Journals (Sweden)

    Rajabzadeh Aliakbar

    2012-05-01

    Full Text Available Abstract Background Maternal epileptic seizures during pregnancy can affect the hippocampal neurons in the offspring. The polysialylated neural cell adhesion molecule (PSA-NCAM, which is expressed in the developing central nervous system, may play important roles in neuronal migration, synaptogenesis, and axonal outgrowth. This study was designed to assess the effects of kindling either with or without maternal seizures on hippocampal PSA-NCAM expression in rat offspring. Methods Forty timed-pregnant Wistar rats were divided into four groups: A Kind+/Seiz+, pregnant kindled (induced two weeks prior to pregnancy rats that received repeated intraperitoneal (i.p. pentylenetetrazol, PTZ injections on gestational days (GD 14-19; B Kind-/Seiz+, pregnant non-kindled rats that received PTZ injections on GD14-GD19; C Kind+/Seiz-, pregnant kindled rats that did not receive any PTZ injections; and D Kind-/Seiz-, the sham controls. Following birth, the pups were sacrificed on PD1 and PD14, and PSA-NCAM expression and localization in neonates’ hippocampi were analyzed by Western blots and immunohistochemistry. Results Our data show a significant down regulation of hippocampal PSA-NCAM expression in the offspring of Kind+/Seiz+ (p = 0.001 and Kind-/Seiz+ (p = 0.001 groups compared to the sham control group. The PSA-NCAM immunoreactivity was markedly decreased in all parts of the hippocampus, especially in the CA3 region, in Kind+/Seiz+ (p = 0.007 and Kind-/Seiz+ (p = 0.007 group’s newborns on both PD1 and 14. Conclusion Our findings demonstrate that maternal seizures but not kindling influence the expression of PSA-NCAM in the offspring’s hippocampi, which may be considered as a factor for learning/memory and cognitive impairments reported in children born to epileptic mothers.

  20. PSA testing without clinical indication for prostate cancer in relation to socio-demographic and clinical characteristics in the Danish Diet, Cancer and Health Study

    DEFF Research Database (Denmark)

    Karlsen, Randi V; Larsen, Signe B; Christensen, Jane

    2013-01-01

    associations between socio-demographic or clinical characteristics and PSA testing without clinical indication. Material and methods. In the Danish Diet, Cancer and Health Cohort, we identified 1051 men with PC diagnosed in 1993-2008. Diagnostic and clinical characteristics were obtained from medical records......, and socio-demographic information was retrieved from administrative registers. We used general logistic regression analysis to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between socio-demographic or clinical characteristics and PSA testing without clinical indication. Cox...

  1. Outcome and complications of radical prostatectomy in patients with PSA <10 ng/ml: comparison between the retropubic, perineal and laparoscopic approach.

    Science.gov (United States)

    Salomon, L; Levrel, O; Anastasiadis, A G; Saint, F; de La Taille, A; Cicco, A; Vordos, D; Hoznek, A; Chopin, D; Abbou, C-C

    2002-01-01

    The objective of this work was to evaluate the oncological outcomes and complications of prostate cancer patients with prostate specific antigen (PSA)catetherization (12.1 days), and length of hospital stay (12.1 days) were higher in the retropubic group (P0.05). The actuarial 3-year recurrence-free survival rate was 89.3%, 89.2% and 86.2% (P>0.05) for retropubic, perineal and laparoscopic approach, respectively. It can be concluded that in patients with preoperative PSA<10 ng/ml, clinical outcome and complication rates were similar, regardless of the choice of surgical approach.

  2. Har lægers risikovillighed og symptomer på udbrændthed betydning for brugen af PSA-tests?

    DEFF Research Database (Denmark)

    Pedersen, Anette Fischer; Carlsen, Anders Helles; Vedsted, Peter

    2016-01-01

    Denne artikel er baseret på undersøgelsen "Association of GP's risk attitudes, level of empathy, and burnout status with PSA testing in primary care, som er publiceret i British Journal of General Practice, December 2015; 65(44): 845-851......Denne artikel er baseret på undersøgelsen "Association of GP's risk attitudes, level of empathy, and burnout status with PSA testing in primary care, som er publiceret i British Journal of General Practice, December 2015; 65(44): 845-851...

  3. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels.

    Science.gov (United States)

    Nishimura, K; Arichi, N; Tokugawa, S; Yoshioka, I; Namba, Y; Kishikawa, H; Takahara, S; Ichikawa, Y

    2008-01-01

    The aim was to assess whether hepatocyte growth factor (HGF) and interleukin (IL)-6 in combination with prostate volume are able to accurately detect prostate cancer in patients with gray-zone prostate-specific antigen (PSA) levels. A total of 159 patients with PSA levels of <10 ng ml(-1) were enrolled. Forty-two (35.3%) were diagnosed with prostate cancer, whereas 117 (64.7%) had no cancer and were used as benign group. HGF and IL-6 density (HGFD and IL-6D, respectively) values were calculated by dividing serum HGF and IL-6 levels with prostate volume. Median IL-6 (2.3 pg ml(-1)) levels for the prostate cancer group were significantly higher than those for the benign group before adjustment for age (1.7 pg ml(-1)) (P=0.0098). After age adjustments, median IL-6 (2.17 pg ml(-1)), HGFD (0.00972 ng ml(-1) cm(-3)), and IL-6D (0.0848 pg ml(-1) cm(-3)) values for the prostate cancer group were significantly higher than those for the benign group (IL-6, 1.78 pg ml(-1); HGFD, 0.00732 ng/ml/cc; and IL-6D, 0.049 pg/ml/cc; P=0.0416, 0.007 and 0.0005, respectively). In receiver operating characteristic analyses, the areas under the curves for HGFD (0.64) and IL-6D (0.68) were significantly greater than those for HGF (0.52) and IL-6 (0.61) (P=0.0006 and 0.019, respectively). With an HGFD cutoff value of 0.00392 ng ml(-1) cm(-3) (sensitivity=100%, specificity=11%), 11.1% of the benign group were able to avoid unnecessary biopsies without missing prostate cancer. HGF and IL-6 levels in combination with prostate volume were shown to be useful parameters for prostate cancer screening in patients with gray-zone PSA levels.

  4. Aerosol Characterization at PSA from Spectral and Broadband Measurements of Solar Radiation; Caracterizacion de los Aerosoles en la PSA a partir de Medidas Espectrales y de Banda Ancha de Radiacion Solar

    Energy Technology Data Exchange (ETDEWEB)

    Salvador, P.; Polo, J.; Campos, A.; Espinar, B.

    2006-07-01

    When passing through the atmosphere, the solar radiation suffers extinction processes with and intensity that depends on the atmosphere state. Some of the attenuation mechanisms, in particular those oflicht scattering, are spectrally selective, and thus, the solar spectrum at the earth's surface can change drastically from one place to another. This fact can be used on the determination of some of the Earth atmosphere components. The case of aerosol turbidity has a particular interest due to its high variability. In mis work different methodologies for aerosol characterization are presented, Aerosol optical depth, turbidity and Angstrom exponent are determined by them. Moreover, a comparison among the different methods is established and two heat haze events occurring during summer in PSA (Tabernas) are analyzed. (Author) 18 refs.

  5. Multiparametric MRI of the prostate with three functional techniques in patients with PSA elevation before initial TRUS-guided biopsy

    Science.gov (United States)

    Hohmuth, Horst; Cozub-Poetica, Corina; Bernand, Stefan; Beer, Meinrad; Jaeger, Horst

    2015-01-01

    Objective: Multiparametric MRI (mp-MRI) of the prostate is increasingly being used for local staging and detection of recurrence of prostate cancer (PCA). In patients with elevated prostate-specific antigen (PSA), mp-MRI could provide information on the position of the cancer, allowing adjustments to be made to the needle depth and direction before repeat transrectal ultrasound (TRUS)-guided biopsy to ensure accurate sampling of lesions. The purpose of the prospective study was to evaluate mp-MRI of the prostate in patients with PSA elevation before initial TRUS-guided biopsy. Methods: mp-MRI was performed in 94 patients using a 1.5-T scanner (MAGNETOM Aera®; Siemens Healthcare, Erlangen, Germany) and 16-channel phased-array body coil (Siemens Healthcare). T2 weighted images (T2WI), diffusion-weighted imaging (DWI), dynamic contrast-enhanced (DCE) MRI and MR spectroscopy were obtained. TRUS-guided random biopsies and additional targeted biopsies of suspicious MRI areas were performed. Results: Additional targeted biopsies were obtained in 17 of 43 (40%) patients with PCA. 11 of 17 targeted biopsies contained PCA. 5 of 11 PCAs were diagnosed only by additional targeted biopsies. Sensitivity of mp-MRI in patients was 97.7% and specificity was 11.8%. mp-MRI was false negative in one patient. Sensitivity of mp-MRI in 207 lesions was 80.9% and specificity was 44.7%. In a logistic regression model, the apparent diffusion coefficient value was the only significant parameter to differentiate malignant and benign lesions. Conclusion: mp-MRI should be performed in patients with PSA elevation before initial TRUS-guided biopsy to allow additional targeted biopsies from suspicious areas of MRI. We recommend mp-MRI with T2WI, DWI, DCE MRI and MR spectroscopy. DWI as the most reliable technique should be used in every mp-MRI. Advances in knowledge: DWI is the most reliable technique in mp-MRI of the prostate. PMID:26268144

  6. The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L. major

    DEFF Research Database (Denmark)

    Kemp, M; Handman, E; Kemp, K

    1998-01-01

    The promastigote surface antigen-2 (PSA-2) is a Leishmania parasite antigen, which can induce Th1-mediated protection against murine leishmaniasis when used as a vaccine. To evaluate PSA-2 as a human vaccine candidate the specific T-cell response to PSA-2 was characterised in individuals immune...... to cutaneous leishmaniasis. Peripheral blood mononuclear cells from Sudanese individuals with a past history of self-healing cutaneous leishmaniasis proliferated vigorously in response to PSA-2 isolated from Leishmania major, whereas the antigen did not activate cells from presumably unexposed Danes...... and that these cells were the major source of interferon-gamma. The results show that Th1-like cells recognising PSA-2 are expanded during infection by L. major and that they maintain their Th1-like cytokine profile upon reactivation in vitro. Since immunity to cutaneous leishmaniasis is mediated by antigen...

  7. Overexpression of the novel senescence marker β-galactosidase (GLB1 in prostate cancer predicts reduced PSA recurrence.

    Directory of Open Access Journals (Sweden)

    Jennifer Wagner

    Full Text Available Senescence is a terminal growth arrest that functions as a tumor suppressor in aging and precancerous cells and is a response to selected anticancer compounds. Lysosomal-β-galactosidase (GLB1 hydrolyzes β-galactose from glycoconjugates and is the origin of senescence-associated β-gal activity (SA-β-gal. Using a new GLB1 antibody, senescence biology was investigated in prostate cancer (PCa tissues.In vitro characterization of GLB1 was determined in primary prostate epithelial cell cultures passaged to replicative senescence and in therapy-induced senescence in PCa lines using chemotherapeutic agents. FFPE tissue microarrays were subjected to immunofluorescent staining for GLB1, Ki67 and HP1γ and automated quantitative imaging initially using AQUA in exploratory samples and Vectra in a validation series.GLB1 expression accumulates in replicative and induced senescence and correlates with senescent morphology and P16 (CDKN2 expression. In tissue arrays, quantitative imaging detects increased GLB1 expression in high-grade prostatic intraepithelial neoplasia (HGPIN, known to contain senescent cells, and cancer compared to benign prostate tissues (p<0.01 and senescent cells contain low Ki67 and elevated HP1γ. Within primary tumors, elevated GLB1 associates with lower T stage (p=0.01, localized versus metastatic disease (p=0.0003 and improved PSA-free survival (p=0.03. Increased GLB1 stratifies better PSA-free survival in intermediate grade PCa (0.01. Tissues that elaborate higher GLB1 display increased uniformity of expression.Increased GLB1 is a valuable marker in formalin-fixed paraffin-embedded (FFPE tissues for the senescence-like phenotype and associates with improved cancer outcomes. This protein addresses a lack of senescence markers and should be applicable to study the biologic role of senescence in other cancers.

  8. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.

    Science.gov (United States)

    Wei, R J; Li, T Y; Yang, X C; Jia, N; Yang, X L; Song, H B

    2016-06-03

    Bone metastasis is a common complication in prostate cancer patients that can cause bone pain and pathological fracture. This study tested serum levels of prostate specific antigen (PSA), alkaline phosphatase (ALP), bone sialoprotein (BSP), collagen type I pyridine crosslinking peptide (ICTP) in prostate cancer patients and the significance of the receiver operator characteristic (ROC) curve in the diagnosis of prostate cancer bone metastases. Eighty-three prostate cancer patients were enrolled including 42 in the bone metastases group and 41 in the non-bone metastases group. Serum levels of BSP, ALP, ICTP, and PSA were highest in the bone metastases group followed by the non-bone metastases group, hyperplasia group, and then the control group (P Gleason score, serum levels were highest in the poorly differentiated group followed by moderately differentiated and well-differentiated groups (P bone metastases were 80.95, 57.14, 69.05, 71.43%, respectively, and the specificity of the same markers were 72.80, 64.80, 76.80, and 88.80%, respectively. Combined detection of the four markers improved sensitivity to 97.62% and the negative-predictive value increased to 97.60%. PSA + BSP showed the best efficiency when combining two markers. In conclusion, serum levels of BSP, ALP, ICTP, and PSA increased in patients with bone metastases, and combined detection of all markers could improve the positive-predictive value.

  9. Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography

    NARCIS (Netherlands)

    Breeuwsma, Anthonius J.; Pruim, Jan; van den Bergh, Alphons C. M.; Leliveld, Anna M.; Njman, Rien J. M.; Dierckx, Rudi A. J. O.; de Jong, Idle J.

    2010-01-01

    PURPOSE: An elevated serum prostate-specific antigen (PSA) level cannot distinguish between local-regional recurrences and the presence of distant metastases after treatment with curative intent for prostate cancer. With the advent of salvage treatment such as cryotherapy, it has become important to

  10. The Role of C11-Choline-PET/CT-Guided Secondary Lymphadenectomy in Patients with PSA Failure after Radical Prostatectomy: Lessons Learned from Eight Cases

    Directory of Open Access Journals (Sweden)

    Thomas Martini

    2012-01-01

    Full Text Available Introduction. 11C-choline-PET/CT is a promising technique for detection/restaging of patients with biochemical failure (BF after curative therapy for prostate cancer (PCA. The aim of this paper was to evaluate the PSA response in patients with BF after radical prostatectomy (RP who underwent secondary lymphadenectomy (LAD due to 11C-choline-PET/CT findings. Material and Methods. Eight patients with BF and positive lymph nodes in 11C-choline-PET/CT after RP were retrospectively included in the study. Extended LAD until the common iliac arteries was performed in all patients. Results. Six of 8 patients had histologically proven lymph node metastases. Four patients showed an initial PSA reduction after LAD, and in 4 patients the PSA increased. Two of the latter had no histological lymph node metastases. Conclusions. Because 50% of our patients showed an initial PSA response, our data suggest that positive 11C-choline-PET/CT after RP and BF could help to select patients that could benefit from secondary LAD.

  11. A Study on the Risk Reduction Effect by MLCS (Mid-loop Level Control System) of EUAPR using the Low-Power and Shutdown PSA Result

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Keunsung; Choi, Sunmi [KHNP CRI, Daejeon (Korea, Republic of); Kim, Eden [FNC Technology Co., Yongin (Korea, Republic of)

    2016-10-15

    The EU-APR design has been developed in order to expand and diversify the global nuclear power market of APR1400. For the improvement of shutdown risk for the EUAPR, the mid-loop level control system (MLCS) is considered during mid-loop operation for the EU-APR, which is not incorporated into SKN 3 and 4 (APR1400 Type) in Korea. Commonly, the risk associated with the NPP can be identified through the PSA. Thus, this paper discusses the low power and shutdown (LPSD) risk reduction effect by MLCS using the Low-Power and Shutdown PSA Result. LPSD level 1 PSA models for EU-APR have been developed. The risk reduction effect by MLCS is discussed. Because the loss of shutdown cooling function during mid-loop is one of the most vulnerable events, the MLCS have a significant influence on CDF in LPSD PSA. The shutdown risk of domestic power plants would likely be reduced if the MLCS is adopted in all operating NPPs in Korea during the mid-loop operation. It is expected that this work will contribute to reduce shutdown risk of domestic power plants.

  12. Exploring Prostate Cancer Genome Reveals Simultaneous Losses of PTEN, FAS and PAPSS2 in Patients with PSA Recurrence after Radical Prostatectomy

    Science.gov (United States)

    Ibeawuchi, Chinyere; Schmidt, Hartmut; Voss, Reinhard; Titze, Ulf; Abbas, Mahmoud; Neumann, Joerg; Eltze, Elke; Hoogland, Agnes Marije; Jenster, Guido; Brandt, Burkhard; Semjonow, Axel

    2015-01-01

    The multifocal nature of prostate cancer (PCa) creates a challenge to patients’ outcome prediction and their clinical management. An approach that scrutinizes every cancer focus is needed in order to generate a comprehensive evaluation of the disease, and by correlating to patients’ clinico-pathological information, specific prognostic biomarker can be identified. Our study utilized the Affymetrix SNP 6.0 Genome-wide assay to investigate forty-three fresh frozen PCa tissue foci from twenty-three patients. With a long clinical follow-up period that ranged from 2.0–9.7 (mean 5.4) years, copy number variation (CNV) data was evaluated for association with patients’ PSA status during follow-up. From our results, the loss of unique genes on 10q23.31 and 10q23.2–10q23.31 were identified to be significantly associated to PSA recurrence (p < 0.05). The implication of PTEN and FAS loss (10q23.31) support previous reports due to their critical roles in prostate carcinogenesis. Furthermore, we hypothesize that the PAPSS2 gene (10q23.2–10q23.31) may be functionally relevant in post-operative PSA recurrence because of its reported role in androgen biosynthesis. It is suggestive that the loss of the susceptible region on chromosome 10q, which implicates PTEN, FAS and PAPSS2 may serve as genetic predictors of PSA recurrence after radical prostatectomy. PMID:25679447

  13. Exploring Prostate Cancer Genome Reveals Simultaneous Losses of PTEN, FAS and PAPSS2 in Patients with PSA Recurrence after Radical Prostatectomy

    Directory of Open Access Journals (Sweden)

    Chinyere Ibeawuchi

    2015-02-01

    Full Text Available The multifocal nature of prostate cancer (PCa creates a challenge to patients’ outcome prediction and their clinical management. An approach that scrutinizes every cancer focus is needed in order to generate a comprehensive evaluation of the disease, and by correlating to patients’ clinico-pathological information, specific prognostic biomarker can be identified. Our study utilized the Affymetrix SNP 6.0 Genome-wide assay to investigate forty-three fresh frozen PCa tissue foci from twenty-three patients. With a long clinical follow-up period that ranged from 2.0–9.7 (mean 5.4 years, copy number variation (CNV data was evaluated for association with patients’ PSA status during follow-up. From our results, the loss of unique genes on 10q23.31 and 10q23.2–10q23.31 were identified to be significantly associated to PSA recurrence (p < 0.05. The implication of PTEN and FAS loss (10q23.31 support previous reports due to their critical roles in prostate carcinogenesis. Furthermore, we hypothesize that the PAPSS2 gene (10q23.2–10q23.31 may be functionally relevant in post-operative PSA recurrence because of its reported role in androgen biosynthesis. It is suggestive that the loss of the susceptible region on chromosome 10q, which implicates PTEN, FAS and PAPSS2 may serve as genetic predictors of PSA recurrence after radical prostatectomy.

  14. Serum concentrations of the biomarkers CA125, CA15-3, CA72-4, tPSA and PAPP-A in natural and stimulated ovarian cycles

    Directory of Open Access Journals (Sweden)

    Melissa Stemp

    2014-06-01

    Conclusion: Ovarian stimulation reduced serum PAPP‐A levels, CA125 and CA15‐3 levels were generally unaffected by ovarian stimulation but displayed cyclical changes throughout both natural and stimulated cycles, whilst tPSA and CA72-4 were not affected by the stage of the cycle or ovarian stimulation.

  15. PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy

    DEFF Research Database (Denmark)

    dos Santos, Rodrigo Mattos; de Jesus, Carlos Márcio Nóbrega; Trindade Filho, José Carlos Souza

    2008-01-01

    The aim of the present study was to examine the impact of polymorphisms in prostate-specific antigen (PSA) and androgen-related genes (AR, CYP17, and CYP19) on prostate cancer (PCa) risk in selected high-risk patients who underwent prostate biopsy. Blood samples and prostate tissues were obtained...... for DNA analysis. Single-nucleotide polymorphisms in the 50-untranslated regions (UTRs) of the PSA (substitution A>G at position-158) and CYP17 (substitution T>C at 50-UTR) genes were detected by polymerase chain reaction (PCR)-restriction fragment length polymorphism assays. The CAG and TTTA repeats...... in the AR and CYP19 genes, respectively, were genotyped by PCR-based GeneScan analysis. Patients with the GG genotype of the PSA gene had a higher risk of PCa than those with the AG or AA genotype (OR=3.79, p=0.00138). The AA genotype was associated with lower PSA levels (6.44 +/- 1.64 ng=mL) compared...

  16. Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners

    NARCIS (Netherlands)

    Van der Meer, Saskia; Kollen, Boudewijn J.; Hirdes, Willem H.; Steffens, Martijn G.; Hoekstra-Weebers, Josette E. H. M.; Nijman, Rien M.; Blanker, Marco H.

    Objective To determine the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) publication in 2009 on prostate-specific antigen (PSA) level testing by Dutch general practitioners (GPs) in men aged 40 years. Materials and Methods Retrospective study with a Dutch insurance

  17. Towards One-Step Quantitation of Prostate-Specific Antigen (PSA) in Microfluidic Devices: Feasibility of Optical Detection with Nanoparticle Labels

    NARCIS (Netherlands)

    Barbosa, Ana I.; Wichers, J.H.; Amerongen, van A.; Reis, Nuno M.

    2017-01-01

    Rapid and quantitative prostate-specific antigen (PSA) biomarker detection would be beneficial to cancer diagnostics, improving early detection and therefore increasing chances of survival. Nanoparticle-based detection is routinely used in one-step nitrocellulose-based lateral flow (LF)

  18. Risk assessment methods in radiotherapy: Probabilistic safety assessment (PSA); Los metodos de analisis de riesgo en radioterapia: Analisis Probabilistico de seguridad (APS)

    Energy Technology Data Exchange (ETDEWEB)

    Ramirez Vera, M. L.; Perez Mulas, A.; Delgado, J. M.; Barrientos Ontero, M.; Somoano, F.; Alvarez Garcia, C.; Rodriguez Marti, M.

    2011-07-01

    The understanding of accidents that have occurred in radiotherapy and the lessons learned from them are very useful to prevent repetition, but there are other risks that have not been detected to date. With a view to identifying and preventing such risks, proactive methods successfully applied in other fields, such as probabilistic safety assessment (PSA), have been developed. (Author)

  19. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.

    Science.gov (United States)

    Sanli, Yasemin; Kuyumcu, Serkan; Sanli, Oner; Buyukkaya, Fikret; İribaş, Ayça; Alcin, Goksel; Darendeliler, Emin; Ozluk, Yasemin; Yildiz, Sevda Ozel; Turkmen, Cüneyt

    2017-11-01

    To investigate the relationship between serum PSA level, Gleason score of PCa and the outcomes of Ga(68)-PSMA PET/CT in patients with recurrent PCa. A total of 109 consecutive patients (median age 71 years; range 48-89 years) who had PSA recurrence after RP and/or hormonotherapy and/or radiotherapy were included in this study. Local recurrences, lymph node metastasis (pelvic, abdominal and/or supradiaphragmatic), bone metastases (oligometastatic/multimetastatic) and other metastatic sites (lung, liver, brain, etc) were documented. In 91(83.4%) patients at least one lesion characteristic for PCa was detected by(68)Ga-PSMA PET/CT. The median serum total PSA (tPSA) was 6.5 (0.2-640) ng/ml.There was a significant difference between (68)Ga-PSMA PET/CT positive and negative patients in terms of serum total PSA value. No statistical significance was found between positive and negative (68)Ga-PSMA PET/CT findings in terms of Gleason score. Local recurrence was detected in 56 patients. whereas lymph node metastases were demonstrated in 46 patients. Pelvic nodal disease was the most frequent presentation followed by abdominal and supradiaphragmaticnodal involvement. Bone metastases [oligometastasis, (n = 20); multimetastasis, (n = 35)⦌ were also detected in 55 patients. In the ROC analysis for the study cohort, the optimal cut-off value of total serum PSA was determined as 0.67 ng/ml for distinguishing between positive and negative (68)Ga-PSMA PET/CT images, with an area under curve of 0.952 (95% CI 0.911-0.993). (68)Ga-PSMA PET/CT was found to be an effective tool for the detection of recurrent PCa. Even though no relationship was detected between the GS and (68)Ga-PSMA PET/CT findings, serum total PSA values may be used for estimating the likelihood of positive (68)Ga-PSMA PET/CT results.

  20. High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy?

    Science.gov (United States)

    Mahal, B A; Chen, M-H; Bennett, C L; Kattan, M W; Sartor, O; Stein, K; D'Amico, A V; Nguyen, P L

    2015-07-01

    Although commonly used, early initiation of salvage androgen deprivation therapy (ADT) has not been proven to enhance survival. We evaluated whether prostate-specific antigen (PSA) anxiety or health literacy are associated with use of early salvage ADT among men with recurrent prostate cancer after radiotherapy. The prospective Comprehensive, Observational, Multicenter, Prostate Adenocarcinoma Registry was used to study 375 men with biochemically recurrent prostate cancer after external beam radiation or brachytherapy. Multivariable logistic regression was used to determine whether PSA anxiety and health literacy are associated with salvage ADT as initial management after biochemical recurrence. Sixty-eight men (18.1%) received salvage ADT as initial management for PSA recurrence. Men with high PSA anxiety were twice as likely to receive salvage ADT compared with men who did not have high PSA anxiety on both univariable [28.8% versus 13.1%; odds ratio (OR) 2.15; 95% confidence interval (CI) 1.16-4.00; P = 0.015] and multivariable analysis [adjusted OR (AOR) 2.36; 95% CI 1.21-4.62; P = 0.012]. Furthermore, men who had higher levels of health literacy were nearly half as likely to undergo salvage ADT compared with men who had lower levels of health literacy on univariable analysis (15.2% versus 26.3%; OR 0.50; 95% CI 0.29-0.88; P = 0.016), with a trend toward this association on multivariable analysis (AOR 0.58; 95% CI 0.32-1.05; P = 0.07). Among men with PSA recurrence after radiotherapy, odds of use of salvage ADT were nearly twice as great among men with high PSA anxiety or low health literacy, suggesting that these men are receiving higher rates of unproven treatment. Given that early salvage ADT is costly, worsens quality of life, and has not been shown to improve survival, quality improvement strategies are needed for these individuals. © The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights

  1. Trends in prostate cancer incidence and mortality before and after the introduction of PSA testing in the Slovak and Czech Republics.

    Science.gov (United States)

    Ondrusova, Martina; Ondrus, Dalibor; Karabinos, Juraj; Muzik, Jan; Kliment, Jan; Gulis, Gabriel

    2011-01-01

    As two neighboring countries in central Europe with national cancer registries, the Slovak (SR) and Czech Republics (CR) are countries with a medium global rate in the occurrence of prostate cancer. This paper analyzes the incidence of prostate cancer and mortality before and after the introduction of PSA testing in the two Republics and the possible reasons for any differences discovered and compares the results with selected regions and countries of the world. In the Slovak Republic, prostate cancer incidence (age-adjusted to the world standard population) has risen from 14.6/100,000 in 1968 (95% CI, ±1.5772) to 36.2/100,000 in 2005 (95% CI, ±2.0678). The estimated annual increase in the incidence during the period 1968-1991 (before nationwide PSA testing) was 0.421; from 1991 (when nationwide PSA testing began) to up to 2003 it was 0.941. Mortality rates grew from 7.3/100,000 in 1968 to 14.9/100,000 in 2005. In spite of the geographic proximity of the two countries, the increase in incidence occurred faster in the Czech than in the Slovak Republic, from 15.8/100,000 in 1977 (95% CI, ±0.9748) to 59.5/100,000 in 2005 (95% CI, ±1.7187). The estimated annual increase in incidence in the Czech Republic for the period of 1977-1991 was 0.581. From 1991 (when national PSA testing began) until 2003, it was 1.981. In the period before 1991, mortality rose more sharply in the Czech than in the Slovak Republic, whereas after the introduction of PSA testing mortality stabilized more quickly in the Czech than in the Slovak Republic. In the Slovak Republic, a significant reduction in mortality was observed after 2002 and has continued to the present and probably is not affected only by the results connected with the increase in PSA testing. The difference in the incidence and mortality of prostate cancer in the Slovak and the Czech Republics results from a difference in the intensity of PSA testing as well as from the introduction of complex, more effective treatment in

  2. Role of 18F-Choline PET/CT in guiding biopsy in patients with risen PSA levels and previous negative biopsy for prostate cancer.

    Science.gov (United States)

    Jiménez Londoño, G A; García Vicente, A M; Amo-Salas, M; Fúnez Mayorga, F; López Guerrero, M A; Talavera Rubio, M P; Gutierrez Martin, P; González García, B; de la Torre Pérez, J A; Soriano Castrejón, Á M

    To study 18F-Choline PET/CT in the diagnosis and biopsy guide of prostate cancer (pCa) in patients with persistently high prostate-specific antigen (PSA) and previous negative prostate biopsy. To compare the clinical risk factors and metabolic variables as predictors of malignancy. Patients with persistently elevated PSA in serum (total PSA >4ng/mL) and at least a previous negative or inconclusive biopsy were consecutively referred for a whole body 18F-Choline PET/CT. Patient age, PSA level, PSA doubling time (PSAdt) and PSA velocity (PSAvel) were obtained. PET images were visually (positive or negative) and semiquantitatively (SUVmax) reviewed. 18F-Choline uptake prostate patterns were defined as focal, multifocal, homogeneous or heterogeneous. Histology on biopsy using transrectal ultrasound-guided approach was the gold standard. Sensitivity (Se), specificity (Sp) and accuracy (Ac) of PET/CT for diagnosis of pCa were evaluated using per-patient and per-prostate lobe analysis. Receiver-operating-characteristic (ROC) curve analysis was used to assess the value of SUVmax to diagnose pCa. Correlation between PET/CT and biopsy results per-prostate lobe was assessed using the Chi-square test. Univariate and multivariate logistic regression analysis were applied to compare clinical risk factors and metabolic variables as predictors of malignancy. Thirty-six out of 43 patients with histologic confirmation were included. In 11 (30.5%) patients, pCa was diagnosed (Gleason score from 4 to 9). The mean values of patient age, PSA level, PSAdt and PSAvel were: 65.5 years, 15.6ng/ml, 28.1 months and 8.5ng/mL per year, respectively. Thirty-three patients had a positive PET/CT; 18 had a focal pattern, 7 multifocal, 4 homogeneous and 4 heterogeneous. Se, Sp and Ac of PET/CT were of 100%, 12% and 38% in the patient based analysis, and 87%, 29% and 14% in the prostate lobe based analysis, respectively. The ROC curve analysis of SUVmax showed an AUC of 0.568 (p=0.52). On a lobe

  3. Técnica para obtenção do aparelho geniturinário e dosagem do PSA (Prostate Specific Antigen no hamster sírio, Mesocricetus auratus Technique for collecting blood for PSA (Prostate Specific Antigen dosing and genitourinary system obtaining in syrian hamster, Mesocricetus auratus

    Directory of Open Access Journals (Sweden)

    Dimas José Araújo Vidigal

    2004-12-01

    Full Text Available Objetivo: Expor a técnica utilizada na colheita de sangue para dosagem do PSA ( Prostate Specific Antigen e retirada do aparelho geniturinário no hamster sírio, Mesocricetus auratus, e correlacionar os achados do PSA com as alterações histológicas dos anexos sexuais desse roedor. Métodos: Foram usados no experimento trinta (n= 30 Hamsters: dez (n=10 animais considerados jovens com idade média no momento da morte de 47,5 dias e vinte (n=20 animais considerados adultos com idade superior à um ano. Após serem anestesiados com cloridrato de quetamina e diazepam, foi colhido diretamente da veia cava, em nível de abdome superior, cerca de 1,5mL a 2,0mL de sangue para dosagem do PSA totalpelo método ELISA, com antígeno humano. Morriam após colheita do sangue. Constatado a morte do animal, fazia-se a laparotomia retirando-se em monobloco todo aparelho geniturinário para estudo histológico dos anexos sexuais. Correlacionou-se o PSA com as alterações histológicas encontradas. Resultados: Os animais após serem anestesiados com cloridrato de quetamina e diazepam intraperitonealmente, obteve-se um excelente plano anestésico, que possibilitou colher via trans-dérmica da veia cava inferior em abdome superior sangue para dosagem do PSA. O animal morria após colheita do sangue. Fazia-se a laparotomia, com retirada em monobloco do aparelho geniturinário para estudo histológico e comparação das alterações encontradas nos anexos sexuais com o PSA dosado. Entre os Hamsters Jovens a média do PSA encontrado foi de 0,252ng/mL. Desvio Padrão (DP = 0,36. Entre os Hamsters adultos esta média foi de 0,325 ng/mL, DP= 0,12 . Quando comparou-se as médias do PSA entre os dois grupos de jovens e adultos obteve-se p= 0,0427. Dentre os Hamsters jovens, três apresentaram PSA não detectado. A análise histológica mostrou que, entre os animais jovens, não foi identificada qualquer alteração das estruturas microscópicas da próstata, ves

  4. PSA-Based Screening Outcomes, Dietary Heterocyclic Amine Exposure, and Prostate Cancer Risk in African Americans: Annual Report (Year 1 of 3)

    Energy Technology Data Exchange (ETDEWEB)

    Bogen, K T

    2006-01-18

    Prostate cancer (PC) is the second leading cause of male U.S. cancer deaths, with African-Americans having the highest rate of PC mortality worldwide, as well as more abnormal results from screening tests that correlate with current or eventual PC. A 3-year prospective clinic-based study is studying the performance of current (PSA and DRE) vs. (% free PSA) clinical biomarkers of PC risk in 400 African-American men 50 to 70 years of age who undergo PC screening in Oakland, CA (East Bay San Francisco area), as well as possible association of PC screening results for these men with their dietary exposures to the cancer-causing heterocyclic amine, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) that forms when meat is cooked. This study expands an ongoing NIH-funded study (by the same research team) to add a new %-free-PSA test, results of which will be compared with PSA/DRE results and PhIP exposures estimated by dietary interviews. For 392 men studied under the NIH protocol, an odds ratio (95% CL) of 32 (3.2, 720) for highly elevated PSA ({ge}20 ng/mL) was observed in the highest 15% vs. the lower 50% of estimated daily PhIP intakes. Approximately 100 additional men have completed participation in the expanded NIH/DOD-supported study. This study will help define the potential value of improved screening and dietary/behavioral intervention to reduce PC risk, namely, prevention of PhIP intake by avoiding overcooked meats.

  5. Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4–10 ng/mL

    Directory of Open Access Journals (Sweden)

    Yongqiang Zhou

    2017-01-01

    Full Text Available This study aims to evaluate the effectiveness and clinical performance of a panel of urinary biomarkers to diagnose prostate cancer (PCa in Chinese men with PSA levels between 4 and 10 ng/mL. A total of 122 patients with PSA levels between 4 and 10 ng/mL who underwent consecutive prostate biopsy at three hospitals in China were recruited. First-catch urine samples were collected after an attentive prostate massage. Urinary mRNA levels were measured by quantitative real-time polymerase chain reaction (qRT-PCR. The predictive accuracy of these biomarkers and prediction models was assessed by the area under the curve (AUC of the receiver-operating characteristic (ROC curve. The diagnostic accuracy of PCA3, PSGR, and MALAT-1 was superior to that of PSA. PCA3 performed best, with an AUC of 0.734 (95% CI: 0.641, 0.828 followed by MALAT-1 with an AUC of 0.727 (95% CI: 0.625, 0.829 and PSGR with an AUC of 0.666 (95% CI: 0.575, 0.749. The diagnostic panel with age, prostate volume, % fPSA, PCA3 score, PSGR score, and MALAT-1 score yielded an AUC of 0.857 (95% CI: 0.780, 0.933. At a threshold probability of 20%, 47.2% of unnecessary biopsies may be avoided whereas only 6.2% of PCa cases may be missed. This urinary panel may improve the current diagnostic modality in Chinese men with PSA levels between 4 and 10 ng/mL.

  6. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).

    Science.gov (United States)

    Roobol, M J; van der Cruijsen, I W; Schröder, F H

    2004-05-01

    In the early detection of prostate cancer (CaP) uncertainty exists concerning the most appropriate biopsy procedure. Within the European Randomized Study of Screening for Prostate Cancer (ERSPC) lateralized sextant biopsies are used. False-negative results of sextant biopsies have led to the extensive use of procedures using 12 or more biopsy cores. The ERSPC offers the opportunity to study the yield of repeat biopsies after 4 years in men who had negative sextant biopsies and a prostate-specific antigen (PSA) level of 4.0 mg/mL or more at the first screening round. Between August 1996 and May 1998, a total of 6876 men (age 55 to 74 years) were randomized to the screening arm and actually underwent screening. The numbers and levels of biopsy indicators, as well as possible predictors for biopsy outcome, in the second screening round, such as prostate volume, volume change over time, prostate-specific antigen density (PSAD), PSA velocity, and age, were calculated and compared for participants with positive and negative biopsies in round 2. The positive predictive value (PPV) and detection rates, as well as parameters of aggressiveness, were evaluated for second-round biopsy-detected and interval CaP cases. Of the 728 men with a PSA level of 4.0 mg/mL or more who underwent biopsy at initial screening, 553 were eligible for a second screening visit after 4 years. Of these, 272 (49.2%) actually underwent screening. Eighteen CaP cases were detected with 217 biopsies, indicated by a PSA level of 3.0 ng/mL or more (PPV 8.3%). Eight interval cases were identified by linking to the Cancer Registry. These 26 cases would have increased the PPV and detection rate of the initial screening round from 36.1% to 39.7% and from 3.8% to 4.2%, respectively. Most of these cases (23 of 26 or 88.5%) were organ confined and amenable to potentially curative treatment. Although the results of this study may have been biased by the low rate of availability/eligibility of participants for

  7. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?

    Science.gov (United States)

    Nielsen, Matthew E; Makarov, Danil V; Humphreys, Elizabeth; Mangold, Leslie; Partin, Alan W; Walsh, Patrick C

    2008-08-01

    The new American Society for Therapeutic Radiology and Oncology/Radiation Therapy Oncology Group consensus definition of biochemical failure after radiotherapy for prostate cancer is defined as a prostate-specific antigen level at or greater than the absolute nadir PSA level plus 2 ng/mL. Because this definition inevitably will be used to compare cancer control rates after radiotherapy to those after surgery, this study examined the effect of this comparison. We reviewed the data from 2570 men who had undergone radical prostatectomy from 1985 to 2004. Biochemical failure was defined as any measurable PSA level of 0.2 ng/mL or greater. We evaluated how the nadir+2 definition affected the failure rate when applied to this series. The actuarial 5, 10, and 15-year biochemical recurrence-free survival probability with failure defined as a PSA level of 0.2 ng/mL or more and a PSA level of 2 ng/mL or more was 88.6%, 81.2%, and 78.1% and 94.6%, 89.4%, and 84.3%, respectively (P <0.0001). The median time to biochemical progression was 2.8 years for the greater than 0.2 ng/mL definition and 7.9 years for the 2 ng/mL or more definition. The nadir+2 definition systematically overestimated the biochemical recurrence-free survival, even after stratifying patients into standard prognostic risk groups, especially in men who developed local recurrence. When applied to a mature series of surgically treated patients with localized prostate cancer, the American Society for Therapeutic Radiology and Oncology "nadir+2" definition resulted in a systematic delay in the determination of biochemical failure. Because patients in this series who experienced a detectable PSA level took more than 5 years to progress to a PSA level of 2 ng/mL or greater, the 5-year biochemical control rates with the definition of 0.2 ng/mL or more should be compared with the 10-year biochemical control rates using the nadir+2 definition.

  8. [Effect of compound Chinese traditional medicine PC-SPES II in inhibiting proliferation of human prostate cancer cell LNCaP and on expressions of AR and PSA].

    Science.gov (United States)

    Zhang, Bi-yan; Li, Yu-feng; Lai, Yun; Li, Yun-sen; Chen, Zi-jun

    2015-03-01

    To investigate the effect of compound Chinese traditional medicine PC-SPES II I in inhibiting proliferation of human prostate cancer cell LNCaP based on the androgen receptor (AR) signaling pathway. The effect of PC-SPES II on LNCaP cell proliferation was detected by MTT assay. According to the findings, at the mass concentration of 180-1 440 mg x L(-1), PC-SPES II significantly inhibited the proliferation of LNCaP cells; the IC50 of PC-SPES II at 24 h and 48 h were 311.48, 199.01 mg x L(-1), respectively. The flow Cytometry detection showed 240 mg x L(-1) PC-SPES II arrested cells in G2/M phase, and an obvious apoptotic peak appeared before G0/G1 peak and rose over time. Meanwhile, Hoechst 33258 staining revealed apoptotic cellular morphology. Annexin V-FITC/PI staining manifested an increase in apoptotic cell ratio at the PC-SPES II concentration of 480 mg x L(-1) in a dose dependent manner. The prostate specific antigen (PSA) secretion of LNCaP cells was tested by PSA ELISA kit. Besides, compared with 25 mg x L(-1) Bic, 480 mg x L(-1) PC-SPES II significantly reduced the cell secretion of PSA. The AR and PSA mRNA and protein expressions were detected by qRT-PCR and Western blot. According to the results, after the induction of LNCaP cells with synthetic androgen 25 μg x L(-1) R1881, 240-480 mg x L(-1) PC-SPES II notably down-regulated the AR and PSA mRNA and protein expressions and inhibited the translocation of AR from cytoplasm to nucleus. In summary, PC-SPES II significantly can inhibit the in vitro proliferation of LNCaP cells and arrest cell cycle arrest in G2/M phase. Its mechanism may be associated with the down-regulation of the AR and PSA expressions and the inhibition of AR nuclear translocation.

  9. Prostate Health Index (Phi and Prostate Cancer Antigen 3 (PCA3 significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.

    Directory of Open Access Journals (Sweden)

    Matteo Ferro

    Full Text Available Many efforts to reduce prostate specific antigen (PSA overdiagnosis and overtreatment have been made. To this aim, Prostate Health Index (Phi and Prostate Cancer Antigen 3 (PCA3 have been proposed as new more specific biomarkers. We evaluated the ability of phi and PCA3 to identify prostate cancer (PCa at initial prostate biopsy in men with total PSA range of 2-10 ng/ml. The performance of phi and PCA3 were evaluated in 300 patients undergoing first prostate biopsy. ROC curve analyses tested the accuracy (AUC of phi and PCA3 in predicting PCa. Decision curve analyses (DCA were used to compare the clinical benefit of the two biomarkers. We found that the AUC value of phi (0.77 was comparable to those of %p2PSA (0.76 and PCA3 (0.73 with no significant differences in pairwise comparison (%p2PSA vs phi p = 0.673, %p2PSA vs. PCA3 p = 0.417 and phi vs. PCA3 p = 0.247. These three biomarkers significantly outperformed fPSA (AUC = 0.60, % fPSA (AUC = 0.62 and p2PSA (AUC = 0.63. At DCA, phi and PCA3 exhibited a very close net benefit profile until the threshold probability of 25%, then phi index showed higher net benefit than PCA3. Multivariable analysis showed that the addition of phi and PCA3 to the base multivariable model (age, PSA, %fPSA, DRE, prostate volume increased predictive accuracy, whereas no model improved single biomarker performance. Finally we showed that subjects with active surveillance (AS compatible cancer had significantly lower phi and PCA3 values (p<0.001 and p = 0.01, respectively. In conclusion, both phi and PCA3 comparably increase the accuracy in predicting the presence of PCa in total PSA range 2-10 ng/ml at initial biopsy, outperforming currently used %fPSA.

  10. Study of serum antioxidant capacity and relation with CA 19-9 and PSA in patients with gastrointestinal tract and prostate tumors.

    Science.gov (United States)

    López Vélez, M; Martínez Martínez, F

    2011-09-01

    We undertook the present study to investigate the possible relation between total antioxidant capacity (TAC) and tumor marker (TM) values in serum samples of patients with and without gastrointestinal tract and prostate tumors. We measured the TAC using trolox equivalent antioxidant capacity (TEAC) and oxygen radical absorption capacity (ORAC) assays in 80 serum samples: 20 presented elevated values of CA 19-9; 20 had elevated PSA levels and two groups of 20 samples had values within reference ranges respectively. Total antioxidant capacity - measured using the two different analytical methods - was higher in serum samples from patients with elevated CA 19-9 and PSA levels. This antioxidant status, measured by ORAC assay, correlated significantly with CA 19-9 (r: 0.502, Pantioxidant capacity in these pathological processes could contribute to improve diagnosis of these patients. Copyright © 2011 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

  11. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.

    Science.gov (United States)

    Beheshti, Mohsen; Haim, Silke; Zakavi, Rasoul; Steinmair, Martin; Waldenberger, Peter; Kunit, Thomas; Nader, Michael; Langsteger, Werner; Loidl, Wolfgang

    2013-06-01

    We evaluated the potential of (18)F-fluoromethyldimethyl-2-hydroxyethyl-ammonium (FCH) PET/CT in the detection of recurrent disease or distant metastases and correlated its diagnostic accuracy with prostate-specific antigen (PSA) levels in prostate cancer patients with biochemical evidence of recurrence. Furthermore, the influences of androgen deprivation therapy (ADT) and its duration on (18)F-FCH PET were assessed in this study. This prospective study included 250 prostate cancer patients with PSA relapse who underwent (18)F-FCH PET/CT. At the time of (18)F-FCH PET/CT imaging, the mean PSA level was 46.9 ± 314.7 ng/mL and 55.2% (138/250) of patients were receiving ADT. Overall, ADT was performed on 67.2% (168/250) of patients after initial treatment. Imaging was performed on an integrated PET/CT system. Acquisition started 1 min after intravenous injection of (18)F-FCH (4.07 MBq/kg of body weight) with dynamic PET images in the pelvic region during 8 min (1 min/frame) followed by a static semi-whole-body acquisition. The final diagnosis of positive PET lesions was based on histopathology or a consensus of clinical findings, additional imaging, or follow-up imaging modalities. (18)F-FCH PET/CT was able to correctly detect malignant lesions in 74% (185/250) of patients but was negative in 26% (65/250). In 28% of patients, only 1 lesion was detected (69/250); from these, 65.2% (45 patients) had a local recurrence, 18.8% (13 patients) a single lymph node, and 15.9% (11 patients) a solitary bone metastasis. The sensitivity of the (18)F-FCH PET was significantly higher (P = 0.001) in patients with ongoing ADT (85%; confidence interval, 80%-91%) than in patients without ADT (59.5%; confidence interval, 50%-69%). (18)F-FCH PET sensitivity was 77.5%, 80.7%, 85.2%, and 92.8% for the trigger PSA levels of more than 0.5, 1.0, 2.0, and 4.0 ng/mL, respectively. Scan sensitivity was 33% in patients with a trigger PSA level of less than 0.3 ng/mL and 77% in patients with a

  12. [A comparaison between the total PSA, the Gleason score and the bone scintiscan results for different age groups].

    Science.gov (United States)

    Rusu, Daniela; Rusu, Valeriu; Stefănescu, Cipriana; Rusu, Maria; Răileanu, Irena; Stătescu, Ana Maria

    2010-01-01

    The aim of the study is to compare de results of the bone scintigraphy of prostate cancer patients in different age groups with their total PSA (PSAt) and with their histopathological test results. MATERIALS AND METODS: Of the 180 patients with prostate cancer who were analyzed by Scintiscan in the last five years in our laboratory, 86 have a known PSAt value, and of these, 55 have a known Gleason Score. The 180 patients were divided into three age groups: (1) 70 years. The 86 patients with a known PSAt were also divided into five groups according to their PSAt value and the 55 patients with a known Gleason Score were divided in three groups. The scintigraphy results included all the patients in 3 groups, according to the presence, the absence or the likelihood of having bone metastasis. The 33 patients with proven bone metastasis were divided, according to their numbers, into the four Soloway groups. Among the patients with PSAt >20 ng/mL, considered high risk for bone metastases, according to the Recomandations of CCAF, 21 (32.81%) of the 64 patients do not show the presence of bone metastases. For PSAt >50 ng/mL, all 5 patients sau egal 100 ng/mL do not have metastases. 10 (43.4 %) of the 23 patients with a Gleason Score bone metastasis for a high PSAt value is reversely proportional to age. In our study there is no direct correlation between Gleason Score and the bone scan results.

  13. Effects of monomers on the properties of palm-oil-based radiation curable pressure sensitive adhesives (PSA) - a prepolymer method

    Energy Technology Data Exchange (ETDEWEB)

    Hilmi Mahmood, Mohd E-mail: hilmi@mint.gov.my; Abdullah, Zahid; Sakurai, Yasuo; Zaman, Khairul; Mohd. Dahlan, Hj

    2001-01-01

    Various low glass transition temperature (T{sub g}) acrylate and methacrylate monomers were mixed with epoxidised palm oil acrylate (EPOLA) with the ratio of 50/50 prior to curing with electron beam (EB) irradiation. Methacrylate monomers such as dicyclopentenyloxyethyl methacrylate (DCPOEMA) and isobornyl methacrylate (ISBMA), although displaying relatively high adhesive properties were finally excluded from being further utilised as monomers for PSA because of a very slow curing speed. Literally, it is suggested that poorer adhesive performances of the cured films made from 50/50 : EPOLA/monomer mixture as compared to that of 100% monomer was attributed to the lack of compatibility between EPOLA and the particular monomers. Further compatibility investigations were continued using formulations prepared via the prepolymer route cured by ultraviolet (UV) irradiation and the results showed that several monoacrylate monomers with polar and non-polar groups exhibited high curing speed as well as good compatibility with EPOLA as shown by their cured film properties such as surface tackiness, peel adhesion and creep resistance. It is also suggested that these monomers were acting as surfactants for EPOLA which consequently enhance their compatibility upon mixing. (author)

  14. Experimental and computational investigation of adsorption performance of TC-5A and PSA-5A for manned spacecraft

    Directory of Open Access Journals (Sweden)

    Liu Meng

    2015-12-01

    Full Text Available Two kinds of molecular sieve materials, TC-5A and PSA-5A, were produced to satisfy with special requirement of manned space flight. Their CO2 adsorption performances were investigated and compared through two experiments, the thermo gravimetric analysis (TGA experiment and packed bed column experiment. Besides, some kinetic equations were compared according to the TGA experimental data, and their errors were analyzed. Finally, the classic linear driving force (LDF model is improved to the new Avrami’s model, and two models are analyzed based on the packed bed data. The TGA data shows that the CO2 loading has an approximately linear relationship with the CO2 concentration, and the best fit adsorption temperature range is from 283 to 303 K. The packed bed column results show that water vapor in air can affect the CO2 adsorption performance badly. The new Avrami’s model is proved more suitable to reflect the complex adsorption mechanism for two molecular sieves. The materials are proved having much better adsorption capacity than the other adsorbents with room temperature and low CO2 concentration (⩽1.0% in volume, and they can meet the aerospace requirements. This work will benefit the optimal design and simulation of the air revitalization (AR system for Chinese manned spacecraft.

  15. The neural plasticity theory of depression: assessing the roles of adult neurogenesis and PSA-NCAM within the hippocampus.

    Science.gov (United States)

    Wainwright, Steven R; Galea, Liisa A M

    2013-01-01

    Depression is a devastating and prevalent disease, with profound effects on neural structure and function; however the etiology and neuropathology of depression remain poorly understood. Though antidepressant drugs exist, they are not ideal, as only a segment of patients are effectively treated, therapeutic onset is delayed, and the exact mechanism of these drugs remains to be elucidated. Several theories of depression do exist, including modulation of monoaminergic neurotransmission, alterations in neurotrophic factors, and the upregulation of adult hippocampal neurogenesis, and are briefly mentioned in the review. However none of these theories sufficiently explains the pathology and treatment of depression unto itself. Recently, neural plasticity theories of depression have postulated that multiple aspects of brain plasticity, beyond neurogenesis, may bridge the prevailing theories. The term "neural plasticity" encompasses an array of mechanisms, from the birth, survival, migration, and integration of new neurons to neurite outgrowth, synaptogenesis, and the modulation of mature synapses. This review critically assesses the role of adult hippocampal neurogenesis and the cell adhesion molecule, PSA-NCAM (which is known to be involved in many facets of neural plasticity), in depression and antidepressant treatment.

  16. Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap*

    Science.gov (United States)

    Franca, Carlos Antônio da Silva; Vieira, Sérgio Lannes; Carvalho, Antonio Carlos Pires; Bernabe, Antonio Jose Serrano; Penna, Antonio Belmiro Rodrigues Campbell

    2014-01-01

    Objective To evaluate the relationship between two year PSA nadir (PSAn) after brachytherapy and biochemical recurrence rates in prostate cancer patients. Materials and Methods In the period from January 1998 to August 2007, 120 patients were treated with iodine-125 brachytherapy alone. The results analysis was based on the definition of biochemical recurrence according to the Phoenix Consensus. Results Biochemical control was observed in 86 patients (71.7%), and biochemical recurrence, in 34 (28.3%). Mean PSAn was 0.53 ng/ml. The mean follow-up was 98 months. The patients were divided into two groups: group 1, with two year PSAn < 0.5 ng/ml after brachytherapy (74 patients; 61.7%), and group 2, with two year PSAn ≥ 0.5 ng/ml after brachytherapy (46 patients; 38.3%). Group 1 presented biochemical recurrence in 15 patients (20.3%), and group 2, in 19 patients (43.2%) (p < 0.02). The analysis of biochemical disease-free survival at seven years, stratified by the two groups, showed values of 80% and 64% (p < 0.02), respectively. Conclusion Levels of two year PSAn ≥ 0.5 ng/ml after brachytherapy are strongly correlated with a poor prognosis. This fact may help to identify patients at risk for disease recurrence. PMID:25741055

  17. Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherapy

    Directory of Open Access Journals (Sweden)

    Carlos Antônio da Silva Franca

    2014-04-01

    Full Text Available Objective To evaluate the relationship between two year PSA nadir (PSAn after brachytherapy and biochemical recurrence rates in prostate cancer patients. Materials and Methods In the period from January 1998 to August 2007, 120 patients were treated with iodine-125 brachytherapy alone. The results analysis was based on the definition of biochemical recurrence according to the Phoenix Consensus. Results Biochemical control was observed in 86 patients (71.7%, and biochemical recurrence, in 34 (28.3%. Mean PSAn was 0.53 ng/ml. The mean follow-up was 98 months. The patients were divided into two groups: group 1, with two year PSAn < 0.5 ng/ml after brachytherapy (74 patients; 61.7%, and group 2, with two year PSAn ≥ 0.5 ng/ml after brachytherapy (46 patients; 38.3%. Group 1 presented biochemical recurrence in 15 patients (20.3%, and group 2, in 19 patients (43.2% (p < 0.02. The analysis of biochemical disease-free survival at seven years, stratified by the two groups, showed values of 80% and 64% (p < 0.02, respectively. Conclusion Levels of two year PSAn ≥ 0.5 ng/ml after brachytherapy are strongly correlated with a poor prognosis. This fact may help to identify patients at risk for disease recurrence.

  18. Can delayed time to referral to a tertiary level urologist with an abnormal PSA level affect subsequent Gleason grade in the opportunistically screened population?

    LENUS (Irish Health Repository)

    O'Kelly, Fardod

    2013-09-01

    There is growing conflict in the literature describing the effect of delayed treatment on outcomes following radical prostatectomy. There is also evidence to suggest progression of low-risk prostate cancer to develop higher grades and volumes of prostate cancer during active surveillance. It is unknown as to what affect a delay in referral of those men with abnormal screened-PSA levels have on subsequent Gleason grade.

  19. Résultats de la biopsie prostatique chez les patients algériens avec un PSA élevé et/ou un toucher rectal suspect

    Directory of Open Access Journals (Sweden)

    M. Benatta

    2012-09-01

    Conclusion: 49.2% des 331 biopsies colligées étaient positives pour adénocarcinome de la prostate. Des associations significatives ont été retrouvées entre l’âge et le cancer, les résultats du Toucher Rectal et la biopsie prostatique, ainsi qu'entre le taux de PSA et le nombre de carottes positives.

  20. A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.

    Science.gov (United States)

    Pantuck, A J; Pettaway, C A; Dreicer, R; Corman, J; Katz, A; Ho, A; Aronson, W; Clark, W; Simmons, G; Heber, D

    2015-09-01

    The primary objective of this study was to compare the effects of pomegranate juice on PSA doubling times (PSADT) in subjects with rising PSA levels after primary therapy for prostate cancer. Double-blind, placebo-controlled multi-institutional study, evaluated the effects of pomegranate liquid extract on serum PSA levels. The primary end point of this study was change in serum PSADT. Additional secondary and exploratory objectives were to evaluate the safety of pomegranate juice and to determine the interaction of manganese superoxide dismutase (MnSOD) AA genotype and pomegranate treatment on PSADT. One-hundred eighty-three eligible subjects were randomly assigned to the active and placebo groups with a ratio of 2:1 (extract N=102; placebo N=64; juice N=17). The majority of adverse events were of moderate or mild grade. Median PSADT increased from 11.1 months at baseline to 15.6 months in the placebo group (P0.05). Placebo AA patients experienced a 1.8 month change in median PSADT from 10.9 months at baseline to 12.7 months (P=0.22), while extract patients experienced a 12 month change in median PSADT from 13.6 at baseline to 25.6 months (P=0.03). Compared with placebo, pomegranate extract did not significantly prolong PSADT in prostate cancer patients with rising PSA after primary therapy. A significant prolongation in PSADT was observed in both the treatment and placebo arms. Men with the MnSOD AA genotype may represent a group that is more sensitive to the antiproliferative effects of pomegranate on PSADT; however, this finding requires prospective hypothesis testing and validation.

  1. Inhibition of the DHT-induced PSA secretion by Verbascum xanthophoeniceum and Serenoa repens extracts in human LNCaP prostate epithelial cells.

    Science.gov (United States)

    Marcoccia, D; Georgiev, M I; Alipieva, K I; Lorenzetti, S

    2014-08-08

    Verbascum xanthophoeniceum is a mullein plant, typical of Balkan region and some parts of Turkey, traditionally used as phytotherapeutic agent due to its anti-inflammatory properties. It is rich in phenylethanoid and iridoid metabolites whose anti-inflammatory properties are under characterization. The role of Verbascum xanthophoeniceum crude methanolic extract and its isolated phenylethanoid glycoside verbascoside have been evaluated, in comparison to a saw palmetto extract, on a human in vitro model of androgen-regulated prostate epithelium, the LNCaP cell line. Cytotoxicity and DHT-induced free and total PSA secretion have been thoroughly studied. We have found that similar to saw palmetto, Verbascum xanthophoeniceum extract and its isolated phenylethanoid glycoside verbascoside have no cytotoxicity in human LNCaP prostate epithelial cells, whereas an inhibitory effect on the DHT-induced free and total PSA secretion, a recognized anti-androgen like activity, has been shown in case of both Verbascum xanthophoeniceum extract and pure verbascoside. Furthermore, in the absence of the endogenous androgen DHT, an androgen-like activity in Verbascum xanthophoeniceum is detectable as it is for saw palmetto, suggesting that a mixed androgen-antiandrogen activity is present. For the first time, Serenoa repens and Verbascum xanthophoeniceum extracts have shown an absence of cytotoxicity and an inhibitory effect on DHT-induced PSA secretion in an in vitro model of human prostate epithelium, whereas the phenylethanoid glycoside verbascoside appeared to explain only part of the Verbascum xanthophoeniceum inhibitory activity on PSA secretion. Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

  2. Predictive value of PSA velocity over early clinical and pathological parameters in patients with localized prostate cancer who undergo radical retropubic prostatectomy

    Directory of Open Access Journals (Sweden)

    Martinez Carlos A.L.

    2004-01-01

    Full Text Available OBJECTIVES: To analyze the behavior of the prostate specific antigen velocity (PSAV in localized prostate adenocarcinoma. MATERIALS AND METHODS: We conducted a retrospective study of 500 men who had localized prostate adenocarcinoma, who underwent radical retropubic prostatectomy between January 1986 and December 1999. The PSAV was calculated for each patient and subsequently, the values were correlated with 5 groups: age, initial PSA value, clinical stage, tumor volume and Gleason score. RESULTS: The behavior of PSAV presented statistic significance with an increment between 1.3 ng/mL and 9.6 ng/mL, ranging from 38.6% and 59.8% when compared with the initial PSA value (p < 0.0001, clinical stage (p = 0.0002, tumor volume (p < 0.0001 and Gleason score (p = 0.0009. CONCLUSION: PSAV up to 2.5 ng/mL/year is associated with factors of good prognosis, such as initial PSA below 10 mg/mL, clinical stage T1, tumor volume below 20% and Gleason score lower than 7.

  3. Molecular phylogeny and evolution of the order Tribonematales (Heterokonta, Xanthophyceae) based on analysis of plastidial genes rbcL and psaA.

    Science.gov (United States)

    Maistro, Silvia; Broady, Paul A; Andreoli, Carlo; Negrisolo, Enrico

    2007-05-01

    Tribonematales is an order of filamentous algae in the class Xanthophyceae (Heterokonta). Few molecular studies, all with a limited taxon sampling, have previously investigated its evolutionary history and phylogenetic relationships. We sequenced the chloroplast-encoded rbcL and psaA genes of several tribonematalean species and of several coccoid and siphonous forms that previous studies revealed to be strictly related to Tribonematales. Multiple alignments included mostly new sequences obtained from 42 taxa. Phylogenetic reconstructions were performed using the maximum likelihood method. The rbcL and psaA data sets were analyzed independently and combined in a single multiple alignment. Neither rbcL nor psaA genes showed intraspecific sequence variation. The former proved to be a better diagnostic marker than the latter for characterization of species. We explored effects produced on phylogenetic outcomes by selected genes. Congruent results were obtained from analyses performed on single gene multiple alignments as well as on the combined data set. There is strong statistical support for trees that show several currently recognized taxonomic groups to be polyphyletic. The siphonous orders Botrydiales and Vaucheriales do not form a clade. Botrydiales and Tribonematales are polyphyletic as are the families Botrydiaceae, Centritractaceae and Tribonemataceae and the genera Xanthonema and Bumilleriopsis. We tentatively define new boundaries of the Tribonematales to include both coccoid and filamentous species having a bipartite cell wall and also the siphonous members of the genus Botrydium. Also, our results support morphological convergence at all taxonomic ranks in the evolution of the Xanthophyceae.

  4. An electrochemical biosensor to simultaneously detect VEGF and PSA for early prostate cancer diagnosis based on graphene oxide/ssDNA/PLLA nanoparticles.

    Science.gov (United States)

    Pan, Lung-Hsuan; Kuo, Shin-Hung; Lin, Tzu-Yang; Lin, Chih-Wen; Fang, Po-Yu; Yang, Hung-Wei

    2017-03-15

    Early diagnosis of prostate cancer (PCa) is critical for the prevention of metastasis and for early treatment; therefore, a simple and accurate device must be developed for this purpose. In this study, we reported a novel fabrication method for producing a dual-modality biosensor that can simultaneously detect vascular endothelial growth factor (VEGF) and prostate-specific antigen (PSA) in human serum for early diagnosis of PCa. This biosensor was constructed by coating graphene oxide/ssDNA (GO-ssDNA) on an Au-electrode for VEGF detection, and incorporated with poly-L-lactide nanoparticles (PLLA NPs) for signal amplification and PSA detection. The results showed that this biosensor has wide liner detection ranges (0.05-100ng/mL for VEGF and 1-100ng/mL for PSA), as well as high levels of sensitivity and selectivity (i.e., resisting interference from external factors, such as glucose, ascorbic acid human serum protein, immunoglobulin G, and immunoglobulin M), and demonstrated a high correlation with an enzyme-linked immunosorbent assay for sample detection in patients. Therefore, this biosensor could be utilized for early clinical diagnosis of PCa in the future. Copyright © 2016 Elsevier B.V. All rights reserved.

  5. Post-transcriptional control of chloroplast gene expression. Accumulation of stable psaC mRNA is due to downstream RNA cleavages in the ndhD gene.

    Science.gov (United States)

    Del Campo, Eva M; Sabater, Bartolomé; Martín, Mercedes

    2002-09-27

    Intergenic cleavages, intron splicing, and editing of primary transcripts of the plastid ndhH-D operon produce multiple overlapping RNAs, of which the most abundant by far is the monocistronic 400-nucleotide mRNA of psaC (encoding the PsaC protein of photosystem I), in contrast with the low level of transcripts of the six ndh genes. Like other plastid operons containing genes for functionally unrelated proteins, the contrasting accumulation of ndh and psaC transcripts provides a model to investigate the mechanisms of the post-transcriptional control of gene expression, a feature of chloroplast genetic machinery, with a minimum of interference by transcriptional control. In leek (Allium porrum L), the ndhD transcript (which follows the psaC gene and ends the ndhH-D operon) requires C --> U editing to restore its start codon and may be used as a marker for the processing of psaC and ndhD transcripts. By determining the editing state and 5' end sequences of specific transcripts, we demonstrated that stable monocistronic psaC mRNA results from downstream cleavages in the ndhD sequence, which renders non-functional ndhD transcripts as by-products. Alternative psaC-ndhD intergenic cleavages produce complete mRNAs for both genes, but only take place in precursors containing editing-restored ndhD start codons. Hence, post-transcriptional control acts by promoting the ndhD cleavage alternative, which allows the accumulation of psaC mRNA at the expense of ndhD mRNA levels.

  6. Synthesis and characterization of rare earth molybdates nanoparticles for detection of specific prostatic cancer (PSA); Preparacao e caracterizacao de nanoparticulas de molibdatos de terras raras para deteccao do antigeno especifico da prostata (PSA)

    Energy Technology Data Exchange (ETDEWEB)

    Dias, Clarissa Lombardi

    2013-07-01

    The interest in using rare earths to investigate the properties and functions of biochemical systems as well as to determinate biological substances has increased in several fields, including biomarkers in immunology (fluoro immunoassays). Nowadays the use of lanthanides in the diagnosis of various diseases have become more important through the development of commercial diagnostic kits. As main feature, these rare earths can show a long lifetime, photo stability and emission bands of atomic like behavior and well defined, in the visible region, demonstrating unique advantages when compared to other luminescent species. The present work had as its goal to synthesize rare earth molybdates by the co-precipitation method as well as to characterize these materials by X-ray diffraction, near infrared spectroscopy, thermogravimetric analysis, scanning electronic microscopy, transmission electronic microscopy and luminescent studies. In this work, three different studied were developed: the influence of the vortex speed variation during co-precipitation in the structure of the final product, morphology and luminescence properties; the influence of the annealing temperature also in the structure, morphology and luminescence properties; and the influence of concentration of the doping in the luminescence properties. Another important step of this work was the functionalization of nanoparticles using an organosilane (APTES) to coat and establish points for binding the particles to biological species. It was proved that this process was very efficient by the characterization results and the silica incorporation was well succeeded. Specific prostatic cancer (PSA) was then linked to the functionalized nanoparticles to diagnostic prostatic cancer by fluoroimmunoassay and levels for detection were established. (author)

  7. Speciation of Sb(III) and Sb(V) in meglumine antimoniate pharmaceutical formulations by PSA using carbon nanotube electrode.

    Science.gov (United States)

    Santos, Vivian Silva; Santos, Wilney de Jesus Rodrigues; Kubota, Lauro Tatsuo; Tarley, César Ricardo Teixeira

    2009-09-08

    A new and simple electroanalytical method for speciation of Sb(III) and Sb(V) in pharmaceutical formulation by potentiometric stripping analysis (PSA) using a multiwall carbon nanotube paste electrode was developed. All instrumental and chemical parameters influencing the performance of the method were carefully assessed and optimized. Trivalent antimony was determined in acid medium (pH 3.6) under the optimized condition (deposition potential of -0.7 V, deposition time of 180 s, ionic strength of 0.3M and oxidant mercury concentration of 10 mg l(-1)). Total antimony was determined after quantitative reduction of Sb(V) with l-cysteine (1.5%, w/v) and its concentration was calculated from difference between the total antimony and Sb(III). The developed method provided two distinct linear calibration one ranging from 10 up to 50 microg l(-1) and other from 100 up to 800 microg l(-1) with respective correlation coefficient of 0.9978 and 0.9993, presenting a detection limit of 6.2 microg l(-1). Repeatability for the six independent samples expressed in terms of relative standard deviation was found to be 3.01 and 1.39% for 40.0 and 300.0 microg l(-1) antimony concentration, respectively. Results on the effect of foreign substances [Al(III), Mg(II), Fe(III), Cd(II), Zn(II) and meglumine] on analytical signal of antimony showed no interference even using high content of foreign ions in the analyte:interferent ratio up to 1:100. The proposed method was successfully applied for the speciation of Sb(III) and Sb(V) in pharmaceutical formulation and the accuracy was assessed from addition and recovery tests as well as comparing with graphite furnace atomic absorption spectrometry (GF AAS) technique used as reference analytical method.

  8. [Usefulness of screening for prostate cancer with prostate specific antigen (PSA) in the medical checkup ("human dock") at Onomichi Municipal Hospital: clinical significance of the cases diagnosed as prostate cancer].

    Science.gov (United States)

    Oeda, Tadashi; Kusumi, Norihiro; Takamoto, Atsushi

    2010-01-01

    The usefulness of the screening for prostate cancer with prostate specific antigen (PSA) in the medical checkup ("Human Dock") at Onomichi Municipal Hospital was evaluated. From April 1997 to December 2007, serum PSA of 1,234 male (median age: 59) was measured in the medical checkup and each parameter of screening was evaluated. In addition, for the cases with prostate cancer, results of treatment and clinical significance were assessed. PSA was elevated in 82 cases (6.6%), aged 42-87 (median 64), in which PSA varied 3.1-66.5 ng/ml (median 5.4). Trans-rectal biopsy was performed in 35 cases and prostate cancer was detected in 15 (42.9% of biopsied cases and 1.2% of whole group), aged 58-81 (median 70), with PSA value 4.2-66.5 ng/ml (median 10.3). Clinical stage of these cases was cT1cN0M0 in 12 and cT2aN0M0 or more in 3, Gleason score was 3 + 3 in 4 and 3 + 4 or more in 11. Initial treatment was radical prostatectomy in 12, androgen-deprivation therapy in 2 and external beam irradiation in 1. During the follow-up for 8-107 months (median 60), 14 were alive with good control and 1 was alive with relapse. Only one case was "clinically insignificant" cancer (impalpable and localized and tumor volume less than 0.5 ml and Gleason score 3 + 3 or less). Most of the prostate cancers detected in the medical checkup were clinically significant, therefore, PSA screening doesn't result in overtreatment and it is meaningful to perform PSA screening in the medical checkup.

  9. Cervical Cancer PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2014-01-15

    In this 30 second public service announcement, a mother talks about the importance of protecting 11-12 year-old boys and girls with HPV vaccination. (Una madre habla sobre la importancia de proteger a los niños y las niñas de 11 a 12 años con la vacuna contra el VPH.).  Created: 1/15/2014 by National Center for Immunizations and Respiratory Diseases (NCIRD).   Date Released: 1/15/2014.

  10. Hispanic Health PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-05-05

    This 60 second public service announcement is based on the May 2015 CDC Vital Signs report. About one in six people living in the U.S. are Hispanic. The two leading causes of death in this group are heart disease and cancer, accounting for two out of five deaths. Unfortunately, many Hispanics face considerable barriers to getting high quality health care, including language and low income. Learn what can be done to reduce the barriers.  Created: 5/5/2015 by Office of Minority Health & Health Equity (OMHHE).   Date Released: 5/5/2015.

  11. Heart Age PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-09-01

    This 60 second public service announcement is based on the September 2015 CDC Vital Signs report. Your heart age is the age of your heart and blood vessels as a result of your risk factors for heart attack and stroke. If you smoke or have high blood pressure, your heart age will be much higher than your actual age. Learn what you can do to lower your heart age and keep it low.  Created: 9/1/2015 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 9/1/2015.

  12. Childhood Obesity PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-08-06

    This 60 second public service announcement is based on the August 2013 CDC Vital Signs report. The rate of obesity among low-income preschoolers has declined, but one in eight is still obese. This program briefly discusses what can be done.  Created: 8/6/2013 by Centers for Disease Control and Prevention (CDC).   Date Released: 8/6/2013.

  13. HPV Vaccine PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2014-01-15

    In this 30 second public service announcement, a mother talks about the importance of protecting 11-12 year-old boys and girls with HPV vaccination. (Una madre habla sobre la importancia de proteger a los niños y las niñas de 11 a 12 años con la vacuna contra el VPH.).  Created: 1/15/2014 by National Center for Immunizations and Respiratory Diseases (NCIRD).   Date Released: 1/15/2014.

  14. HIV Testing PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2017-11-28

    This 60 second public service announcement is based on the December 2017 CDC Vital Signs report. In the U.S., about 15 percent of people who have HIV don't know they have it. Learn about the importance of testing, early diagnosis, and treatment.  Created: 11/28/2017 by Centers for Disease Control and Prevention (CDC).   Date Released: 11/28/2017.

  15. Be Brave PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-08-04

    In this 60-second public service announcement, gynecologic cancer survivor, Jenny Allen, urges women to see a doctor if symptoms last two weeks or more.  Created: 8/4/2011 by National Center for Chronic Disease Prevention and Health Promotion.   Date Released: 8/4/2011.

  16. Opioid Prescribing PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2017-07-06

    This 60 second public service announcement is based on the July 2017 CDC Vital Signs report. Higher opioid prescribing puts patients at risk for addiction and overdose. Learn what can be done about this serious problem.  Created: 7/6/2017 by Centers for Disease Control and Prevention (CDC).   Date Released: 7/6/2017.

  17. Heroin Epidemic PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-07-07

    This 60 second public service announcement is based on the July 2015 CDC Vital Signs report. Heroin use and heroin-related overdose deaths are increasing. Most people are using it with other drugs, especially prescription opioid painkillers. Learn what can be done to prevent and treat the problem.  Created: 7/7/2015 by National Center for Injury Prevention and Control (NCIPC).   Date Released: 7/7/2015.

  18. Secondhand Smoke PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-02-03

    This 60 second public service announcement is based on the February 2015 CDC Vital Signs report. Secondhand smoke kills more than 400 infants and 41,000 adult nonsmokers every year. Learn what can be done to prevent secondhand smoke exposure.  Created: 2/3/2015 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 2/3/2015.

  19. Wound Infections PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2017-10-25

    This 30 second public service announcement is about how to avoid a wound infection after a disaster.  Created: 10/25/2017 by Centers for Disease Control and Prevention (CDC).   Date Released: 10/25/2017.

  20. Trucker Safety PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-03-03

    This 60 second public service announcement is based on the March 2015 CDC Vital Signs report. In 2012 in the United States, about 317,000 motor vehicle crashes involved a large truck. Twenty-six thousand truck drivers and their passengers were injured in these crashes, and about 700 died. Learn what can be done to help truck drivers stay safe.  Created: 3/3/2015 by National Institute for Occupational Safety and Health (NIOSH).   Date Released: 3/3/2015.

  1. Preventing Melanoma PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-06-02

    This 60 second public service announcement is based on the June 2015 CDC Vital Signs report. Skin cancer is the most common form of cancer in the U.S. In 2011, there were more than 65,000 cases of melanoma, the most deadly form of skin cancer. Learn how everyone can help prevent skin cancer.  Created: 6/2/2015 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 6/2/2015.

  2. Diarrheal Diseases PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2017-10-25

    This 30 second public service announcement is about the risk of diarrheal diseases after a disaster.  Created: 10/25/2017 by Centers for Disease Control and Prevention (CDC).   Date Released: 10/25/2017.

  3. [Results of a series of transrectal ultrasound guided biopsy of the prostate in 6000 patients. Part I: pathology, digital rectal examination, transrectal ultrasound, and PSA].

    Science.gov (United States)

    Rodríguez-Patrón Rodríguez, Rafael; Mayayo Dehesa, Teodoro; Alonso González, Mónica; Burgos Revilla, Francisco Javier; Lennie Zucharino, Alberto

    2005-09-01

    To analyze the results of transrectal ultrasound (TRUS) guided biopsy of the prostate in 6000 patients, and their relation to common-use clinical parameters. We collected PSA, digital rectal examination, TRUS characteristics, and pathology report in a data- base including 6000 patients who underwent sextant TRUS biopsy from 1994 to December 2002. 861 of them underwent more than one biopsy, accounting for a total of 7127 biopsies. Sextant biopsy with samples from the most lateral portions of the prostate was the standard procedure so that they included peripheral zone only. We analyze pathological results and their relation with clinical variables. Total percentage of cancer in biopsy samples was 42.6%, with 39.1% in the first biopsy. Overall, repeated biopsies resulted in a 3.5% diagnostic yield increase. PIN or focal glandular atypia were detected in 2.0% and 2.1% of the cases respectively. The percentage of patients with Gleason score =first biopsy to 70% in the third. Similarly, single core involvement increased from 21.% to 65%. Digital rectal examination and presence of hypoechogenic nodules specificity were 82.6 and 78.2% respectively. The incidence of prostate cancer with PSA between 4 and 10 ng/ml was 29.6%, 16.7% in those with PSA lower than 4 ng/ml. TRUS biopsy of the lateral prostatic areas offers a good diagnostic yield in comparison with most series of extensive biopsies. The sensitivity of TRUS has decreased but it maintains a high specificity which should not be forgotten when planning the TRUS strategy

  4. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.

    Science.gov (United States)

    Yli-Hemminki, Tytti H; Laurila, Marita; Auvinen, Anssi; Määttänen, Liisa; Huhtala, Heini; Tammela, Teuvo L J; Kujala, Paula M

    2013-10-01

    To assess whether histological signs of inflammation are associated with an increased risk of subsequent prostate cancer (PCa) in men with elevated serum prostate-specific antigen (PSA) concentrations and benign initial biopsy. Study subjects were men aged 54-67 years with an elevated PSA (≥4 ng/mL or 3-4 ng/mL and free to total PSA ratio ≤0.16 or positive digital rectal examination), but a benign biopsy result within the Finnish population-based randomised screening trial for PCa, which started in 1996. A total of 293 prostate biopsies without PCa or suspicion of malignancy from the first screening round in the Tampere centre were re-evaluated by a uropathologist to assess histological inflammation. Results of the subsequent screening rounds were obtained from the trial database and PCa diagnoses made outside the screening were obtained from the Finnish Cancer Registry. The median length of follow-up was 10.5 years. Cox regression analysis was used to assess PCa risk after the initial benign biopsy. Histological inflammation was found in 66% of the biopsies. Subjects with inflammation at the biopsy had a slightly lower PCa risk in the second screening round (18 vs 27%, rate ratio 0.69, 95% confidence interval [CI] 0.35-1.34) relative to men without inflammation. In further follow-up, the PCa risk remained nonsignificantly lower (hazard ratio [HR] 0.71, CI 0.46-1.10; P = 0.13). The risk was not appreciably affected by adjustment for age, PSA, prostate volume and family history of PCa (HR 0.67, CI 0.42-1.07; P = 0.092). Histological inflammation in a prostate biopsy among men with an initial false-positive screening test was not associated with an increased risk of subsequent PCa, but instead with a decreased risk which was of borderline significance. Inflammation in prostate biopsy is not a useful risk indicator in PCa screening. © 2013 BJU International.

  5. PSA e medidas antropométricas em índios da Amazônia: avaliação da comunidade Parkatejê PSA and anthropometric measurements among Amazon Indians: an evaluation of the Parkatejê community

    Directory of Open Access Journals (Sweden)

    Homero Oliveira de Arruda

    2003-10-01

    Full Text Available OBJETIVO: O rastreamento com o PSA (antígeno prostático específico para detecção precoce de câncer de próstata em uma comunidade nativa tem grande importância epidemiológica. Assim, realizou-se estudo com objetivo de verificar a ocorrência do câncer da próstata em uma tribo indígena da Amazônia e uma possível relação entre o aculturamento, a presença de sobrepeso (índice de massa corporal e o aparecimento da doença. MÉTODOS: Foi realizado um levantamento dos hábitos e medidas antropométricas em 22 homens com idade presumida maior de 50 anos, de uma tribo isolada de 363 índios, autodenominados Parkatejê e Kikatêjê, vivendo na região Amazônica (Pará. Além dos exames físico e hematológicos, foram realizadas dosagens de PSA total e PSA livre. RESULTADO: Os níveis séricos de PSA total variaram de 0,35 a 25,8 ng/ml. Três nativos apresentaram PSA maior que 4,0 ng/ml e outros dois evidenciaram PSA entre 2,5 e 4,0 ng/ml. Biopsia prostática em dois nativos revelou a presença de adenocarcinoma de próstata em um e neoplasia intraepitelial em outro. Sobrepeso com índice de massa corporal >25 Kg/m² e relação cintura-quadril >0,9 foram observados em 68,1% e 72,7% do grupo estudado. CONCLUSÕES: Mudanças nutricionais decorrentes do contato com a civilização, como substituição da caça e fibras vegetais por alimentos mais calóricos, estão aumentando a freqüência de sobrepeso na comunidade indígena. Devido à associação entre incidência de câncer de próstata, dieta gordurosa e menor atividade física, pode-se presumir que o futuro testemunhará mais casos da neoplasia prostática, visto que vários de seus membros já evidenciaram altos níveis séricos de PSA.OBJECTIVE: PSA (prostate-specific antigen screening for early detection of prostate cancer in a native community is of great epidemiological importance. The study was conducted with the objective of verifying the occurrence of prostate cancer among

  6. Identification of Streptococcus pneumoniae lytA, plyA and psaA genes in pleural fluid by multiplex real-time PCR.

    Science.gov (United States)

    Sanz, Juan Carlos; Ríos, Esther; Rodríguez-Avial, Iciar; Ramos, Belén; Marín, Mercedes; Cercenado, Emilia

    2017-08-14

    The aim was to evaluate the utility of a multiplex real-time PCR to detect Streptococcus pneumoniae lytA, plyA and psaA genes in pleural fluid (PF). A collection of 81 PF samples was used. Sixty were considered positive for S. pneumoniae according to previous results (54 by an in-house lytA gene PCR and eight by universal rRNA PCR). The sensitivity for detection of the lytA, plyA and psaA genes by multiplex PCR was 100% (60/60), 98.3% (59/60) and 91.7% (55/60), respectively. The detection of all three genes was negative in 21 samples formerly confirmed as negative for S. pneumoniae (100% specificity) by the other procedures (9 by in-house lytA PCR and 12 by rRNA PCR). The use of this multiplex PCR may be a useful option to identify S. pneumoniae directly in PF samples. Copyright © 2017 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

  7. Improvement in the Ppy/V{sub 2}O{sub 5} hybrid as a cathode material for Li ion batteries using PSA as an organic additive

    Energy Technology Data Exchange (ETDEWEB)

    Boyano, I.; Bengoechea, M.; de Meatza, I.; Miguel, O.; Ochoteco, E.; Rodriguez, J. [CIDETEC, Energy Department, Paseo Miramon 196, Parque Tecnologico de San Sebastian, 20009 Donostia-San Sebastian (Spain); Cantero, I. [CEGASA, C/Artapadura, 11, 01013 Vitoria-Gasteiz (Spain); Lira-Cantu, M.; Gomez-Romero, P. [Instituto de Ciencia de Materiales de Barcelona (CSIC), Campus UAB, 08193 Bellaterra, Barcelona (Spain)

    2007-04-15

    With the aim of improving the electrochemical properties of this candidate cathodic material for lithium ion batteries, a vanadium oxide (V{sub 2}O{sub 5}) and polypyrrole (Ppy) hybrid was prepared using pyridinesulfonic acid (PSA) as additive. The hybrid synthesis has been carried out in the literature by chemical polymerization of pyrrole in the host inorganic matrix, using the V{sub 2}O{sub 5} dispersed in an acidic solution as an oxidizing agent. In this work the hybrid has been synthesised with PSA giving good results compared to other samples of the pristine V{sub 2}O{sub 5} and to the Ppy/V{sub 2}O{sub 5} hybrid without additive. An improvement of about 20% in the charge storage capacity has been achieved. The reasons for this improvement are discussed and analyzed using different experimental techniques. The hybrid material has the added advantage of an improved performance without the addition of any binder or conducting element as a cathode in a lithium ion battery. (author)

  8. Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia.

    Science.gov (United States)

    Leidinger, Petra; Keller, Andreas; Milchram, Lisa; Harz, Christian; Hart, Martin; Werth, Angelika; Lenhof, Hans-Peter; Weinhäusel, Andreas; Keck, Bastian; Wullich, Bernd; Ludwig, Nicole; Meese, Eckart

    2015-01-01

    Although an increased level of the prostate-specific antigen can be an indication for prostate cancer, other reasons often lead to a high rate of false positive results. Therefore, an additional serological screening of autoantibodies in patients' sera could improve the detection of prostate cancer. We performed protein macroarray screening with sera from 49 prostate cancer patients, 70 patients with benign prostatic hyperplasia and 28 healthy controls and compared the autoimmune response in those groups. We were able to distinguish prostate cancer patients from normal controls with an accuracy of 83.2%, patients with benign prostatic hyperplasia from normal controls with an accuracy of 86.0% and prostate cancer patients from patients with benign prostatic hyperplasia with an accuracy of 70.3%. Combining seroreactivity pattern with a PSA level of higher than 4.0 ng/ml this classification could be improved to an accuracy of 84.1%. For selected proteins we were able to confirm the differential expression by using luminex on 84 samples. We provide a minimally invasive serological method to reduce false positive results in detection of prostate cancer and according to PSA screening to distinguish men with prostate cancer from men with benign prostatic hyperplasia.

  9. Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia.

    Directory of Open Access Journals (Sweden)

    Petra Leidinger

    Full Text Available Although an increased level of the prostate-specific antigen can be an indication for prostate cancer, other reasons often lead to a high rate of false positive results. Therefore, an additional serological screening of autoantibodies in patients' sera could improve the detection of prostate cancer. We performed protein macroarray screening with sera from 49 prostate cancer patients, 70 patients with benign prostatic hyperplasia and 28 healthy controls and compared the autoimmune response in those groups. We were able to distinguish prostate cancer patients from normal controls with an accuracy of 83.2%, patients with benign prostatic hyperplasia from normal controls with an accuracy of 86.0% and prostate cancer patients from patients with benign prostatic hyperplasia with an accuracy of 70.3%. Combining seroreactivity pattern with a PSA level of higher than 4.0 ng/ml this classification could be improved to an accuracy of 84.1%. For selected proteins we were able to confirm the differential expression by using luminex on 84 samples. We provide a minimally invasive serological method to reduce false positive results in detection of prostate cancer and according to PSA screening to distinguish men with prostate cancer from men with benign prostatic hyperplasia.

  10. Evaluation of the Impact That PARs Have on the Hydrogen Risk in the Reactor Containment: Methodology and Application to PSA Level 2

    Directory of Open Access Journals (Sweden)

    Ahmed Bentaib

    2010-01-01

    Full Text Available This paper presents a methodology and its application to a Level 2 Probabilistic Safety Assessment (PSA-2, to evaluate the impact of the Passive Autocatalytic Recombiners (PARs on the hydrogen risk in the reactor containment in case of a severe accident. Among the whole set of accidental scenarios calculated in the framework of the PSA-2, nine have been selected as representative in terms of the in-vessel hydrogen production rate and in-vessel total produced hydrogen mass. Five complementary scenarios have been added as representative of the core reflooding situations. For this set of selected scenarios the evolution of the conditions in the containment (i.e., pressure, temperature, and composition during the in-vessel phase of the accident has been evaluated by means of a lumped parameter approach. The use of spray systems in the containment has also been considered as well as the presence of recombiners. Moreover, the ignition by recombiners of the flammable atmosphere has been considered.

  11. Utility of RhoC and ZAG protein expression as biomarkers for prediction of PSA failure following radical prostatectomy for high grade prostate cancer.

    Science.gov (United States)

    Mills, John; Oliver, Alice; Sherwin, Justin C; Frydenberg, Mark; Peters, Justin S; Costello, Anthony; Harewood, Laurence; Love, Christopher; Redgrave, Nicholas; van Golen, Kenneth L; Bailey, Michael; Pedersen, John

    2012-10-01

    To assess the prognostic utility of semi-quantiative expression of RhoC protein in whole prostates from patients who had radical prostatectomies for high grade prostate cancer (PCa). Subjects who had surgery >55 months previously with primary Gleason pattern 4 PCa were identified from practice records, archival tissues were retrieved for review and RhoC immunohistochemistry, and ZAG expression was also assessed as a control. Eighty-nine subjects were included in the study; 57 had a rising prostate specific antigen (PSA) post-operatively ('cases') and 32 did not ('controls'). By univariate analysis, expression of both RhoC and ZAG proteins was greater in controls than cases, but this was significant only for ZAG. By multivariate analysis, Gleason variables (patterns and score), extraprostatic extension and decreased RhoC staining all contributed to predicting PSA failure (p ZAG expression was inversely correlated with Gleason pattern and hence was not independently predictive in our multivariate model. Increased RhoC expression predicted a good outcome after radical prostatectomy. ZAG staining also correlated with a favourable outcome but was not independently predictive due to its relationship with Gleason pattern.

  12. The effect of high level natural ionizing radiation on expression of PSA, CA19-9 and CEA tumor markers in blood serum of inhabitants of Ramsar, Iran.

    Science.gov (United States)

    Heidari, Mohammad Hassan; Porghasem, Mohsen; Mirzaei, Nazanin; Mohseni, Jafar Hesam; Heidari, Matine; Azargashb, Eznollah; Movafagh, Abolfazl; Heidari, Reihane; Molouki, Aidin; Larijani, Leila

    2014-02-01

    Since several high level natural radiation areas (HLNRAs) exist on our planet, considerable attention has been drawn to health issues that may develop as the result of visiting or living in such places. City of Ramsar in Iran is an HNLRA, and is a tourist attraction mainly due to its hot spas. However, the growing awareness over its natural radiation sources has prompted widespread scientific investigation at national level. In this study, using an ELISA method, the level of expression of three tumor markers known as carcinoembryonic antigen (CEA), prostate-specific antigen (PSA) and carcino antigen 19-9 (CA19-9) in blood serum of 40 local men of Ramsar (subject group) was investigated and compared to 40 men from the city of Noshahr (control group). Noshahr was previously identified as a normal level natural radiation area (NLNRA) that is some 85 km far from Ramsar. According to statistical analysis, there was a significant difference in the levels of PSA and CA19-9 markers between the two groups (p Ramsar being considerably higher. CEA level did not show any difference. Although some of the volunteers tested positive to the markers, they were in good health as confirmed by the physician. Moreover, the high number of positive markers in Noshahr was considerable. Therefore, future study is needed to further validate this result and to determine the level of positivity to tumor markers in both cities. Copyright © 2013 Elsevier Ltd. All rights reserved.

  13. Presence of a [3Fe-4S] cluster in a PsaC variant as a functional component of the photosystem I electron transfer chain in Synechococcus sp. PCC 7002.

    Science.gov (United States)

    Pérez, Adam A; Ferlez, Bryan H; Applegate, Amanda M; Walters, Karim; He, Zhihui; Shen, Gaozhong; Golbeck, John H; Bryant, Donald A

    2017-09-15

    A site-directed C14G mutation was introduced into the stromal PsaC subunit of Synechococcus sp. strain PCC 7002 in vivo in order to introduce an exchangeable coordination site into the terminal FB [4Fe-4S] cluster of Photosystem I (PSI). Using an engineered PSI-less strain (psaAB deletion), psaC was deleted and replaced with recombinant versions controlled by a strong promoter, and the psaAB deletion was complemented. Modified PSI accumulated at lower levels in this strain and supported slower photoautotrophic growth than wild type. As-isolated PSI complexes containing PsaCC14G showed resonances with g values of 2.038 and 2.007 characteristic of a [3Fe-4S]1+ cluster. When the PSI complexes were illuminated at 15 K, these resonances partially disappeared and two new sets of resonances appeared. The majority set had g values of 2.05, 1.95, and 1.85, characteristic of FA-, and the minority set had g values of 2.11, 1.90, and 1.88 from FB' in the modified site. The S = 1/2 spin state of the latter implied the presence of a thiolate as the terminal ligand. The [3Fe-4S] clusters could be partially reconstituted with iron, producing a larger population of [4Fe-4S] clusters. Rates of flavodoxin reduction were identical in PSI complexes isolated from wild type and the PsaCC14G variant strain; this implied equivalent capacity for forward electron transfer in PSI complexes that contained [3Fe-4S] and [4Fe-4S] clusters. The development of this cyanobacterial strain is a first step toward translation of in vitro PSI-based biosolar molecular wire systems in vivo and provides new insights into the formation of Fe/S clusters.

  14. Principios para un sistema de pago por servicio ambiental (PSA) en la cuenca alta del Río Sauce grande (provincia de Buenos Aires, Argentina) para mitigar problemas ambientales

    OpenAIRE

    Denegri, Gerardo; Gaspari, Fernanda Julia; Delgado, María Isabel; Rodríguez Vagaría, Alfonso M.; Senisterra, Gabriela Elba

    2012-01-01

    La cuenca hidrográfica, analizada como un sistema, proporciona servicios valiosos para la población, resultantes del correcto uso de suelo. El Pago por Servicios Ambientales (PSA) es un mecanismo de compensación directo por medio del cual los proveedores de un servicio ambiental reciben un pago por parte de los usuarios. Como hipótesis se plantea que existen condiciones socio-económicas que permiten aplicar un PSA en la cuenca. El objetivo del trabajo es presentar un diagnóstico integral de l...

  15. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.

    Science.gov (United States)

    Eminaga, Okyaz; Hinkelammert, Reemt; Titze, Ulf; Abbas, Mahmoud; Eltze, Elke; Bettendorf, Olaf; Semjonow, Axel

    2014-01-01

    We investigated whether patients with organ-confined prostate cancer (PCa) and positive surgical margins (SMs) had a similar biochemical recurrence (BCR) risk compared with patients with pT3a and preoperative prostate-specific antigen (PSA) levels ≤ 10ng/ml. Furthermore, we examined the effects of incorporating SM status, Gleason score (Gls), and preoperative PSA level into the discrimination accuracy of the current tumor node metastasis-staging system. We analyzed 863 PCa patients treated with radical prostatectomy from 1999 to 2008. Only individuals with pT2N0 or pT3N0, without neoadjuvant or adjuvant therapy, were included. We performed chi-square automatic interaction detection analysis to generate a classification model for predicting BCR by analyzing interactions between age at surgery, SM status, Gls, PSA, and tumor stage, tumor volume and relative tumor volume. Cox regression analyses tested the relationship between SM status and BCR rate after stratification according to T-stage and the novel classification. The predictive and discrimination accuracy of the current T-stage and of the classification model was quantified with time-dependent receiver operating characteristics and integrated discrimination improvement. The topographical association between extracapsular extension of PCa and positive SM was analyzed in patients with pT3aR1 using a computational reconstruction diagram of the prostate. The chi-square automatic interaction detection analysis found interactions among pT Stage, SM status, PSA and Gls and generated a classification model for BCR prediction: pT2R0, pT2R1, pT3a PSA ≤ 10 ng/ml, pT3a PSA>10 ng/ml and pT3b. Men with pT2R1 had a shorter time to BCR compared with men with pT3a-PSA ≤ 10 ng/ml (PpT2R1/pT3a-PSA>10 ng/ml>pT2R1/pT3a PSA ≤ 10 ng/ml>pT2R0 (Pextension and positive SM was found in patients with pT3aR1 (P = 0.01). Patients with pT2R1 develop a similar BCR risk to that of patients with pT3a PSA ≤ 10 ng/ml. Gls≥7b is

  16. Ultrasensitive amperometric immunosensor for PSA detection based on Cu2O@CeO2-Au nanocomposites as integrated triple signal amplification strategy.

    Science.gov (United States)

    Li, Faying; Li, Yueyun; Feng, Jinhui; Dong, Yunhui; Wang, Ping; Chen, Lei; Chen, Zhiwei; Liu, Hui; Wei, Qin

    2017-01-15

    In this work, a novel label-free electrochemical immunosensor was developed for the quantitative detection of prostate specific antigen (PSA). To this end, the amino functionalized cuprous oxide @ ceric dioxide (Cu2O@CeO2-NH2) core-shell nanocomposites were prepared to bond gold nanoparticles (Au NPs) by constructing stable Au-N bond between Au NPs and -NH2. Because the synergetic effect presents in Cu2O@CeO2 core-shell loaded with Au NPs (Cu2O@CeO2-Au), it shows better electrocatalytic activity towards the reduction of hydrogen peroxide (H2O2) than single Cu2O, Au NPs and Cu2O@CeO2. Featured by large specific surface area, good biocompatibility and good electrochemical properties which can greatly improve the electronic transmission rate, Cu2O@CeO2-Au was used as transducing materials to achieve efficiently capture antibodies and triple signal amplification of the proposed immunosensor. Under the optimal conditions, the proposed immunosensor exhibited a wide linear range from 0.1pg/mL to 100ng/mL with a low detection limit of 0.03pg/mL (S/N=3). Furthermore, the proposed label-free immunosensor has been used to determine PSA in human serum with satisfactory results. Meanwhile, it displayed good reproducibility, acceptable selectivity, and long-term stability, which had promising application in bioassay analysis. Copyright © 2016 Elsevier B.V. All rights reserved.

  17. Doctors' perspectives on PSA testing illuminate established differences in prostate cancer screening rates between Australia and the UK: a qualitative study.

    Science.gov (United States)

    Pickles, Kristen; Carter, Stacy M; Rychetnik, Lucie; Entwistle, Vikki A

    2016-12-05

    To examine how general practitioners (GPs) in the UK and GPs in Australia explain their prostate-specific antigen (PSA) testing practices and to illuminate how these explanations are similar and how they are different. A grounded theory study. Primary care practices in Australia and the UK. 69 GPs in Australia (n=40) and the UK (n=29). We included GPs of varying ages, sex, clinical experience and patient populations. All GPs interested in participating in the study were included. GPs' accounts revealed fundamental differences in whether and how prostate cancer screening occurred in their practice and in the broader context within which they operate. The history of prostate screening policy, organisational structures and funding models appeared to drive more prostate screening in Australia and less in the UK. In Australia, screening processes and decisions were mostly at the discretion of individual clinicians, and varied considerably, whereas the accounts of UK GPs clearly reflected a consistent, organisationally embedded approach based on local evidence-based recommendations to discourage screening. The GP accounts suggested that healthcare systems, including historical and current organisational and funding structures and rules, collectively contribute to how and why clinicians use the PSA test and play a significant role in creating the mindlines that GPs employ in their clinic. Australia's recently released consensus guidelines may support more streamlined and consistent care. However, if GP mindlines and thus routine practice in Australia are to shift, to ultimately reduce unnecessary or harmful prostate screening, it is likely that other important drivers at all levels of the screening process will need to be addressed. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

  18. Human kallikrein 2 (hK2), but not prostate-specific antigen (PSA), rapidly complexes with protease inhibitor 6 (PI-6) released from prostate carcinoma cells.

    Science.gov (United States)

    Saedi, M S; Zhu, Z; Marker, K; Liu, R S; Carpenter, P M; Rittenhouse, H; Mikolajczyk, S D

    2001-11-01

    Human kallikrein 2 (hK2) is a secreted, trypsin-like protease that shares 80% amino acid sequence identity with prostate-specific antigen (PSA). hK2 has been shown to be a serum marker for prostate cancer and may also play a role in cancer progression and metastasis. We have previously identified a novel complex between human kallikrein 2 (hK2) and protease inhibitor 6 (PI-6) in prostate cancer tissue. PI-6 is an intracellular serine protease inhibitor with both antitrypsin and antichymotrypsin activity. In the current study we have shown that PI-6 forms a rapid in vitro complex with hK2 but does not complex with PSA. Recombinant mammalian cells expressing both hK2 and PI-6 showed hK2-PI-6 complex in the spent media only after cell death and lysis. Similarly, LNCaP cells expressing endogenous hK2 and PI-6 showed extracellular hK2-PI-6 complex formation concurrently with cell death. Immunostaining of prostate cancer tissues with PI-6 monoclonal antibodies showed a marked preferential staining pattern in cancerous epithelial cells compared with noncancerous tissue. These results indicate that the hK2-PI-6 complex may be a naturally occurring marker of tissue damage and necrosis associated with neoplasia. Both hK2 and PI-6 were shed into the lumen of prostate cancer glands as granular material that appeared to be cellular necrotic debris. The differential staining pattern of PI6 in tissues suggests a complex regulation of PI-6 expression that may play a role in other aspects of neoplastic progression. Copyright 2001 Wiley-Liss, Inc.

  19. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA

    Directory of Open Access Journals (Sweden)

    Ilka Kristiansen

    2017-05-01

    Full Text Available Aims: Determining the origin of metastases is an important task of pathologists to allow for the initiation of a tumor-specific therapy. Recently, homeobox protein Hox-B13 (HOXB13 has been suggested as a new marker for the detection of prostatic origin. The aim of this study was to evaluate the diagnostic sensitivity of HOXB13 in comparison to commonly used immunohistochemical markers for prostate cancer. Materials and methods: Histologically confirmed prostate cancer lymph node metastases from 64 cases were used to test the diagnostic value of immunohistochemical markers: prostate specific antigen (PSA, Prostatic acid phosphatase (PSAP, prostate specific membrane antigen (PSMA, homeobox gene NKX3.1, prostein, androgen receptor (AR, HOXB13, and ETS-related gene (ERG. All markers were evaluated semi-quantitatively using Remmele's immune reactive score. Results: The detection rate of prostate origin of metastasis for single markers was 100% for NKX3.1, 98.1% for AR, 84.3% for PSMA, 80.8% for PSA, 66% for PSAP, 60.4% for HOXB13, 59.6% for prostein, and 50.0% for ERG. Conclusions: Our data suggest that HOXB13 on its own lacks sensitivity for the detection of prostatic origin. Therefore, this marker should be only used in conjunction with other markers, preferably the highly specific PSA. The combination of PSA with NKX3.1 shows a higher sensitivity and thus appears preferable in this setting.

  20. State of the art on the probabilistic safety assessment (P.S.A.); Etat de l'art sur les etudes probabilistes de surete (E.P.S.)

    Energy Technology Data Exchange (ETDEWEB)

    Devictor, N.; Bassi, A.; Saignes, P.; Bertrand, F

    2008-07-01

    The use of Probabilistic Safety Assessment (PSA) is internationally increasing as a means of assessing and improving the safety of nuclear and non-nuclear facilities. To support the development of a competence on Probabilistic Safety Assessment, a set of states of the art regarding these tools and their use has been made between 2001 and 2005, in particular on the following topics: - Definition of the PSA of level 1, 2 and 3; - Use of PSA in support to design and operation of nuclear plants (risk-informed applications); - Applications to Non Reactor Nuclear Facilities. The report compiled in a single document these states of the art in order to ensure a broader use; this work has been done in the frame of the Project 'Reliability and Safety of Nuclear Facility' of the Nuclear Development and Innovation Division of the Nuclear Energy Division. As some of these states of the art have been made in support to exchanges with international partners and were written in English, a section of this document is written in English. This work is now applied concretely in support to the design of 4. Generation nuclear systems as Sodium-cooled Fast Reactors and especially Gas-cooled Fast Reactor, that have been the subject of communications during the conferences ANS (Annual Meeting 2007), PSA'08, ICCAP'08 and in the journal Science and Technology of Nuclear Installations. (authors)

  1. A cluster-randomised, parallel group, controlled intervention study of genetic prostate cancer risk assessment and use of PSA tests in general practice--the ProCaRis study

    DEFF Research Database (Denmark)

    Kirkegaard, Pia; Vedsted, Peter; Edwards, Adrian

    2013-01-01

    PSA-testen er det bedste og mest anvendte værktøj til at opspore prostatacancer. Testen er dog behæftet med fejlkilder, som kan føre til overflødig udredning, diagnosticering og behandling. Ved udredning tages biopsier med risiko for behandlingskrævende infektion. Behandlingen for prostatacancer...... fører ofte til vandladningsproblemer og impotens, og den har ikke vist sig specielt effektiv i behandling af den aggressive prostatacancer. Risikoen for overdiagnostik og overbehandling betyder, at PSA-testen ikke anvendes til generel screening for prostatakræft. Alligevel får mange patienter taget en...... PSA-test - ofte flere gange - måske fordi de ser sig selv som værende i særlig risiko. I ProCaRis-studiet får udvalgte praksis i Region Midtjylland mulighed for at tilbyde en genetisk risikovurdering for prostatakræft til patienter, som skal have en PSA-test. Den genetiske risikovurdering kan afgøre...

  2. PERFORMANCE AND DURABILITY OF THE PSA PEUGEOT CITROEN'S DPF SYSTEM ON A TAXI FLEET IN THE PARIS AREA

    Energy Technology Data Exchange (ETDEWEB)

    COROLLER, P; PLASSAT, G

    2003-08-24

    The use of Diesel engines has strongly increased during the last years and now represents 40% of the sales in Europe and up to 50% of the number of cars in circulation for some countries. This success is linked not only to the economical aspect of the use of such vehicles, but also to the recent technological improvements of these engines. The new technical solutions (high pressure direct injection, turbocharger) have indeed allowed the increase of these engine performances while decreasing their fuel consumption, pollutant emissions and noise level. From an environment point of view, Diesel engines are nevertheless penalized by their particulates and NOx emissions. The study and the treatment of the particulate, highly criticized for their potential impact on health, are the subject of numerous works of characterizations and developments. PSA Peugeot Citroen has recently (2000) launched its particulate filter technology on several types of vehicles (500,000 vehicles with DPF have been sold today). In order to evaluate the durability of this technology over a long period of time, a study program has been set-up by ADEME (French Environmental Agency), IFP Powertrain, PSA Peugeot Citroen and Taxis G7 (a Parisian taxis Company). The objective is to study the evolution of five taxis and their after-treatment system performances over 80,000km mileage--which corresponds to the recommended mileage before the first DPF maintenance--in hard urban driving conditions, as well over 120,000km, after the DPF maintenance and remanufacturing. More specifically, the following evaluations are being performed at regular intervals (around 20,000km): regulated gaseous pollutant emissions on NEDC cycle, particulate emissions and unregulated pollutant emissions. The results obtained until now have not shown any degradation of the particulate filter efficiency (more than 90%). This paper presents the methodology set-up, and the explanation of the first results obtained. Indeed, a more

  3. Integration of the functional reliability of two passive safety systems to mitigate a SBLOCA+BO in a CAREM-like reactor PSA

    Energy Technology Data Exchange (ETDEWEB)

    Mezio, Federico, E-mail: federico.mezio@cab.cnea.gov.ar [CNEA, Sede Central, Av. Del Libertador 8250, CABA (Argentina); Grinberg, Mariela [CNEA, Centro Atómico Bariloche, S.C. de Bariloche, Río Negro (Argentina); Lorenzo, Gabriel [CNEA, Sede Central, Av. Del Libertador 8250, CABA (Argentina); Giménez, Marcelo [CNEA, Centro Atómico Bariloche, S.C. de Bariloche, Río Negro (Argentina)

    2014-04-01

    Highlights: • An estimation of the Functional Unreliability was performed using RMPS methodology. • The methodology uses an improved response surface in order to estimate the FU. • The FU may become relevant to be analyzed in the Passive Safety Systems. • There were proposed two ways to incorporate the FU into an APS. - Abstract: This paper describes a case study of a methodological approach for assessing the functional reliability of passive safety systems (PSS) and its treatment within a probabilistic safety assessment (PSA). The functional unreliability (FU) can be understood as the failure probability of PSS to fulfill its mission due to the impairment of the related passive safety function. The safety function accomplishment is characterized and quantified by a performance indicator (PI), which is a measure of how far the system is from verifying its mission. PI uncertainties are estimated from uncertainty propagation of selected parameters. A methodology based on the reliability methodology for passive system (RMPS) one is used to estimate the FU associated to the isolation condensers (ICs) in combination with the accumulators (medium pressure injection system) of a CAREM-like integral advanced reactor. A small break loss of coolant accident with black-out is selected as an evaluation case. This implies success of reactor shut-down (inherent) and failure of residual heat removal by active systems. The safety function to accomplish is to refill the reactor pressure vessel (RPV) in order to avoid core damage. For this case, to allow the discharge of accumulators into RPV, the pressure must be reduced by the IC. The methodology for passive safety function assessment considers uncertainties in code parameters, besides uncertainties in engineering parameters (design, construction, operation and maintenance), in order to perform Monte Carlo simulations based on best estimate (B-E) plant model. Then, response surfaces based on PI are used for improving the

  4. {sup 68}Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour

    Energy Technology Data Exchange (ETDEWEB)

    Uprimny, Christian; Kroiss, Alexander Stephan; Decristoforo, Clemens; Guggenberg, Elisabeth von; Kendler, Dorota; Scarpa, Lorenza; Di Santo, Gianpaolo; Roig, Llanos Geraldo; Maffey-Steffan, Johanna; Virgolini, Irene Johanna [Medical University Innsbruck, Department of Nuclear Medicine, Innsbruck (Austria); Fritz, Josef [Medical University Innsbruck, Department of Medical Statistics, Informatics and Health Economics, Innsbruck (Austria); Horninger, Wolfgang [Medical University Innsbruck, Department of Urology, Innsbruck (Austria)

    2017-06-15

    Prostate cancer (PC) cells typically show increased expression of prostate-specific membrane antigen (PSMA), which can be visualized by {sup 68}Ga-PSMA-11 PET/CT. The aim of this study was to assess the intensity of {sup 68}Ga-PSMA-11 uptake in the primary tumour and metastases in patients with biopsy-proven PC prior to therapy, and to determine whether a correlation exists between the primary tumour-related {sup 68}Ga-PSMA-11 accumulation and the Gleason score (GS) or prostate-specific antigen (PSA) level. Ninety patients with transrectal ultrasound biopsy-proven PC (GS 6-10; median PSA: 9.7 ng/ml) referred for {sup 68}Ga-PSMA-11 PET/CT were retrospectively analysed. PET images were analysed visually and semiquantitatively by measuring the maximum standardized uptake value (SUV{sub max}). The SUV{sub max} of the primary tumour and pathologic lesions suspicious for lymphatic or distant metastases were then compared to the physiologic background activity of normal prostate tissue and gluteal muscle. The SUV{sub max} of the primary tumour was assessed in relation to both PSA level and GS. Eighty-two patients (91.1%) demonstrated pathologic tracer accumulation in the primary tumour that exceeded physiologic tracer uptake in normal prostate tissue (median SUV{sub max}: 12.5 vs. 3.9). Tumours with GS of 6, 7a (3+4) and 7b (4+3) showed significantly lower {sup 68}Ga-PSMA-11 uptake, with median SUV{sub max} of 5.9, 8.3 and 8.2, respectively, compared to patients with GS >7 (median SUV{sub max}: 21.2; p < 0.001). PC patients with PSA ≥10.0 ng/ml exhibited significantly higher uptake than those with PSA levels <10.0 ng/ml (median SUV{sub max}: 17.6 versus 7.7; p < 0.001). In 24 patients (26.7%), 82 lymph nodes with pathologic tracer accumulation consistent with metastases were detected (median SUV{sub max}: 10.6). Eleven patients (12.2%) revealed 55 pathologic osseous lesions suspicious for bone metastases (median SUV{sub max}: 11.6). The GS and PSA level correlated with

  5. Effects of monomers on the properties of palm-oil-based radiation curable pressure sensitive adhesives (PSA) — a prepolymer method

    Science.gov (United States)

    Hilmi Mahmood, Mohd; Abdullah, Zahid; Sakurai, Yasuo; Zaman, Khairul; Mohd. Dahlan, Hj

    2001-01-01

    Various low glass transition temperature ( Tg) acrylate and methacrylate monomers were mixed with epoxidised palm oil acrylate (EPOLA) with the ratio of 50/50 prior to curing with electron beam (EB) irradiation. Methacrylate monomers such as dicyclopentenyloxyethyl methacrylate (DCPOEMA) and isobornyl methacrylate (ISBMA), although displaying relatively high adhesive properties were finally excluded from being further utilised as monomers for PSA because of a very slow curing speed. Literally, it is suggested that poorer adhesive performances of the cured films made from 50/50 : EPOLA/monomer mixture as compared to that of 100% monomer was attributed to the lack of compatibility between EPOLA and the particular monomers. Further compatibility investigations were continued using formulations prepared via the prepolymer route cured by ultraviolet (UV) irradiation and the results showed that several monoacrylate monomers with polar and non-polar groups exhibited high curing speed as well as good compatibility with EPOLA as shown by their cured film properties such as surface tackiness, peel adhesion and creep resistance. It is also suggested that these monomers were acting as surfactants for EPOLA which consequently enhance their compatibility upon mixing.

  6. Conversion to monotherapy with luteinizing-hormone releasing hormone agonist or orchiectomy after reaching PSA nadir following maximal androgen blockade is able to prolong progression-free survival in patients with metastatic prostate cancer: A propensity score matching analysis.

    Science.gov (United States)

    Min, Gyeong Eun; Ahn, Hanjong

    2017-06-01

    The present study evaluated androgen deprivation methods to determine the approach that most improves the progression-free survival (PFS) of patients with metastatic prostate cancer. Patients had received continuous maximal androgen blockade (MAB) or monotherapy [luteinizing-hormone releasing hormone (LHRH) agonist or orchiectomy] following the reaching of the prostate specific antigen (PSA) nadir. The medical records of 293 patients who received MAB following a diagnosis of metastatic prostate cancer were retrospectively reviewed. Following attainment of the PSA nadir and treatment with MAB, patients were maintained on continuous MAB (group CMAB) or converted to monotherapy (group MONO). Disease progression, defined as progression to castration-resistant prostate cancer, was evaluated and compared between the treatment modalities. PFS was compared between patients who received CMAB vs. MONO using 2:1 (102:53) propensity score matching; the basic clinicopathological characteristics (age, Gleason score, PSA and extent of bone metastasis) were similar between the groups. Disease progression was observed in 70.9% of all patients, with a median treatment period of 22.7 months. The median PFS time was 19.5 months in the CMAB group and 28.8 months in the MONO group (P=0.008). Kaplan-Meier analysis demonstrated that PFS was significantly associated with the type of maintenance androgen deprivation therapy (ADT; log rank bone metastasis were independent predictors of prolonged PFS. In this propensity score matched-analysis, conversion to monotherapy with a LHRH agonist or orchiectomy following attainment of the PSA nadir with initial MAB, prolonged the PFS, suggesting that monotherapy maintenance following initial MAB may benefit patients by reducing side effects without decreasing treatment efficacy.

  7. Is there a role for {sup 11}C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

    Energy Technology Data Exchange (ETDEWEB)

    Castellucci, Paolo [University of Bologna, Service of Nuclear Medicine, Department of Haematology-Oncology and Laboratory Medicine, Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant' Orsola-Malpighi, Bologna (Italy); Azienda Ospedaliero-Unversitaria di Bologna Policlinico Sant' Orsola-Malpighi, UO di Medicina Nucleare, PAD. 30, Bologna (Italy); Fuccio, Chiara; Santi, Ivan; Nanni, Cristina; Allegri, Vincenzo; Montini, Gian Carlo; Ambrosini, Valentina; Boschi, Stefano; Fanti, Stefano [University of Bologna, Service of Nuclear Medicine, Department of Haematology-Oncology and Laboratory Medicine, Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant' Orsola-Malpighi, Bologna (Italy); Rubello, Domenico; Marzola, Maria Cristina [Sanata Maria della Misericordia Hospital, Department of Nuclear Medicine, Medical Physics, Radiology, Service of Nuclear Medicine, PET/CT Centre, Rovigo (Italy); Schiavina, Riccardo; Martorana, Giuseppe [University of Bologna, Service of Urology, Department of Specialist Surgery and Anaesthesiology, Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant' Orsola-Malpighi, Bologna (Italy)

    2011-01-15

    The aim of this study was to evaluate the potential usefulness of whole-body {sup 11}C-choline PET/CT in the re-staging of prostate cancer (PC) patients previously treated with radical prostatectomy (RP), who presented a mild increase of prostate-specific antigen (PSA) <1.5 ng/ml (early biochemical relapse) during follow-up (FU). We evaluated 102 consecutive patients (mean age = 68 years, range = 54-82 years) previously treated with RP and who presented during FU a mild increase of trigger PSA serum levels <1.5 ng/ml: mean 0.86 {+-} 0.40 ng/ml (range 0.2-1.5) and median 0.93 ng/ml (range 0.67-1.10). In this patient series {sup 11}C-choline PET/CT was used as the first imaging examination at the time of the detection of a mild serum PSA increase <1.5 ng/ml. {sup 11}C-Choline PET/CT was performed following standard procedures in our centre. At the time of PET/CT, 86 patients were not receiving any pharmacologic treatment, while 16 were under anti-androgenic therapy. Positive PET findings were validated by: (a) transrectal ultrasound (TRUS)-guided biopsy in cases of local recurrence, (b) surgical lymphadenectomy, (c) other imaging procedures or (d) FU lasting for at least 12 months. Univariate and multivariate analyses were used to evaluate the following variables: age, TNM staging, Gleason score, time from RP to the biochemical relapse, anti-androgen therapy at the time of {sup 11}C-choline PET/CT scan, trigger PSA value and PSA kinetics, i.e. PSA doubling time (PSAdt) and PSA velocity (PSAvel), in order to assess the significant predictive factors related to the findings of a positive {sup 11}C-choline PET/CT scan. Overall, {sup 11}C-choline PET/CT showed positive findings in 29 of 102 patients (28% of cases). In detail, {sup 11}C-choline PET/CT detected: local relapse in 7 patients, bone metastases in 13 patients (4 single and 9 multiple) and lymph node metastases in 9 patients (6 single and 3 multiple). Positive PET findings were validated by: (a) TRUS

  8. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

    Science.gov (United States)

    Castellucci, Paolo; Fuccio, Chiara; Rubello, Domenico; Schiavina, Riccardo; Santi, Ivan; Nanni, Cristina; Allegri, Vincenzo; Montini, Gian Carlo; Ambrosini, Valentina; Boschi, Stefano; Martorana, Giuseppe; Marzola, Maria Cristina; Fanti, Stefano

    2011-01-01

    The aim of this study was to evaluate the potential usefulness of whole-body (11)C-choline PET/CT in the re-staging of prostate cancer (PC) patients previously treated with radical prostatectomy (RP), who presented a mild increase of prostate-specific antigen (PSA) <1.5 ng/ml (early biochemical relapse) during follow-up (FU). We evaluated 102 consecutive patients (mean age = 68 years, range = 54-82 years) previously treated with RP and who presented during FU a mild increase of trigger PSA serum levels <1.5 ng/ml: mean 0.86 ± 0.40 ng/ml (range 0.2-1.5) and median 0.93 ng/ml (range 0.67-1.10). In this patient series (11)C-choline PET/CT was used as the first imaging examination at the time of the detection of a mild serum PSA increase <1.5 ng/ml. (11)C-Choline PET/CT was performed following standard procedures in our centre. At the time of PET/CT, 86 patients were not receiving any pharmacologic treatment, while 16 were under anti-androgenic therapy. Positive PET findings were validated by: (a) transrectal ultrasound (TRUS)-guided biopsy in cases of local recurrence, (b) surgical lymphadenectomy, (c) other imaging procedures or (d) FU lasting for at least 12 months. Univariate and multivariate analyses were used to evaluate the following variables: age, TNM staging, Gleason score, time from RP to the biochemical relapse, anti-androgen therapy at the time of (11)C-choline PET/CT scan, trigger PSA value and PSA kinetics, i.e. PSA doubling time (PSAdt) and PSA velocity (PSAvel), in order to assess the significant predictive factors related to the findings of a positive (11)C-choline PET/CT scan. Overall, (11)C-choline PET/CT showed positive findings in 29 of 102 patients (28% of cases). In detail, (11)C-choline PET/CT detected: local relapse in 7 patients, bone metastases in 13 patients (4 single and 9 multiple) and lymph node metastases in 9 patients (6 single and 3 multiple). Positive PET findings were validated by: (a) TRUS-guided biopsy in 7 patients with local

  9. Hydrogen production with CO 2 capture by coupling steam reforming of methane and chemical-looping combustion: Use of an iron-based waste product as oxygen carrier burning a PSA tail gas

    Science.gov (United States)

    Ortiz, María; Gayán, Pilar; de Diego, Luis F.; García-Labiano, Francisco; Abad, Alberto; Pans, Miguel A.; Adánez, Juan

    In this work it is analyzed the performance of an iron waste material as oxygen carrier for a chemical-looping combustion (CLC) system. CLC is a novel combustion technology with the benefit of inherent CO 2 separation that can be used as a source of energy for the methane steam reforming process (SR). The tail gas from the PSA unit is used as fuel in the CLC system. The oxygen carrier behaviour with respect to gas combustion was evaluated in a continuous 500 W th CLC prototype using a simulated PSA off-gas stream as fuel. Methane or syngas as fuel were also studied for comparison purposes. The oxygen carrier showed enough high oxygen transport capacity and reactivity to fully convert syngas at 880 °C. However, lower conversion of the fuel was observed with methane containing fuels. An estimated solids inventory of 1600 kg MW th -1 would be necessary to fully convert the PSA off-gas to CO 2 and H 2O. An important positive effect of the oxygen carrier-to-fuel ratio up to 1.5 and the reactor temperature on the combustion efficiency was found. A characterization of the calcined and after-used particles was carried out showing that this iron-based material can be used as oxygen carrier in a CLC plant since particles maintain their properties (reactivity, no agglomeration, high durability, etc.) after more than 111 h of continuous operation.

  10. Effect of finasteride on serum prostate-specific antigen (PSA and on prostate of hamster Mesocricetus auratus (hMa Efeito da finasterida no antígeno prostático específico (PSA sérico e na próstata do hamster Mesocricetus auratus (hMa

    Directory of Open Access Journals (Sweden)

    Dimas José Araújo Vidigal

    2010-02-01

    Full Text Available PURPOSE: Evaluate the effects of finasteride on the serum PSA and on the prostate of hamster-Mesocricetus auratus(hMa. METHODS: Twenty hMa male adults were split in groups control and experimental (n=10. Animals of the experimental group received 7.14ng/mL of finasteride, subcutaneously (SC on the back three times per week, during 90 days. The finasteride dose was equivalent to 5.0mg administered to a 70kg man. At the end of the experiment the mean age for the animals in the control group was 15.2±1.13months and for the experimental group was 17.7±0.67 months. There was a statistically significant difference between mean ages of both groups (t value=5.98; p=0.001. The animals of the control group weighted 129.0±18.8g and the experimental group weighted 145.0±15.5g, t=1.88 e p=0.0514. The serum PSA was assessed through ELISA method. Prostates of those animals were collected and processed to histology and morphometry: the diameter of the acinous glands and the acinous epithelium, apoptosis, AgNORs and cellularity were assessed in both groups. RESULTS: Serum PSA decreased in the experimental group, 0.003ng/mL versus 0.763ng/mL, H= 7.982 e p= 0.0047. Decrease in the acinous area occurred in animals that received finasteride, 238.000±24.600 μm² versus 398.600±55.320 μm²; t= 2.653; p= 0.0122. A remarkable decrease in the area of the acinous epithelium occurred in the animals that received finasteride, 111.900±12.820 μm² versus 160.400±18.430 μm² t= 2.162; p= 0.0361. AgNORs were less expressed in finasteride treated animals, 2.846±0.877 versus 3.68 ±1.07 argyrophilic clusters for μm², p= OBJETIVO: Avaliar o efeito da finasterida no PSA sérico e na próstata do hamster-Mesocricetus auratus (hMa. MÉTODOS: 20 hMa adultos machos foram divididos em grupos de 10 animais. No experimento foram administrados 7,14 ng/mL de finasterida, subcutâneo (SC, no dorso, três vezes por semana, por 90 dias, dose equivalente a 5,0 mg usada em homem

  11. Summary of the GK15 ground‐motion prediction equation for horizontal PGA and 5% damped PSA from shallow crustal continental earthquakes

    Science.gov (United States)

    Graizer, Vladimir;; Kalkan, Erol

    2016-01-01

    We present a revised ground‐motion prediction equation (GMPE) for computing medians and standard deviations of peak ground acceleration (PGA) and 5% damped pseudospectral acceleration (PSA) response ordinates of the horizontal component of randomly oriented ground motions to be used for seismic‐hazard analyses and engineering applications. This GMPE is derived from the expanded Next Generation Attenuation (NGA)‐West 1 database (see Data and Resources; Chiou et al., 2008). The revised model includes an anelastic attenuation term as a function of quality factor (Q0) to capture regional differences in far‐source (beyond 150 km) attenuation, and a new frequency‐dependent sedimentary‐basin scaling term as a function of depth to the 1.5  km/s shear‐wave velocity isosurface to improve ground‐motion predictions at sites located on deep sedimentary basins. The new Graizer–Kalkan 2015 (GK15) model, developed to be simple, is applicable for the western United States and other similar shallow crustal continental regions in active tectonic environments for earthquakes with moment magnitudes (M) 5.0–8.0, distances 0–250 km, average shear‐wave velocities in the upper 30 m (VS30) 200–1300  m/s, and spectral periods (T) 0.01–5 s. Our aleatory variability model captures interevent (between‐event) variability, which decreases with magnitude and increases with distance. The mixed‐effect residuals analysis reveals that the GK15 has no trend with respect to the independent predictor parameters. Compared to our 2007–2009 GMPE, the PGA values are very similar, whereas spectral ordinates predicted are larger at T<0.2  s and they are smaller at longer periods.

  12. Diagnosis of prostate cancer in patients with persistently elevated PSA and tumor-negative biopsy in ambulatory care. Performance of MR imaging in a multi-reader environment

    Energy Technology Data Exchange (ETDEWEB)

    Scheidler, J. [Radiologisches Zentrum Muenchen-Pasing, Muenchen (Germany); Weoeres, I.; Scharf, M.; Siebels, M. [Urologische Gemeinschaftspraxis Pasing (Germany); Brinkschmidt, C. [Gemeinschaftspraxis Pathologie, Starnberg (Germany); Zeitler, H.; Heuck, A. [Radiologisches Zentrum Muenchen (Germany); Panzer, S. [Unfallklinik Murnau (Germany). Radiologie

    2012-02-15

    Purpose: False-negative results are obtained in approx. 20 % of prostate cancer (PCa) patients (pts) at initial systematic transrectal biopsy (Bx), in particular when digital rectal examination (DRE) or transrectal ultrasound (TRUS) is negative. The aim of this study was to assess whether MR endorectal imaging of the prostate in a multi-reader ambulatory care setting may assist in patient selection for re-biopsy. Materials and Methods: 115 consecutive pts with persistent PSA elevation, negative Bx, DRE and TRUS were examined using T2w axial and coronal and T1w axial sequences for tumor diagnosis. MR images were prospectively read as tumor-suspicious or tumor-negative by the MR radiologist on duty. Additionally, a retrospective readout of a prostate MR expert and an abdominal imaging fellowship-trained radiologist was performed to evaluate the effect of the reader's experience on tumor detection. Imaging findings were compared to the results of the repeat Bx (61 pts) or the clinical course of at least two years. Results: For the prospective reading, the sensitivity of MRI was 83 %, the specificity was 69 %, the PPV was 33 % and the NPV was 96 %. ROC analysis revealed a significantly better performance of the prostate MR imaging expert compared to the abdominal imaging radiologist (area under ROC 0.88 vs. 0.66, p < 0.001). Based on the prospective reading, a pre-test probability for PCa of 17.4 % as in our study can be reduced to 5 % when obtaining a tumor-negative result in MRI. Conclusion: MR imaging in a multi-reader ambulatory care setting assists in patient selection for re-biopsy. Reducing the post-test probability for PCa to 5 % allows for further follow-up instead of re-biopsy in MR tumor-negative patients. Specific training and experience improve tumor detection in prostate MR imaging. (orig.)

  13. Evite las picaduras - PSA (:30) (Fight the Bite PSA [:30])

    Centers for Disease Control (CDC) Podcasts

    2012-08-21

    Este Anuncio de Servicio Público de 30 segundos explica cómo protegerse del Virus del Nilo Occidental.  Created: 8/21/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 8/21/2012.

  14. Arthritis in America PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2017-03-07

    This 60 second public service announcement is based on the March 2017 CDC Vital Signs report. Many adults in the United States have arthritis. Learn how to reduce the pain of arthritis, as well as manage the condition.  Created: 3/7/2017 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 3/7/2017.

  15. Preventing Norovirus Outbreaks PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2014-06-03

    This 60 second public service announcement is based on the June 2014 CDC Vital Signs report. Norovirus infects about 20 million Americans each year. Learn how to protect yourself and your family from this very contagious, potentially serious illness.  Created: 6/3/2014 by National Center for Immunization and Respiratory Diseases (NCIRD).   Date Released: 6/3/2014.

  16. Cancer and Obesity PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2017-10-04

    This 60 second public service announcement is based on the October 2017 CDC Vital Signs report. Obesity is a leading cancer risk factor. Unfortunately, two out of three U.S. adults weigh more than recommended. Find out what can be done to help people get to and keep a healthy weight.  Created: 10/4/2017 by Centers for Disease Control and Prevention (CDC).   Date Released: 10/4/2017.

  17. The Domino Effect PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2017-10-24

    This 30 second public service announcement is about a deadly chain reaction in your body called sepsis.  Created: 10/24/2017 by Centers for Disease Control and Prevention (CDC).   Date Released: 10/24/2017.

  18. The Great Outdoors PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2016-05-18

    A man and a woman are getting ready for a hike. The woman reminds him about sun protection.  Created: 5/18/2016 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 5/18/2016.

  19. Child Passenger Safety PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2014-02-04

    This 60 second public service announcement, based on the February 2014 Vital Signs release, discusses the importance of buckling up to reduce injuries and save lives.  Created: 2/4/2014 by National Center for Injury Prevention and Control (NCIPC).   Date Released: 2/4/2014.

  20. HPV Vaccine Safety PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2014-01-15

    In this 30 second public service announcement, a mother talks about the importance of protecting 11-12 year-old boys and girls with HPV vaccination. (Una madre habla sobre la importancia de proteger a los niños y las niñas de 11 a 12 años con la vacuna contra el VPH.).  Created: 1/15/2014 by National Center for Immunizations and Respiratory Diseases (NCIRD).   Date Released: 1/15/2014.

  1. Preventing Teen Pregnancy PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-04-07

    This 60 second public service announcement is based on the April 2015 CDC Vital Signs report. Teen births in the U.S. have declined, but still, more than 273,000 infants were born to teens ages 15 to 19 in 2013. Learn about the most effective types of birth control.  Created: 4/7/2015 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 4/7/2015.

  2. STD Awareness Month PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2011-04-19

    April is National STD Awareness Month. STDs can affect anyone. Many STDs don't have symptoms so it's important to get tested.  Created: 4/19/2011 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.   Date Released: 4/19/2011.

  3. PSA (:60) Moho/ Hongos (Mold)

    Centers for Disease Control (CDC) Podcasts

    2017-10-25

    Este anuncio de servicio público de 60 segundos habla sobre la importancia de eliminar el moho (hongos) después de una emergencia.  Created: 10/25/2017 by Centers for Disease Control and Prevention (CDC).   Date Released: 10/25/2017.

  4. Preventing Stroke Deaths PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2017-09-06

    This 60 second public service announcement is based on the July 2017 CDC Vital Signs report. Higher opioid prescribing puts patients at risk for addiction and overdose. Learn what can be done about this serious problem.  Created: 9/6/2017 by Centers for Disease Control and Prevention (CDC).   Date Released: 9/6/2017.

  5. Are You Listening? PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2015-09-08

    This radio public service announcement encourages women to learn the symptoms of gynecologic cancer and pay attention to what their bodies are telling them.  Created: 9/8/2015 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 9/8/2015.

  6. Alcohol Poisoning Deaths PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-01-06

    This 60 second Public Service Announcement is based on the January 2015 CDC Vital Signs report. In the United States, an average of six people die every day from alcohol poisoning. Learn what you can do to prevent binge drinking and alcohol poisoning.  Created: 1/6/2015 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 1/6/2015.

  7. Are You Listening? PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-09-08

    This radio public service announcement encourages women to learn the symptoms of gynecologic cancer and pay attention to what their bodies are telling them.  Created: 9/8/2015 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 9/8/2015.

  8. PSA: Topic of gender violence

    OpenAIRE

    Accensi Martínez, Maria Cinta

    2016-01-01

    Breu reflexió sobre la violència existent actualment envers les dones. Breve reflexión sobre la violencia existente actualmente hacia las mujeres. Brief reflection on currently existing violence against women.

  9. African American Health PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2017-05-02

    This 60 second public service announcement is based on the May 2017 CDC Vital Signs report. The life expectancy of African Americans has improved, but it’s still an average of four years less than whites. Learn what can be done so all Americans can have the opportunity to pursue a healthy lifestyle.  Created: 5/2/2017 by Centers for Disease Control and Prevention (CDC).   Date Released: 5/2/2017.

  10. Prescription Painkiller Overdoses PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-07-02

    This 60 second public service announcement is based on the July 2013 CDC Vital Signs report. Prescription painkiller overdoses are an under-recognized and growing problem among women. This program includes things that women and health care providers can do to reduce the risk of overdose.  Created: 7/2/2013 by Centers for Disease Control and Prevention (CDC).   Date Released: 7/2/2013.

  11. Maladi Kolera PSA (:60) (Cholera)

    Centers for Disease Control (CDC) Podcasts

    2010-02-18

    This is an important public health announcement about ways you can prevent the spread of cholera. Language: Haitian Creole.  Created: 2/18/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 2/18/2010.

  12. Mutational analysis of photosystem I of Synechocystis sp. PCC 6803: the role of four conserved aromatic residues in the j-helix of PsaB.

    Directory of Open Access Journals (Sweden)

    Wu Xu

    Full Text Available Photosystem I is the light-driven plastocyanin-ferredoxin oxidoreductase in the photosynthetic electron transfer of cyanobacteria and plants. Two histidyl residues in the symmetric transmembrane helices A-j and B-j provide ligands for the P700 chlorophyll molecules of the reaction center of photosystem I. To determine the role of conserved aromatic residues adjacent to the histidyl molecule in the helix of B-j, we generated six site-directed mutants of the psaB gene in Synechocystis sp. PCC 6803. Three mutant strains with W645C, W643C/A644I and S641C/V642I substitutions could grow photoautotrophically and showed no obvious reduction in the photosystem I activity. Kinetics of P700 re-reduction by plastocyanin remained unaltered in these mutants. In contrast, the strains with H651C/L652M, F649C/G650I and F647C substitutions could not grow under photoautotrophic conditions because those mutants had low photosystem I activity, possibly due to low levels of proteins. A procedure to select spontaneous revertants from the mutants that are incapable to photoautotrophic growth resulted in three revertants that were used in this study. The molecular analysis of the spontaneous revertants suggested that an aromatic residue at F647 and a small residue at G650 may be necessary for maintaining the structural integrity of photosystem I. The (P700⁺-P700 steady-state absorption difference spectrum of the revertant F647Y has a ∼5 nm narrower peak than the recovered wild-type, suggesting that additional hydroxyl group of this revertant may participate in the interaction with the special pair while the photosystem I complexes of the F649C/G650T and H651Q mutants closely resemble the wild-type spectrum. The results presented here demonstrate that the highly conserved residues W645, W643 and F649 are not critical for maintaining the integrity and in mediating electron transport from plastocyanin to photosystem I. Our data suggest that an aromatic residue is

  13. Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherapy; A relacao entre PSA nadir de dois anos e recidiva bioquimica no tratamento do cancer de prostata com braquiterapia de semente de iodo-125

    Energy Technology Data Exchange (ETDEWEB)

    Franca, Carlos Antonio da Silva; Vieira, Sergio Lannes; Penna, Antonio Belmiro Rodrigues Campbell, E-mail: carlosfranca@cremerj.org.br [Instituto Brasileiro de Oncologia (IBO), Rio de Janeiro, RJ (Brazil); Radioterapia Botafogo, Rio de janeiro, RJ (Brazil); Carvalho, Antonio Carlos Pires [Universidade Federal do Rio de Janeiro (UFRJ), RJ (Brazil); Bernabe, Antonio Jose Serrano [Radioterapia Botafogo, Rio de janeiro, RJ (Brazil)

    2014-03-15

    Objective: to evaluate the relationship between two year PSA nadir (PSAn) after brachytherapy and biochemical recurrence rates in prostate cancer patients. Materials and methods: In the period from January 1998 to August 2007, 120 patients were treated with iodine-125 brachytherapy alone. The results analysis was based on the definition of biochemical recurrence according to the Phoenix Consensus. Results: biochemical control was observed in 86 patients (71.7%), and biochemical recurrence, in 34 (28.3%). Mean PSAn was 0.53 ng/ml. The mean follow-up was 98 months. The patients were divided into two groups: group 1, with two year PSAn < 0.5 ng/ml after brachytherapy (74 patients; 61.7%), and group 2, with two year PSAn ≥ 0.5 ng/ml after brachytherapy (46 patients; 38.3%). Group 1 presented biochemical recurrence in 15 patients (20.3%), and group 2, in 19 patients (43.2%) (p < 0.02). The analysis of biochemical disease-free survival at seven years, stratified by the two groups, showed values of 80% and 64% (p < 0.02), respectively. Conclusion: levels of two year PSAn ≥ 0.5 ng/ml after brachytherapy are strongly correlated with a poor prognosis. This fact may help to identify patients at risk for disease recurrence. (author)

  14. Estudio de inteligencia de mercados para la importación de tubería de acero carbón para PSA Colombia S.A.S.

    OpenAIRE

    2012-01-01

    Estudio de inteligencia de mercados para la importación de tuberia de acero carbon para PSA Colombia S.A.S, SCH 40 de 2" revisar la viabilidad de la compra local versus la compra en el exterior analizando tres proveedores Estados Unidos, China y Brasil. En el presente trabajo se estudian los mercados para la importación de tubería de Acero Carbón SCH40, se realiza el análisis de cada área del proceso de comercialización y se establece en términos técnicos, comerciales, financieros, logísticos...

  15. Mensuração de hormônios andrógenos, estrógeno, fosfatase ácida prostática (PAP e antígeno prostático específico (PSA em cães adultos com próstata normal e hiperplásica

    Directory of Open Access Journals (Sweden)

    Veridiana Maria Brianezi Dignani de Moura

    2006-02-01

    Full Text Available Prostatic diseases have been a common problem in middle age and older intact male dogs. Among these, benign prostatic hyperplasia (BHP is the most frequent, age-related and hormonal-dependent condition of human and canine prostate. Blood samples were collected from 37 male intact dogs, tree years old dogs or more to determine androgens, estrogen, prostatic acid phosphatase (PAP and prostatic specific antigen (PSA according to histopathological aspects. Low levels of estrogen and high levels of prostatic specific antigen (PSA were founded in dogs with BHP, respectively. Seric and urinary PAP levels were high in dogs with hyperplasia.

  16. Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA.

    Science.gov (United States)

    De Visschere, P; Lumen, N; Ost, P; Decaestecker, K; Pattyn, E; Villeirs, G

    2017-01-01

    To determine the added value of dynamic contrast-enhanced imaging (DCE) over T2-weighted imaging (T2-WI) and diffusion-weighted imaging (DWI) for detection of clinically significant prostate cancer (csPC) in patients with elevated prostate-specific antigen (PSA). Two hundred and forty-five patients with elevated PSA underwent multiparametric (mp) magnetic resonance imaging (MRI) of the prostate before biopsy. mpMRI was performed using a 3 T MRI system without an endorectal coil. Patients underwent transrectal ultrasound-guided systematic 12 core biopsy followed by radical prostatectomy (n=68), radiation therapy (n=91), or clinical follow-up for at least 2 years (n=86). csPC was defined as Gleason score ≥3+4 and/or tumour volume of ≥0.5 ml, and/or tumour stage ≥T3a. The MRI findings were scored according to the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) and an alternative overall assessment category (PI-RADSv2Alt) based on only T2-WI and DWI. In 144 patients (58.8%), csPC was found within 2 years after MRI. With scoring according to the PI-RADSv2 guidelines, DCE was not needed for determination of the overall assessment category in 80.8% (198/245) of patients. Receiver operating characteristic (ROC) analysis showed an area under the curve of 0.79 (95% confidence interval [CI]: 0.74-0.85) for PI-RADSv2 and 0.79 (95% CI: 0.73-0.85) for PI-RADSv2Alt. The added value of DCE over T2-WI and DWI is limited when using PI-RADSv2 for diagnosis of csPC in patients with elevated PSA before biopsy. An alternative overall assessment score using only T2-WI and DWI yielded similar performance to PI-RADSv2. Copyright © 2016 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

  17. (68)Ga-PSMA PET/CT mapping of prostate cancer biochemical recurrence following radical prostatectomy in 270 patients with PSA<1.0ng/ml: Impact on Salvage Radiotherapy Planning.

    Science.gov (United States)

    Calais, Jérémie; Czernin, Johannes; Cao, Minsong; Kishan, Amar U; Hegde, John V; Shaverdian, Narek; Sandler, Kiri A; Chu, Fang-I; King, Chris R; Steinberg, Michael L; Rausher, Isabel; Schmidt-Hegemann, Nina-Sophie; Poeppel, Thorsten; Hetkamp, Philipp; Ceci, Francesco; Herrmann, Ken; Fendler, Wolfgang P; Eiber, Matthias; Nickols, Nicholas G

    2017-11-09

    Background: Target volume delineations for prostate cancer (PCa) salvage radiotherapy (SRT) after radical prostatectomy are usually drawn in the absence of visibly recurrent disease. Gallium-68 Prostate Specific Membrane Antigen Positron Emission Tomography/Computed Tomography ((68)Ga-PSMA-11 PET/CT) detects recurrent PCa with sensitivity superior to standard of care imaging at serum prostate specific antigen (PSA) values low enough to impact target volume delineations for routine SRT. To i) map the recurrence pattern of PCa early biochemical recurrence (BCR) after radical prostatectomy with (68)Ga-PSMA-11 PET/CT in patients with serum PSA levels PET/CT-defined disease, and iii) assess the potential impact of (68)Ga-PSMA-11 PET/CT on SRT. Patients and Methods: This is a post-hoc analysis of an intention-to-treat population of 270 patients who underwent (68)Ga-PSMA-11 PET/CT at 4 institutions for BCR after prostatectomy without prior radiotherapy at PSAPET/CT by a radiation oncologist blinded to the PET component. (68)Ga-PSMA-11 PET/CT images were analyzed by a nuclear medicine physician. PSMA-positive lesions not covered by planning volumes based on the consensus CTV were considered to have a major potential impact on treatment planning. Results: The median PSA at the time of (68)Ga-PSMA-11 PET/CT was 0.48 ng/ml (range 0.03-1). One-hundred-thirty-two/270 patients (49%) had a positive (68)Ga-PSMA-11 PET/CT. Fifty-two/270 (19%) had at least one PSMA-positive lesion not covered by the consensus CTV. Thirty-three/270 (12%) had extra-pelvic PSMA-positive lesions and 19/270 (7%) had PSMA-positive lesions within the pelvis but not covered by consensus CTV. The two most common (68)Ga-PSMA-11 PET-positive lesion locations outside the consensus CTV were bone (23/52, 44%) and perirectal lymph nodes (16/52, 31%). Conclusion: Post-hoc analysis of (68)Ga-PSMA-11 PET/CT implies a major impact on SRT planning in 52/270 patients (19%) with PCa early BCR (PSAPET/CT investigating its

  18. Biopsia prostática randomizada: ¿influye el número de muestras y el valor del PSA para la detección del cáncer prostático?

    OpenAIRE

    Kozima, S.; Costanza, J.; Cubillos, S.; Espitaleta, J.D.; Hernández Pinzón, J.; Gallo, J.C.; Larrañaga, N.

    2016-01-01

    Objetivo: Determinar si la realización de un mayor número de muestras según el valor del antígeno prostático específico (PSA) incrementa la detección del cáncer prostático (CaP). Materiales y métodos: Se estudió transversalmente a 994 pacientes sometidos a una biopsia prostática transrrectal ecodirigida randomizada (BPTE), con sospecha de CaP. Los casos fueron divididos en dos grupos: A (esquema de 8 muestras y ampliado) con protocolo normal (n = 819) y B (esquema de 12 muestras o más) con...

  19. SODA-IIoT4Automotive: Blockchain to keep the Automotive ECU up-to-date : Co-designed with PSA Group and Valeo, SODA-IIoT4Automotive offers a secure way to update automotive ECU software/firmware.

    OpenAIRE

    Bouzerna, Nabil; Venelle, Benjamin; Boulanger, Antoine

    2017-01-01

    International audience; Automotive vehicles are composed of several dozens of Electronic Control Units (ECU). With the increasing connectivity of the vehicles, the update of the ECU software will soon be performed Over-The-Air (OTA). This includes the update of the in-vehicle infotainment, but also the more critical ECUs such as the body, motion and Advanced Driving Assistance Systems (ADAS) ECUs.For PSA and Valeo the accountability and the availability of ECU software updates are crucial, pa...

  20. A comparative study of primary secondary amino (PSA) and multi-walled carbon nanotubes (MWCNTs) as QuEChERS absorbents for the rapid determination of diazepam and its major metabolites in fish samples by high-performance liquid chromatography-electrospray ionisation-tandem mass spectrometry.

    Science.gov (United States)

    Li, Jincheng; Zhang, Jing; Liu, Huan; Wu, Lidong

    2016-01-30

    A simple and fast modified quick, easy, cheap, effective, rugged, and safe (QuEChERS) method is presented for the determination of diazepam and its three major metabolites, nordiazepam, temazepam and oxazepam (benzodiazepines) in fish samples by liquid chromatography-electrospray ionisation-tandem mass spectrometry. Muscle tissues were extracted with acetonitrile, and then cleaned with primary secondary amino (PSA) adsorbents. The cleanup effect of PSA was compared with that of multi-walled carbon nanotubes (MWCNTs) in term of extraction efficiency. The better results were obtained when PSA was used. The chromatography separation was achieved within 5.0 min on a C18 column. The limit of detection was 0.5 µg kg(-1) and the limit of quantification was 2.5 µg kg(-1). Average recoveries of diazepam and its main metabolites were in the range of 88.5-110.1%, with a relative standard deviation lower than 10.0%. The proposed method for fish samples gives good recoveries, linearity, precision and accuracy. © 2015 Society of Chemical Industry.

  1. Binding of AR to SMRT/N-CoR complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB.

    Science.gov (United States)

    Trtkova, K; Paskova, L; Matijescukova, N; Strnad, M; Kolar, Z

    2010-01-01

    Signaling through the androgen receptor (AR) plays a critical role in prostate cancer progression. The AR is a classical nuclear receptor (NR) providing a link between signaling molecule and transcription response. Histone deacetylase inhibitors- (HDACI) have antiproliferative and proapoptotic effects on prostate cancer cells and their implication in silence AR signaling may have potential therapeutic use. We aimed to study the inhibitory effects of the corepressor SMRT (Silencing Mediator for Retinoid and Thyroid -hormone receptors) which forms a complex together with nuclear receptor corepressor (N-CoR) and with histone deacetylase 3 (HDAC3) on AR activity.The androgen-sensitive prostate cancer cell line LNCaP and androgen-insensitive prostate cancer cell line C4-2 both AR-positive, and androgen-insensitive DU145 and PC3 prostate cancer cell lines were treated with two HDACIs, sodium butyrate (NaB) and/or trichostatin A (TSA). We amplified immunoprecipitated DNA by conventional PCR and in the -following step we used the chromatin immunoprecipitation (ChIP) analysis coupled with quantitative PCR for monitoring NaB induced formation of AR-SMRT/N-CoR complex binding on the PSA promoter. The co-immunoprecipitation assay revealed increase in AR-SMRT formation in NaB treated cells. Simultaneously, the Western blot analysis showed a significant decrease in AR protein expression. In conclusion, the inhibitory effect of NaB on AR gene expression seems to be specific and unique for prostate cancer AR-positive cell lines and corresponds with its ability to stimulate AR-SMRT complex formation. We suggest that AR and SMRT/N-CoR corepressors may form a stable complex in vitro and NaB may facilitate the interaction between AR nuclear steroid receptor and SMRT corepressor prote.

  2. Tratamiento térmico de materiales en el Horno Solar de la PSA: líneas actuales de actividad

    Directory of Open Access Journals (Sweden)

    Cañadas, I.

    2004-04-01

    Full Text Available Concentrated solar energy gives controlled high flux density with a wide wavelength spectrum by means of solar furnaces, which design allows to attain very high heating rates and very high temperatures up to 3500 K. Solar furnaces are specially suitable for transformation or synthesis process, these installations are devoted to research in the fields of material characterization and treatment as well as chemical processes. During 2001, several test campaigns have been carried out in the Solar Furnace at the Plataforma Solar de Almería in collaboration with different European research institutes, under the umbrella of the European Commission`s Improving Human Potential Programme. Thus different lines of work have been launched demonstrating the feasibility and potential use of solar furnaces for such R&D field.

    La energía solar concentrada permite proporcionar de forma controlada altas densidades de flujo energético con un amplio espectro de longitudes de onda mediante el uso de hornos solares, cuyo diseño permite alcanzar velocidades de calentamiento muy altas y temperaturas de hasta 3500ºC. Los hornos solares, por sus características, son especialmente adecuados para aplicaciones que conlleven la transformación o síntesis de materiales, siendo instalaciones dedicadas a la investigación en los campos de tratamiento y caracterización de materiales y procesos químicos. Durante el año 2001 en el Horno Solar de la Plataforma Solar de Almería se han realizado varias campañas de ensayos en colaboración con distintos centros de investigación europeos dentro del programa IHP de la Comisión Europea, abordándose diversas líneas de trabajo que han vuelto a demostrar la viabilidad y potencialidad del uso de los hornos solares para el tratamiento de materiales.

  3. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.

    Science.gov (United States)

    Chiang, I-Ni; Chang, Shang-Jen; Pu, Yeong-Shiau; Huang, Kuo-How; Yu, Hong-Jen; Huang, Chao-Yaun

    2009-01-01

    We retrospectively compared 6- and 12-core prostate biopsies in Taiwanese men and evaluated the impact of prostate volume (PV), prostate-specific antigen (PSA), and PSA density (PSAD) on the prostate cancer detection rate (PCDR). 1,086 consecutive patients with a total PSA of 4.1-20.0 ng/ml and/or abnormal digital rectal examination undergoing first-time transrectal ultrasound-guided biopsy were included. Group I patients (n = 562) underwent sextant biopsy and group II patients (n = 524) underwent sextant biopsy with an extra three lateral cores on both sides. The patients were further stratified into subgroups according to PV (cut-off: 35 ml), PSA (cut-off: 10.0 ng/ml), and PSAD (cut-off: 0.2). Prostate cancer was diagnosed in 228/1,086 (21.0%) patients. The PCDR was higher in group II (23.7%) than group I (18.5%). 12-Core biopsy yielded a significantly higher PCDR than 6-core biopsies in patients with PV >35 ml, PSA 4.1-10.0 ng/ml, PSAD 0.20. 12-Core biopsy yielded a significantly higher PCDR in Taiwanese men with a total PSA of 4.1-20.0 ng/ml, especially in patients with PSA 4.1-10.0 ng/ml, PSAD 35 ml. Copyright 2009 S. Karger AG, Basel.

  4. Motor Vehicle Crash Injuries PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2014-10-07

    This 60 second Public Service Announcement is based on the October 2014 CDC Vital Signs report. Motor vehicle crashes are costly and preventable. Learn what can be done to help prevent motor vehicle injuries.  Created: 10/7/2014 by National Center for Injury Prevention and Control (NCIPC).   Date Released: 10/7/2014.

  5. Preventing Prescription Drug Overdose PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2014-07-01

    This 60 second public service announcement is based on the July 2014 CDC Vital Signs report. Every day, 46 people in the U.S. die from an overdose of prescription opioid painkillers. Learn what can be done to make painkiller prescribing safer and help prevent overdoses.  Created: 7/1/2014 by National Center for Immunization and Respiratory Diseases (NCIRD).   Date Released: 7/1/2014.

  6. Cancer and Tobacco Use PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2016-11-10

    This 60 second public service announcement is based on the November 2016 CDC Vital Signs report. There is a long list of cancers linked to tobacco use, the leading preventable cause of cancer and cancer deaths. Learn more here.  Created: 11/10/2016 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 11/10/2016.

  7. Cervical Cancer is Preventable! PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2014-11-05

    This 60 second Public Service Announcement is based on the November 2014 CDC Vital Signs report. Every visit to a doctor or nurse is an opportunity to prevent cervical cancer. Women can get a Pap test and HPV test to help prevent cervical cancer and adolescent boys and girls can get the HPV vaccination series to help prevent cervical and other cancers.  Created: 11/5/2014 by National Center for Injury Prevention and Control (NCIPC).   Date Released: 11/5/2014.

  8. Cancers Caused by HPV PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2014-01-15

    In this 30 second public service announcement, a mother talks about the importance of protecting 11-12 year-old boys and girls with HPV vaccination. (Una madre habla sobre la importancia de proteger a los niños y las niñas de 11 a 12 años con la vacuna contra el VPH.).  Created: 1/15/2014 by National Center for Immunizations and Respiratory Diseases (NCIRD).   Date Released: 1/15/2014.

  9. Cervical Cancer PSA (:30) (No Tag)

    Centers for Disease Control (CDC) Podcasts

    2014-01-15

    In this 30 second public service announcement, a mother talks about the importance of protecting 11-12 year-old boys and girls with HPV vaccination. (Una madre habla sobre la importancia de proteger a los niños y las niñas de 11 a 12 años con la vacuna contra el VPH.).  Created: 1/15/2014 by National Center for Immunizations and Respiratory Diseases (NCIRD).   Date Released: 1/15/2014.

  10. Hospital Actions Affect Breastfeeding PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-10-06

    This 60 second public service announcement is based on the September 2015 CDC Vital Signs report. Your heart age is the age of your heart and blood vessels as a result of your risk factors for heart attack and stroke. If you smoke or have high blood pressure, your heart age will be much higher than your actual age. Learn what you can do to lower your heart age and keep it low.  Created: 10/6/2015 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 10/6/2015.

  11. Making Health Care Safer PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-03-05

    This 60 second public service announcement is based on the March 2013 CDC Vital Signs report, which discusses lethal infections from carbapenem-resistant Enterobacteriaceae, or CRE, germs and ways health care providers can help stop CRE infections.  Created: 3/5/2013 by Centers for Disease Control and Prevention (CDC).   Date Released: 3/5/2013.

  12. It Happened To Me PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-03-16

    A woman who has cancer warns people after she was infected with hepatitis C when a healthcare worker re-used a syringe for her chemotherapy. She endorses the "One and Only" campaign to promote safe injection practices.  Created: 3/16/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 3/16/2010.

  13. HIV and Injection Drug Use PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2016-11-29

    This 60 second public service announcement is based on the December 2016 CDC Vital Signs report. Sharing needles, syringes, and other injection equipment puts you at risk for getting HIV and other infections, including hepatitis. Learn how to reduce your HIV risk.  Created: 11/29/2016 by National Center for HIV/AIDS, Viral Hepatitis, Sexual Transmitted Diseases and Tuberculosis Prevention (NCHHSTP).   Date Released: 11/29/2016.

  14. HPV Vaccine Safety PSA (:30) (No Tag)

    Centers for Disease Control (CDC) Podcasts

    2014-01-15

    In this 30 second public service announcement, a mother talks about the importance of protecting 11-12 year-old boys and girls with HPV vaccination. No CDC tag at the end. (Una madre habla sobre la importancia de proteger a los niños y las niñas de 11 a 12 años con la vacuna contra el VPH.).  Created: 1/15/2014 by National Center for Immunizations and Respiratory Diseases (NCIRD).   Date Released: 1/15/2014.

  15. Native Americans With Diabetes PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2017-01-10

    This 60 second public service announcement is based on the January 2017 CDC Vital Signs report. Diabetes is the leading cause of kidney failure and Native Americans have a greater chance of having diabetes than any other racial group in the U.S. Learn how to manage your diabetes to delay or prevent kidney failure.  Created: 1/10/2017 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 1/10/2017.

  16. When Food Bites Back PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-06-04

    This 60 second public service announcement is based on the June 2013 CDC Vital Signs report. It discusses food poisoning and specifically, Listeria. If you're 65 or older, have a weakened immune system, or are pregnant, you must be especially careful when selecting, preparing, and storing food.  Created: 6/4/2013 by Centers for Disease Control and Prevention (CDC).   Date Released: 6/4/2013.

  17. Diabetes PSA (:60) Step By Step

    Centers for Disease Control (CDC) Podcasts

    2009-10-24

    First steps to preventing diabetes. For Hispanic and Latino American audiences.  Created: 10/24/2009 by National Diabetes Education Program (NDEP), a joint program of the Centers for Disease Control and Prevention and the National Institutes of Health.   Date Released: 10/24/2009.

  18. Diabetes PSA (:60) Not Too Late

    Centers for Disease Control (CDC) Podcasts

    2009-10-24

    Doctor who suggests small steps to prevent diabetes.  Created: 10/24/2009 by National Diabetes Education Program (NDEP), a joint program of the Centers for Disease Control and Prevention and the National Institutes of Health.   Date Released: 10/24/2009.

  19. Diabetes PSA (:30) Step By Step

    Centers for Disease Control (CDC) Podcasts

    2009-10-24

    First steps to preventing diabetes. For Hispanic and Latino American audiences.  Created: 10/24/2009 by National Diabetes Education Program (NDEP), a joint program of the Centers for Disease Control and Prevention and the National Institutes of Health.   Date Released: 10/24/2009.

  20. Diabetes PSA (:30) Not Too Late

    Centers for Disease Control (CDC) Podcasts

    2009-10-24

    Doctor who suggests small steps to prevent diabetes.  Created: 10/24/2009 by National Diabetes Education Program (NDEP), a joint program of the Centers for Disease Control and Prevention and the National Institutes of Health.   Date Released: 10/24/2009.

  1. Think Sepsis. Time Matters. PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2016-08-23

    This 60 second public service announcement is based on the August 2016 CDC Vital Signs report. Sepsis is a medical emergency and can happen quickly. Learn the signs of sepsis and how to prevent it.  Created: 8/23/2016 by National Center for Injury Prevention and Control (NCIPC).   Date Released: 8/23/2016.

  2. PSA (:30) Enfermedades diarreicas (Diarrheal Diseases)

    Centers for Disease Control (CDC) Podcasts

    2017-10-25

    Este anuncio de servicio público de 30 segundos habla sobre cómo prevenir las enfermedades diarreicas después de una emergencia.  Created: 10/25/2017 by Centers for Disease Control and Prevention (CDC).   Date Released: 10/25/2017.

  3. Dental Sealants Prevent Cavities PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2016-10-18

    This 60 second public service announcement is based on the October 2016 CDC Vital Signs report. Dental sealants, applied soon after a child's permanent molars come in, can protect against cavities for up to nine years. Applying sealants in schools for low-income children could save millions in dental treatment costs.  Created: 10/18/2016 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 10/18/2016.

  4. PSA (:30) Infecciones de heridas (Wound Infections)

    Centers for Disease Control (CDC) Podcasts

    2017-10-25

    Este anuncio de servicio público de 30 segundos habla sobre cómo evitar que las heridas se infecten después de una emergencia.  Created: 10/25/2017 by Centers for Disease Control and Prevention (CDC).   Date Released: 10/25/2017.

  5. Safe Sleep for Babies PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2018-01-09

    This 60 second public service announcement is based on the January 2018 CDC Vital Signs report. Every year, there are about 3,500 sleep-related deaths among U.S. babies. Learn how to create a safe sleep environment for babies.  Created: 1/9/2018 by Centers for Disease Control and Prevention (CDC).   Date Released: 1/9/2018.

  6. Too Loud for Too Long! PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2017-02-07

    This 60 second public service announcement is based on the February 2017 CDC Vital Signs report. Being around too much loud noise—like a leaf blower or rock concert—can cause permanent hearing loss. Learn how to prevent hearing loss.  Created: 2/7/2017 by National Institute for Occupational Safety and Health (NIOSH).   Date Released: 2/7/2017.

  7. Motor Vehicle Crash Deaths PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2016-07-06

    This 60 second public service announcement is based on the July 2016 CDC Vital Signs report. In the U.S., about 90 people die in motor vehicle crashes each day and thousands more are injured, resulting in hundreds of millions of dollars in direct medical costs each year. Learn what you can do to stay safe.  Created: 7/6/2016 by National Center for Injury Prevention and Control (NCIPC).   Date Released: 7/6/2016.

  8. Let's Stop HIV Together PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2012-07-16

    This public service announcement features 22 individuals who encourage others in the fight against HIV.  Created: 7/16/2012 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).   Date Released: 7/16/2012.

  9. Alcohol Screening and Counseling PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2014-01-07

    This 60 second public service announcement is based on the January 2014 CDC Vital Signs report. Millions of Americans drink too much, a dangerous behavior that can lead to serious health problems. Alcohol screening and counseling can help.  Created: 1/7/2014 by Centers for Disease Control and Prevention (CDC).   Date Released: 1/7/2014.

  10. Preventing Pregnancy in Younger Teens PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2014-04-08

    This 60 second public service announcement is based on the April 2014 CDC Vital Signs report. Births to teens are declining, still, more than 305,000 teens ages 15 to 19 gave birth. This program discusses what health care providers, parents, and teens can do to help prevent teen pregnancy.  Created: 4/8/2014 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 4/8/2014.

  11. Protect Patients from Antibiotic Resistance PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2016-03-03

    This podcast is based on the March 2016 CDC Vital Signs report. Patients can get serious healthcare-associated infections, or HAIs, while receiving medical treatment in a healthcare facility. Learn how to prevent healthcare-associated infections.  Created: 3/3/2016 by National Center for Emerging and Zoonotic Infectious Diseases (NCEZID).   Date Released: 3/3/2016.

  12. Preventing Repeat Teen Births PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-04-02

    This 60 second public service announcement is based on the April 2013 CDC Vital Signs report, which discusses repeat teen births and ways teens, parents and guardians, health care providers, and communities can help prevent them.  Created: 4/2/2013 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/2/2013.

  13. I Had To Do Something PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-03-16

    A woman whose stepson died from a healthcare infection endorses the "One and Only" campaign to promote safe injection practices.  Created: 3/16/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 3/16/2010.

  14. Kadav Moun PSA (:60) (Human Remains)

    Centers for Disease Control (CDC) Podcasts

    2010-02-18

    This is an important public health announcement about safety precautions for those handling human remains. Language: Haitian Creole.  Created: 2/18/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 2/18/2010.

  15. Maladi Kolera 1 PSA (:30) (Cholera 1)

    Centers for Disease Control (CDC) Podcasts

    2010-02-18

    This is an important public health announcement about cholera symptoms and ways you can prevent the spread of disease. Language: Haitian Creole.  Created: 2/18/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 2/18/2010.

  16. Maladi Kolera 2 PSA (:30) (Cholera 2)

    Centers for Disease Control (CDC) Podcasts

    2010-02-18

    This is an important public health announcement about cholera prevention and food preparation tips you can use to prevent the spread of disease. Language: Haitian Creole.  Created: 2/18/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 2/18/2010.

  17. The managerial dilemma between the prescribed task and the real activity of operators: some trends for research for PSA; Le dilemme managerial entre la tache prescrite et l`activite reelle des operateurs: quelques tendances de la recherche pour les EPS

    Energy Technology Data Exchange (ETDEWEB)

    Montmayeul, R.; Mosneron Dupin, F.; LLory, M.

    1993-11-01

    Whatever the level in an organization, the management needs safety indicators to assist decision making on safety. As an indicator, PSA (Probabilistic Safety Assessment) through PHRA (Probabilistic Human Reliability Assessment) accounts for some aspects of human reality. In spite of the limitations of PSAs as a tool in assisting the processing of safety problems, three possible channels for development and progress are suggested ``internal`` improvement of PSAs, by enhancing data and human-behaviour models; extension of the classical applications of PSAs for the purpose of reflection and speculation, and for querying the potential influence of a certain number of factors concerning human behaviour; the extension of PSAs themselves, by developing organizational indicators. Research has been undertaken to evaluate the feasibility of using methods developed for analysis of the psychosocial climate of a company to set up a ``safety culture`` or ``safety climate`` indicator. Such an organizational indicator would reflect perception and opinion of the personnel at a given time, and make it possible to follow their evolutions; effective interpretation of the results needs to be done with the staff concerned. PSA and other indicators are only tools for analysis and aids for decision making, they cannot replace any part of the technical and scientific debate which must be on-going for all aspects of safety. (authors). 20 refs.

  18. Prostate Cancer Screening: the role of biopsy, PSA, PSA dynamics and isoforms

    NARCIS (Netherlands)

    P.F.J. Raaijmakers (René)

    2009-01-01

    textabstractIn the beginning of the past century, A. Astraldi urologist from Buenos Aires, Argentina, recognized the importance of early detection of prostate cancer and was unsatisfied with the available diagnostic tools he had to his disposal. The only diagnostic means for the urologist at that

  19. Arraying prostate specific antigen PSA and Fab anti-PSA using light assisted molecular immobilization technology

    DEFF Research Database (Denmark)

    Parracino, Antonietta; Neves Petersen, Teresa; Gennaro, Ane Kold Di

    2010-01-01

    Continuous 295nm excitation of bovine apo-α-lactalbumin (apo-bLA) results in an increase of tryptophan fluorescence quantum yield and in a progressive red-shift in tryptophan fluorescence emission. Furthermore, 295nm excitation in apo-bLA leads to disulphide bridges breakage, leading to free thio...... in many fluorescence spectroscopy studies of proteins. Prolonged illumination of any disulphide bridge containing protein will have photochemical consequences, such as disulphide bond disruption. We may not be able to observe proteins using UV light without perturbing them....

  20. Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer

    Directory of Open Access Journals (Sweden)

    Ahmad Anies Shahab

    2013-03-01

    Conclusions: PSA and PSAD cutoff point for Indonesian men in this series is relatively different from international consensus. Furthermore, these data show that PSA and PSAD cutoff point must be adjusted to racial variation to discriminate between malignant and benign disease. Urinary retention is a significant factor for PSA cutoff increase.

  1. PSA de radio Mes de Concientización sobre las ETS PSA de radio (30 seg) (STD Awareness Month PSA (:30))

    Centers for Disease Control (CDC) Podcasts

    2011-04-19

    Abril es el Mes Nacional de Concientización sobre las Enfermedades de Transmisión Sexual (ETS). Las ETS pueden afectar a cualquier persona. Muchas ETS no tienen síntomas, por lo que es importante hacerse pruebas de detección.  Created: 4/19/2011 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.   Date Released: 4/20/2011.

  2. Making Health Easier: Active Living in Austin, TX PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-06-07

    A local Austin, Texas, woman started a walking group to make physical activity fun for herself and community.  Created: 6/7/2013 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 6/7/2013.

  3. Prevent Snow from Blocking your Tailpipe PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2014-12-11

    If it's snowing, make sure your vehicle’s tailpipe is clear of snow before starting the engine to prevent carbon monoxide poisoning.  Created: 12/11/2014 by National Center for Environmental Health (NCEH).   Date Released: 12/11/2014.

  4. Making Health Easier: Healthy Schools in Chicago, IL PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-05-21

    To help Chicago schools increase access to healthy food, Health Educator April Lillstrom utilized community partnerships to provide school gardens, salad bars, and nutrition education to students.  Created: 5/21/2013 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 5/21/2013.

  5. Making Health Easier: Healthy Schools in Minnesota PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-06-05

    To bring healthier meals to students at the Dover-Eyota elementary school in Minnesota, school officials and parents started a partnership with local farmers. The farm-to-school program has brought better food, like watermelon and corn on the cob, to the children while building ties within the community.  Created: 6/5/2013 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 6/5/2013.

  6. Making Health Easier: Active Living in Philadelphia, PA PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-06-07

    Making communities bike-friendly can help reduce traffic congestion and increase the physical activity of residents. Learn how one Philadelphia resident worked with his community to make Philadelphia a more bike-friendly city.  Created: 6/7/2013 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 6/7/2013.

  7. Children Need More Fruits and Vegetables! PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2014-08-05

    This 60 second public service announcement is based on the August 2014 CDC Vital Signs report. Children in the U.S. aren't eating enough fruits and vegetables. Learn what you can do to impact this problem.  Created: 8/5/2014 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 8/5/2014.

  8. New PSA high concentration solar furnace SF40

    Science.gov (United States)

    Rodriguez, Jose; Cañadas, Inmaculada; Zarza, Eduardo

    2016-05-01

    A new solar furnace has been designed and built at Plataforma Solar de Almería. In this work, its main components such as heliostat, concentrator, attenuator and test table, and the method used to align them are described. Other equipment like the auxiliary systems necessary for the solar operation, vacuum chamber and gas system are outlined too. Finally, the thermal characteristics of the focus were measured during a test campaign, where different planes along the optical axis were scanned with a radiometer, and the peak flux was obtained and is presented in the last section of this report.

  9. Have You Been Tested for Colorectal Cancer? PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-11-05

    This 60 second public service announcement is based on the November 2013 CDC Vital Signs report. Colorectal cancer screening saves lives, but only if you get tested. If you’re between 50 and 75, talk with your doctor about which test is best for you. If you have inflammatory bowel disease or a family history of colorectal cancer or polyps, ask your doctor if you should start screening before age 50.  Created: 11/5/2013 by Centers for Disease Control and Prevention (CDC).   Date Released: 11/5/2013.

  10. Cancers Caused by HPV PSA (:30) (No Tag)

    Centers for Disease Control (CDC) Podcasts

    2014-01-15

    In this 30 second public service announcement, a mother talks about the importance of protecting 11-12 year-old boys and girls with HPV vaccination. (Una madre habla sobre la importancia de proteger a los niños y las niñas de 11 a 12 años con la vacuna contra el VPH.).  Created: 1/15/2014 by National Center for Immunizations and Respiratory Diseases (NCIRD).   Date Released: 1/15/2014.

  11. Message from Terrence Howard: Screening for Colorectal Cancer PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2010-04-13

    A message from the actor/musician Terrence Howard about the importance of screening for colorectal cancer.  Created: 4/13/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/13/2010.

  12. Message from Terrence Howard: Screening for Colorectal Cancer PSA (:20)

    Centers for Disease Control (CDC) Podcasts

    2010-04-13

    A message from the actor/musician Terrence Howard about the importance of screening for colorectal cancer.  Created: 4/13/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/13/2010.

  13. E-cigarette Ads and Youth PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2016-01-05

    This 60 second public service announcement is based on the January 2016 CDC Vital Signs report. Most electronic cigarettes, or e-cigarettes, contain nicotine, which is highly addictive and may harm brain development. More than 18 million middle and high school students were exposed to e-cigarette ads. Exposure to these ads may be contributing to an increase in e-cigarette use among youth. Learn what can be done to keep our youth safe and healthy.  Created: 1/5/2016 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 1/5/2016.

  14. Binge Drinking Among Women and Girls PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-01-08

    This 60 second public service announcement is based on the January 2013 CDC Vital Signs report, which presents information about binge drinking among women and girls. Binge drinking is defined for women as four or more drinks in a short period of time. It puts women and girls at greater risk for breast cancer, sexual assault, heart disease, and unintended pregnancy.  Created: 1/8/2013 by Centers for Disease Control and Prevention (CDC).   Date Released: 1/8/2013.

  15. Preventable Deaths from Heart Disease and Stroke PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-09-03

    This 60 second public service announcement is based on the September 2013 CDC Vital Signs report. More than 800,000 Americans die each year from heart disease and stroke. Learn how to manage all the major risk factors.  Created: 9/3/2013 by Centers for Disease Control and Prevention (CDC).   Date Released: 9/3/2013.

  16. Physical Activity and Adults with Disabilities PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2014-05-06

    This 60 second public service announcement is based on the May 2014 CDC Vital Signs report. Adults with disabilities who get no aerobic physical activity are 50 percent more likely to have heart disease, stroke, diabetes, or cancer. Learn what you can do to help.  Created: 5/6/2014 by National Center on Birth Defects and Developmental Disabilities (NCBDDD).   Date Released: 5/6/2014.

  17. HIV Care Saves Lives: Viral Suppression is Key PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2014-11-25

    This 60 second Public Service Announcement is based on the December 2014 Vital Signs. For people living with HIV, Viral suppression is critical. By getting tested and taking HIV medicines, individuals living with HIV can achieve very low levels of HIV in the body.  Created: 11/25/2014 by National Center for Injury Prevention and Control (NCIPC).   Date Released: 11/25/2014.

  18. Early Detection of Viral Hepatitis Can Save Lives - PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-05-12

    Early detection of viral hepatitis can help prevent liver damage, cirrhosis, and even liver cancer.  Created: 5/12/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 5/12/2010.

  19. Hepatitis C: What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-05-07

    This 60 second public service announcement is based on the May 2013 CDC Vital Signs report. It discusses hepatitis C, a serious viral infection, and the need for everyone born from 1945 through 1965 to get tested.  Created: 5/7/2013 by Centers for Disease Control and Prevention (CDC).   Date Released: 5/7/2013.

  20. Prostate Volume and PSA Cutoff Values as Predictive Indices for ...

    African Journals Online (AJOL)

    Background: Benign prostatic hyperplasia (BPH) is a non malignant enlargement of the prostate. This study was conducted to determine the pattern of presentation of BPH with and without acute urinary retention (AUR) and to determine the risk factors for acute urinary retention, in addition, to assess the results of doxazosin ...

  1. Diabetes – Get Real PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2009-10-24

    Small steps to prevent diabetes.  Created: 10/24/2009 by National Diabetes Education Program (NDEP), a joint program of the Centers for Disease Control and Prevention and the National Institutes of Health.   Date Released: 10/24/2009.

  2. El Dr. Huerta habla sobre la diabetes PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2009-10-24

    Doctor discusses risks of type 2 diabetes (in Spanish).  Created: 10/24/2009 by National Diabetes Education Program (NDEP), a joint program of the Centers for Disease Control and Prevention and the National Institutes of Health.   Date Released: 10/24/2009.

  3. Diabetes – Get Real PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2009-10-24

    Small steps to prevent diabetes.  Created: 10/24/2009 by National Diabetes Education Program (NDEP), a joint program of the Centers for Disease Control and Prevention and the National Institutes of Health.   Date Released: 10/24/2009.

  4. ADHD in Young Children: What You Should Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2016-05-03

    This 60 second public service announcement is based on the May 2016 CDC Vital Signs report. For children ages two to five who have ADHD, behavior therapy is recommended before prescribing medicine. This therapy teaches parents ways to improve their child’s behavior and can work as well as medicine, without the risk of side effects.  Created: 5/3/2016 by National Center for Emerging and Zoonotic Infectious Diseases (NCEZID).   Date Released: 5/3/2016.

  5. Message from Jimmy Smits: La Vida Real PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-04-13

    A message in Spanish from actor Jimmy Smits about the importance of screening for colorectal cancer.  Created: 4/13/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/13/2010.

  6. Message from Jimmy Smits: La Vida Real PSA (:20)

    Centers for Disease Control (CDC) Podcasts

    2010-04-13

    A message in Spanish from actor Jimmy Smits about the importance of screening for colorectal cancer.  Created: 4/13/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/13/2010.

  7. Jackie’s Story PSA (:15)

    Centers for Disease Control (CDC) Podcasts

    2013-05-06

    A young mom’s world is turned upside-down when she’s diagnosed with cervical cancer. Learn what she’s doing to protect her kids from HPV-related cancers.  Created: 5/6/2013 by National Center for Immunization and Respiratory Diseases (NCIRD).   Date Released: 10/30/2013.

  8. Jackie’s Story PSA (:30) 2

    Centers for Disease Control (CDC) Podcasts

    2013-05-06

    A young mom’s world is turned upside-down when she’s diagnosed with cervical cancer. Learn what she’s doing to protect her kids from HPV-related cancers.  Created: 5/6/2013 by National Center for Immunization and Respiratory Diseases (NCIRD).   Date Released: 10/30/2013.

  9. Jackie’s Story PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2013-05-06

    A young mom’s world is turned upside-down when she’s diagnosed with cervical cancer. Learn what she’s doing to protect her kids from HPV-related cancers.  Created: 5/6/2013 by National Center for Immunization and Respiratory Diseases (NCIRD).   Date Released: 10/30/2013.

  10. Making Health Easier: Worksite Wellness in Minnesota PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-06-04

    When firefighters in Minnesota discovered that over 50 percent of firefighter deaths were cardiovascular-related, they decided to implement healthy changes in the workplace. The firefighters now manage a garden near the fire station and eat fresh broccoli, squash, and tomatoes between shifts.  Created: 6/4/2013 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 6/4/2013.

  11. 11C-choline PET/CT and PSA kinetics.

    Science.gov (United States)

    Castellucci, Paolo; Picchio, Maria

    2013-07-01

    The role of PET/CT with radiolabelled (18)F-choline or (11)C-choline in patients with prostate cancer after primary treatment has not been established yet and there are no guidelines on the appropriate use of this emerging modality. According to the literature, choline PET/CT may have a role in restaging the disease in patients with biochemical relapse for the detection of local and/or lymph node and/or distant recurrence. The aim of this brief review is to summarize the results of the most relevant published studies with particular focus on the relationship between prostate-specific antigen levels and kinetics and the sensitivity of choline PET/CT for optimizing the selection of patients who may benefit the most from this diagnostic procedure, especially early after biochemical recurrence.

  12. Updating the Psoriatic Arthritis (PsA) Core Domain Set

    DEFF Research Database (Denmark)

    Orbai, Ana-Maria; de Wit, Maarten; Mease, Philip J

    2017-01-01

    24 focus groups with 130 patients from 7 countries representing 5 continents to identify patient domains. We achieved consensus through 2 rounds of separate surveys with 50 patients and 75 physicians, and a nominal group technique meeting with 12 patients and 12 physicians. We conducted a workshop......-related quality of life, and systemic inflammation, which were recommended for all RCT and LOS. These were important, but not required in all RCT and LOS: economic cost, emotional well-being, participation, and structural damage. Independence, sleep, stiffness, and treatment burden were on the research agenda...

  13. Cote de Pablo: I Was Lucky PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-09-08

    Actress Cote de Pablo talks about her own cervical cancer scare and shares advice for other women.  Created: 9/8/2015 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 9/8/2015.

  14. Cote de Pablo: I Was Lucky PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2015-09-08

    Actress Cote de Pablo talks about her own cervical cancer scare and shares advice for other women.  Created: 9/8/2015 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 9/8/2015.

  15. Zika and Pregnancy: What You Should Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2016-04-01

    This 60 second Public Service Announcement is based on the April 2016 CDC Vital Signs report. A pregnant woman who is infected with Zika virus can pass it to her fetus which is linked to microcephaly, a serious birth defect. This podcast discusses how to protect yourself from Zika virus.  Created: 4/1/2016 by National Center for Emerging and Zoonotic Infectious Diseases (NCEZID).   Date Released: 4/1/2016.

  16. Review of health effects models for Level 3 PSA

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Seung Hee; Kim, Ju Youl [FNC Technology Co., Yongin (Korea, Republic of); Han, Seok Jung [KAERI, Daejeon (Korea, Republic of)

    2016-05-15

    Many international organizations have developed health risk models. Especially, as radiation-induced cancer is an important part among health effects, development has been focused on cancer risk model. This paper reviewed the cancer risk models of international agencies; United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), National Academy of Sciences (NAS) and International Commission on Radiological Protection (ICRP). Moreover, as pre-research for improving the health risk model in Korea, this paper analyzed the three methodologies and specific details in modeling. International agencies have developed radiation-induced cancer risk model reflecting the recent A-bomb survivor LSS data. This paper reviewed the recent cancer risk model of UNSCEAR, NAS and ICRP. All three models were based on ERR and EAR model in the form of a multiplication of dose-response model and modification function. Lifetime risk was calculated as a function of exposure age and gender.

  17. Prostatic Specific Antigen (PSA) Relationship to Patients Age ...

    African Journals Online (AJOL)

    Hp 630 Dual Core

    4. Tomomi Kimura East meets West: ethnic differences in prostate cancer epidemiology between East Asians and caucasians chin J cancer. 2012 September; 31(9): 421 429. doi: 10.5732/cjc.011.10324. 5. Bjarne K. Jacobsen, Synn·ve F. Knutsen, Gary E. Fraser Does high soy milk intake reduce prostate cancer incidence?

  18. Keep Food, Water, and Medications Safe PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2017-10-25

    This 60 second public service announcement is about the need to keep food, water and medications safe after a disaster.  Created: 10/25/2017 by Centers for Disease Control and Prevention (CDC).   Date Released: 10/25/2017.

  19. Making Health Easier: Healthy Schools in Philadelphia, PA PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-06-07

    A middle school student is making healthy changes in his life, like eating less junk food, thanks to healthy changes at his school.  Created: 6/7/2013 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 6/7/2013.

  20. Alcohol and Pregnancy: Why Take the Risk? PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2016-02-02

    This public service announcement is based on the February 2016 CDC Vital Signs report. More than three million women in the U.S. are at risk for exposing their developing baby to alcohol. Drinking alcohol during pregnancy can cause physical, behavioral, and intellectual disabilities that can affect a child’s whole life. Learn what can be done to keep developing babies healthy.  Created: 2/2/2016 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 2/2/2016.